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ABSTRACT 
Among the physiological and metabolic changes occurring with ageing, the ageing of heart function 
is a key determinant of health. The death number from CVDs is expected to reach over 23.6 million 
by 2030. An estimated 17.9 million people died from CVDs in 2019 in the UK, representing 32% of 
all global deaths. Evidence suggested that the Mediterranean diet supplemented with extra virgin 
olive oil (EVOO) (25-50 ml/day) is highly reported as associated with a reduction of CV risk factors. 
However, the acceptability of the Mediterranean diet and the feasibility of this dietary pattern which 
includes consumption of olive oil remains unknown among Caucasians and East Asians in Northeast 
England. An Online Survey with two ethnicities in equal number and similar mean age and BMI that 
were undertaken for this PhD programme indicating that the acceptability and frequency of olive oil 
intake among East Asians is higher with a great MD score (8.02±SD1.8) (p<0.001) while Caucasians 
who consume olive oil were scored higher for MD score (6.51±SD2.2) (p<0.001), scored higher for 
MD acceptability (10.21±SD2.3) (p=0.017) and reported lower perceived barriers to healthy eating 
(PBHE) (1.81±SD4.0) (p=0.03) than non-consumers. Olive oil intake is likely to be positively 
associated with older age, higher MD score, higher MD acceptability and lower PBHE in both 
ethnicities. Evidence examining the effectiveness of nuts and olive oil, on both traditional and novel 
CV risk factors, in a comprehensive study in adults with different ethnic background is lacking. Our 
systematic reviews and meta-analysis of previous relevant literature on nuts that were undertaken 
for this PhD programme showed that nuts improve TC (MD: -7.54; 95% CI: -10.2 to -4.89; p < 0.00001; 
I2= 59%, n=66), HDL (MD: 0.89; 95% CI: 0.04 to 1.75; P=0.04; I2= 53%; n=67), LDL (MD: -7.21; 95% 
CI: -9.38 to -5.04; P< 0.00001; I2= 68%; n=68), TG (MD: -8.83; 95% CI: -13.12 to -4.53; P< 0.0001; 
I2= 64%; n=65) and FMD (MD: 0.74; 95% CI: 0.09 to 1.39; P=0.03; I2=5%, n=10). The non-Asian 
group potentially tends to benefit more CV biomarkers with moderate nut consumption than Asian 
group. Olive oil systematic review reported that olive oil improves biomarker - PAI-1 (MD: -1.02ng/ml, 
95% CI: -1.92 to -0.12; p = 0.03, I2 = 0%). Nevertheless, studies on olive oil on different ethnicities 
were lacking. A 6-week, cross-over, randomised controlled dietary interventional study with 2 weeks 
interventional duration was undertaken to test the effects of EVOO on cardiovascular health. Overall, 
this study provided evidence on the benefits of over a 2-week period produced a positive effect on 
24-hour SBP including daytime SBP, night-time DBP and MAP and TC, LDL for all participants. For 
East Asians, olive oil exerts a beneficial effect on 24-hour SBP and daytime SBP, MAP while night-
time DBP was improved among Caucasians following EVOO. EVOO intake also has a positive effect 
on blood lipids - TC and circulating biomarkers - sE-selectin in East Asians while LDL and non-HDL 
are improved among Caucasians after EVOO intake. The findings reported in the present thesis 
could be valuable to health professionals to develop more effective interventions and could also help 
the public to make better informed food choices relating to cardiovascular health.
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1 Cardiovascular health and CVDs in Britain and East Asia 
1.1 cardiovascular disease 
Cardiovascular disease (CVDs) encompasses all the conditions concerning the heart and 
circulatory systems. CVDs refers to the degeneration and interruption of arteries and 
inadequate supply of oxygen to the muscle of the heart - coronary heart disease (CHD), the 
brain including cerebrovascular and carotid artery disease and the extremities, particularly 
the lower limbs (peripheral vascular disease). CVD involves the processes of 
atherosclerosis (lesions in the arterial wall) and thrombosis (blood clotting) as well as 
changes to the function of the arterial lining (American Heart Association 2019). 
Atherosclerosis is a complex disease of the arteries, as fatty materials called atheroma 
builds up in the lining of artery walls and narrows arteries. Over time it grows bigger until 
the passageways through the arteries become roughened and clogged with fatty deposits 
that they cannot left enough blood flow freely (Lusis, 2000).   
 
1.2 Epidemiologic characterization for cardiovascular health  
In the early 20th century, CVDs were responsible for nearly 10% of all deaths globally. At 
the beginning of the 21st century, CVDs account for nearly one half of all deaths in the 
developed world and 25% of all deaths in developing countries (Sokoła-Wysoczańska, 
Wysoczański et al. 2018). Evidence (Townsend, Wilson et al. 2016) suggested that CVD 
remain the leading cause and accounts for 17.3 million deaths per year. The mortality of 
CVD in Europe accounted for 45% of all deaths - 49% among women and 40% among men. 
Over 4 million people die from CVDs across Europe annually, with 1.4 million of these 
deaths before the age of 75. The death number from CVDs is expected to reach over 23.6 
million by 2030 (World Health Organization 2020).  
 
Study reported that the majority of patients with coronavirus (COVID-19) have underlying 
CVD as 7% of patients experience myocardial injury from the infection (22% of critically ill 
patients) (Clerkin, Fried et al. 2020) and acute cardiac injury was reported to become the 
most reported cardiovascular abnormality during the pandemic of coronavirus (COVID-19), 
with average incidence of 8-12% (Bansal 2020). Another current research news found that 
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UK citizen suffering with health conditions such as heart disease, stroke and other their risk 
factors such as diabetes, obesity, hypertension is at increased risk of complications from 
coronavirus and the increased risk of COVID-19 complications in cardiovascular disease to 
an abundance of a receptor that serves as a gateway for the virus to jump into the lungs 
and heart as evidence indicated that 45% of the Covid-19 deaths in English citizens who 
also had a history of cardiovascular diseases (British Heart Foundation 2021). Review study 
has been observed that mortality rates in patients of coronavirus disease 2019 (COVID-19) 
have been examined approximately 10.5% cases in patients with cardiovascular disease 
and a mortality rate of 52% was recorded in patients with heart failure, while 12% recovered 
ultimately (Dan et al., 2020). 
In China, a meta-analysis comprising Chinese patients showed that pre-existing CVD was 
associated with a significantly increased risk of a severe form of COVID-19 (OR = 3.14; 95% 
CI: 2.32-4.24; I2 = 0%; Q = 8.68, P= 0.73) and overall risk of COVID-19 all-cause mortality 
(OR = 11.08; 95% CI: 2.59-47.32; I2 = 55%; P = 0.11) (Aggarwal, Cheruiyot et al. 2020).  
 
The current urgent exposure to CVD risk factors is highly impacted by the environment in 
which an individual lifestyle including dietary consumption, which means that the majority 
of CVDs result from risk factors that may be controlled and treated, which include 
hypertension, cholesterol, diabetes, tobacco use, lack of physical activity, and 
overweight/obesity (Sokoła-Wysoczańska, Wysoczański et al. 2018). 
 
1.2.1 CVD in the UK – emphasis in the North East of England 
Around 7.6 million people - 4 million males and 3.6 million females live with CVD in the UK 
and around 650,000 people of those have heart failure while 1.9 million people are living 
with coronary heart disease (CHD), which is responsible for around 63,000 deaths in the 
UK each year. Around 15 million adults (28% of adults) experience high blood pressure in 
the UK (British Heart Foundation 2021).  
Between 2015 and 2017, almost 30% of all North East residents dying from CVD were aged 
under 75 years (Public Health England 2019) and the rate of premature CVD mortality in 
NE was the second highest of all the English regions and significantly higher than the 
national rate (Valerie et al, 2020). The gap in the under 75 age-standardised CVD mortality 
rate between the North East and England has narrowed over the past 15 years however 
the rates in the North East is still significantly (14%) greater than the England rate (Public 
Health England 2019). By 2030, the population in England aged 65-84y will potentially rise 
by 29% and those over 85 by 61%. Treatment and care for people with long term conditions 
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is estimated at £7.4 billion per year, and annual costs to the wider economy being an 
estimated £15.8 billion in the UK (Public Health England 2019). 
In addition, evidence (Public Health England 2019) showed that an estimated 81% of 
Disability-adjusted Life Years (DALYs) due to CVD in the North East England can be 
attributed to cardiovascular risk factors. 71% of DALYs are the result of cardiovascular risk 
factors such as hypertension or high body mass index (BMI). 55% of DALYs are attributable 
to behavioural risks, such as poor diet or smoking habits (Public Health England 2019). 
Evidence estimated that 60% of North East English citizens have a raised cholesterol level 
(Waterall 2015). Moreover, evidence also indicated that 1 in 250 and 1 in 500 persons 
experience familial hypercholesterolaemia, which is a genetic reason of raised cholesterol 
levels (Public Health England 2019). 
 
1.2.2 CVDs in East Asia – emphasis in China 
East Asians have an increased risk of death from overall CVDs (Chen, Copeland et al. 
2013). The incidence of CVDs among Chinese adults are lower than that found in most 
economically developed countries, however it had risen in a strikingly fast rate over the past 
several decades (Zhao, Chong et al. 2001). In China, the upwards tendency of the 
proportion of patients with CVD were closely associated with the increased number of 
cardiovascular risk factors and population ageing (Li and Ge 2014). The prevalence of 
cardiovascular risk factors such as dyslipidemia was 62.1% overall, with 33.5% high total 
cholesterol (TC), 43.9% triglyceride (TG), 0.6% low-density lipoprotein cholesterol (LDL-C) 
and 8.8% for low high-density lipoprotein cholesterol (HDL-C). In those with dyslipidemia in 
China, the proportion of Chinese subjects who were aware, treated, and controlled was low, 
which is 14.4, 33.9, and 19.9%, respectively (Zhang, Xing et al. 2017). A cross-sectional 
study (Zhu, Xi et al. 2020) with 56,716 Chinese residents aged 40 years and above from six 
cities in Northern China from September 2015 to June 2017 reported that 22.7% of 
participants had a high 10-year risk of CVD (Zhu, Xi et al. 2020). Individuals with high 
socioeconomic status should be encouraged to change their unhealthy lifestyle habits and 
greater medical resources should be invested for individuals residing in rural areas (Zhu, Xi 
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1.3 Definitions of ‘ethnic groups’  
The UK’s Economic Social Research Council (ESRC) refers to ethnic groups as ‘people of 
the same race or nationality with a long shared history and a distinct culture’ and defined 
ethnicity as the ‘intangible quality, or sense of being, derived from that shared racial or 
cultural affiliation’ (Leung and Stanner 2011). 
1.3.1 Chinese immigration and the prevalence of CVD among Chinese immigration in 
the UK 
The UK has a rich mix of cultures and culturally diverse communities and Chinese is one of 
the biggest minority ethnic groups (South Asians, Black African‐Caribbean and the Chinese) 
living in the UK (Leung and Stanner 2011). 33% of ethnic Chinese people (120,250) in the 
United Kingdom reside in London, comprising 1.5% of the city's population. Manchester, 
second-most populous urban area, is home to the largest Chinese population, with 3.4% of 
all Chinese people living there. This is followed by Birmingham (3.2%) and Barnet, Tower 
Hamlets and Southwark (all at 2.1%). British Chinese communities, which are descended 
from overseas Chinese when they immigrated to the UK, are found in many major UK cities 
including London, Manchester, Birmingham, Belfast, Newcastle, Glasgow, Edinburgh, 
Cardiff, Liverpool, Sheffield, Nottingham, and Aberdeen. Among these immigrants, 23.7% 
of people from the Chinese ethnic group were born in the UK and over half (55.3%) were 
born in Eastern Asia. 34.5% of adults from the Chinese ethnic group were overweight or 
obese, which is the lowest percentage out of all ethnic groups (Gov.UK 2020).  
 
It is believed that minority ethnic groups are more likely to experience poorer health 
outcomes, such as higher rates of CVD, type 2 diabetes and obesity, compared with the 
mainstream population since migration and mobility to foreign latitudes is believed to be 
responsible for health differentials between origin and destination and people who migrate 
are more likely to experience diseases due to exposure to new lifestyles and environment 
(Cappuccio 2004). The differences in health outcomes also may reflect the interaction 
between different diet patterns and other health behaviours and genetic predisposition 
which vary across different ethnic groups (Leung and Stanner 2011). 
The health of Chinese immigrants in the UK is controversial. Studies (Gong and Zhao 2015, 
Jin, Ding et al. 2015) reported that Chinese immigrants, having both higher prevalence and 
higher mortality rates from CHD compared with mainland Chinese citizens. Chinese 
immigrants also appear to have a higher prevalence of cardiac risk factors such as 
hypertension, higher cholesterol, poorer dietary patterns, and higher prevalence of obesity 
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after migrating to Western countries, and the risk increases with longer length of residence. 
In the meanwhile, CVD in Chinese immigrants also have had consistently higher stroke 
mortality  (Dassanayake, Gurrin et al. 2011). However, while Chinese people had a lower 
incidence of CHD compared with white Caucasians (odds ratio 0.29; 95% CI: 0.24–0.34) 
but higher short-term mortality after first hospitalization for acute myocardial infarction 
compared with whites (odds ratio 1.34; 95% CI, 1.04–1.73) (Jin, Ding et al. 2015). Another 
study from Newcastle upon Tyne reported that in a cross-sectional study of 380 Chinese 
and 625 European adults aged around 25 to 64 years old, there was significantly lower (P 
< 0.001) CHD prevalence among Chinese (4.9%) compared to European origin men (16.6%) 
(Forouhi and Sattar 2006). However, there is still a lack of enough research focusing on 
CVD status among Chinese immigrant groups. 
 
1.4 Non-modifiable factor - Genetic factors affect cardiovascular health 
Gene-environment interaction impacts on cardiovascular health and genetic factors are 
irreversible (Kelishadi and Poursafa 2014) and evidence (Kelishadi and Poursafa 2014) 
suggested that the ethnic disparities in cardiovascular risk varies is due to genetic 
differences. A research of susceptibility loci for coronary artery disease suggested that 4 
loci associating with coronary artery disease were common amongst the Han Chinese 
population and European populations, 4 were unique to the Han Chinese (Lu, Wang et al. 
2012). Different ethnicity background determines cultural food preferences, therefore 
genetic factors contribute to cultural cuisine preferences, plus modulate the association 
between dietary components and adverse cardiovascular health outcomes (Leu, Chung et 
al. 2019).  
 
1.4.1 The difference of body composition between East Asians and Caucasians 
affecting cardiovascular health  
Genetic differences are at the root of different body fat patterns in different ethnic groups-
Asians and Caucasians (Harvard T.H. Chan 2021). Different body composition from 
Caucasians and East Asians determines different effects of dietary interventions (Goss, 
Goree et al. 2013). Asians were reported to have greater predisposition towards adiposity 
at higher BMI compared to Caucasians (Haldar, Siok Ching et al. 2015). For the same BMI, 
Asians tend to have a higher body fat percentage (3% to 5% higher total body fat), a 
prominent abdominal obesity, a higher intramyocellular lipid and/or a higher liver fat content 
compared to Caucasians. Similarly, Asians are more likely to have a much greater 
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predisposition to risks of hypertension and cardiovascular diseases than their white 
European counterparts (Pan, Flegal et al. 2004, Wen, David Cheng et al. 2009, Haldar, Siok 
Ching et al. 2015, Harvard T.H. Chan 2020).  
In China, mainland Chinese males had a greater degree of central fat deposition pattern 
than that Caucasians men (Wang, Li et al. 2011). Chinese males had significantly higher 
percentage of body fat both with respect to entire body (Chinese: 23.7%±0.2% vs. 
Cuacasians:22.4%±0.2%) and the trunk area (Chinese: 25.0%±0.3% vs. Caucasians: 
23.2%±0.3%) compared to their Caucasian counterparts. At all same BMIs, Chinese men 
were reported as having significantly higher fasting glucose levels (Chinese: 5.7±1.0 
mmol/L vs. Caucasians: 5.2±1.0 mmol/L) but lower HDL-C levels (Chinese: 0.8±1.0 mmol/L 
vs. Caucasians: 1.0±1.0 mmol/L) than Caucasian men (Wang, Li et al. 2011).  
Evidence (Harvard T.H. Chan 2021) suggested that for every 11 pounds Asians gained in 
their adulthood, Asians had an 84 percent increase their risk factors of cardiovascular 
diseases such as type 2 diabetes. Caucasians who gained weight also experienced higher 
diabetes risks, however, to a much lesser degree than Asians (Harvard T.H. Chan 2021). 
The phenomenon that East Asians gain body weight in Western countries is probably 
because that even though immigrants might arrive in new countries with a health advantage 
including generally a healthier body weight. Nevertheless, it was reported that genetic and 
epi-genetic factors, alongside with body size preference, socio-economic factors and stress 
exposure, may play an crucial part in growing unhealthy weight gain among migrant 
populations (Murphy, Robertson et al. 2017). This tendency of unhealthy weight gain is 
likely to lead to overweight during first few years of migration, and such weight gain tends 
to lead to increased obesity risk in migrant populations within 10 to 15 years after migration 
(Murphy, Robertson et al. 2017). 
 
1.4.2. Gender for cardiovascular health 
Gender differences of CVDs are mainly caused by innate genes and environmental 
influences (Gao, Chen et al. 2019). Males are not only reported to have a higher incidence 
of CVD than females in general (Gao, Chen et al. 2019), but also to have an earlier age 
development of CVD incidence and a higher propensity of developing coronary heart 
disease than female (Bots, Peters et al. 2017). Evidence showed that more men have higher 
rate of living with and dying of coronary heart disease (CHD) than women and men also 
experienced more hospital discharges for CVD as well as CHD (Mosca, Barrett-Connor et 
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al. 2011). The prevalence of CHD is higher in men within each age stratum until after 75 
years of age (Mosca, Barrett-Connor et al. 2011). In addition, prospective population based 
study (Millett, Peters et al. 2018) found that almost 472,000 male citizens in the UK aged 
40 to 69 had a far higher risk of heart attack than women over 7 years of follow-up and while 
the incidence of myocardial infarction (MI) was higher in men than in women, some risk 
factors were more strongly associated with MI in women compared with men. 
Lifestyle risk factors also vary by gender (Mosca, Barrett-Connor et al. 2011) as cigarette 
smoking remains more common among men than women (23.1% versus 18.1%) (Mosca, 
Barrett-Connor et al. 2011). However, female smokers had about 3.4 times the risk of having 
a heart attack as women who had never smoked, while male smokers had 2.2 times the 
risk of men who had never smoked (Millett, Peters et al. 2018).  
Nevertheless, study (Eric and I-Min 2010) reported that although the magnitude of 
association with risks of CVDs appeared stronger in women than in men, comparisons 
across gender are limited by the fact that the various studies applied varied questionnaires 
for assessing physical activity combined with diverse categorizations (e.g., by amount of 
energy expended, intensity of activities, duration, or frequency) of physical activity for 
analyses. 
 
1.4.3 Ageing from chronological age to vascular age 
Human lifespan is restricted, everyone accepts this “biologically” obvious. “Nothing lives 
forever”, however, in this statement people think of ageing process, which are subject to 
natural wear and tear during human life. As ageing is a global phenomenon and developing 
interventions to promote health in early and later life are a priority of health research (Levine 
et al., 2018), however, evidence (WHO 2018) suggested that the prevalence of healthy 
ageing was relatively low. By 2030, approximately 20% of the global population, who will be 
aged 65 or older and in this age group, cardiovascular diseases will result in 40% of all 
deaths. Also, the cost to treat cardiovascular disease was expected to be triple in that time 
(North and Sinclair 2012). People become dissimilar from their contemporaries of the same 
chronological age as they become older mostly due to long-term unhealthy lifestyle factors 
 
The risk for CVD starts around 40-45 years old. People during such age are more likely to 
experience vascular risk factors such as dyslipidaemia, hypertension or endothelial 
dysfunction due to unhealthy lifestyle including unhealthy dietary patterns (O'Doherty, 
Cairns et al. 2016). Statistics showed that heart failure is largely a disease of the elderly 
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with 50% of all heart failure diagnoses and 90% of all heart failure deaths occurring in the 
segment of the population over age 70 (Strait and Lakatta 2012).   
 
Aging, as a major risk factor for CVDs, not only increases the prevalence of CVDs but is 
also associated with impaired responses to CVDs because ageing results in structural 
changes and functional decline of the cardiovascular system (Fajemiroye, da Cunha et al. 
2018). Human biological ageing is inevitable (Vijg and Le Bourg 2017) and chronological 
age is the most significant non-modifiable risk factor for developing CVDs (Hollis, Newson 
et al. 2016). Healthy ageing refers to survival to a specific age, being free of chronic 
diseases, autonomy in activities of daily living, wellbeing, good quality of life, high social 
participation, only mild cognitive or functional impairment, and little or no disability (Fuchs, 
Scheidt-Nave et al. 2013). Individuals do not age at the same pace leading to the concept 
of biological aging, also called functional or physiological ageing, which relates to declines 
in function (Vijg and Le Bourg 2017). Wide variation exists in ageing among people as 
characterised by the degree to which body functions decline, including declines in cognition, 
physical capability, physiological and metabolic functions, and psychosocial wellbeing 
(Murman 2015). Among the physiological and metabolic changes occurring with biological 
ageing, the ageing of heart function is the key determinant of health (McPhee, French et al. 
2016).  
Cardiovascular ageing is accompanied by changes in vascular structure as well as function, 
especially in the large arteries along with age-related impairment of vascular function is the 
result of phenotypic alterations of different cell types, such as endothelial cells, smooth 
muscle cells and pericytes (Donato Anthony, Machin Daniel et al. 2018). Poor vascular 
ageing is considered to be the most important risk factor affecting cardiovascular 
homeostasis (Costantino, Paneni et al. 2016).  
 
1.4.4 Body composition factors 
Measures such as body mass index (BMI), grip strength and body composition including 
body mass index, body fat/lean percentage are good indicators of cardiovascular disease 
mortality risk (Sözmen, Belgin et al. 2016). 
Evidence strongly suggested that the likelihood of a greater number of CV risk factors is 
greater among those who are overweight (body fatness≥20%), high BMI, than lean 
participants (body fat <20%) (Amirabdollahian and Haghighatdoost 2018). The likelihood of 
multiple CV risk factors is greater among those with high body fatness in apparently healthy 
young men (Liberato, Maple-Brown et al. 2013). Furthermore, body mass index (BMI), waist 
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circumference (WC) and waist-to-height ratio (WHtR) are strongly shown to be associated 
with serum lipid, and TC, TG, LDL-C and HDL-C. Also, BMI, WC and WHtR were closely 
related to the incidence of dyslipidemia in females, including high TG, high LDL-C and low 
HDL-C (Zhang, Gu et al. 2019). Hyper LDL cholesterolemia is significantly associated with 
percent body fat, but not with body mass index or waist circumference, in men (Oda 2017). 
Evidence (Beyer, Sanghvi et al. 2018) indicated that handgrip strength, an inexpensive, 
reproducible and easy to implement measure, is associated with risk for cardiovascular 
incidents and mortality. Stronger hand grip strength may be associated with cardiac 
functions and structures that help reduce the risk of cardiovascular incidents (Beyer, 
Sanghvi et al. 2018). Their study of including over 4,600 people (Beyer, Sanghvi et al. 2018) 
reported that better handgrip strength is associated with having a healthier heart structure 
and function as participants with stronger hand grips were often pumping more blood per 
heartbeat despite having a lower heart mass.  
 
 
1.5 Modifiable factor - Behavioral risk factors for cardiovascular health 
1.5.1 Physical activities 
Physical activity is defined as any bodily movement produced by skeletal muscles that 
requires energy expenditure (World Health Organization 2018). Physical activity refers to 
movement including during leisure time, for transport to get to and from places, or as part 
of a individual's work. A physically inactive lifestyle contributes to traditional cardiovascular 
risk factors, such as high BP, higher triglycerides, lower HDL-C and obesity (Lavie Carl, 
Ozemek et al. 2019). Previous randomized controlled trials suggested the benefits of 
aerobic exercise on blood pressure (Seamus and Whelton 2002) as well as cholesterol 
levels (Durstine and Grandjean 2001). The inverse association between physical activity 
and risk of developing CVDs is shown in both genders (Eric and I-Min 2010). Physical 
activity has also been shown to decrease levels of novel cardiovascular risk factors and 
improve endothelial function (EF), such as IL-6, sICAM-1 and sVCAM-1(Palmefors, 
DuttaRoy et al. 2014). Physical activity is associated with a 35% reduction in CVDs mortality 
and 33% reduction in all-cause mortality in comparison with sedentary lifestyle (Nocon, 
Hiemann et al. 2008).  Study (Lear, Hu et al. 2017) reported that compared with low physical 
activity (<150 minutes per week of moderate intensity physical activity), moderate (150-750 
minutes per week) and high physical activity (>750 minutes per week) were associated with 
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graded reduction in mortality (hazard ratio 0.80, 95% CI: 0.74-0.87 and 0.65, 0.60-0.71; 
p<0·0001), and major CVD (HR: 0.86, 0.78-0.93; p<0.001), thus higher physical activity was 
associated with lower risk of CVD and mortality.  
25% of adults in the North East do not achieve the minimum recommended levels of 
physical activity each week (at least 150-300 minutes of moderate-intensity aerobic physical 
activity) compared to 22% across England (Public Health England 2019). In China, the 
population in urban China was reported as having low physical activity during leisure time 
and a majority of the physical activity is work related. Moreover, with the increasing 
urbanization taking place in China, rates of physical activity could decline substantially over 
a relatively short period of time. This could have a negative impact on increasing risks of 
CVDs (Muntner, Gu et al. 2011). Recent study (Liu, Liu et al. 2020) also demonstrated that 
wide adoption of the physical activity recommendations would have considerable health 
impacts to the Chinese population and maintaining the recommended moderate to vigorous 
physical activity (MVPA) level could reduce the cardiovascular risk. 
 
1.5.2 Tobacco smoking 
Tobacco smoking increases the risk of contracting a wide range of chronic diseases, such 
as cardiovascular disease (Vidyasagaran, Siddiqi et al. 2016). Stopping smoking at any age 
is beneficial compared with continuing to smoke (West 2017). It was estimated to be 
approximately 1 billion tobacco smokers worldwide, amounting to around 30% of men and 
7% of women (Gowing, Ali et al. 2015).   
In Britain, tobacco smoking is estimated to lead to the premature death of approximately 6 
million individuals worldwide and 96,000 annually (Smoking and Health 2015). Tobacco 
smoking increases risk of CHD by elevating blood pressure and the tendency of blood 
clotting while lowering exercise tolerance and blood levels of HDL-C (Buttar, Li et al. 2005). 
Evidence suggested that even smokeless tobacco use leads to accelerated 
atherothrombosis similar to smoking (Gupta, Gupta et al. 2013). Meta-analysis 
(Vidyasagaran, Siddiqi et al. 2016) observed that smokeless tobacco significantly increased 
risk of IHD deaths (odds ratios: 1.15, 95% 95% CI: 1.01-1.30) and stroke deaths (OR:1.39, 
95% CI: 1.29-1.49).  
Passive smoking and second-hand smoking is also one of the harmful factors for 
cardiovascular health (Khoramdad, Vahedian-azimi et al. 2020). Meta-analysis of 18 studies 
including 10672 participants (Khoramdad, Vahedian-azimi et al. 2020) suggested that 
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passive smoking increase the risk of CVD incidence by 28% (adjusted RR = 1.28; 95% CI: 
1.09, 1.50), where the highest risk was associated with those who were exposed to second‐
hand smoke at home and at work (adjusted RR = 1.41; 95% CI: 0.73, 2.70). 
In China, for both gender in the same birth cohort (Wu, Zhu et al. 2020), the mortality rate 
of CVD attributable to smoking rapidly increased from 7.38 (95%CI: 6.34, 8.58) per 100,000 
in the 30-34 age-group to 360.15 (95%CI: 338.97, 382.67) per 100,000 in the 75-79 age-
group in China. Study (Jaana, Hanna et al. 2015) from Europe observed that smoking, as 
a strong independent risk factor of cardiovascular events and mortality, even at older age, 
increases cardiovascular mortality by over five years, and smoking cessation in any age 
groups has always been beneficial in reducing the risks of cardiovascular diseases. 
 
1.5.3 Dietary patterns between Western and East Asian  
Cardiovascular diseases are increasing mostly due to over utilization of fats from diets 
(Upadhyay 2015). Evaluating the full diversity of diet-related risk pathways, focusing on 
foods and overall diet patterns, rather than single isolated nutrients is of vital important 
(Mozaffarian 2016).  
Typical western diet is likely to consist of high intakes of saturated fatty acid (SFA), trans-
fat, salt, free sugar and excess calories. Conversely, intakes of polyunsaturated fatty acids 
(PUFAs), monounsaturated fatty acids (MUFAs) are insufficient (Anand, Hawkes et al. 
2015). Resident food-environment characteristics, such as availability of grocery stores, 
convenience stores, and fast-food restaurants in the UK, are not consistently associated 
with diet quality or adiposity and could be related to determinants of CVD health (Anand, 
Hawkes et al. 2015).  
Asian diets contain white rice as a main staple (Hu, Liu et al. 2011). White rice contributes 
approximately 30% of energy to diets in Asia. in China and Japan (Chan, Malik et al. 2009), 
a high consumption of foods with a high glycaemic index or load, such as white rice, doubles 
the risk of type 2 diabetes. Salt is another major part of Asian diets that is consumed in 
excess. The body needs 230-460 mg per day of sodium, and Asians average more than 
4600 mg per day, which is excessive than the recommendation that adults should take no 
more than 6 grams of salt (2.4 grams of sodium) per day. Overconsumption of salt leads to 
high blood pressure, which is one of the main cardiovascular risk factors. In Japan and 
China, homemade meals with added soy sauce and salt, either while cooking or at the table, 
were the largest sources of sodium in the diet (Brown, Tzoulaki et al. 2009). Rural 
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communities in Asia often rely on salting as a method of food preservation, which may 
contribute to excessive salt intake (Chen, Gu et al. 2009).  
Comparing with traditional East Asian eating habits without heavily sweetened drinks, sugar 
has become a growing problem in contemporary East Asian diets, which include a variety 
of teas, such as chai or bubble tea, that contain many calories and sugar in large serving 
sizes (Chan, Malik et al. 2009). Modern Asian foods also incorporate unhealthy fats such 
as lard into making Chinese desserts, such as Chinese rice pudding, and gutter oil, which 
leads to cheaper meal prices in private restaurants, food booth for many price-sensitive 
consumers after work. Trans fats are also increasingly part of packaged foods in East Asia 
due to their ability to prolong shelf life, yet there are no regulations requiring trans-fat content 
be disclosed to the public. It was reported that higher intake of trans fats is associated with 
poor cardiovascular health, and its risk factors such as weight gain as well as insulin 
resistance (Chan, Malik et al. 2009). 
The traditional Southern River-style Jiangnan diet from China is reported to be similar to the 
Healthy Plate Recommendation by Harvard Nutrition (Swartzberg and Margen 2001) and 
the Jiangnan diet has gained in favour due to its apparent cardiometabolic disease ‐
protection effect similar to that of the Mediterranean diet (Wang, Lin et al. 2020). Various 
southern diets, such as the Huaiyang, Aihui, and Zhejiang diets share common features, 
including high consumption of vegetables and fruits in season, freshwater fish and shrimp, 
and legumes; moderate consumption of wholegrain rice, plant oils (mainly rapeseed oil), 
and red meat; and relatively low consumption of salt, or millet wine. Steaming or boiling in 
clear soup and lukewarm‐fire frying are the preferred cooking styles (Wang, Lin et al. 2020).  
However, one study including 2659 subjects in Southeast China, Zhejiang province from 
2010 to 2012 (Zhang, Wang et al. 2015) reported that the structure of the Chinese diet has 
been shifting away from the traditional diet toward high-fat, low-carbohydrate and low-fibre 
diets (Zhang, Wang et al. 2015). While the intake of carbohydrate in total energy in Chinese 
was lower than that in Japanese and American subjects, the Chinese food had lower daily 
intakes of fibre, calcium, phosphorus, potassium, selenium, vitamin A, vitamin B1, vitamin 
B2 and vitamin C, compared with the Japanese, American and Italian diets. However, 
intakes of sodium, iron, copper and vitamin E were higher among Chinese people relative 
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1.5.3.1 Dietary pattern in minority ethnic – East Asians (oriental ethnicity) in the UK 
Dietary intake variations provide valuable clues when examined by migration status 
(Landman and Cruickshank 2001). Minority ethnic groups in the UK generally experience 
poorer health outcomes and suffer health inequalities compared with the mainstream white 
population, commonly attributed to the interaction between health behaviour patterns and 
genetic predisposition (Leung and Stanner 2011). In addition, few nutritional and dietary 
interventions have been carried out to explore the dietary needs of the Chinese previously.  
The majority of the Chinese in the UK have family roots from Hong Kong and mainland 
China, with a smaller percentage from Malaysia, Vietnam, Singapore and Taiwan (Leung 
and Stanner 2011). The previous generation of Hong Kong citizens living in Britain during 
the 19th century inherited and adopted Asian-style diets incorporating unhealthy oils, such 
as those containing trans-fat and animal fat - salted butter, lard into cooking. Trans fats are 
also increasingly part of packaged foods in East Asia due to their ability to prolong shelf life, 
yet there are no laws requiring trans-fat content be disclosed to the public.  
Evidence presented that traditional foods to shift after migration is via the process of 
acculturation (the assimilation of habits to that of the host country) (Leung and Stanner 
2011). This change has been associated with poorer eating habits, especially in younger 
generations. Second generation offspring of former migrants are likely to adopt mainstream 
dietary patterns, with higher fat consumptions and lower vegetable, fruit and pulse intake 
compared with their first-generation parents. These changing dietary habits, alongside 
insufficient levels of physical activity, which is common among minority ethnic groups, might 
impact on the health of these minority ethnic groups (Leung and Stanner 2011). In addition, 
language and communication (e.g. poor interpretation services) and cultural differences (e.g. 
varying perspectives and beliefs on health) were identified as barriers to adopt healthier 
diets of minority ethnic groups such as Chinese immigrants (Leung and Stanner 2011). 
 
1.5.3.2 British dietary pattern  
Britain’s unhealthy diet is associated with the concern of growing obesity and cardiovascular 
health issues such as heart attack, strokes since processed food such as crisps, chicken 
nuggets and poor-quality ready-made meals which are high in saturated fat, salt and sugars 
made up over half of the meals consumed in the average household (Mertens, Markey et 
al. 2017). While there has been reduction in the consumption of salt, sugar and red meat 
within the last ten years, there has been little change in the falling consumption of fruit, 
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vegetables and fibre, with high consumption of processed foods. In general, UK 
consumption still falls well short of nutritional guidelines (Mertens, Markey et al. 2017).  
A study (Mertens, Markey et al. 2017) reported that British citizens with dietary pattern 
mainly characterised by high consumption of white bread, butter, lard, chips and sugar-
sweetened beverages and lower intake of wholegrain bread, was associated with higher 
CVDs (HR 1.35: 95% CI: 1.10, 1.67) and stroke (HR 1.77; 95% CI: 1.18, 2.63) incidence. 
Across the North East of England, evidence (Public Health England 2019) reported that 
approximately 25% of adults in the North East have no regular consumption of the 
recommended five portions of fruit and vegetables each day, although local authorities in 
the region are already using planning regulations to restrict the concentrations of fast-food 
takeaways where necessary. 
 
1.5.4 Binge drinking 
Modest to moderate amounts of alcohol consumption were reported to experience lower 
CVD rates compared with those who are abstinent or who consume heavily (Toma, Paré et 
al. 2017). However, binge drinking was defined as consuming over 14 units per week in 
both genders (a units of alcohol is 8 g or 10 ml of pure alcohol) and heavy episodic drinking 
are associated with an increased risk of mortality (NHS, 2020). Alcohol abuse was 
associated with an increased risk of incident atrial fibrillation (AF) (hazard ratio [HR]: 2.14; 
95% confidence interval [CI]: 2.08 to 2.19; p < 0.0001), myocardial infarction (MI) (HR: 1.45; 
95% CI: 1.40 to 1.51; p < 0.0001), and congestive heart failure (CHF) (HR: 2.34; 95% CI: 
2.29 to 2.39; p < 0.0001) (Whitman, Agarwal et al. 2017).  
British population cohort study (Bell, Daskalopoulou et al. 2017) suggested that heavy 
drinking (exceeding guidelines: UK weekly/daily of 21/3 and 14/2 units for men and women, 
respectively) conferred an increased risk of presenting with unheralded coronary death 
(hazard ratio:1.21, 95% confidence interval:1.08 to 1.35), heart failure (1.22, 1.08 to 1.37), 
ischaemic stroke (1.33, 1.09 to 1.63) and peripheral arterial disease (1.35; 1.23 to 1.48). In 
the North East of England, data suggested that 20% of adults in the North East regularly 
consume alcohol above the current low risk limit of 14 units a week but only one quarter of 
adults realise that alcohol can cause CVD (Public Health England 2019). In China, heavy 
drinkers experienced an approximately 1.3 fold and 1.7 fold greater risk for coronary heart 
disease and hypertension, respectively (OR: 1.252, 95% CI: 1.012 to 1.549; OR: 1.741, 
95% CI: 1.519 to 1.994, respectively) compared with that of the non-drinking group (Li, Bai 
et al. 2016). 
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1.6 Traditional and novel risk factors for cardiovascular health 
CVDs and atherosclerosis result from a combination of risk factors rather than just a single 
significant risk factor (Frostegård 2013). When multiple factors are at co-existence, the 
effects are augmented and exacerbated, which result in accelerated CVD development and 
increased mortality. Cardiovascular risk scores, such as the Framingham Risk Score is 
used to estimate the risks of developing CVDs in individuals before its clinical onset (Payne 
2012). 
CVD risk scores mainly incorporate the effects of well-established (or traditional) risk factors 
including hypercholesterolemia (dyslipidemia) (an abnormal amount of lipids) such as 
elevated LDL-C, especially with small LDL particle size, HDL-C less than 40mg/dL for men, 
less than 50 mg/dL for women; hypertension (greater than or equal to 140/90mm Hg or on 
antihypertensive medication), hyperglycemia, smoking, insulin resistance, diabetes, 
overweight or obesity, metabolic syndrome, inactivity, unhealthy diet, older age (45 years 
of age or older for men; 55 years or older for women), stress and a family history of 
premature CHD. Despite increasing evidence on the potential predictive power of other risk 
factors including high level of C-reactive protein (CRP), oxidation of LDL-C and high levels 
of triglycerides in the blood, these have not been integrated into these risk scores. Several 
emerging risk factors have shown their value in predicting CVDs and these are discussed 
below (Benjamin Emelia, Muntner et al. 2019).  
 
1.6.1 Traditional CVDs risk factors 
In CVD risk populations, rigorous control of blood cholesterol is recommended. A lipid profile, 
including total cholesterol, LDL-cholesterol, and HDL-cholesterol is a blood test which 
measures the concentrations of fats and cholesterol in the blood and they are also well-
recognized risk factors for CVDs (Table 1.1) (Grundy Scott, Stone Neil et al. 2019).  
 
Table 1.1 The optimal cholesterol level of healthy people. 
 Total 
cholesterol 






Ideal is 60 or 
higher; 40 or higher 
for men and 50 or 
Less than 100 
(2.59 mmol/L); 
with CVD or 
Less than 149; 
ideal is <100 
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* the lower 
the better 
higher for women is 
acceptable 





200–239 n/a 130–159 150–199 
High 240 or higher 60 or higher 160 or higher; 190 
considered very 
high 
200 or higher; 
500 considered 
very high 
Low n/a less than 40 n/a n/a 
All values are in mg/dl (milligrams per deciliter) and are based on fasting measurements. 
 
1.6.1.1 Total cholesterol 
In Western and Asian populations, epidemiological evidence showed the strong direct 
associations between total cholesterol and risks of CHD and ischemic stroke, both in middle 
and old age among both gender (Boehme, Esenwa et al. 2017). The American Heart 
Association (AHA) has defined untreated total cholesterol (TC) levels <200 mg/dl as one of 
the seven components of ideal cardiovascular health (Benjamin Emelia, Muntner et al. 
2019). High total cholesterol was considered as the ninth and tenth-leading risk factor 
attributable to disability-adjusted life-years (DALYs) for men and women respectively in 
2015 (Forouzanfar, Afshin et al. 2016).  
 
According to one Korean cohort study (Yi, Shin et al. 2018), TC was inversely associated 
with stroke mortality (HR per 39 mg/dL; 95% CI = 0.80-0.95) in the range <200 mg/dL. TC 
was positively associated with stroke mortality in the upper range 200–349 mg/dL. The 
associations were similar in middle-aged (40-64 years) and elderly (≥65 years) adults and 
each 1 mmol/L (39 mg/dL) higher TC was associated with 11% higher mortality from stroke 
(95% CI: 2%-21%) in the elderly. Both middle-aged (39%) and elderly (23%) adults had 
higher ischemic stroke mortality associated with TC ≥240 mg/dL, compare to <200 mg/dL. 
One Chinese cohort study (Zhu, Lu et al. 2019) from Ningbo reported that individuals in the 
highest TC variability had 41% higher risk of CVD mortality (HR = 1.41, 95%CI: 1.10 to 
1.81). Another meta-analysis suggested that raised TC is significantly stronger factor for 
CVD in men compared to women as the pooled relative risks (95% CI) for CHD associated 
with a 1 mmol/L increase in TC was 1.20 (1.16; 1.24) in women and 1.24 (1.20; 1.28) in 








Triglyceride (TG) is the main form of dietary fat consisting of glycerol combined with three 
fatty acids or fats (saturated fat, unsaturated fat or both) combined with glycerol, a form of 
glucose. TG are the main source of energy supplying from diets and being made in liver  
(Heart UK 2019). Following food consumption, fats from foods are broken down in the liver 
into triglycerides. In addition, the liver converts excess calories (e.g., from drinking too much 
alcohol, sugar drinks, or eating too much fatty foods or meat) into triglycerides. These fatty 
triglycerides are released into blood circulation and are transported through the human body 
and utilized as energy or stored as fat. However, while TG plays an important role in 
metabolism, synthesis of hormones and building cells, high levels of TG in the bloodstream 
increase the risk of poor cardiovascular health (Alves-Bezerra and Cohen 2017). 
 
Individuals with elevated triglyceride levels are at increased risk for cardiovascular disease 
(Ohmura 2019). Raised circulating TG levels were associated with increased CHD risk, 
adjustment for established coronary risk factors (Lee, Chang et al. 2017).  A meta-analysis 
of 29 western studies showed that there was a significant association between TG values 
and CHD risk in Western populations (Odds Ratio (OR) 1.72; 95% confidence interval (CI), 
1.56 to 1.90) (Sarwar, Danesh et al. 2007). In the Asia-Pacific region, participants with high 
triglyceride levels had a 70% (95% CI, 47 to 96) greater risk of CHD death compared with 
those with normal triglyceride level (Patel, Barzi et al. 2004). A Chinese cross-sectional 
survey (Ren, Ren et al. 2018) reported that a low level of triglyceride was associated with 
decreased risk of CVD (OR, 0.91, 95% CI: 0.88‐0.93; OR, 0.94, 95% CI: 0.92‐0.97) among 
patients with less 15 years of duration of diabetes but increased risk of CVD. Another study 
(Nichols, Philip et al. 2019) showed that the high TG group (Rate ratio (RR), 1.30; 95% CI: 
1.08‐1.58; P = 0.006) was 30% more likely to experience CVD such as non‐fatal MI than 
normal TG group. The rate of experiencing CVD such as non‐fatal stroke (RR:1.23, 1.01‐
1.49, P = 0.037) was 23% higher among high TG group than normal TG group.  
 
1.6.1.3 LDL-cholesterol 
Low density lipoprotein-cholesterol (LDL-C) is the major carriers of cholesterol in humans, 
and it is well recognized that hyperlipidemia, specifically elevated circulating LDL-C induces 
atherosclerosis and is a strong risk factor for heart diseases as excessive accumulation of 
LDLs at the arterial wall are the lipoproteins implicated in causing atherogenic plaque 
formation. The observational evidence supporting the importance of lifelong exposure to 
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elevated LDL levels as a cause of atherosclerotic cardiovascular disease (Gidding Samuel 
and Allen Norrina 2019).  
Lower LDL-C levels were not only independently associated with a lower ischemic heart 
disease (IHD) mortality but also reduce cardiovascular risk independently of presence of 
inflammation (Storey, Staplin et al. 2018). On average, evidence showed that 1 mmol/L 
lower TC was associated with about a half (Hazard ratio (HR), 0.44; 95% CI: 0.42-0·48), a 
third (HR:0.66; CI:0.65-0.68), and a sixth (HR:0.83; CI:0.81-0.85) lower IHD mortality for 
both genders at ages 40-49, 50-69, and 70-89 years, respectively (Lewington, Whitlock et 
al. 2007). In addition, evidence suggested that a 10 mg/dL increase in LDL-C was 
associated with a 12% increase in CVD risk (Howard Barbara, Robbins David et al. 2000). 
Furthermore, in the study of 90000 participants in randomized trials of cholesterol-lowering 
treatment, a 1 mmol/l reduction in low-density lipoprotein cholesterol (LDL-C) was 
associated with a 23% reduction in coronary events, regardless of whether the initial 
diastolic blood pressure was above or below 90 mm Hg (Lewington and Clarke 2005).  
1.6.1.4 HDL-cholesterol 
High-density lipoprotein cholesterol (HDL-C) has more protein than LDL-C, allowing more 
cholesterol to be taken from the body’s cells, resulting in greater transport and removal of 
cholesterol through the liver, where it is broken down and excreted in the bile (Feingold and 
Grunfeld 2000). HDL-C is one of the independent predictors of CVDs risk, lower levels of 
HDL-C increases risk of CVDs and higher levels have a cardio-protective effect (Mahdy Ali, 
Wonnerth et al. 2012). More importantly, HDL-C particles are presented to act as a 
protective factor against atherosclerosis via multiple biological mechanisms such as 
effluxing cellular cholesterol, diminishing cellular death, decreasing vascular constriction, 
reducing inflammatory response and protecting from pathological oxidation (Orozco-Beltran, 
Gil-Guillen et al. 2017).  
The association between low HDL-C and atherosclerotic cardiovascular disease was shown 
by the Framingham study that HDL-C is a strong and independent cardiovascular risk factor 
for CVD and that the increase of HDL-C of 10 mg/L leads to a CHD risk reduction of 3% in 
women and by 2% in men (Mahdy Ali, Wonnerth et al. 2012). A study (Lewington, Whitlock 
et al. 2007) indicated that an increase of 0.33 mmol/L HDL-C was associated with a 
reduction of ischaemic heart disease (IHD) mortality by about a third within every age group 
and in both genders. Another study also showed that a 10 mg/dL decrease in HDL-C 
cholesterol associated with a 22% increase in CVD risk (Howard Barbara, Robbins David 
et al. 2000). Furthermore, HDL-C is reported to have a strong inherited basis with heritability 
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estimates of 40-60%, yet could be increased it to optimal levels by altering dietary patterns 
(Weissglas-Volkov and Pajukanta 2010).   
 
1.6.1.5 Blood pressure 
Hypertension, also known as high blood pressure is a long term condition in which the blood 
pressure in the arteries is persistently elevated (World Health Organization 2019). Each 
time the heart beats, the heart pumps blood into the vessels. Blood pressure is created by 
the force of blood pushing against the walls of blood vessels (arteries) as it is pumped by 
the heart. The higher the pressure the harder the heart has to pump (World Health 
Organization 2015). The excess strain and resulting damage from high blood pressure 
causes the coronary arteries serving the heart to slowly become narrowed from a buildup 
of fat, cholesterol and other substances that together are called plaque, in which chronic 
process is known as atherosclerosis (Rahman and Woollard 2017).  
The ideal adult SBP is defined as within the range of 90 -139 mmHg, while the ideal adult 
DBP is defined as within the range of 60 - 89 mmHg, equal to or above 140/90 mmHg is 
indicative of hypertension (World Health Organization 2016). Evidence suggested that 
individuals with long term hypertension are at four times the risk of developing CVD (Zhou, 
Bentham et al. 2017). The WHO targets have called for a 25% reduction in the prevalence 
of high blood pressure by 2025 (World Health Organization 2016). Raised blood pressure 
affects 1.13 billion people worldwide (World Health Organization 2019) and long term 
elevated SBP is a leading global health risk (Forouzanfar, Liu et al. 2017). Long term high 
blood pressure is a major risk factor for heart failure, atrial fibrillation, chronic kidney disease, 
heart valve diseases, aortic syndromes, and dementia, in addition to coronary heart disease 
and stroke although high blood pressure does not cause any symptoms (Fuchs and 
Whelton 2020).  
In the UK, nearly 30% of adults have high blood pressure (Townsend N, Bhatnagar P et al. 
2015). In mainland China, hypertension prevalence was higher in the east region (32.6%) 
followed by the northeast region (31.8%) with inadequate awareness and treatment as 
44.6% were aware of their condition, 35.2% were taking antihypertensive medication, and 
11.2% achieved adequate BP control (Li, Lv et al. 2015). Additionally, statistic showed that 
systolic hypertension, with aging, tends to be a more significant issue as a result of 
progressive stiffening and loss of compliance of larger arteries as diastolic pressure, 
however, it is more likely to be elevated among people younger than 50 years (Saiz, 
Gorricho et al. 2018). After the age of 65, hypertension, considered a typical condition of 
aging, occurs in more than two thirds of individuals (Chobanian, Bakris et al. 2003). In 
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addition, evidence suggested that over 90% of individuals who are free of hypertension at 
55 years of age are likely to develop it during their remaining lifespan (Lionakis, Mendrinos 
et al. 2012). In addition, seasonal variation of blood pressure is heightened in older adults 
is shown to be responsible for the greater cardiovascular disease mortality of elderly 
subjects during the winter (Kollias et al, 2020).  
 
1.6.1.6 Ambulatory blood pressure  
Ambulatory blood pressure monitoring (ABPM), refers to the records of BP readings across 
a 24-hour period which can be aggregated to yield overall 24-hour BP pattern or grouped 
to reflect daytime and nighttime BP pattern (Turner, Viera et al. 2015) compared with the 
traditional method of taking a BP reading under clinical setting and ABPM technically 
provides a more precise assessment of true BP than standard one-time measurement. 
Firstly, the sensitivity of pressure variability in ABPM depends on the factors such as 
circadian changes, BP variation with different environmental and emotional differences. 
Secondly, the advantage of ABPM is to rule out white-coat effect hypertension and identify 
masked hypertension, plus helps to reduce the number of possible false readings, along 
with the added benefit of understanding the dynamic variability of BP. Evidence (Dadlani, 
Madan et al. 2019) suggested that ABPM, involving serial assessment of upper arm 
pressures over 24 hours, usage of a small, automated, oscillometric device yields mean 
daily BP, revealing the time-integrated exposure of the brachial artery to BP throughout the 
day is a better predictor of major cardiovascular events than BP measurements at clinic 
settings as ABPM helps in reducing the number of possible false readings, along with the 
added benefit of understanding the dynamic variability of BP.  
Higher 24-hour and nighttime BP readings were significantly associated with greater risks 
of death and a composite of cardiovascular outcomes and BP is normally highest during the 
day and lowest at night and absence of this rhythm is a predictor of cardiovascular morbidity 
and mortality. Evidence also showed that people with high 24-hour monitoring was better 
than one-off clinic reading had the highest risk of death (Hermida, Crespo et al. 2019).  
From a Japanese study (Eguchi, Pickering et al. 2008), higher awake (SBP <135, 135-150, 
and >150 mm Hg) and sleep SBPs (<120, 120-135, and >135 mm Hg), predicted higher 
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1.6.2 Novel risk factors for cardiovascular disease 
Over the past few decades, apart from the traditional risk factors for cardiovascular diseases, 
epidemiological evidence emphasised the importance of processes, including endothelial 
dysfunction, the inflammatory processes involved in formation of plaque, and blood clotting 
and the tendency of oxidation in the subendothelial space (Badimon, Padró et al. 2012) 
(Table 1.2). 
Table 1.2. Novel circulating biomarkers 
 Parameter Range *Minimum detectable dose 
1 sICAM-1 100 - 200 ng/ml 150 pg/ml 
2 sVCAM-1 338.0 -1148.0 ng/ml 300 pg/ml 
3 PAI-1 The upper limit at 50 mg/ml;  
2-15 AU/ml 
35 pg/ml 
4 sP-selectin Range from 19 - 521 ng/ml 20 pg/ml 
5 sE-selectin 8.3 -116.9 ng/ml 30 pg/ml 
6 IL-6 0 - 16.4 pg/ml 3 pg/ml 
7 CRP Below 3.0 mg/l. 34 pg/ml 
8 Human SDC1 
/ Syndecan-1 
Peaked at up to 500 ng/ml;  
50–100 ng/ml 
14 pg/ml 
*The minimum detectable is according to the Sigma-Aldrich certificate of analysis/Protocol; *Keep in 
mind the normal reference range varies between labs. 
 
Inflammatory processes play a basal role in the pathogenesis of atherosclerotic vascular 
disease (Raggi, Genest et al. 2018), which is highlighted by the high cardiovascular risk of 
systemic inflammatory disorders (Thomas and Lip 2017). 
Due to the complexities of CVD pathogenesis, no single biomarker is available to estimate 
absolute risk of future cardiovascular events. In addition, not all biomarkers are equal, and 
the functions of many biomarkers overlap. Some offer better prognostic information than 
others, and some are better suited to predict the pathogenesis of particular cardiovascular 
events (Buchan, Thomas et al. 2012). The identification of the most appropriate set of 
biomarkers can provide a detailed picture of the specific nature of the cardiovascular event 
(Buchan, Thomas et al. 2012). Novel biomarkers such as CRP, PAI-1, IL-6 have generated 
significant interest and tend to be widely investigated within the scientific community 
because they may provide additional means of improving CVD risk evaluation (Buchan, 
Thomas et al. 2012).  
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1.6.2.1 Pro-Inflammatory cytokines: C-reactive protein (CRP) 
C-reactive protein (CRP), as an early marker of inflammation or infection, is an acute-phase 
inflammatory protein that elevates up to 1,000-fold at sites of infection in serum during 
inflammatory conditions such as rheumatoid arthritis and cardiovascular diseases 
(Emerging Risk Factors, Kaptoge et al. 2010). CRP plasma, is normally at concentrations 
of less than 10 mg/l in the blood (World Health Organization 2014). During infectious or 
inflammatory disease states, CRP levels rise rapidly within the first 6 to 8 hours and peak 
at levels of up to 350–400 mg/l after 48 hours (World Health Organization 2014) and 
increase from around 1 µg/ml to over 500 µg/ml within 24-72 h of severe tissue damage 
(Sproston and Ashworth 2018). CRP is synthesized primarily in liver hepatocytes but also 
by smooth muscle cells, macrophages, endothelial cells, lymphocytes, and adipocytes 
(Sproston and Ashworth 2018). Elevating circulating levels of CRP is associated with 
many non-communicable diseases and cardiovascular risk factors  such as CHD, ischemic 
stroke, hypertension, metabolic syndrome, obesity, smoking, hypertension and peripheral 
artery disease (Shrivastava, Singh et al. 2015). Meta-analyses of CVD mortality risk has 
shown significant associations with CRP (HR 1.31, 95% CI: 1.02 to 1.68, p=0.033) (Barron, 
Lara et al. 2015).  
Low plasma level of CRP (below 3.0 mg/l) is an indicator of health while high levels is an 
indication of inflammation in coronary heart disease (CHD). In healthy young adults, the 
median concentration of CRP is 0.8 mg/l, following an acute-phase stimulus, values may 
increase from less than 50 μg/l to more than 500 mg/l, that is 10,000-fold (Shrivastava, 
Singh et al. 2015).  
The Cardiovascular Health Study Rural Health Promotion Project (Tracy, Lemaitre et al. 
1997) with elderly participants of both gender identified CRP as a strong, independent risk 
factor for CHD. A large-scale prospective study documented a strong association between 
the predictive power of CRP and CHD risk with CRP levels being a more reliable biomarker 
of cardiovascular disease than LDL-C (Li, Sun et al. 2017). Meta-analysis showed that 
adjusted for all Framingham risk variables, the estimate of relative risk for incident CHD was 
1.58 (95% CI, 1.37 to 1.83) for CRP levels greater than 3.0 mg/l compared with those with 
levels less than 1.0 mg/l (Buckley, Fu et al. 2009). 
 
1.6.2.2 Pro-inflammatory cytokines - Interleukin-6 (IL-6) 
Interleukin-6 (IL-6) is a pro-inflammatory cytokine and immunoregulating cytokine produced 
from adipose tissue  (Buchan, Thomas et al. 2012).  IL-6 acts on the liver to stimulate the 
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production of CRP and fibrinogen in an inflammatory response (Sproston and Ashworth 
2018). IL-6 is elevated in patients with coronary heart disease and a marker of inflammation 
related to cardiovascular risk (Bacchiega, Bacchiega et al. 2017). 
IL-6 levels increase with age and IL-6 levels are reported to be associated with higher 
mortality in nondisabled individuals more than age 65 from both cardiovascular and non-
cardiovascular causes (Reiss, Siegart et al. 2017). A study which discovered within people 
with pre-existing stable coronary artery disease that higher IL-6 was associated with a 
poorer prognosis over an average follow-up of about six years as data showed that each 1 
pg/ml increase in IL-6 was associated with a 1.70 pg/ml (95% CI:1.23-2.45) increased 
relative odds of subsequent myocardial infarction (MI) or sudden death (Fisman, Benderly 
et al. 2006). In a clinical study of 263 patients admitted to a hospital in Beijing, Chinese 
participants with ST-segment elevation MI, who were reported to have elevated circulating 
levels of IL-6 were correlated with higher cardiovascular mortality over 3 years of follow-up 
(Reiss, Siegart et al. 2017). 
 
1.6.2.3 Plasminogen activator inhibitor (PAI-1) 
Plasma concentrations of plasminogen activator inhibitor (PAI-1) is shown to be an potential 
independent risk factor for CVD (Ridker, Brown et al. 2004). Higher circulating PAI-1 levels 
are associated with increased risk of CVD and are associated with hypertension, diabetes 
mellitus, triglyceride levels, and homocysteine, and inversely related to HDL-C (Tofler, 
Massaro et al. 2016).  
One study (Tofler, Massaro et al. 2016) showed that mean PAI-1 levels were 29.1 ± SD19.2 
ng/ml for participants with incident CVD versus 22.1±SD16.5 ng/ml for those without 
incident CVDs. The same study (Tofler, Massaro et al. 2016) indicated that elevated PAI-1 
reduce the capacity of the fibrinolytic system to prevent fibrin deposition in vessel walls and 
thrombus formation. Furthermore, as a marker of endothelial injury, PAI-1 could be an 
intermediary mechanism by which other risk factors injurious to the endothelium exert their 
effect (Tofler, Massaro et al. 2016). In another meta-analysis (Song, Burgess et al. 2017), 
it indicated a causal effect of elevated PAI-1 level on CHD risk. Moreover, a meta-analysis 
(Jung, Motazedian et al. 2018) also reported that elevated plasma PAI-1 levels 6.11 ng/ml 
(95% CI, 3.27-8.96) are associated with myocardial infarction, or cerebrovascular accident 
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1.6.2.4 Soluble cell adhesion molecules (sCAMs) – sICAM-1 and sVCAM-1 
Adhesion molecules play an important role in platelet leukocyte interaction and leukocyte 
migration into the vessel wall, thus adhesion molecules are important players in the 
atherosclerosis process underlying cardiovascular diseases such as CHD (Kiechl, Paré et 
al. 2011). Evidence (Wang and Connolly 2010, Lam, Vijayan et al. 2015) showed that the 
levels of soluble adhesion molecules, including soluble vascular cellular adhesion molecule-
1 (sVCAM-1), soluble intercellular adhesion molecule-1 (sICAM-1), and soluble E-selectin 
(sE-selectin), and soluble P-selectin (sP-selectin) were associated with increased risk of 
future death from CV causes among populations with CHD. Another previous study 
(Demerath, Towne et al. 2001) found a significant independent association between the 
concentrations of sICAM-1, sVCAM-1, e-selectin and cardiovascular risk factors including 
smoking, waist-hip ratio (WHR), blood pressure, high density lipoprotein cholesterol and 
total cholesterol in 592 healthy white adults aged 18-82 years. However, while E-selectin 
and P-selectin mediate transient rolling of leukocytes along the endothelium, sICAM-1 and 
sVCAM-1 mediate stronger attachment of leukocytes to the endothelium (Kunutsor, Bakker 
et al. 2017). 
sICAM-1, as a general marker of a pro-inflammatory status, is expressed by endothelial 
cells in response to inflammatory cytokines and sICAM-1 participates in the adhesion of 
neutrophils to the endothelium, an crucial phase in the extravasation of neutrophils at the 
site of inflammation (Stoner, Lucero et al. 2013) and as suggested to be used as a marker 
of  low-grade inflammation (Kilic, Findikoglu et al. 2015).  Evidence showed that sICAM-1 
appears consistently related to incident CAD as sICAM-l correlates with acute phase 
reactants like CRP, and provides similar predictive information to CRP in settings of primary 
prevention in healthy populations (Lam, Vijayan et al. 2015). Previous data from a case-
control study (Haim, Tanne et al. 2002) found that baseline serum concentrations of sICAM-
1 were significantly higher in cases versus controls (375 vs. 350 ng/ml; p<0.05). Each 100 
ng/ml increase in sICAM-1 concentration was associated with 1.27 (95% confidence interval 
[CI]: 1.00 to 1.63) higher relative odds of coronary incidents (Haim, Tanne et al. 2002) 
sVCAM-1 is expressed on both large and small vessels after the endothelial cells are 
stimulated by cytokines (Stoner, Lucero et al. 2013). sVCAM-1 is shown to be not appear 
as a risk factor in healthy individuals, but emerges as a strong risk predictor in patients 
experiencing pre-existing disease (Stoner, Lucero et al. 2013) because by contrast with 
sICAM-1, sVCAM-1 is not expressed in baseline conditions, but is rapidly induced by pro-
atherosclerotic conditions in humans (Stoner, Lucero et al. 2013). Study (Tchalla, Wellenius 
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et al. 2015) found that elevated VCAM-1 level is associated with cardiovascular risk factors 
as sVCAM-1 concentration was 1195 ± 438ng/mL in controlled hypertensives and 1250 ± 
445ng/mL in uncontrolled hypertensives (p=0.008). Another previous study from the 
Netherlands (Jager, van Hinsbergh et al. 2000) in a 7.4 year follow-up of 631 participants, 
demonstrated that elevated sVCAM-1 levels to be independently associated with 
cardiovascular mortality (relative risks per 100 ng/ml sVCAM-1 increase, 1.10 [1.05-1.15] 
after adjustment for age, sex, and glucose tolerance status) in subjects with type 2 diabetes.  
 
1.6.2.5   Selectins - sP-Selectin and sE-Selectin 
Soluble P-selectin (sP-selectin), is a member of the cellular adhesion molecule family, which 
also includes VCAM and ICAM-1 (Stoner, Lucero et al. 2013) while sE-selectin is a surface 
glycoprotein molecule expressed on endothelial cells (ECs) upon activation by cytokines 
and is therefore considered a superior marker of endothelial dysfunction compared to the 
other cell adhesion molecules, while sICAM-1 and sVCAM-1 are expressed on both ECs 
and leukocytes (Stoner, Lucero et al. 2013).  
One study (Stoner, Lucero et al. 2013) reported that sP-selectin plays a key role in diseases 
associated with injury and arterial thrombosis. Increased expression of sP-selectin is 
observed in coronary artery disease, acute myocardial infarction, stroke, and peripheral 
artery diseases. Previous evidence (Blankenberg, Rupprecht Hans et al. 2001) indicated 
that increased levels of E-selectin have been observed in patients with acute coronary 
syndromes (ACS).  A study from the UK (Krishnamoorthy, Khoo et al. 2013) found that 
higher levels of soluble E‐selectin levels are associated with an increased risk of cardio 
adverse events (acute myocardial infarction, ischaemic stroke and all‐cause mortality) as 
the highest tertile of E‐seletion was associated with more adverse events [upper vs. lowest 
tertile, RR 3·7, 95% CI (2·51–5·31), P < 0.001; upper vs. middle tertile, RR 6·5, 95% CI 
(3·56–11·91), P < 0·001]. Another meta-analysis (Pletsch-Borba, Watzinger et al. 2019) 
found a consistent positive association between E-Selectin and cardiovascular risk factor 
such as T2D as E-Selectin was associated with higher T2D risk HR SD: 1.34 (95% CI: 1.16, 
1.54; I2 = 63%, n = 9 studies). Study (Pawelczyk, Kaczorowska et al. 2017) indicated that 
a strong correlation between higher sP-selectin concentration and enhanced LDL (p = 
0.001), total cholesterol (p = 0.02) as the level of sP-selectin (p < 0.001) were significantly 
higher in groups of stroke patients compared with the controls. In addition, another study 
(Bielinski, Berardi et al. 2015) showed that a positive linear association between sP-selectin 
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levels and the rate of incidence of CHD (HR 1.63, 95% CI 1.15 to 2.30) after adjustments 
for traditional risk factors. 
 
1.6.2.6 Human plasma syndecan-1 (SDC1)   
Syndecan-1, as a transmembrane proteoglycan that exerts its functions mainly via its 
heparane sulfate chains, is a promising novel biomarker, correlated not only with the degree 
of cardiac fibrosis but also with the severity of liver fibrosis (Miftode, Şerban et al. 2019). 
From one recent Chinese study (Liu, Wang et al. 2019) in heart failure (HF) patients, higher 
plasma syndecan-1 levels was reported to be an independent risk factor for the incidence 
of adverse cardiovascular events. 
A previous study observed that the particularity of the syndecan-1 molecule, related to lipid 
metabolism, showed that membrane syndecan-1 can mediate the binding and uptake of the 
very low-density lipoprotein cholesterol (VLDL-C) (Deng, Foley et al. 2012). A later study 
(Tromp, Van Der Pol et al. 2014) indicated that plasma syndecan-1 levels in 567 patients 
with chronic heart failure twice the cut-off value was associated with an increased risk of 
all-cause mortality after 18 months of follow-up. Similarly, study (Neves, Meneses et al. 
2015), investigating 201 patients with acute decompensated heart failure found that the 
level of syndecan-1 was associated with in-hospital mortality rates and also showed a 
significant separation of 6-month survival curves for patients with low and high levels. A 
recent review (Freitas, Lima et al. 2020) indicated that increased expression of syndecan-
1 is observed in myocardial infarction (MI) and protects against an exacerbated 
inflammatory response. 
 
1.6.3 Other determinants on cardiovascular health 
Healthy dietary patterns and healthy lifestyle are seen as modifiable weapons in the fight 
against cardiovascular diseases and the most effective means in which to prevent the 
occurrence of CVDs in society in spite of the fact that biological determinant of 
cardiovascular health has been considered irreversible (Kreatsoulas and Anand 2010, 
Kumar 2017). 
Apart from the behavioral factors as well as traditional biomarkers shown above, it is crucial 
to address the socio-economic factors such as food, housing, financial instability, and 
healthcare access that promote the development of risk factors for cardiovascular diseases 
(Parekh, Desai et al. 2020). The amount of the population (8.8%) who had CVDs, compared 
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to non-CVDs respondents, food insecurity (27.5% vs. 21.2%), financial insecurity (18.2% 
vs. 8.32%) were significantly higher among those with CVDs. While financial insecurity 
showed 2 times higher odds of CVDs (AOR 2.14 [1.73–2.66]) compared to non-CVDs 
(Parekh, Desai et al. 2020). 
 
1.6.3.1 Socioeconomic determinants of cardiovascular health 
Socioeconomic status measures such as education, income and occupation have been 
explored extensively associated with cardiovascular health and low social economic 
conditions is associated with a greater prevalence of CVD risk factors (Havranek, Mujahid 
et al. 2015).  
Lower levels of educational attainment are associated with a higher prevalence of 
cardiovascular risk factors, higher incidence of cardiovascular events, and higher 
cardiovascular mortality, independent of sociodemographic factors (Rosengren, Smyth et 
al. 2019). A study by (Mackenbach, Cavelaars et al. 2000) examined the higher mortality 
among individuals with lower education in the United States and 11 Western European 
countries and the result reported that a widening education-based difference in 
cardiovascular death was responsible for 17.4% of the overall gap in life expectancy, 
second only to cancer.  
The burden of CVDs is rising disproportionately among lower income countries and 
populations and CVD was more prevalent in lower income households (Havranek, Mujahid 
et al. 2015). Evidence (WHO 2017) showed that citizens who live in low- and middle-income 
countries are likely to experience less or even zero benefit of integrated primary health care 
programmes for early detection and treatment of people with risk factors compared to 
citizens in high-income countries and over three quarters of CVD deaths take place in low- 
and middle-income countries. A large study (Schultz, Kelli et al. 2018) in the United States 
and Finland found an increased risk of nonfatal myocardial infarction and sudden cardiac 
death in the low-income cohorts that persisted after adjusting for smoking and alcohol 
consumption (Schultz, Kelli et al. 2018). 
Unemployment has been associated with increased risk of CVD (Schultz, Kelli et al. 2018). 
Higher status occupations were associated with less hypertension and protective service 
workers such as firefighters had the lowest rates of treatment for established hypertension. 
Epidemiological studies of unemployment and health are particularly difficult because of 
potential “effect-cause” relationships, in which unemployment is a consequence of poor 
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health rather than the reverse, and because of confounding by factors such as low 
educational attainment that might predict both unemployment and poor health. Nonetheless, 
the preponderance of evidence supports the position that job loss leads to illness (Havranek 
Edward, Mujahid Mahasin et al. 2015).  
Linguistic and cultural differences contribute to poorer cardiovascular health in 
disadvantaged groups (Havranek Edward, Mujahid Mahasin et al. 2015). Culture is as 
commonly used as a system of beliefs and behaviours characteristic of a definable group 
that is transmitted without biological inheritance. Misunderstandings rooted in differing 
cultural perceptions of disease can play an important causal role in health disparities 
(Havranek Edward, Mujahid Mahasin et al. 2015). 
 
1.7 Dietary intervention – the Mediterranean diet to improve cardiovascular health 
Dietary interventions delivering comprehensive management towards improving the risk 
factors for CVD are essential (Li and Ge 2014). Promising data emerged from well-designed 
randomized trials and meta-analyses, and unprecedented progress was made in the last 
few decades in discovering novel effective dietary strategies for CVD prevention and 
treatment (Ravera, Carubelli et al. 2016). An Asian population cohort (Leu, Chung et al. 
2019) indicated that a healthy diet pattern, such as the Mediterranean diet, could possibly 
modify and reduce the genetic risk of cardiovascular diseases such as myocardial infraction 
and the impact of dietary pattern was analysed based on the adherence to the 
Mediterranean Diet Score. 
A study (Scholl 2012) reported that the low-fat-high-carbohydrate (LFHC) diet proposed for 
CVD prevention was recommended to individuals with overweight, metabolic syndrome, 
and type 2 diabetes, although the main emphasis of LFHC diet was lowering of TC and 
LDL-C, irrespective of the known effects of such a high glycaemic load on HDL-C and 
glucose metabolism. There are no studies showing that the whole of “The Japan Diet” is 
more beneficial than the Western diet (Teramoto 2017). Insufficient epidemiological studies 
allow the meta-analysis of researching on “The Japan Diet” (Liyanage, Ninomiya et al. 2016) 
or the Dietary Approaches to Stop Hypertension (DASH) diet (Siervo, Lara et al. 2015). The 
DASH Diet is in fact a Mediterranean-style diet with 10 portions of fruits and vegetables per 
day, more dairy products, low sodium content, and less sugar and starch, discourages 
sugar-sweetened foods and beverages (Scholl 2012). However, the DASH trials were not 
designed to evaluate the impact of DASH diet on CVD clinical events. Further improvements 
in cardiovascular risk factors were seen when part of the carbohydrate in DASH was 
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replaced with either monounsaturated fat or protein (Appel, Sacks et al. 2005). Furthermore, 
DASH diet has reported a poor compliance and being challenging to be maintained as salt 
intake is required to be 2,300 mg/day and potentially as low as 1,500 milligrams daily (Kwan, 
Wong et al. 2013). The Portfolio Diet, which includes 30 g/day of nuts, 20 g/day of viscous 
fibre (i.e., oats, barley, legumes), 80 g/day of vegetable protein (soy, beans, chickpeas, 
lentils), and 2 g/day of plant sterols (plant sterol margarine) from plant foods lowers LDL-C 
by up to 30% within four weeks, similar to statins. Reductions of 13%-23% are maintained 
when this diet was extended to 12 months. However, no RCT has evaluated the impact of 
this diet on CVD clinical events (Anand, Hawkes et al. 2015). 
Since cardiovascular risk factors such as diabetes, all of which have been reported to be 
associated with worse outcomes of the coronavirus disease 2019 (COVID-19), the 
Mediterranean diet, as highly recommended healthy dietary pattern, prevents diabetes from 
improving glucose control in diabetic patients, exerts anti-inflammatory and 
immunomodulatory effects was reported to be a promising and relatively obtainable 
approach in daily life to attenuate the severity of COVID-19 infection  (Angeliki et al,  2020; 
Maria Ida et al, 2020). 
In addition, according to Ana et al, (2021), adherence to the Mediterranean-style diet play 
an essential role in the establishment of proper dietary pattern in lockdown situations in 
Spain, particularly among older population since Mediterranean-style diet was evidently 
shown to contribute to the prevention of weight gain, BMI due to high levels of isolation, 
prevention of neurodegenerative illness with anxiety, depression and also to the 
modification of the immune and inflammatory response (Ana et al., 2020).  
Strong evidence from prospective cohort studies and randomized trials shows reduced CHD 
with the consumption of a Mediterranean diet (MD) (Mente, Koning et al. 2009). Therefore, 
MD is widely believed as a cardio-friendly determinant of the wide difference in CVD 
prevalence between Mediterranean and the Western populations since the traditional 
dietary MD pattern followed by Mediterranean populations in the early 1960s (Ros, 
Martínez-González et al. 2014). Plus, due to the ingredients in MD, MD is believed to have 
beneficial impacts on the majority of cardiovascular risk factors, such as body mass index, 
waist circumference, blood lipids, blood pressure, inflammatory markers and adhesion 
molecules, and diabetes. Evidence (Tuttolomondo, Simonetta et al. 2019) reported that 
these advantages of the Mediterranean diet are maintained in comparison of a low-fat diet. 
MD is characterized by the following: 1) abundant use of olive oil; 2) high consumption of 
plant foods (fruits, vegetables, legumes, cereals, nuts, and seeds); 3) frequent but moderate 
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intake of wine (especially red wine) with meals; 4) moderate consumption of fish, seafood, 
fermented dairy products (yogurt and cheese), poultry, and eggs; and 5) low consumption 
of red and processed meat and sweets (Ros, Martínez-González et al. 2014, Ravera, 
Carubelli et al. 2016). In the PREDIMED study, MD supplemented with EVOO (1 liter/week), 
compared to the control group (low-fat diet), was able to significantly reduce 
proinflammatory cytokines (IL-6, sP-selectin, sVCAM-1 and sICAM-1) in subjects at high 
cardiovascular risk (Casas, Sacanella et al. 2014). 
 
1.7.1 Extra virgin olive oil in the Mediterranean diet  
Extra virgin olive oil (EVOO) is responsible for a large proponent of cardio benefits 
associated with the Mediterranean diet as it is a fundamental ingredient of this diet 
(Mazzocchi, Leone et al. 2019). EVOO is associated with reduced risks of cardiovascular 
disease and mortality in individuals at high cardiovascular risk in the PREDIMED study 
(Guasch-Ferré, Hu et al. 2014). The consumption of 50 ml/day of EVOO may reduce the 
possibility of developing coronary artery disease (CAD) by 37%, and the incidence of major 
cardiovascular events by 30% (Estruch, Ros et al. 2013). Recent studies (Nocella, 
Cammisotto et al. 2018, Zamora-Zamora, Martínez-Galiano et al. 2018, George, Marshall 
et al. 2019, Schwingshackl, Krause et al. 2019, Tsartsou, Proutsos et al. 2019) illustrated 
the healthy benefits of olive oil intake as well as the benefits of nutraceutic properties in 
olive oil to cardiovascular health.  
 
1.7.1.1 Composition of extra virgin olive oil (EVOO) 
EVOO is mainly composed of triglycerides (97%-99%) and minor compounds (1%-3%), 
which are the principal components responsible for its biological properties and sensory 
attributes (Jimenez-Lopez, Carpena et al. 2020).  
Depending on its origin and extraction process, in terms of the lipid content of EVOO, EVOO 
predominantly has a high content of monounsaturated fatty acids (MUFAs), especially with 
oleic acid being the fraction representing 55%-83%, followed by the minor fractions of 
polyunsaturated fatty acids (PUFAs), representing 4% to 20% such as linoleic acid (LA) (the 
shortest-chain of the common omega-6 fatty acids) and alpha-linolenic acids (ALA) (a type 
of omega-3 fatty acid). Saturated fatty acids (SFA), representing 8% to 14%, such as 
palmitic and stearic acids. This lipid profile has been linked to protective effects on coronary 
and inflammatory disorders but also as anti-thrombotic and regulators of blood pressure 
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(Jimenez-Lopez, Carpena et al. 2020). Regarding bioactive compounds, their main 
representatives are the same of oil in general, namely minor phenolic compounds such as 
hydroxytyrosol and derivatives (oleuropein and tyrosol), tocopherols but also other 
compounds as hydrocarbons (i.e., squalene) (Lombardo, Grasso et al. 2018).  
To present antioxidant activity in body, minor components preserving other components are 
presents, such as vitamin E; Among the antioxidants present in EVOO is hydroxytyrosol. 
This compound exhibits anti-inflammatory and anti-teratogenic activity, improving the lipid 
profile, and reducing oxidative stress and the activation of inflammatory cells. Oleuropein, 
another antioxidant found in olive oil has also been associated with the improvement of anti-
inflammatory parameters.  
Bioactive components of EVOO demonstrated improvements in inflammatory status, 
oxidative stress, and endothelial dysfunction (Wongwarawipat, Papageorgiou et al. 2018). 
Besides that, during recent years, unsaponifiable fraction (minor components) constitutes 
1%-2% of the total content of EVOO, containing aliphatic and triterpenic alcohols, sterols, 
hydrocarbons, tocopherols, β-carotene, phytosterols, pigments and volatile compounds 
also received attention owing to its health benefits, such as blood cholesterol control (Kyçyk, 
Aguilera et al. 2016) (Table 1.3).  
 
Table 1.3. Nutritional components present in extra virgin olive oil. 
Component Amount Per 100 g Olive Oil 
Energy 884 kcal/3699 kJ 
Carbohydrates, fibre 0-0.2 g 
Protein 0 
Fat 
• saturated FA 
• mono-unsaturated FA 
• poly-unsaturated FA 
100 g 
• 14 g 
• 73 g (up to 73% of RDA) 
• 13 g 
Cholesterol 0 
Vitamin A 0-157 µg 
Vitamin E 0-37 mg (up to 72–96% RDA) 
Vitamin K 55-60 µg (up to 50–75% RDA) 
Sodium 1-2 mg 
Potassium 0-1 mg 
Calcium 0-1 mg 
Magnesium 0-1 mg 
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Phosphor 0-2 mg 
Iron 100-560 µg (up to 7% RDA) 
Zinc 10-60 µg 
Copper 0-70 µg 
Chlorophyll 0.5-1.6 mg 
(Poly)phenols and phenolic compounds 






Values might differ considerably according to olive cultivar, climate conditions, and production 
process of oil (Rizwan, Benincasa et al. 2018).  
 
1.7.1.2 The effects of composition of extra virgin olive oil on cardiovascular health 
Polyphenols are the most abundant dietary antioxidants present in EVOO, which possess 
a wide range of health effects in the prevention of CVD (Mozaffarian and Wu 2018). PUFAs, 
as omega-3 fatty acid, α-linolenic acid (ALA), eicosapentaenoic acid (EPA), and 
docosahexaenoic acid (DHA), were reported as potential anti-atherogenic agents for the 
atherosclerotic process (Shahidi and Ambigaipalan 2018). Mechanisms, through which they 
might reduce CV risk, include improvements in the lipid and lipoprotein profile, oxidation, 
thrombosis, endothelial function, blood pressure, plaque stability, CV mortality, platelet 
aggregation, modulating concentration or expression of pro-inflammatory markers 
(adhesion molecules, cytokines, etc.), and immune cells (Shahidi and Ambigaipalan 2018). 
Meta-analysis of 16 randomized placebo-controlled trials in 901 participants reported that 
omega-3 PUFA intake (0.45-4.5 g/day, for 56 days) increased FMD by 2.30% (95% CI: 0.89, 
3.72%, p = 0.001) compared with the placebo group (Wang, Liang et al. 2012).  
Olive oil phenolic compounds impact a huge beneficial effect on inflammation (Souza, 
Marcadenti et al. 2017) because the concentration of phenolic compounds in EVOO (551.4 
mg/kg; ranging from 50-800 mg/kg) is higher than regular olive oil (206.7 mg/kg), and refined 
olive oil (198-62.0 mg/kg), and the concentration of phenolic compounds in EVOO is 
influenced by the extraction procedure of the oil. EVOO is obtained by mechanical 
processes, while refined olive oil (ROO) is subjected to both physical and chemical 
procedures. Even If ROO presents a similar composition of fatty acids, due to the low 
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phenolic content, it does not bring the same beneficial effects when compared with EVOO 
(Souza, Marcadenti et al. 2017).   
Phenols such as hydroxytyrosol (HT) and derivatives (oleuropein complex and tyrosol) are 
primarily responsible for the beneficial effects of EVOO in the prevention and progression 
of atherosclerosis, by improving endothelial function (Moreno-Luna, Muñoz-Hernandez et 
al. 2012), antioxidant effect (Del Carlo, Sacchetti et al. 2004), the high density lipoprotein 
function (Hernáez, Fernández-Castillejo et al. 2014) and reducing the concentration and the 
atherogenicity of the low density lipoprotein (Fernández-Castillejo, Valls et al. 2016). To 
ensure the cardiovascular benefits of olive oil, the European Food Safety Authority 
recommends the daily intake of 5 mg of HT or its derivatives, which can be obtained by the 
daily consumption of at least 20 g of EVOO. 
The ratio of unsaponifiable matter in the olive oil is about 1 to 2% and much of this fraction 
is represented by phytosterols, which are recognized by their biological effects in EVOO 
(Kyçyk, Aguilera et al. 2016). Evidence (Gylling, Plat et al. 2014) suggested that a daily 
dose of 2–3 g of plant sterols or phytosterols is associated with an LDL-C reduction of 
around 6–15% of the total concentration. These reductions were also observed in a meta-
analysis (Demonty, Ras et al. 2009) where after administering a daily dose of 2.15 g of 
phytosterols, LDL-C was reduced by 8.8%. In another meta-analysis (Rocha, Ras et al. 
2016) of 20 RCTs with 1308 participants, the effect of phytosterols intake on pro-
inflammatory markers observed that the significant reductions of CRP levels (−0.10 mg/dL) 
after plan sterols’ intake. 
 
1.7.2 Nuts in the Mediterranean diet 
The Mediterranean diet supplemented with nuts provides primary cardiovascular disease 
prevention benefits (Widmer et al., 2014). A Mediterranean diet supplemented with 30 g of 
mixed nuts (walnuts, almonds and hazelnuts) per day also showed beneficial effects on the 
lipid profile compared with advice on a low-fat diet in diabetic and non-diabetic participants 
in the PREDIMED study, a randomized trial of dietary intervention for the primary prevention 
of cardiovascular disease (Ramon et al, 2006). 
Meta-analysis of prospective cohort studies (Liu et al, 2020) showed that per 0.5 
serving/day increase in total nut consumption was associated with lower risk of 
cardiovascular disease (relative risk [RR], 0.92; 95% CI, 0.86–0.98), coronary heart disease 
(RR, 0.94; 95% CI, 0.89–0.99), and stroke (RR, 0.89; 95% CI, 0.83–0.95). 
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A meta-analysis of observational studies (Kelly 2010) reported an inverse relationship 
between nut consumption and cardiovascular disease, with an approximately 40% 
decrease in the incidence of primary cardiovascular disease with consumption of at least 
four nut servings per week and up to 10% reduction with a single serving per week.  
Randomized controlled trial with walnuts (Ma et al., 2010) almonds (Jenkins et al, 2008), 
hazelnuts (Mercanligil et al, 2006), pistachios (Alaupovic et al, 2008), macadamias (Griel et 
al.,2008), and peanuts  (Lokko et al., 2007) showed LDL-cholesterol reductions ranging 
from 4% to 11% versus comparator diets, confirming the cholesterol-lowering efficacy of 
various nut types. 
 
1.7.2.1 Nutrient composition of nuts 
Nuts are nutrient dense foods with complex matrices rich in unsaturated fatty and other 
bioactive compounds, such as high-quality vegetable protein, fiber, minerals, tocopherols, 
phytosterols, and phenolic compounds (Ros 2010). 
With the exception of chestnuts, which contain little fat, nuts have a high total fat content, 
ranging from 46% in cashews and pistachios to 76% in macadamia nuts, and they provide 
20 to 30 kJ/g (Ros and Mataix, 2006). The fatty acid composition of nuts is beneficial 
because the saturated fatty acid (SFA) content is low (4 -16%) and almost half of the total 
fat content is made up of unsaturated fat, monounsaturated fatty acids MUFA (oleic acid) in 
large majority of nuts, similar proportions of MUFA and polyunsaturated fatty acids (PUFA), 
mostly linoleic acid, in Brazil nuts, a predominance of PUFA over MUFA in pine nuts, and 
mostly PUFA, both linoleic acid and α-linolenic acid (ALA), the plant omega-3 fatty acid, in 
walnuts (Ros and Mataix, 2006). In addition, nuts are rich in arginine, an amino acid needed 
to make a molecule called nitric oxide that relaxes constricted blood vessels and eases 
blood flow. They also contain vitamin E, folate, potassium, fiber, and other healthful 
nutrients (Ros and Mataix, 2006). Among the constituents of nuts there are significant 
amounts of essential micronutrients such as sizeable amounts of folate that are also 
associated with an improved health status when consumed at doses beyond those 
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1.7.2.2 The effects of composition of nuts on cardiovascular health 
Nuts are rich sources of antioxidant vitamins (e.g., tocopherols) and phenolic compounds, 
necessary to protect the germ from oxidative stress and preserve the reproductive potential 
of the seed, but also bioavailable after consumption and capable of providing a significant 
antioxidant load (Blomhoff et al., 2006). 
Walnuts are considered to be more anti-inflammatory than other nuts as walnuts are the 
only nuts that contain substantial amounts of ALA, which is described as one of the more 
anti-inflammatory fatty acids. Walnuts are also particularly rich in the phenolic compound 
ellagic acid, which evokes a reduction in concentrations of other inflammatory 
biomarkersstudies (Karlsson et al, 2010; Papoutsi et al., 2008). Almonds in particular are 
especially rich in α-tocopherol, while walnuts contain significant amounts of its isomer γ-
tocopherol, which has been investigated much less than α-tocopherol, but is increasingly 
recognized as a relevant antiatherogenic molecule (Wagner et al, 2004). Remarkably, in all 
nuts most of the antioxidants are located in the pellicle or outer soft shell, as shown for 
almonds  (Chen et al, 2005) and peanuts (Lou et al, 2004), and 50% or more of them are 
lost when the skin is removed (Blomhoff et al, 2006). 
Nuts are cholesterol-free, but their fatty fraction contains sizeable amounts of chemically 
related noncholesterol sterols belonging to a heterogeneous group of compounds known 
as plant sterols or phytosterols (Segura et al, 2006). Phytosterols interfere with cholesterol 
absorption and thus help lower blood cholesterol when present in sufficient amounts in the 
intestinal lumen. The mechanism of action of phytosterols has been linked to their 
hydrophobicity, which is higher than cholesterol because of a bulkier hydrocarbon molecule 
and entails a higher affinity for micelles than has cholesterol. 
Compared to other common foods, nuts have an optimal nutritional density with respect to 
healthy minerals, such as calcium, magnesium, and potassium. Like that of most vegetables, 
the sodium content of raw or roasted but otherwise unprocessed nuts is very low, ranging 
from undetectable in hazelnuts to 18 mg/100 g in peanuts (Segura et al, 2006). In addition, 
A high intake of calcium, magnesium and potassium, together with a low sodium intake, is 
associated with protection against bone demineralization, arterial hypertension, insulin 
resistance, and overall cardiovascular risk (Cordain et al, 2005).  
As a result, the macronutrient, micronutrient and non-nutrient components of nuts shown in 
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Table 1.4. Average nutrient composition of nuts (per 100 g). 






















Almonds 2418 50.6 3.9 32.2 12.2 12.2 0.00 21.3 8.8 29 120 
Brazil nuts 
(dried) 
2743 66.4 15.1 24.5 20.6 20.5 0.05 14.3 8.5 22 NR 
Cashews 2314 46.4 9.2 27.3 7.8 7.7 0.15 18.2 5.9 25 158 
Hazelnuts 2629 60.8 4.5 45.7 7.9 7.8 0.09 15.0 10.4 113 96 
Macadamia 
nuts 
3004 75.8 12.1 58.9 1.5 1.3 0.21 7.9 6.0 11 116 
Peanuts 2220 49.2 6.8 24.4 15.6 15.6 0.00 25.8 8.5 145 220 
Pecans 2889 72.0 6.2 40.8 21.6 20.6 1.00 9.2 8.4 22 102 
Pine nuts 
(dried) 
2816 68.4 4.9 18.8 34.1 33.2 0.16 13.7 3.7 34 141 
Pistachios 2332 44.4 5.4 23.3 13.5 13.2 0.25 20.6 9.0 51 214 
Walnuts 2738 65.2 6.1 8.9 47.2 38.1 9.08 15.2 6.4 98 72 
Data for raw nuts, except where specified. SFA, saturated fatty acids; MUFA, monounsaturated fatty acids; PUFA, 
polyunsaturated fatty acids; LA, linoleic acid; ALA, α-linolenic acid; PS, plant sterols; NR, not reported. 
Source: US Department of Agriculture Nutrient Data Base. 
 
1.8 Acceptability of the Mediterranean diet in the UK and China 
A healthy diet is a significant adaptable determinant of vascular healthy ageing (Marsman, 
Belsky et al. 2018). Worldwide, humans have scrutinised micro and macronutrients in order 
to find the optimal dietary balance that minimise the insidious effects of ageing for years 
(Mooney and Mc Auley 2016). As the Mediterranean diet has been widely accepted as 
being associated with a lower risk of chronic diseases such as cardiovascular mortality 
(Estruch, Ros et al. 2018, Rosato, Temple et al. 2019), coronary diseases (Dontas, Zerefos 
et al. 2007), obesity, type 2 diabetes, mellitus and metabolic syndrome in adults (Kastorini, 
Milionis et al. 2011, Huo, Du et al. 2015), the protective effect of the Mediterranean diet as 
an important lifestyle strategy for reducing the incidence of cardiovascular disease and 
promoting longevity has been highly recommended (Sofi 2009, Buckland, Agudo et al. 
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2011). Nonetheless, the feasibility to implement a Mediterranean diet in non‐Mediterranean 
regions such as China or UK remains uncertain and requires further exploration.  
While the Mediterranean-type diet is reported to be comparably easily transposable to non-
Mediterranean regions (Speed 2004), the Mediterranean diet is difficult to be widely adopted 
since it  is not only a list of foods, it encompasses a social, cultural, and agricultural way of 
life. Cooking and preparing foods brings conviviality and sharing of food for festivities, 
celebrations, social, and religious traditions and with family and friends (Lăcătușu, 
Grigorescu et al. 2019). It embodies frugality, biodiversity, seasonality, minimizing waste 
and long-term sustainability. In addition, current Western countries like the UK are among 
the highest global consumers of meat.  
In the UK, the typical diet consumed by UK adults is considerably different to the 
Mediterranean diet, being low in fruit and vegetables, legumes, oily fish and wholegrains, 
and high in saturated fat and sugar (Hoffman and Gerber 2013). Barriers such as perceived 
difficulty of living in a colder climate, body weight, cultural difference, and lower income was 
reported  to limit Mediterranean diet adoption by adults at high risk of cardiovascular disease 
from a Northern European population (Moore, McEvoy et al. 2018). In addition, a survey 
study (Francis, Young et al. 2018) from Northeast England including 554 individuals (86.9 % 
female)  also presented the result that the adherence to the overall MD is currently low, 
however, the MD guidelines are seen as acceptable by the local population including 
overweight and obese individuals from the Northeast England. 
China was reported to have a comparable higher acceptability of Mediterranean diet than 
the UK during previous years (Woo, Woo et al. 2001). Questionnaire research (Woo, Woo 
et al. 2001) suggested that in Hong Kong and China, more women in the middle age group 
(35-54y) had a high healthy Mediterranean score than other age groups, and overall more 
female subjects had high scores than men. After investigating the dietary patterns of a 
Chinese population living in Hong Kong, Guangdong province in Southern China, Sydney 
and San Francisco (Woo, Woo et al. 2001), Guangdong province had the highest number 
of subjects with high healthy Mediterranean score. The large majority of the Chinese 
population who consume a diet comparable to the traditional Mediterranean diet, whether 
in China or in Western countries are likely to have health benefits concerning coronary heart 
disease and survival. The study reported that most Chinese participants were aged 40 years 
and over and it was believed that there is less geographical variation in dietary habits among 
the older population, reflecting a tradition of remaining more traditional Chinese diet patterns 
rather than adopting `Westernized' diets than younger generation (Woo, Woo et al. 2001). 
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Britain was reported to have a promising tendency for adopting MD as one randomized 
controlled trial conducted in Britain suggested that the acceptability of the Mediterranean 
diet as a healthy eating guide among healthy British older adults is likely to be encouragingly 
feasible (Lara, Turbett et al. 2015) and MD guidelines are likely to be accepted by the British 
population including overweight and obese young individuals. Furthermore, MD is also 
recommended to be promoted in work-place settings for working employees in the England 
(Papadaki, Wood et al. 2015). 
 
Research questions raised from the present Chapter 1: 
The work described in this chapter raised the following questions: 
1. What is the acceptability and frequency consumption of nuts and emphasis in olive 
oil consumption among Caucasians (mostly British living in Northeast England) 
and East Asians (mostly Chinese living in Newcastle upon Tyne of Northeast 
England)?  
 
2. What is the state of the evidence from interventional studies assessing the impact 
of foods including nuts as well as olive oil consumption on CVD risk factors?  
 
3. Is the effect of these interventions on cardiovascular risk factors similar between 
different ethnic population namely Caucasians and East Asians living in the 
Northeast England? 
 
These questions were addressed in Chapter 2 to Chapter 5. In the survey chapter 
(Chapter 2), nuts and olive oil consumption among 142 East Asians and 142 Caucasians 
and their association with PREDIMED score, perceived barriers and acceptability of the 
Mediterranean diet will be explored and presented. Systematic and quantitative evaluation 
of the evidence from randomized controlled trials, is presented in Chapter 3 and Chapter 
4, reporting the associations between olive oil and nuts intake and risk of CVDs. Overall, 
the combination of the findings from the survey and systematic reviews will determine the 
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CHAPTER 2 
Nuts, olive oil consumption in Mediterranean diet among East Asians and 
Caucasians and their association with MD acceptability, PREDIMED score and 
perceived barriers to healthy eating: an online survey 
 
Abstract 
Objectives.   
PREDIMED studies indicate that the Mediterranean diet (MD) supplemented with nuts and 
olive oil resulted in a reduction of around 28% and 30% cardiovascular risks respectively 
around the Mediterranean basin but provided unclear effects on Asians and British 
populations. Therefore, this study aims to identify different degree of acceptability, feasibility 
and consumption of walnuts and olive oil between East Asians (mostly Chinese) and 
Caucasians (mostly British) to inform the design of nutritional interventions to improve 
cardiovascular health for both ethnicities in the near future. 
Study design.  
From August 2017 to April 2018, responses from East Asians and Caucasians were 
collected via an anonymous online Survey named “Public Opinions of the Mediterranean 
Diet”. Data analyses included two-step cluster analysis, t-tests and Chi-square tests 
analysing data. Results from 142 Caucasians (87.3% female; mean age: 32.8±SD12.2; BMI: 
22.8±SD2.8) resident in the North East of England and 142 East Asians (78.2% female; 
mean age: 32.8±SD10.9; BMI: 22.4±SD2.7) from Shanghai, China was presented.  
The main outcome measures: total acceptability guidelines of the Mediterranean diet (MD 
acceptability), a 14-item PREDIMED score (MDPS) and perceived barriers to healthy eating 
(PBHE) were used to compare the two ethnic groups. Within the same ethnicity, the group 
that consumed olive oil and walnuts was also compared with the group that do not consume 
these foods by assessing and comparing PBHE, MDPS and MD acceptability. In addition, 
the association between PBHE and variables including age, BMI, eat out frequency, MD 
acceptability, MDPS, consumption of olive oil and walnuts and ethnicity was analysed. 
Conclusion.   
This Bristol Online Survey of Caucasians (n=142) and East Asians (n=142) adults with 
similar age, BMI suggested that overall East Asians have a better health indicator than 
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Caucasians as East Asians is associated with a greater MD score and a higher MD 
acceptability.  
Walnuts consumption was higher among older age Caucasians and in lower BMI East 
Asians population. Olive oil consumption in both ethnicities, especially in Caucasians is 
closely positively associated with older age, higher MD score, higher MD acceptability and 
lower PBHE among all three interventions. East Asians reported as eating out more than 
Caucasians due to cultural behaviour.  
Olive oil consumption should be highly recommended to consume among Asians as well 
as Caucasians. Future clinical trials should focus on identifying what positive health effects 
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2.1 Introduction 
2.1.1 Mediterranean diet acceptability 
A Mediterranean style diet is likely to produce a beneficial effect on the occurrence of 
several chronic diseases, primarily CVD, which are closely linked to lifestyle and eating 
habits (Rees, Hartley et al. 2012). Systematic reviews of observational prospective studies 
have reported that greater adherence to a Mediterranean diet (MD) is associated with a 
significant improvement in health status and a significant reduction in overall mortality, as 
well as in morbidity and mortality from CVD and other chronic diseases (Sofi, Cesari et al. 
2008, Sofi, Abbate et al. 2010). A 2-point increase (scale from 0 to 7-9 points) in adherence 
to a Mediterranean dietary pattern was associated with an 8% reduction in all-cause 
mortality, and a 10% reduction in CVD incidence or mortality (Sofi, Abbate et al. 2010). 
The feasibility to implement a Mediterranean diet with high olive oil and nuts consumption 
beyond the Mediterranean regions such as China or Western countries has remained 
controversial and worthy of follow-up (Murphy and Parletta 2018). One previous 
questionnaire from Glasgow (Papadaki and Scott 2002) reported that due to the barriers of 
high price, limited availability and poor quality of familiar foods in the UK, it is difficult to 
maintain healthy eating behaviours when Greek people migrated to the UK. Similarly, a 
relatively current qualitative research (Papadaki, Thanasoulias et al. 2016) in Southwest 
England found that MD was challenging for adults as cost, taste and cooking skills can be 
considered as adherence barriers in different workplaces. In addition, barriers concerning 
MD adoption were also identified as perceived difficulty living in a colder climate, perceived 
impact on body weight, acceptability of a MD and cultural differences among adults with 
high CVD risk from Northern Europe (Moore 2017). However, a previous study (Papadaki 
and Scott 2008) from Scotland found that the 6-month MD consumption was successful at 
sustaining and MD improved blood lipids profile after 3-month follow-up. Additionally, 
patients with diagnosis of CHD from a Northern European population were reported to have 
a significant increase (P < 0.01) in Mediterranean diet score (MDS) at 6 and 12 months 
follow-up (Logan, Woodside et al. 2010). 
The reason why the Mediterranean diet is difficult to be widely adopted is because the 
Mediterranean diet is not simply a list of foods. It encompasses a social, cultural, and 
agricultural way of life (Murphy and Parletta 2018). In addition, Western countries like the 
UK are among the highest global consumers of meat. Therefore, it was not surprising that 
one of the dietary instructions difficult for participants to adhere to was restricting red meat 
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intake (Davis, Hodgson et al. 2017). Nevertheless, it is currently believed that MD has a 
relatively high compliance outside the Mediterranean region (Murphy and Parletta 2018). 
Comparing with the Mediterranean diet, which favours simple meals with earthy, light 
flavours, Asian diets tend to focus on a balance between salty, sweet, sour and spicy 
flavours, as well as crunchy and soft textures. Asians tend to favour strong flavours and 
use rich sauces and infused oils to dress their foods. However, the Chinese diet was shown 
to shift away from the traditional Chinese diet toward high-fat, low-carbohydrate and low-
fibre diets (Zhang, Wang et al. 2015). Limitation of trans fat to below 1% of daily calories is 
recommended (European Commission 2011), however, Asian diets incorporate unhealthy 
oils into cooking, especially in restaurant, such as those containing trans-fat such as 
margarine, maize oil, ground hook oil and animal fat such as lard. Oil-bearing processed 
food including cookies, cakes, bread, fried chips, popcorn, instant noodles, non-dairy 
creamer, whipped topping and ice-cream which contains trans fatty acid (TFA) are likely to 
be the most essential source of hydrogenated vegetable oil consumption for Chinese 
(Jiang, Xia et al. 2013). Research (Dhaka, Gulia et al. 2011) indicated the direct association 
of trans fatty acids with cardiovascular diseases, disorders of nervous system, diabetes 
and obesity. Natural fats and oils are a combination of monounsaturated, polyunsaturated 
and saturated fatty acids while trans fatty acids are unsaturated fatty acids that contain at 
least one double bond in the trans configuration. Trans fats are also increasingly part of 
packaged foods in Asia due to their ability to prolong shelf life, yet there are no laws 
requiring trans-fat content be disclosed to the public (T.H.Chan 2018). Nevertheless, food-
based dietary guidance from China only suggested no more than 25–30 g of cooking oil 
(Wang, Lay et al. 2016) but still lack suggestion to consume healthy oil such as olive oil.  
Although East Asian and Western diets remain significantly different in macro- and micro-
nutrient composition, both dietary patterns have aspects that can be considered, 
respectively, as adverse and protective in relation to the major adult cardiovascular 
diseases. In both Asian and Western countries, as dietary-associated risk is the most 
important behavioural factor influencing global health, it appears the best target in the 
challenge against CVD (Zhou, Stamler et al. 2003).  
Table 2.1 compares three major dietary recommendations in Mediterranean areas, UK and 
China. Table 2.1 showed that Mediterranean diet with more vegetables, olive oil, nuts 
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Table 2.1. Comparison of current dietary intakes recommendations of Chinese 
populations versus UK populations versus Mediterranean diet pyramids 
Foods  Mediterranean Diet 
(PREDIMED study) 
British Diet  Chinese Diet  
Fruits ≥3 units per day 
(including natural fruit 
juices) 
 
≥ 5 portions of fruits and 
vegetables (each portion 
80g) per day 
200 – 350 g per day 
Vegetables ≥2 servings (≥1 portion 
raw or as a salad) (1 
serving : 200 g) 






≥3 servings per week (1 
serving:150 g) 




3-4 servings a week 
 
≥ 2 portions a week Soybean and nuts: 50 – 
150 g per day 
Oil Olive oil as the main 
added lipid: ≥4 tbsp daily 
Vegetable oil, rapeseed 
oil and sunflower oil 
sparingly  
Cooking oil (pork oil: 25-
30g) per day 
Fish or 
shellfish  
≥3 servings per week (1 
serving 140g of fish or 4–
5 units or 200 g of 
shellfish)  
≥ 2 portions (each 
portion 140 g) a week 
40 -75 g per day 
Poultry 1-3 times a week  ≥ 2 portions a week 40 -75 g per day 
Dairy  2 servings a day 
 
Lower fat options when 
possible 





<1 serving per day (1 
serving: 100–150 g) 
No more than 70g per 
day 






<1 serving per day Consume infrequently 





<1 serving per day (1 










<3 times per week N/A N/A 
Water 1.5 to 2.0 L a day 6-8 glasses a day 1500 – 1700 ml per day 
Wine  ≥7 glasses per day (1 
serving = 125ml) 
Less than 175ml of wine 
or 568ml of larger or ale 





Regular practice of 
moderate physical activity 
(at least 30 minutes 
throughout the day) 
At least 150 minutes of 
moderate intensity 
activity –30 minutes at 
least 5 days per week 
6000 walking steps per 
day 
 
2.1.2 Olive oil acceptability  
Olive oil, a main component of Mediterranean diet, depending on its origin and extraction 
process, is high in monounsaturated fatty acids (MUFAs) such as oleic acid (55-83%) 
containing low levels of α-linolenic acid (ALA) - a member of the omega-3 family of fats 
(Smith, Kelly et al. 2003) and αALA (Pan, Chen et al. 2012). Due to its high concentration 
of phenol compounds, virgin olive oil tastes bitter and pungent therefore many people do 
not like to consume it (Vitaglione, Savarese et al. 2015). Extra-Virgin olive oil (EVOO), which 
is considered an unrefined oil since it's not treated with chemicals or altered by temperature, 
contains most of the natural vitamins and minerals found in olive oil.  
There is evidence indicating growing appeal and potentially acceptability of olive oil outside 
Mediterranean countries. Olive oil imports to China is reported to be 43,400 metric tons in 
the year of 2013, and an increase of 5.8% from the previous year, up 13% from the same 
period a year earlier despite the fact that olive oil accounted for only 1% of China’s total 
edible oil consumption in 2013. In 2017, the National Institute of Italian Statistics showed 
that Italian olive oil exports to China increased by €40 million (Philip 2018). China, as a non-
Mediterranean country with non-Mediterranean climate, is taking olive cultivation as an 
important part of its agricultural development (Su, Sun et al. 2018). In China, the olive 
industries have been concentrated in several western provinces in Gansu, Sichuan, Yunnan, 
Chongqing, and Hubei. Although the olive oil business started to play an important role in 
the economic and social development of western China in recent years, the business scope 
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The culinary use of olive oil is relatively new to UK consumers and is regarded as a set of 
particular attributes rather than as an everyday cooking oil (Garcia, Aragonés et al. 2002). 
Currently, olive oil has become an established commodity in the UK. The UK’s imports of 
olive oil in 2019 exceeded 84 thousand tonnes, at a value of €220 million. Between 2015 
and 2019, imports increased annually by 5% in volume, but decreased in value by -2%. This 
decrease in import value reflects the lower import prices, especially during 2019 (CBI - 
Ministry of Foreign Affairs 2020).  
Evidence indicated that citizens in Uruguay, which is an emerging olive-growing country, 
are unacquainted with the sensory traits of extra virgin olive oil, and prefer defective, 
ordinary virgin olive oils  (Gámbaro, Ellis et al. 2013). It also indicated that habituation to 
the bitter and pungent VOO is possible (Vitaglione, Savarese et al. 2015). However, 
bitterness and pungency can be the sensory drivers toward a healthy choice and are 
expected to be increased in the market as an effective strategy to direct consumers choices 
(Vitaglione, Savarese et al. 2015). People with a higher concern toward health related 
issues are more likely to consume olive oil, but subjective knowledge is shown to be an 
important factor (Cavallo 2015). 
 
2.1.3 Nuts acceptability  
Nuts are not only tasty, but also provide numerous health benefits. Nuts contain fatty acids 
such as omega 3, that help lower cholesterol, prevent heart disease, and control diabetes. 
There are several nuts that have a high concentration of omega-3 fatty acids, adding a daily 
handful to your diet can deliver health benefits (Chang, Alasalvar et al. 2016). Walnuts have 
more omega-3 than any other nut. Just 1/4 cup of walnuts provides 2.5 g of the essential 
fatty acid. Data presented in Chapter 3 provide evidence on the beneficial effects of nuts 
consumption on blood lipids, lipids particles and endothelial function.  
In the UK, 44% of existing buyers are buying nuts as an alternative to snacks. China is one 
of the main exporting almonds country with a growth of 40.063 import from 2004 to 2014 
(International Nuts & Dried Fruit 2016). Nuts sales have been soaring as the nuts and seeds 
market in the UK registered a positive compound annual growth rate of 6.28% during the 
period 2012 to 2017 with a sales value of GBP 538.73 Million in 2017, an increase of 5.74% 
over 2016. The market achieved its strongest performance in 2016, when it grew by 6.48% 
over its previous year and its weakest performance in 2017, when it increased by 5.74% 
over 2016 (Global Data - Research And Markets 2020). The data reported the average 
purchase weekly of nuts and edible seeds is 42 g in the UK in 2018 (Nils-Gerrit 2020).  
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2.1.4 Purpose of this survey chapter  
This online exploratory survey study titled “Public Opinions of the Mediterranean Diet” aims 
to evaluate consumption, feasibility and acceptability of olive oil as well as walnuts among 
adult individuals in the population with an emphasis on Caucasian and East Asian. The 
association between foods and indices of health such as age, BMI, MD score, MD 
acceptability and PBHE was investigated.  
This survey, however, further informs the planned human trials which aim to test 
effectiveness of interventions with either nuts or olive oil, compared with a control group, on 
CV risk factors outcomes between East Asians and Caucasians.  
 
2.2 Methods 
From August 2017 to April 2018, “Public Opinions of the Mediterranean Diet” from the online 
survey (formerly BOS) was conducted and researched around the UK. This study was 
approved by the Northumbria University ethics committee (Registration no. 000892) 
(Appendix A3). A representative sample of 284 respondents in total (142 respondents each 
for Caucasians and East Asians) who complete the online survey (formerly BOS) with the 
similar range of body mass index (BMI) was analysed.  
 
2.2.1 Study design 
The study was an observational, cross-sectional online survey which aimed to collect data 
on dietary habits, perceived barriers to healthy eating (PBHE), health condition, PREDIMED 
scores and total acceptability of Mediterranean dietary guidelines. Given the type of study 
design, this web-based survey chapter is reported following the STROBE statement (von 
Elm, Altman et al. 2007) and the CHERRIES statement (Eysenbach 2004). The checklists 
for these are included in Appendix A5 and A6 respectively.   
 
2.2.2 Sample 
142 Caucasian responses and 142 Asian responses from UK and Shanghai, China were 
recruited and analysed in this online survey study. By design, participants of this study had 
to have regular access to internet and email and, no other inclusion/exclusion criteria were 
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employed. Recruitment was supported by Northumbria University. The study was also 
advertised among staffs and students at Northumbria University. A “snowball” sampling 
procedure was attempted by requesting participants to forward the invitation to join the 
study to others. Participants of this study were recruited in a wide range of individuals in 
terms of education, residence, marital and socioeconomic status, age and ethnicity. 
The recruitment procedure involved two phases. The survey targeted East Asian individuals 
in China, Shanghai. Afterwards, a matched sample of UK based Caucasian individuals, was 
recruited as stated above. These samples were matched for age, body mass index and 
gender balance (this is, similar proportions of men and women). 
 
2.2.3 E-survey 
The survey was developed using Online survey (formerly BOS) for the creation of web forms. 
Participants volunteering to take part in this survey received the uniform resource locator 
(URL) for the survey. Pilot testing of the survey materials for clarity, understanding and time 
taken to complete the survey was undertaken prior to the current survey. 
 
2.2.4 Questionnaire measures 
The questionnaire survey (Appendix A3) comprised 20 questions regarding BMI, alcohol 
consumption frequency, smoking status, and current health diagnosis, dietary habits, eating 
barriers, as well as acceptability of Mediterranean dietary guidelines. In addition, a number 
of questions on sociodemographic characteristics (gender, age, ethnicity, residence, marital 
status, employment and highest educational attainment) were presented at the beginning 
of the survey in order to characterize individuals.  
The online survey included the following questionnaires: Firstly, questions from first to 23rd 
on individual characteristics, demographic information were requested. BMI was estimated 
from self-reported weight and height. Secondly, MD adherence was assessed using the 14-
item PREDIMED score (MDPS) from questions 24th to 27th (Schroder, Fitó et al. 2011). The 
range of possible scores for MDPS is 0-14 with higher scores indicating greater MD 
adherence. The baseline 14-item questionnaire (Appendix A3) was the primary measure 
used in this study to appraise adherence of participants to the Mediterranean diet. One 
additional item investigated “How many servings of walnuts (1 serving = 40g) do you 
consume per week?” Thirdly, a questionnaire requesting participants to identify PBHE from 
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previously published list derived from a pan-EU consumer attitudinal survey (Kearney and 
McElhone 2007).  
 
2.2.5 Statistical analysis 
Body mass index (BMI) was calculated as weight in kilograms divided by the squared height 
in metres. Adherence to the Mediterranean diet was assessed using the 14-item 
PREDIMED score (MDPS) with a range of possible values from 0 to 14, with higher MDPS 
indicating higher adherence, the number of perceived barriers to healthy eating was 
estimated adding up all the barriers indicated by the participant and total acceptability of 
Med diet was calculated out of acceptability for each of the items comprised in MDPS with 
potential values ranging from 0 to 14. were derived to compare between Caucasian and 
East Asian population. Items such as age, BMI, MDPS, PBHE and MD total acceptability of 
Caucasian and East Asian were compared on the basis of whether participants who 
consumed or not walnuts and olive oil were used to be compared between Caucasian and 
East Asian responses who did not consume walnuts and olive oil. Furthermore, the 
association between perceived barriers to healthy eating and age, BMI, MDPS, eat out 
frequency, total acceptability of MD guidance, olive oil, walnuts was analysed among 
Caucasian and East Asian population. Finally, the association between Caucasian/East 
Asian who consume olive oil, walnuts or not and socio-status also was analysed. 
All statistical analyses were conducted with “IBM SPSS Statistics 21” together with 
Microsoft Office Excel 2013” for Windows. Descriptive statistics with mean and standard 
deviations were used to summarise the characteristics of the participants in the study. Two-
step cluster-analysis was used to identify natural groups of PBHE. Step one involved 
creation of pre-clusters from cases by constructing an algorithm known as the Cluster 
feature tree. In Step two, pre-clusters were merged using agglomerative hierarchical 
clustering. Cluster-membership and the optimal number of clusters were determined using 
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2.3 Results 
2.3.1 Participant characteristics 
A representative sample of 21 to 67 years old 284 respondents in total (142 respondents 
each for Caucasians and East Asians) who complete the Online Survey have similar range 
of body mass index (BMI) (Table 2.2).  
 
Table 2.2. Characteristics of participants. 
Ethnicity N Minimum Maximum Mean±SD 
Caucasian Age 142 21 67 32.8±12.2 
BMI 142 17.8 33.6 22.8±2.8 
Female 124 87.3% 
East Asian Age 142 21 68 32.8±10.9 
BMI 142 17.2 33.4 22.4±2.7 
Female 111 78.2% 
Independent-samples T-test 
 
2.3.2. The association between interventions - olive oil and walnuts, and BMI, 
PREDIMED score, barriers and MD acceptability among ethnicities. 
Table 2.3.1 shows that East Asians are overall healthier than Caucasians as MD score 
(p<0.001), and that East Asians have a higher eat out frequency (p<0.001) and MD 
acceptability (p=0.028) are statistically significantly different except PBHE.  
In Table 2.3.2, Caucasians who consume walnuts (n=18) are more likely to eat out 
frequently (p=0.043) than Caucasians who do not consume walnuts (n=124). East Asians 
with older age (35.51±SD13.0) are more likely to consume walnuts (p=0.028).  
In Table 2.3.3, Caucasians (n=104) who consume olive oil were significantly older 
(34.3±SD12.4) (p=0.009), scored higher for MD adherence score (6.51±SD2.2) (p<0.001), 
scored higher for MD acceptability (10.21±SD2.3) (p=0.017) and reported lower PBHE 
(1.81±SD4.0) (p=0.03) than non-consumers of olive oil.  East Asians olive oil consumers 
(n=44) is positively associated with higher MD score (8.02±SD1.8) than those non-olive oil 
consumers (n=98) who have lower MD score (6.83±SD1.6) (p<0.001). 
In Table 2.3.4, Non-walnuts East Asians consumers also show a higher MD score 
(7.17±SD2; p<0.001), higher eat out frequency (14.29±SD15.9; p<0.001) and higher total 
MD acceptability (10.85±SD3.3; p=0.032) than non-walnuts Caucasians consumers. Non-
olive oil East Asians consumers also show a higher eat out frequency (13.66±SD13.3; 
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P<0.001), higher MDPS (6.83±SD1.7; p<0.001) and higher MD acceptability (10.73±SD3.1; 
P=0.001) than non-olive oil Caucasians consumers.  
Among all walnuts’ consumers in both ethnicities, East Asians walnuts consumers also 
show lower BMI (22.27±SD2.5; p=0.042) and higher eat out frequency (13.82±SD11; 
p<0.001) (Table 2.3.4). Among all olive oil consumers in both ethnicities, East Asians olive 
oil consumers show a higher eat out frequency (15.09±SD16.1; P<0.001) and higher MD 
score (8.02±SD1.8; P<0.001) than Caucasians olive oil consumers (Table 2.3.5).   
 
Table 2.3.1   Perceived health status of differences in scores for perceived barriers (PBHE), 
adherence to the Mediterranean diet (MD score), total MD acceptability of the 
Mediterranean diet and eat out frequency between Caucasians and East Asians. 
 Ethnicity N Mean (SD) Sig. (2-tailed) 
Number of perceive barrier to health 
eating (PBHE) 
Caucasian 142 2.33 (4.2)  0.623 
East Asian 142 2.09 (4.1) 
MD score Caucasian 142 6.03 (2.3) <0.001 
East Asian 142 7.20(1.8) 
Eat out frequency (times per month) Caucasian 142 4.72(4.3) <0.001 
East Asian 142 14.11(14.2) 
Total acceptability of MD guidelines Caucasian 142 9.94(2.2) 0.028 
East Asian 142 10.68(3.3) 
 
Table 2.3.2   Perceived health status of differences between walnuts consumption and 
scores for perceived barriers (PBHE), adherence to the Mediterranean diet (MD score), 
total MD acceptability of the Mediterranean guidelines and eat out frequency for 
Caucasians and East Asians. 
Ethnicity Walnuts N Mean (SD) P value 
Caucasian Number of perceive 
barrier to health eating 
No 124 2.44(4.3) 0398 
Yes 18 1.56(3.0) 
MD score No 124 5.99(2.3) 0.618 
Yes 18 6.28(2.1) 
Eat out frequency (times 
per month) 
No 124 4.44(4.0) 0.043 
Yes 18 6.61(5.3) 
BMI No 124 22.69(2.9) 0.207 
Yes 18 23.57(1.7) 
Age No 124 32.45(12.2) 0.399 
Yes 18 35.06(11.8) 
Total MD acceptability No 124 9.97(2.2) 0.735 
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Yes 18 9.78(2.1) 
East Asian Number of perceive 
barrier to health eating 
No 87 1.97(4.2) 0.643 
Yes 55 2.29(3.9) 
MD score No 87 7.17(1.7) 0.836 
Yes 55 7.24(1.9) 
 Eat out frequency (times 
per month) 
No 87 14.29(16.0) 0.849 
Yes 55 13.82(11.1) 
BMI No 87 22.55(2.8) 0.560 
Yes 55 22.27(2.5) 
Age No 87 31.05(9.0) 0.028 
Yes 55 35.51(13.0) 
Total MD acceptability No 87 10.85(3.3) 0.451 
Yes 55 10.42(3.4) 
 
Table 2.3.3   Perceived health status of differences between olive oil consumption and 
scores for perceived barriers (PBHE), adherence to the Mediterranean diet (MD score), 
total MD acceptability of the Mediterranean guidelines and eat out frequency for 
Caucasians and East Asians. 
Ethnicity Olive oil N Mean (SD) Sig. (2-tailed) 
Caucasian Age  No 38 28.63(10.7) 0.009 
Yes 104 34.30(12.4) 
BMI No 38 22.85(2.8) .908 
Yes 104 22.79(2.7) 
Eat out frequency 
(times per month) 
No 38 5.11(5.1) 0.515 
Yes 104 4.58(3.9) 
MD score No 38 4.71(1.9) <0.001 
Yes 104 6.51(2.2) 
Total MD 
acceptability 
No 38 9.21(2.0) 0.017 
Yes 104 10.21(2.3) 
PBHE No 38 3.76(4.9) 0.03 
Yes 104 1.81(4.0) 
East Asian Age No 98 32.53(10.9) 0.692 
Yes 44 33.32(11.0) 
BMI No 98 22.57(2.7) 0.376 
Yes 44 22.14(2.6) 
Eat out frequency 
(times per month) 
No 98 13.66(13.3) 0.582 
Yes 44 15.09(16.1) 
MD score No 98 6.83 (1.6) <0.001 
Yes 44 8.02 (1.8) 
No 98 10.73(3.1) 0.783 
 
 




Yes 44 10.57(3.7) 
PBHE No 98 2.10(4.0) 0.964 
Yes 44 2.07(4.3) 
 
Table 2.3.4. The association of all MD variables including scores for perceived barriers 
(PBHE), adherence to the Mediterranean diet (MD score), total MD acceptability of the 
Mediterranean guidelines and eat out frequency between East Asians and Caucasians 
who adopt walnuts consumption, and the association of all MD variables between East 
Asians and Caucasians who do not consume walnuts.  
Walnuts consumption Ethnicity N Mean (SD) Sig. (2-tailed) 
No Age Caucasian 124 32.45(12.3) 0.338 
East Asian 87 31.05(9.0) 
BMI Caucasian 124 22.69(2.9) 0.710 
East Asian 87 22.55(2.8) 
Eat out frequency 
(times per month) 
Caucasian 124 4.44(4.0) <0.001 
East Asian 87 14.29(15.9) 
MDPS Caucasian 124 5.99(2.3) <0.001 
East Asian 87 7.17(1.7) 
PBHE Caucasian 124 2.44(4.3) 0.421 
East Asian 87 1.97(4.2) 
MD acceptability Caucasian 124 9.97(2.2) 0.032 
East Asian 87 10.85(3.3) 
Yes Age Caucasian 18 35.06(11.8) 0.896 
East Asian 55 35.51(13.0) 
BMI Caucasian 18 23.57(1.67) 0.042 
East Asian 55 22.27(2.5) 
Eat out frequency 
(times per month) 
Caucasian 18 6.61(5.3) <0.001 
East Asian 55 13.82(11.0) 
MDPS Caucasian 18 6.28(2.1) 0.072 
East Asian 55 7.24(1.8) 
PBHE 
 
Caucasian 18 1.56(3.0) 0.469 
East Asian 55 2.29(4.0) 
MD acceptability Caucasian 18 9.78(2.1) 0.45 
East Asian 55 10.42(3.4) 
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Table 2.3.5 The association of all MD variables including scores for perceived barriers 
(PBHE), adherence to the Mediterranean diet (MD score), total MD acceptability of the 
Mediterranean guidelines and eat out frequency between East Asians and Caucasians 
who adopt olive oil consumption, and the association of all MD variables between East 
Asians and Caucasians who do not consume olive oil. 
Olive oil consumption Ethnicity N Mean (SD) Sig. (2-tailed) 
No Age Caucasian 38 28.63(10.7) 0.062 
East Asian 98 32.53(10.9) 
BMI Caucasian 38 22.85(2.8) 0.604 
East Asian 98 22.57(2.7) 
Eat out frequency Caucasian 38 5.11(5.1) <0.001 
East Asian 98 13.66(13.3) 
MDPS Caucasian 38 4.71(1.9) <0.001 
East Asian 98 6.83(1.7) 
PBHE 
 
Caucasian 38 3.76(5.0) 0.067 
East Asian 98 2.10(4.0) 
Total MD 
acceptability 
Caucasian 38 9.21(2.0) 0.001 
East Asian 98 10.73(3.1) 
Yes Age Caucasian 104 34.30(12.4) 0.635 
East Asian 44 33.32(11.0) 
BMI Caucasian 104 22.79(2.7) 0.183 
East Asian 44 22.14(2.6) 
Eat out frequency Caucasian 104 4.58(4.0) <0.001 
East Asian 44 15.09(16.1) 
MDPS Caucasian 104 6.51(2.2) <0.001 
East Asian 44 8.02(1.8) 
PBHE Caucasian 104 1.81(3.7) 0.712 
East Asian 44 2.07(4.3) 
Total MD 
acceptability 
Caucasian 104 10.21(2.3) 0.559 
East Asian 44 10.57(3.7) 
Independent Sample T-test 
 
2.3.3. Mediterranean diet adherence 
The mean 14-item Mediterranean diet score (MDPS) was 6.03±SD2.3 for Caucasian and 
7.2±SD1.8 for East Asian. East Asians reported the greatest adherence to the following 
components of the MDPS: “<7/week servings of red meat, hamburger, or meat products” 
(90.1%), “<7/day servings of sweet or carbonated beverages” (88%) while Caucasians 
reported the greatest adherence to the following components of the MDPS: “≥2 servings of 
vegetables a day” (84.5%), “Preferentially consume chicken turkey or rabbit meat instead 
 
 
- 69 - 
 
of veal, hamburger or sausage” (81.7%), East Asians also reported a higher olive oil 
consumption: “≥4 tablespoons of olive oil a day (14.8%)” than Caucasians “ ≥4 tablespoons 
of olive oil a day (3.5%)” (Table 2.4). There is significant difference of “Used olive oil as 
main fat for cooking in diet (Yes)” (P < 0.001); “≥4 tablespoons of olive oil a day” between 
Caucasians and East Asians (P = 0.001); “<7/week servings of red meat, hamburger, or 
meat products” (P < 0.001); “<1/day servings of butter, margarine, or cream” (P < 0.001); 
“<7/day servings of sweet or carbonated beverages” (P < 0.001); “≥7/week glasses of wine 
(P < 0.001)”;  “≥3/week servings of fish or shellfish” (P < 0.001); “Preferentially consume 
chicken turkey or rabbit meat instead of veal, hamburger or sausage (Yes)” (P=0.013) 
between Caucasians and East Asians (Table 2.4).  
 
 
Table 2.4. Adherence to the individual components of the Mediterranean diet assessed using 




Caucasian East Asian  
(n = 142) (n = 142) 
LSM±SD LSM±SD 
PREDIMED score (MDPS) 6.03±2.3 7.2±1.8 
  % % P-value 
(1) Used olive oil as main fat for cooking in diet 
(Yes) 
73.2 31.0 < 0.001 
(2) ≥4 tablespoons of olive oil a day 3.5 14.8 0.001 
(3) ≥2 servings of vegetables a day (1 serving = 80g 
or 2 broccoil florets, three heaped tablespoons of 
cooked vegetables such as carrots or 3 celery 
sticks) 
84.5 81.0 0.432 
(4) ≥3 servings of fruit a day (1 serving =80g, or 1 
banana, 2 kiwis, or 1 heaped tablespoon of sultanas) 
30.3 26.8 0.511 
(5) <7/week servings of red meat, hamburger, 
or meat products (1 serving =70g, or three slices of 
ham) 
31.7 90.1 < 0.001 
(6) <1/day servings of butter, margarine, or 
cream (1 serving =10g) 
35.9 65.5 < 0.001 
(7) <7/day servings of sweet or carbonated 
beverages (1 serving =150ml) 
41.5 88.0 < 0.001 
(8) ≥7/week glasses of wine (1 serving = 125ml) 9.9 0 < 0.001 
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(9) ≥3/week servings of legumes/pulses (1 serving 
=5 heaped tablespoons cooked) 
29.6 25.4 0.425 
(10) ≥3/week servings of fish or shellfish (1 serving 
=140g) 
23.2 57.7 < 0.001 
(11) <3/week servings of cakes, commercial sweets 
or pastries  
46.5 56.3 0.096 
(12) ≥3/week servings of unsalted nuts including 
peanuts (1 serving =40g) 
21.8 30.3 0.105 
(13) Preferentially consume chicken turkey or 
rabbit meat instead of veal, hamburger or 
sausage (Yes) 
81.7 69 0.013 
(14) ≥3/week consume a meal containing 
vegetables, pasta, rice, or other dishes seasoned 
with tomato based 
sauce 
21.8 30.3 0.105 
 
 
2.3.4. PBHE classification and cluster characteristics 
Two-step cluster analysis produced three discrete clusters of participants based on their 
reports of number of perceived barriers to healthy eating (PBHE) (Table 2.5.1; Table 2.5.2). 
Cluster-1 (n=102) having the largest number of participants was characterised by PBHE as 
“No barriers”. The important PBHE for participants in cluster-3 (n = 21) included “Price”, 
“Perishable” and “Dining out”. Participants in cluster-2 (n=19) reported the importance 
barriers on “Busy lifestyle”, “Working hours” and “Willpower”.  
 
On average, members of cluster-3 were youngest (mean = 30.9 years for Caucasians, 
mean = 29.2 years for East Asians) and reported the lowest MDPS (mean = 4.25), highest 
PBHE (mean = 11 in Caucasians; mean = 10.6 in East Asians) as well as lowest total MD 
acceptability (mean=9.6 in Caucasians; mean=9.1 in East Asians) and the most frequency 
of eating out (mean = 26.4) in East Asians (Table 2.5). In Table 2.5, On the contrary, 
members of cluster-1 with “No barriers” were the leanest (mean BMI = 22.4 kg/m2 for 
Caucasians: mean BMI = 22.3 kg/m2 for East Asians) group, reporting a lowest number of 
PBHE (Mean < 0.01), highest score in MDPS (mean = 7.5) and the least frequency of eating 






- 71 - 
 
Table 2.5 Characteristics of PBHE clusters. 
Ethnicity N Mean Std. Deviation Sig 
Caucasian Total MD 
acceptability 
Cluster 1 102 10.04 2.3 0.697 
Cluster 2 19 9.7 1.5 
Cluster 3 21 9.6 2.2 
Total 142 9.9 2.2  
PBHE Cluster 1 102 0.01 0.1 <0.001 
Cluster 2 19 5.2 1.8 
Cluster 3 21 11.0 2.0 
Total 142 2.3 4.1 
MDPS Cluster 1 102 6.6 2.2 <0.001 
Cluster 2 19 5.00 1.9 
Cluster 3 21 4.05 1.5 
Total 142 6.03 2.3  
BMI Cluster 1 102 22.4 2.2 0.025 
Cluster 2 19 23.3 3.3 
Cluster 3 21 24.1 4.1 
Total 142 22.8 2.7  
Age Cluster 1 102 33.1 12.1 0.731 
Cluster 2 19 33.5 15.8 
Cluster 3 21 30.9 9.2 
Total 142 32.8 12.2  
Eat out 
frequency 
Cluster 1 102 4.3 3.7 0.035 
Cluster 2 19 7.0 7.0 
Cluster 3 21 4.9 2.9 
Total 142 4.7 4.3  
East Asian Total MD 
acceptability 
Cluster 1 105 10.9 3.4 0.054 
Cluster 2 17 11.2 2.8 
Cluster 3 20 9.1 2.9 
Total 142 10.7 3.3  
PBHE Cluster 1 105 0.00 0.0 <0.001 
Cluster 2 17 5.0 1.9 
Cluster 3 20 10.6 3.3 
Total 142 2.1 4.1  
MDPS Cluster 1 105 7.5 1.6 <0.001 
Cluster 2 17 6.7 2.3 
Cluster 3 20 5.8 1.6 
Total 142 7.2 1.8  
BMI Cluster 1 105 22.3 2.5 0.286 
Cluster 2 17 23.4 3.8 
Cluster 3 20 22.6 2.8 
Total 142 22.4 2.7  
 
 




Cluster 1 105 33.1 11.4 0.219 
Cluster 2 17 35.2 10.4 
Cluster 3 20 29.2 7.4 





Cluster 1 105 11.9 9.9 <0.001 
Cluster 2 17 13.5 8.9 
Cluster 3 20 26.4 26.6 
Total 142 14.1 14.2  
 
 
Table 2.5.1 Walnuts consumption of Two-Step Cluster between two ethnicities 
Ethnicity Two Step Cluster Number 3 Total P 
1 2 3 
Caucasian Walnuts No 88 16 20 124 0.483 
Yes 14 3 1 18 
Total 102 19 21 142 
East Asian Walnuts No 67 9 11 87 0.573 
Yes 38 8 9 55 
Total 105 17 20 142 
Two Step Cluster Chi-Square Tests 
 
 
Table 2.5.2 Olive oil consumption of Two-Step Cluster between two ethnicities 
Ethnicity Two Step Cluster Number 3 Total  
1 2 3 P  
Caucasian Olive oil No 22 8 8 38 0.080 
Yes 80 11 13 104 
Total 102 19 21 142  
East Asian Olive oil No 72 13 13 98 0.740 
Yes 33 4 7 44 
Total 105 17 20 142  




2.4.1 Principal findings 
High levels of acceptability of the Mediterranean dietary guidelines were observed among 
both ethnic groups. East Asians participants had slightly but significantly greater adherence 
to the Mediterranean dietary guidelines, as well as acceptability of these guidelines than 
Caucasians participants in this survey study. 
 
 
- 73 - 
 
The acceptability and frequency of olive oil intake among East Asians is higher than 
Caucasians. Caucasians who consume olive oil were significantly older, scored higher for 
MD adherence score, scored higher for MD acceptability and reported lower PBHE than 
non-consumers of olive oil.  Walnuts are most consumed by older age among Caucasians 
as well as lower BMI East Asians population. Olive oil consumption has overall beneficial 
effect on both ethnicities (mostly female: 87.3% in Caucasians, 78.2% in East Asians), and 
olive oil consumption is most closely positively associated with older age, higher MD score, 
higher MD acceptability and lower PBHE in both ethnicities. In addition, in this survey, East 
Asians are shown to be more likely to eat out more frequently than Caucasians because as 
of cultural phenomenon that Chinese habitually treat others with meals in order to stablish 
and maintain, enhance interpersonal relationship. Owing to its function to express the 
central position in the representation and relationship, a dinner or banquet can be used as 
a symbol of the important events in human life, such as wedding, baptism, and religious 
belief in China (Ma 2015). Taken together these results suggest that interventions 
promoting the Mediterranean dietary guidelines are likely to be acceptable among these 
individuals.  
MD scores (score ≥7 based on the score ranging from 0-14) are associated with older age, 
waist circumference, body mass index, high education level (Acar, Gucuk Ipek et al. 2018). 
Previous evidence (Sofi, Cesari et al. 2008) reported that greater adherence to a 
Mediterranean diet is closely associated with a significant improvement in health status, as 
seen by a significant reduction in overall mortality (9%), mortality from cardiovascular 
diseases (9%), and incidence of Parkinson’s disease and Alzheimer’s disease (13%) (Sofi, 
Cesari et al. 2008). These consequences appear to be clinically relevant for public health, 
in particular for encouraging a Mediterranean-like dietary pattern for primary prevention of 
major chronic diseases (Sofi, Cesari et al. 2008, Sofi, Abbate et al. 2009).  
 
Given the strong evidence supporting its efficacy and effectiveness in enhancing health, the 
MD is the dietary pattern of choice when promoting a healthy diet (Martínez-González, 
García-Arellano et al. 2012, Estruch, Ros et al. 2013). The PREDIMED study displayed that 
closer adherence to a MD, e.g. a MDPS of 9 or higher, was associated with significantly 
lower odds ratios for prevalence of obesity and risk of cardiovascular diseases (Martínez-
González, García-Arellano et al. 2012, Estruch, Ros et al. 2013).  
 
Although the East Asians scored higher than the Caucasians, both groups are below the 
scores cut offs suggested as both ethnicities would need to improve in order to get 
protections from CVD risk. This is not unexpected among individuals from non-
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Mediterranean countries who are unlikely to score high on the MD score. Consequently, 
this result justifies the need for dietary interventions to improve the diet of these non-
Mediterranean area groups in order to promote health and prevent chronic diseases such 
as cardiovascular diseases.  
 
The data from this survey research suggested however that East Asian participants (MDPS 
= 7.2±1.8 for East Asians) are less likely to suffer from cardiovascular diseases than 
Caucasians (MDPS = 6.03±2.3 for Caucasians). Importantly, evidence shows that small 
changes such as a two-point increase in MDPS is strongly associated with lower health 
risks (Salas-Salvadó, Bulló et al. 2011, Estruch, Ros et al. 2013).  
 
Based on the cluster analysis, barriers were identified that could potentially limit the 
adoption of healthy eating habits. The pan-European consumer attitudinal survey identified 
“time” as well as “taste” as the most frequent PBHE among the EU population (Kearney and 
McElhone 2007). A telephone-survey in Northern Ireland reported that ‘lack of willpower’ 
and ‘willingness to change’, were the most common PBHE (Appleton, McGill et al. 2010). A 
study offering a “healthy diet” for a 3-day duration to a small group of Scottish middle-age 
adults, identified “time pressures”, “desire for convenience” and “lack of motivation to cook” 
as important PBHE (Macdiarmid, Loe et al. 2013). It is also reported that “busy lifestyle”, 
“irregular working hours”, and “the belief that healthy eating involves lengthy preparation”, 
are key barriers as identified by the younger, more overweight individuals with the lowest 
MDPS and HBS. These “time pressure related” PBHE were reported to be likely to influence 
health behaviours such as reducing physical activity and contribute to the greater 
prevalence of health risk factors including increasing BMI among participants in that cluster 
(Lara, McCrum et al. 2014). The same study also showed that cluster-2 identified “lack of 
willpower” as did our study and “finding it hard to give-up liked foods” as a characteristic 
PBHE identified by older, but leaner participants with higher MDPS and fewer PBHE (Lara, 
McCrum et al. 2014). A meta-analysis (Carpenter 2010) has shown perceived barriers and 
benefits were consistently the strongest predictor of whether an individual adopted a 
preventative health measure.   
 
Further studies (Seguin, Connor et al. 2014) have reported that the largest barrier is 
concerning price and lacking in healthy eating knowledge. Firstly, this barrier may raise the 
question as to whether some respondents might claim these as barriers because they are 
aware that they probably have a health issue needing personal investments (time, money, 
convenience), but doubt their own ability or true intention to act on it especially when they 
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are young. Secondly, the economic barrier was regarded as a culprit to healthy eating. 
Evidence indicated that price modifications are more effective than educational health 
information to motivate people to purchase healthier foods, especially for young people. 
Food prices have increased, with costs 8% higher in real terms than they were in 2007 
(Department for Environment 2015). Since 2008, the price of food has risen 10% more than 
other goods (Griffith, O'Connell et al. 2015). Excluding food bought out of the home, the 
average household spends 11% of their income on food. This is 16% for low-income 
households, who now spend 23% more on food than they did in 2007, compared to the 
average increase of 18%. Thirdly, the barrier “perishable” is likely due to lack of cooking 
skills and food knowledge among young people. Although nationally representative survey 
data found that 89% of respondents said they were able to cook a main dish from basic 
ingredients without help (Adams, Goffe et al. 2015), higher ultra-processed foods 
consumption is associated with erosion of home food preparation skills and infrequent use 
of these skills (Lam and Adams 2017).Then, “Dining out” as a barrier to heathy eating is 
due to the availability of overwhelming unhealthy food available outside of the home. Fast 
food consumption is associated with increased BMI, the likelihood of obesity and body fat 
ratios. The number of food outlets in the UK has increased from 60,760 to 93,285 over the 
last ten years with more fast-food outlets in deprived areas (UK Parliament 2016). Take 
away foods may also come in larger portions. Additionally, “Will power” is a noticeable 
barrier to healthy eating and avoid consuming takeaway foods and it reported that people 
regard healthy eating as difficult to achieve and that it requires great psychological effort to 
maintain a sustainable healthy diet (Vélez-Toral, Rodríguez-Reinado et al. 2020).  
 
Asians were shown to have a greater interest in eating healthy than westerners according 
to a survey report which included 1300 responders from Asia and the Western hemisphere 
(Bary 2017). Around seven in ten of Asian respondents surveyed (68%) were “very 
interested” in healthy eating, as opposed to 38% of western citizens. In addition, 39% Asian 
consumers acknowledged that cutting down on their consumption of meat was crucial to 
achieving a healthy diet and Asian purchasers appeared almost three times likelier (28%) 
than Westerners (10%) to be more willing to purchase a product if it made vegetarian or 
vegan health claims. On the contrary, only 25% of Western consumers agreed with this 
stance (Bary 2017). 
 
Furthermore, another study (Leung and Stanner 2011) reported that Chinese are more likely 
to be not influenced or restricted by religion on food choices than Westerners and have wide 
acceptability of testing and tasting wide range of food types. Chinese adults were less likely 
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to report limiting long-standing and psychological illnesses compared with the general 
population (Heim and MacAskill 2006).  
Dining out frequently is strongly associated with unhealthy lifestyle and uncontrolled dietary 
intake. Individuals who go out to eat end up taking in typically larger than 3.3 ounces per 
meal and taking in an average of 200 more calories than those that away-from-home-dining 
in restaurants, in fast food outlets, and from take-out meals increases the risk of 
cardiovascular diseases and stroke (Haring et al, 2015).  
 
Study reported that the hyperlipidemic subjects, both men and women, tended to dine out 
often and consume more animal-based foods and alcohol (Deng et al, 2012). Systematic 
review found that eating out of the home was strongly associated with an overall higher total 
calorie and fat intake, and greater portion sizes than ones served at home because people 
are more likely to choose “unhealthy” foods as eating out is seen as a “treat” with friends 
(Lachat et al, 2011). Additionally, there is no control over cooking methods or added 
ingredients, such as fat or salt. Research also showed that dining out makes more of a 
chance of eating extras such as entrees and desserts, if alcohol is taken with a meal, this 
may encourage us to eat more. Therefore, reduce the number of times a month for dining 
out is considered to be healthy for people’s lifestyle (Lachat et al, 2011).  
 
2.4.2 Strengths and limitations 
A strength of this relies on the fact that it involved the same number of groups of Asian 
(n=142) and Caucasian individuals (n=142) matched for age and BMI and gender balance 
(participation), in order to minimise the confounding impact from these variables. As 
expected, this online survey produced a good response rate and collection of data at 
virtually no cost. Another strength of the present survey study is that data were collected 
via the online surveys, which is a validated, powerful data collection tool designed for 
experienced organization Academic Research, Education and Public Sector organisations. 
Among the limitations of this study are the fact that the cross-sectional study design does 
not allow to establish cause-and effect. In addition, self-reported information is susceptible 
to recall and social biases such as social desirability (Lara, Scott et al. 2004). A general 
tendency to underreport and misreport weight, and to overreport height, servings of the 
foodstuffs could introduce bias to the self-reported lifestyle risk factors (Jarbøl, Larsen et al. 
2017). The differences between Asians and Caucasians could be related to the possibility 
of including more Asians individuals who were health motivated. As it is common with diet-
related research, the majority of participants were women (87.3% in Caucasians, 78.2% in 
East Asians), this making difficult the generalisation of our findings to the male population. 
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Gender difference exists in perceived healthiness of food within Chinese and Caucasians 
society (Ma 2015, Bärebring et al., 2020). Chinese male members within the family are 
given more food with excessive calories as compared with the female members. Such long-
term sex difference in food distribution in most Chinese families causes different dietary 
behaviour between two genders (Ma 2015). Swedish female residents were more likely than 
men to avoid eating gluten, red meat, white flour and food additives due to perceived 
unhealthiness (Bärebring et al., 2020). Therefore, this results further informs the design of 
our human clinical trial to test the effects of either olive oil or nuts in male participants.  
 
2.5. Conclusions 
In conclusion, this survey study was well received and ascertained to be an efficient 
approach to screen dietary habits, PBHE, and perceptions of health status between 
Caucasians and East Asians. The results of our study are in agreement with our hypothesis 
indicating that individuals reporting more PBHE are likely to have lower MDPS and higher 
BMI in both ethnicities.  
Olive oil consumption in both ethnicities, especially in Caucasians is most closely positively 
associated with older age, higher MD score, higher MD acceptability and lower PBHE 
although all three interventions were presented to exert beneficial effects on both ethnicities. 
This survey study also showed that the acceptability and frequency of olive oil intake among 
East Asians is higher than Caucasians. These findings may help in developing dietary 
interventions promoting the MD acceptability, particularly increasing the consumption of 
olive oil among individuals of both Caucasians and East Asians to promote health benefits. 
 
Research questions raised from the present Chapter 2: 
The work described in this chapter raised the following questions: 
1.    What is the acceptability and frequency consumption of nuts and olive oil consumption 
among Caucasians, and East Asians from the evidence of the systematic review and meta-
analysis?  
2.  What is the state of the evidence from interventional studies assessing the impact of 
dietary interventions including nuts and especially olive oil consumption on CVD risk 
factors?  
3.  Is the effect of olive oil on cardiovascular risk factors similar between different ethnic 
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CHAPTER 3 
Efficacy of nutritional interventions supplementing nuts on cardiovascular risk 
factors among adults’ individuals with two ethnicities – Asian and Non-Asian 
population: A systematic review and meta-analysis of intervention studies. 
Abstract  
Background and aims.   Consumption of nuts has been associated with a decreased risk 
of cardiovascular disease events and death. Nevertheless, factors such as ethnicity plays 
a role in this association is still controversial in clinical trials. Therefore, a systematic review 
and meta-analysis of the evidence on the effect of supplementing nuts on CV risk factors in 
different ethnic groups was proposed.  
Methods.   Medline, Web of Science and Scopus databases were searched from inception 
to August 2017 to identify interventional trials assessing the impact of different types of nuts 
on various cardiovascular risk factors. Inclusion criteria were intervention randomized 
controlled trials reporting effects of nuts on CV risk factors among adults and adolescents. 
The outcomes of interest included blood lipids (total-, HDL-, LDL-C, triglycerides, VLDL-C), 
oxidative stress biomarkers (oxidized-LDL), endothelial function (FMD), blood pressure 
(SBP, DBP) and inflammatory biomarkers (CRP, hs-CRP, IL-6, sICAM-1, sVCAM-1, Apo B, 
Apo A-I and adiponectin). The pooled estimates of mean differences is calculated and their 
95% confidence intervals (CIs) by using random-effects models. The protocol has been 
registered with PROSPERO and the systematic review registration number is 
CRD42018089055. 
Results.   From a total of 383 publications identified, 82 studies were included in the final 
selection and were meta-analyzed. Overall, intervention with daily nuts consumption 
ranging approximately between 4.05g and 128g resulted in a significantly more pronounced 
decrease in total cholesterol (mean difference: -7.54; 95% CI: -10.2 to -4.89; p < 0.00001; 
I2= 59%; n = 66 trials), in HDL-cholesterol ( mean difference: 0.89; 95% CI: 0.04 to 1.75; 
P=0.04; I2= 53%; n=67 trials), in LDL- cholesterol (mean difference: -7.21; 95% CI: -9.38 to 
-5.04; P< 0.00001; I2= 68%; n=68 trials), in TG (mean difference: -8.83; 95% CI: -13.12 to -
4.53; P< 0.0001; I2= 64%; n=65 trials), in VLDL-cholesterol (mean difference:  -2.25; 95% 
CI: -3.74 to -0.77; P=0.003; I2=0%; n=10 trials), in Apo B (mean difference: -4.47; 95% CI: 
-7.01 to -1.94; P=0.0005; I2=64%, n=23 trials), in FMD (mean difference: 0.74; 95% CI: 0.09 
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to 1.39; P=0.03; I2=5%, n=10 trials) and in FFA (mean difference: -0.03; 95% CI: -0.05 to -
0.01; P=0.0009; I2=0%, n=4 trials) as compared to controls, respectively. Subgroup analysis 
indicated that the improvement on biomarkers of oxidized-LDL, SBP, Apo B, Apo A-I, CRP 
and sVCAM-1 were more likely to be shown in the Asian population compared with the non-
Asian population although such differences were not statistically significant. Non-Asian 
population is observed to tend to present a better result on TC, HDL-C, LDL-C, TG, VLDL-
C, FFA, adiponectin, hs-CRP, IL-6 and sICAM-1 after nuts intake than Asian population 
although there are also no statistically significant differences between two ethnicities.  
 
Conclusions. These results provide evidence on the beneficial effects of nuts on blood 
lipids, lipids particles and endothelial function. This review also observed no significant 
different effects after nuts consumption between different ethnicities but showed a valuable 
tendency of improvement on cardiovascular markers among two ethnicities. The non-Asian 
group potentially tends to benefit more cardiovascular biomarkers with moderate nut 
consumption than Asian group. Asian population is likely to show improvements on some 
inflammatory markers. These results provide valuable knowledge for designing future 
human clinical trials. However, future large-scale studies need validate and replicate such 
studies and more studies testing biomarkers need to be required on Asian population with 
nut consumption in the near future. Studies might also specifically need to focus on 
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3.1 Introduction  
 
Globally, total consumption of tree nuts has grown by 59% over the last one decade 
(International Nuts & Dried Fruit 2016). Pecans (70%), cashews (60%), and macadamia 
(59 %), followed by almonds experienced the most significant growth in the last 10 years 
(International Nuts & Dried Fruit 2016). In the UK, according to the latest food report from 
global research organization, 44% of existing buyers are buying nuts as an alternative to 
snacks. China is one of the main exporting almonds country in this world and a growth of 
40.063 import from 2004 to 2014 was reported from International Nuts council (INC) 
(International Nuts & Dried Fruit 2016). Therefore, while people consume more nuts, the 
health benefits of nuts consumption especially for cardiovascular health need to be 
researched and recognized.  
 
As a type of nutrient-dense food, nuts contain a high total fat and nearly one half of the fatty 
acid composition of nuts is made up of unsaturated fat, which comprises monounsaturated 
fatty acids (MUFAs; oleic acid) and mostly polyunsaturated fatty acids (PUFAs) including 
linoleic acid and a-linolenic acid (ALA), the plant omega-3 fatty acid especially in walnuts 
(Ros and Mataix 2006, Ros 2009). In addition, nuts are rich sources of bioactive 
macronutrients too as nuts are an excellent source of protein and often contain a high 
content of L-arginine, the amino acid precursor of the endogenous vasodilator nitric oxide. 
Furthermore, nuts are also a good source of dietary fiber ranging from 4 to 11 g/100 g.  
There are also significant micronutrients among nut constituents. Nuts have sizeable 
amounts of folate and they are rich sources of antioxidant vitamins and phenolic compounds 
(Ros 2009). 
 
3.1.1 Nuts and health 
 
Significant evidence from prospective observational studies and clinical trials consistently 
observed that most nut constituents were shown beneficial effects while clinically tested, in 
isolation or as part of enriched foods, for effects on diverse cardiovascular outcomes, 
including both traditional and novel risk markers (Bao, Han et al. 2013, Estruch, Ros et al. 
2013, Aune, Keum et al. 2016). Previous systematic reviews of high walnut intake (Banel 
and Hu 2009) and of moderate tree nuts intake (Del Gobbo, Falk et al. 2015) significantly 
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resulted in a decrease of total and LDL cholesterol for 4-24 weeks of walnuts intake in 13 
trials and 61 trials.  
 
Although there are plenty of studies suggesting the beneficial effects on nuts consumption 
(O'Neil, Keast et al. 2011), evidence of general nuts consumption on CV markers among 
Asian population health remains inadequate. One latest randomized controlled trial testing 
on an Asian Indian population indicated that a single intervention with pistachios exert 
beneficial effects on the cardio-metabolic profile such as TC, LDL-C, hs-CRP, FFAs, 
adiponectin and TNF- α (Mohan, Gayathri et al. 2018). Moreover, 6-week of interventions 
with mixed nuts exerted favourable effects on lipid parameters such as TC and non-HDL-C 
in Korean women (Lee, Nam et al. 2014). According to one latest Chinese systematic review 
(Xiao, Huang et al. 2017), only walnuts significantly improve endothelial function.  
 
3.1.2 Ethnicity and cardiovascular health 
The term ‘ethnic groups’ was referred by Social Research Council (ESRC) as ‘people of the 
same race or nationality with a long-shared history and a distinct culture’ and ESRC defined 
‘ethnicity’ as the ‘intangible quality, or sense of being, derived from that shared racial or 
cultural affiliation’ (Leung and Stanner 2011). Nowadays, there are a rich mix of cultures 
and culturally diverse communities which are related to changes in society such as 
immigration in the UK (Leung and Stanner 2011). Evidence showed that Chinese 
immigration in the UK tend to show a relatively lower risk of CVD than white British, 
Pakistani and other white populations (Bansal, Fischbacher et al. 2013, Li and Ge 2015). A 
survey was launched in Newcastle upon Tyne in the UK which showed that Chinese males 
had a lower TC (5.1 versus 5.6 mmol/L, p < 0.001), lower LDL-C (3.2 versus 3.6 mmol/L, p 
< 0.001) and lower BMI (23.8 versus 26.1 kg/m2, p < 0.001) than European men. Chinese 
women also had lower lipid levels (TC: 4.9 versus 5.4 mmol/l p < 0.001, LDL-C: 2.8 versus 
3.1 mmol/L p < 0.001); and BMI values (23.5 versus 26.1 kg/m2, p < 0.001) (Harland, Unwin 
et al. 1997). 
However, the proportion of Asian people with a high risk CVDs was substantial at BMIs 
lower than the existing WHO cut-off point for overweight (≥ 25 kg/m2) (Barba, Cavalli-Sforza 
et al. 2004) and CVD mortality and morbidity in China were increasing persistent although 
Chinese adults were less likely to report a long-standing illnesses compared with the 
general population (Leung and Stanner 2011). Beside the fact that Asian and Caucasian 
population has different body composition, fat distribution and the associated metabolic 
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profiles due to genetics (Wulan, Westerterp et al. 2010), lifestyle factor, especially dietary 
factor such as nuts consumption, largely play a critical role in the ageing process of heart 
function.  
Currently no study aims to research different effects of general nuts consumption in different 
ethnic groups – Asian (mostly Chinese) and non-Asian population (mostly Caucasians) as 
a systematic review and meta-analysis. To address this knowledge gap, the aim of this 
systematic review is to do a comprehensively quantitative evaluation of the literature and 
perform a meta-analysis by examining whether or not there is any changes particularly in 
markers of endothelial dysfunction (FMD), blood markers including cell adhesion molecules 
(sVCAM-1, sICAM-1), oxidative damage (oxidised-LDL), markers of inflammation (IL-6, IL-
10, CRP) as well as lipid concentrations (TC, HDL-C, LDL-C, TG, VLDL-C, Apo A-I, Apo B) 
induced by a number of interventions with nuts consumption or nut-enhanced diets.  
 
3.2  Subjects and methods 
This project is a systematic review and meta-analysis of randomized controlled trials (RCTs). 
PROSPERO is an international database of prospectively registered systematic reviews in 
health and social care, welfare, public health, education, crime, justice, and international 
development, where there is a health-related outcome 
(http://www.crd.york.ac.uk/PROSPERO/#index.php). The motivations for registration are 
related to ensure transparency in the review process, helps counter publication bias by 
providing a permanent record of prospectively registered reviews, irrespective of whether 
they are eventually published or not. The protocol has been registered with PROSPERO, 
the International Prospective Register of Systematic Reviews, indexed under (Registration 
number CRD 42018089055). 
This systematic review was undertaken in adherence with the established methods 
recommended by the Cochrane (Higgins and Green 2011) and the Centre for Reviews and 
Dissemination guidelines  (Centre for Reviews and Dissemination 2009, Tacconelli 2010).  
This systematic review is also reported according to PRISMA guidelines (Moher, Liberati et 
al. 2009) (Appendix B1) as PRISMA concentrates on reporting of reviews evaluating 
randomized trials as well as reporting systemic reviews/ meta analyses of a wide range of 
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3.2.1 Search strategy and study inclusion criteria 
A complete search of the interventional trials on nuts was undertaken through August 2017 
in the following electronic databases: MEDLINE (beginning 1990 until August 2017) 
(http://www.pubmed.gov); Scopus (beginning 1966 until 2017) (website: 
https://www.scopus.com/home.uri); Web of Science (beginning 1991) (website: 
http://apps.webofknowledge.com/WOS_GeneralSearch_input.do?product=WOS&search_
mode=GeneralSearch&SID=U2g4OpjuGuzA2LJM3qP&preferencesSaved=). 
The search strategies as performed comprehensively and the following search term were 
covered: (“Cardiovascular risk factors” OR “Cardiovascular diseases”) AND (“endothelial 
function” OR “endothelial dysfunction” OR “flow-mediated dilation” OR “FMD” OR “arterial 
stiffness” OR “carotid intima-media thickness” OR “intercellular adhesion molecule-1” OR 
“ICAM-1” OR “vascular cell adhesion molecule-1” OR “VCAM-1” OR “e-selectin” OR “p-
selectin” OR "dimethylarginine" OR “ADMA” OR " oxidized low density lipoprotein" OR 
"oxidized-LDL" OR “inflammation” OR “C-reactive protein” OR “CRP” OR “LDL cholesterol” 
OR “HDL cholesterol” OR “triglycerides” OR “total cholesterol” ) AND ( “walnuts” OR “nuts”) 
AND (“randomized controlled trial” OR “randomized” OR “clinical trial as topic” OR “placebo” 
OR “randomly” OR “trial”) NOT (“animal”). The systematic review registration is 
CRD42018089055. 
If a site-specific dataset had been published more than once, most current publication was 
used. English language restrictions were imposed, and duplicate citations were removed. 
In addition, a manual search of references from primary or review articles was performed 
to identify additional relevant trials. Literature search was conducted independently by three 
authors (FL, JL, and HMC), with disagreements resolved by consensus. Furthermore, for 
each of the relevant abstracts, full publications were retrieved for evaluation on the basis of 
criteria established a priori. 
3.2.2 Study selection 
The selection of references throughout the search strategy and the data extraction was 
performed consistent with specific criteria which are delineated below/ the following 
inclusion criteria were defined prior to study selection process:  
a) Nutritional/dietary interventions: Interventions with evaluating the use of nuts (in any 
types or doses) versus a control or placebo group.  
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b) Study design: Randomized controlled trials (RCTs) on human subjects with either 
parallel or crossover design – Crossover trials that reported data separately among 
different treatment periods were analysed and recorded as a parallel trial using data 
from the first period; Length of study: minimum intervention period of four days. 
c) Subjects: adults.  
d) No other supplementation. 
e) Assessment of the “outcome of interest”: Markers of inflammation (C-reactive protein, 
interleukin-6, TNF-α, adiponectin); endothelial function/endothelial dysfunction 
(intercellular adhesion molecule-1, vascular cell adhesion molecule-1, flow-mediated 
dilatation, pulse wave velocity, nitric oxide); Blood lipids (plasma TC, HDL-C, LDL-C, 
VLDL-C, TG, Apo B and Apo A-I); Serum markers of oxidative status (e.g., ox-LDL). 
Reporting data on at least one of the following endpoints: total cholesterol, LDL 
cholesterol, HDL cholesterol or triglycerides. 
f) Report of post-intervention mean values (or if not available, change from baseline 
values were used instead) with standard deviation (or basic data which allow to 
calculate these parameters, i.e., standard errors, 95% confidence interval, p-values). 
Exclusion criteria mainly included:  
a) Studies that reported redundant results of the same RCT. 
b) Non-interventional studies and interventions not involving any kinds of nuts; or 
interventions combined interventions in which the effects of nuts cannot be singled 
out; or interventions are acute  
c) Outcomes: non-cardiovascular outcome measures. 
d) PREDIMED studies with the Mediterranean diet 
Two investigators reviewed potentially relevant articles independently with discrepancies 
being resolved through consensus (JL, FL). Institutional review board approval was not 
necessary for this systematic review.  
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3.2.3 Data extraction and management /Strategy for data synthesis 
The full text of studies meeting inclusion criteria was recovered and screened to determine 
eligibility by 2 reviewers (FL, JLG). Following assessment of methodological quality, an 
independent reviewer FL extracted data onto a purpose-designed data extraction form and 
summaries containing the most important results from each paper. Descriptive data 
extracted included: study design, year of publication, country of origin, randomization, 
duration and length of follow-up, design of RCTs (parallel or crossover), methods of analysis, 
completion rates; participant characteristics (population, settings of interventions, baseline 
characteristics, mean (range) age, gender distribution of study participants, sample size); 
outcome measures (dietary and/or nutritional intake, body mass index, CV biomarkers) 
were summarized in Table 3.1; the 2 reviewers confirmed all data entries. Description of 
nuts intervention and respective control. Study quality was assessed using the Cochrane 
risk of bias tool (Higgins and Green 2011, Cuevas-Ramos, Almeda-Valdes et al. 2013). 
The primary outcomes of the analyses were changes in CV risk factors after nuts 
consumption. Measures included blood lipids (TC, LDL-C, and HDL-C, TG, VLDL-C, Apo 
B, Apo A-I, ox-LDL), assessment of endothelial function by FMD, PWV, SBP and DBP.  
3.2.4 Quality assessment 
An assessment of bias in the included manuscript was performed by the Cochrane criteria 
(Higgins JP and S 2008). The objects used for the assessment of manuscripts were 
including: acceptability of random sequence generation, distribution concealment, blinding 
of subjects, employees and consequence assessment, talking of drop-outs, selective 
outcome reporting, and additional possible causes of bias (Higgins and Green 2011). 
3.2.5 Statistical analysis 
The software Review Manager (RevMan Version 5.1 for Windows Copenhagen: The Nordic 
Cochrane Centre, The Cochrane Collaboration, 2011) was used to pool and analyse results 
from the individual studies. Pooled results are reported as mean differences with 95% CIs 
and with two-sided P-values. However, when variables (such as IL-6 or CRP, and ICAM-1) 
were reported by mean differences (MD) and a summary statistic for comparing effect sizes 
across studies were used. Subgroup analysis was undertaken to evaluate the difference of 
cardiovascular markers in two ethnicities based on the participants’ country as well as 
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participants’ ethnicity which are reported from studies included in our review. The subgroup 
of ethnicity was extracted from studies reporting ethnicity of their participants while the 
subgroup of country was extracted from all studies in our review. Because the country of 
published paper does not 100% represent the ethnicity of the participants, therefore in order 
to ensure the accuracy of the ethnicity of including participants, two subgroups were 
abstracted. It reported that studies originated from non-Asian regions are more than studies 
originate from Asian countries. In addition, meta-regression analysis was used to assess 
the association between cardiovascular markers with the amounts and the length of nuts 
consumption.  
A random effects model accounting for inter-study variation was used, thereby minimizing 
potential bias due to methodological differences between studies. Multiple dietary 
intervention arms from three studies were included in the meta-analysis. Following previous 
guidance (Higgins and Green 2011) excessive weightings from “double counts” arising from 
the “shared” group (in this case, the control group) were controlled by splitting the sample 
size of the shared group into approximately equal smaller groups for the comparisons. In 
this analysis we sought to extract and analyse adjusted results from multivariate models, if 
reported in the studies. 
Heterogeneity was evaluated using the I2 statistic (Centre for Reviews and Dissemination 
2009, Higgins and Green 2011). Levels of heterogeneity are commonly regarded as high 
when I2 values are >70%. Publication bias was appraised by visually inspecting the funnel 
plot, and supplemented with calculations of the Egger's regression test (Egger, Davey Smith 
et al. 1997). Quality of studies was assessed using the Jadad system (Jadad, Moore et al. 
1996). 
3.3  Results 
3.3.1 Flow of studies 
The searches yielded 199 citations of which 89 were retrieved for complete review after de-
duplication and results of the screening process through a manual reference search of 
primary and review articles are described in Figure 3.1. In total,  89 publications that met 
inclusion criteria were included in the present systematic review (Table 3.1) (Sabate, Fraser 
et al. 1993, Chisholm, Mann et al. 1998, Spiller, Gates et al. 1998, Kris-Etherton, Pearson 
et al. 1999, Curb, Wergowske et al. 2000, Rajaram, Burke et al. 2001, Iwamoto, Imaizumi 
et al. 2002, Sabate, Haddad et al. 2003, Hiraoka-Yamamoto, Ikeda et al. 2004, Ros, Nunez 
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et al. 2004, Tapsell, Gillen et al. 2004, Chisholm, Mc Auley et al. 2005, Tamizifar B 2005, 
Kocyigit, Koylu et al. 2006, Kurlandsky and Stote 2006, Schutte, Van Rooyen et al. 2006, 
Perez-Martinez, Lopez-Miranda et al. 2007, Sheridan, Cooper et al. 2007, Gebauer, West 
et al. 2008, Griel, Cao et al. 2008, Olmedilla-Alonso, Granado-Lorencio et al. 2008, 
Claesson, Holm et al. 2009, Rajaram, Haddad et al. 2009, Tapsell, Batterham et al. 2009, 
Brennan, Sweeney et al. 2010, Ghadimi Nouran, Kimiagar et al. 2010, Lopez-Uriarte, 
Nogues et al. 2010, Ma, Njike et al. 2010, Rajaram, Connell et al. 2010, Torabian, Haddad 
et al. 2010, West, Krick et al. 2010, Wien, Bleich et al. 2010, Wu, Pan et al. 2010, Casas-
Agustench, López-Uriarte et al. 2011, Davidi, Reynolds et al. 2011, Din, Aftab et al. 2011, 
Li, Liu et al. 2011, Sola, Fito et al. 2011, Tey, Brown et al. 2011, Aronis, Vamvini et al. 2012, 
Chiang, Haddad et al. 2012, Foster, Shantz et al. 2012, Mohamedou, Tacha et al. 2012, 
Sola, Valls et al. 2012, West, Gebauer et al. 2012, Damasceno, Sala-Vila et al. 2013, Liu, 
Liu et al. 2013, Orem, Yucesan et al. 2013, Somerset, Graham et al. 2013, Tey, Gray et al. 
2013, Bento, Cominetti et al. 2014, Burns-Whitmore, Haddad et al. 2014, Colpo, Vilanova 
et al. 2014, Gulati, Misra et al. 2014, Lee, Nam et al. 2014, Moreira Alves, Boroni Moreira 
et al. 2014, Parham, Heidari et al. 2014, Sauder, McCrea et al. 2014, Sweazea, Johnston 
et al. 2014, Berryman, West et al. 2015, Carvalho, Huguenin et al. 2015, Chen, Holbrook et 
al. 2015, Huguenin, Moreira et al. 2015, Jamshed, Sultan et al. 2015, Njike, Ayettey et al. 
2015, Ruisinger, Gibson et al. 2015, Sauder, McCrea et al. 2015, Agebratt, Ström et al. 
2016, Dhillon, Tan et al. 2016, Bamberger, Rossmeier et al. 2017, Lee, Berryman et al. 
2017, Mah, Schulz et al. 2017, Zibaeenezhad, Farhadi et al. 2017, de Souza, Gomes et al. 
2018, Jenkins, Kendall et al. 2018, Jung, Chen et al. 2018, McKay, Eliasziw et al. 2018, 
Mohan, Gayathri et al. 2018) However, 91 studies did not meet the inclusion criteria and 
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Records after duplicates removed 
 (Medline n= 96) 
(Scopus n= 177) 
(Web of Science n= 135) 



















Records screened  
(Total n = 198)  
Records excluded titles/abstracts  
(n = 210) 
Full-text articles assessed 
for eligibility (RCTs). 
(n = 88) 
Final studies included in 
qualitative & quantitative 
synthesis (meta-analysis) 
(n = 82) 
Full-text articles excluded, with reasons  
(n = 110) 
Reasons for paper exclusion: 
Not RCTs (n=23)  
No valuable data provided (n=16)  
Data cannot be analyzed: Statistics could not be 
calculated from the data reported in papers (n=6)  
Acute study (n=11)  
Aim for erectile function (n=1); weight reduction (n=2)  
Inactive placebo/control group (n=14)  
No control group or control group data (n=5)  
PREDIMED study with Med diet (n=18)  
Same study: Studies that reported redundant results of 
the same RCT (n=3) 
Interventions combined interventions in which the 
effects of nuts cannot be singled out (n=6)  
Adolescents (n=2)  
Study cannot be found (n=1)  
Intervention is not nuts (n=2) 
 
Fig. 3.1. PRISMA flow diagram of selection of studies on a variety of nuts consumption and CV risk factors. 
 
 
- 89 - 
 
3.3.2 Literature Search and Study Characteristics 
From the overall pool of 88 RCTs that met the inclusion criteria (Table 3.1), six studies originated from East 
Asian ethnicity in total: 2 studies from Japan, 1 study from South Korean, two studies from Taiwan China and 
one study from Shanghai China. 77 studies originated from non-Asian ethnicity countries: 37 trials from USA, 6 
trials from Spain, five articles from Canada and Brazil respectively, 4 trials from Australia and Iran respectively, 
3 studies from UK and New Zealand respectively, 2 trials from India and Turkey respectively. Single study from 
Greece, Sweden, Pakistan, Morocco, South Africa and Italy respectively. In addition, 22 studies reported 
ethnicity of participants. three papers recruited 100% Caucasian while 14 trials had participants mostly 
constituting of Caucasian (white) population. One study recruited 100% Indians, 2 study recruited 100% 
Japanese, 2 study recruited 100% Chinese. 6 studies out of 88 RCTs are not quantitative synthesized into meta-
analysis. 
Table 3.1 present the general characteristics and results of the 82 included papers. Forty-seven studies used a 
randomized crossover design, and 35 studies are parallel design. The pooled study population meta-analyse 
included 3814 participants who were followed-up for approximately 14 weeks on average and the study duration 
varied between 4 days and 18 months. The mean ages of the samples in these studies ranged from 18 to 75 
years and mean age is 47 years. Participants had existing disease conditions in 58.5% (48/82) of all randomized 
controlled trials (Table 3.1). Table 3.1 shows a brief summary of different dose of nuts for different types of nuts 
in numbers of papers included in this review.  
Overall, intervention of mixes of nuts includes a variety of nut types of cashews, peanuts, walnuts, almonds, 
pistachios, hazelnuts, Brazil nuts, macadamias, pine nuts and pecan nuts which were included in 82 studies. 
The control group consists of a variety of fruits or muffins or habitual diet or qualitative recommendations 
according to the American Heart Association dietary guidelines.  According to Table 3.3, this meta-analysis 
includes most trials examined walnuts (25 studies) followed by pistachios (13 studies). The largest amount of 
nut consumption is pistachio and the average amount per day consumption reaches 76.6 grams. Daily 
consumption of pecans and cashews is also high, and they are 70 grams and 72.3 grams respectively. In addition, 
seven studies do not clarify the dose of nut intake.  
3.3.3 Meta-analysis of studies consuming nuts  
Meta-analysis of effects of nuts consumption was undertaken on 28 outcome parameters. Main biomarkers 
include blood lipids (TC, HDL-C, LDL-C, VLDL-C, Apo A-I and Apo B); inflammatory biomarkers (E-selectin, P-
selectin, ICAM-1, VCAM-1); pro-inflammatory cytokines (CRP, hs-CRP, IL-1, IL-6, TNF-alpha); anti-
inflammatory cytokines (adiponectin, IL-10); chemokines (MCP-1); oxidative stress biomarkers (oxidized LDL); 
markers of nitric oxide bioavailability (FMD); markers of measuring arterial stiffness (PWA, PWV); antioxidant 
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biomarkers (TAC); factors affecting endothelial function (nitric oxide) and blood pressure (SBP, DBP). However, 
only 8 outcomes were presented to be improved after nuts intake.  
Forest plots present pooled mean differences with 95% confidence intervals (CI) for randomized controlled 
studies. For each study in each figure, the shaded square represents the point estimate of the intervention effect. 
The horizontal line joins the lower and upper limits of the 95% CI of these effects. The area of the shaded square 
reflects the relative weight of the study in the respective meta-analysis. The diamond at the bottom of the graph 
represents the pooled MD with the 95% CI for all study groups. Pooled estimates of effects size for all markers 
of positive results after nut consumption are summarized in Table 3.2.  
4 papers representing 156 participants reported results for FFA (mmol/L). Overall, nuts interventions significantly 
reduced by 0.03 (95% CI: -0.05 to -0.01; P=0.0009; I²=0%) in comparison with the control groups; the levels of 
heterogeneity are low: I² = 0% (Fig 3.2).  
Figure 3.2. Effects of nuts consumption on FFA (mmol/L).  
 
Forest plot showing pooled mean differences with 95% confidence intervals (CI) for randomized controlled diets. For each study, the shaded square 
represents the point estimate of the intervention effect. The horizontal line joins the lower and upper limits of the 95% CI of these effects. The area of the 
shaded square reflects the relative weight of the study in the respective meta-analysis. The diamond at the bottom of the graph represents the pooled MD 
with the 95% CI for all study groups. 
 
Markers of blood lipids cholesterol and apolipoproteins – TC, TG, HDL-C, LDL-C, VLDL-C and Apo B 
71 studies representing 3670 participants assessed the impact of nuts on total cholesterol (TC) concentrations 
(Fig 3.3). Overall, nuts intake significantly reduced the level of TC by 7.19 mg/dL (95% CI: -9.66 to -4.72; P < 
0.00001; I²=57%) in comparison with the control groups; the levels of heterogeneity are low: I2 = 57% (Fig 3.3). 
A funnel plot of the mean differences in TC concentrations levels against standard error (SE) of all studies 
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Figure 3.3. Effects of nuts on blood lipids: TC (mg/dL).  
 
Figure 3.4. Effects of nut consumption on blood lipids:  HDL-C (mg/dL). 
67 studies, including 3063 participants, evaluated the impact of nuts consumption on HDL-C. Overall, nut 
consumption significantly increased HDL-C by 0.95 mg/dl (95% CI: 0.16 to 1.74; p=0.02). Heterogeneity levels 
assessed by the I2 test were low at 52% (Figure 3.4). A funnel plot of the mean differences in HDL-C levels 
against SE of all studies indicates that slightly symmetry suggesting the absence of publication bias (Fig. 3.11).  
 




68 studies, including 3059 participants, evaluated the impact of nut consumption on LDL-cholesterol. Overall, 
nut consumption significantly reduced LDL-cholesterol by 7.21 mg/dl (95% CI -9.38 to −5.04; p < 0.00001). 
Heterogeneity levels assessed by the I² test were low at 68% (Fig 3.5). A funnel plot of the mean differences in 
LDL-C levels against standard error (SE) of all studies shows slightly asymmetry (Fig 3.12) suggesting that the 
presence of publication bias.  
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Figure 3.5. Effects of nut consumption on plasma LDL-C (mg/dl). 
 
65 studies, including 3028 participants, evaluated the impact of nut consumption on triglycerides. Overall nut 
consumption significantly reduced triglycerides by 8.83 mmHg (95% CI -13.12 to −4.53; p < 0.0001). 





- 94 - 
 
Figure 3.6. Effects of nut consumption on plasma triglycerides (mg/dl). 
 
Ten studies, including 520 participants, evaluated the impact of nut consumption on plasma VLDL-cholesterol. 
Overall nut consumption significantly reduced plasma VLDL-cholesterol by 2.25 mg/dl (95% CI -3.74 to −0.77; 
p = 0.003). Heterogeneity levels assessed by the I2 test were low at 0% (Fig. 3.7).  
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Figure 3.7. Meta-analysis of studies consuming nuts on plasma VLDL-C (mg/dl). 
 
 
Figure 3.8. Meta-analysis of studies consuming nuts on Apo B (mg/dl). 
23 studies, including 897 participants, evaluated the impact of nut consumption on Apo B. Overall, nut 
consumption significantly reduced Apo B by 4.47 mg/dL (95% CI -7.01 to −1.94; p = 0.0005). Heterogeneity 
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3.3.4 Subgroup analysis 
Table 3.4 reports the difference of outcomes between ethnicity and country subgroups overall. Most outcomes 
comparisons showed no statistically significant difference between Asian and non-Asian groups in either 
subgroup of ethnicity or subgroup of country as P-values were > .05. Only two outcomes – lag time of LDL and 
TAC reported in the subgroup of country observed that there is statistical significance between Asian and non-
Asian groups as p-values equal to 0.0004 and less than 0.0001 respectively and non-Asian population has a 
significant improvement on these two variables. However, only two studies reported lag time of LDL and three 
studies reported TAC.  
Generally, non-Asian populations showed a tendency to have better improvement after nuts consumption in 
blood lipids - TC, HDL-C, LDL-C, and TG; FFA, adiponectin, IL-6, sICAM-1 and hs-CRP than Asian population 
although there is no statistically significant difference between Asian and non-Asian population as shown in 
Table 3.4. Evidence according to Table 3.4 also indicated that nuts consumption showed better results on 
oxidized-LDL, SBP, Apo B, Apo A-I, CRP and sVCAM-1 in Asian individuals compared with non-Asian 
individuals in both subgroups of ethnicity and country although there is no statistically significant difference 
between Asian and non-Asian population.  
In addition, FMD were only reported by non-Asian population based on country origin. DBP in non-Asian groups 
are consistently shown to decrease, but there are two studies originating from Asia reporting opposite results 
concerning DBP. VLDL-C was only reported by non-Asian studies. As for TNF-alpha cytokines, studies reporting 
non-Asian population showed inconsistent results due to inadequate studies from Asian population based on 
Table 3.4.  
Meta-regression analysis (Figure 3.15 ~ 20) was performed by mixed effects regression (unrestricted maximum 
likelihood) to evaluate the relationship of the cardiovascular biomarkers with difference in means in amounts of 
mixed nuts consumption or the length of nuts consumption. The meta-regression analysis showed that greater 
dose of nuts may be associated with lower TG.  
3.3.5 Study quality 
Table 3.5 shows the methodologic quality of included studies in the meta-analysis. The Jadad rating scale was 
used to score the randomized trials from 1 to 5 points (Jadad, Moore et al. 1996, Clark, Wells et al. 1999). From 
a total of 82 papers, 14 studies were rated as 5 points, whereas 13 studies were rated as 4 points. 79 studies 
reported good feasibility and acceptability while one study reported bad feasibility and acceptability as no 
answers from participants to explain the reason why they did not follow (Table 3.1). The other one study reported 
nine dropouts due to poor compliance and another study reported compliance was weak as shown in Table 3.5. 
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61 studies described methods for monitoring or verifying patient compliance. Participant withdrawal or no 
dropouts from all 82 trials were addressed in 69 studies whereas 13 studies did not clarify dropout reasons. All 
82 studies were randomized, but only 32 studies reported the appropriate method of random number generation 
whereas 60 studies did not report generation of random methods. Allocation concealment of treatment were 
addressed in only 6 trials.   
 
 3.3.6 Publication bias 
The visual inspection of funnel plots (see Supplemental Figure 3.9-14) and Egger’s tests provided mixed 
evidence for a publication bias. Egger’s test and publication bias were completed by Comprehensive meta-
analysis V2. Seven outcomes including TC, HDL-C. LDL-C, TG, VLDL-C, Apo B and FMD were reported into 
funnel plots and detected by using Egger’s tests as these outcome parameters were reported by equal or more 
than 10 trials. 
TC (p=0.16368), HDL-C (p=0.31179), LDL-C (p=0.07333), TG (p=0.61396) and VLDL-C (p=0.21059) presented 
no apparent bias as indicated by Egger’s test. However, the plots of TC (Fig. 3.10), HDL-C (Fig. 3.11), LDL-C 
(Fig. 3.12), TG (Fig. 3.13) and VLDL-C (Fig. 3.14) were shown to be asymmetrical. 
Egger’s test observed that publication bias was presented in outcomes including Apo B (P=0.00006) as the plots 
of Apo B (Fig. 3.14) was shown to be asymmetrical.   
 
3.4 Discussion 
3.4.1. Principal findings 
As far we are aware, this is the first meta-analysis of 82 randomized controlled trials involving 3814 participants 
to overall assess the effects after consuming 10 types of nuts on CV risk factors for averagely 14 weeks between 
Asian and non-Asian population. Meta-analysis showed that consuming variable doses of nuts (Table 3.3) 
significantly improved TC, HDL-C, LDL-C, TG and VLDL-C indexes with low heterogeneity in comparison with 
baseline or placebo. Outcomes such as FFA, Apo B and FMD levels also are significantly improved after nuts 
consumption compared with various inactive control diets (Table 3.2). More importantly, our findings highlight 
the different effects after consuming nuts between Asian and non-Asian ethnicity. Subgroup analysis based on 
ethnicity indicated that nuts consumption tended to exert a better result on oxidized-LDL, SBP, Apo A-I, Apo B, 
CRP, TNF-α and sVCAM-1 among the Asian group compared with the non-Asian population although such 
differences were not statistically significant. In comparison, non-Asian population achieved a better improvement 
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on biomarkers including blood lipids such as TC, HDL-C and TG, DBP, FFA, adiponectin, lag time of LDL, TAC, 
hs-CRP, sICAM-1 and IL-6 than Asian group.  
The results of this systematic review and meta-analysis are in agreement with earlier reports such as a 
systematic reviews and meta-analysis of randomized controlled clinical trials. One study revealed that different 
types of nut consumption with different amounts exert no significant effect on CRP, IL6, adiponectin, IL10, and 
TNF-a (Mazidi, Rezaie et al. 2016). To evaluate endothelial function, one of the standard non-invasive tools is 
FMD, which is considered to reflect the local bioavailability of endothelium-derived vasoactive substances such 
as NO or endothelin-1 (Schroeder, Enderle et al. 1999). The systematic review suggested that walnuts 
consumption significantly improved endothelial function with duration less than 18 weeks, nut dose less than 67 
gram per day or subjects with baseline FMD => 8.6% (Xiao, Huang et al. 2017). Correspondingly, a significant 
improvement in FMD with 0.79% of weighted mean differences after nuts intake was observed by a meta-
analysis (Neale, Tapsell et al. 2017) and a meta-analysis of cohort studies also found a significant reduction in 
risk of cardiovascular events per 1% increase in FMD (Inaba, Chen et al. 2010). Decreased values of FMD are 
considered to be early markers of atherosclerosis as well as a predictor of future CVD events (Inaba, Chen et 
al. 2010). 
According to study (Banel and Hu 2009), high-walnuts-enriched diets significantly decreased total and LDL-C 
for trials. Tree nuts overall intake were shown to lowers total cholesterol, LDL cholesterol, Apo B, and 
triglycerides (Del Gobbo, Falk et al. 2015). In addition, a pooled analysis of 25 trials indicated that blood lipids 
including TC, LDL-C and TG are improved after a daily consumption of 67g of nuts (Sabate, Oda et al. 2010). 
However, our finding of no significant effects on blood pressure and inflammatory biomarkers CRP, TNF-α, IL-
6, ICAM-1, VCAM-1 or the anti-inflammatory biomarker adiponectin reflects the body of evidence available. 
Characteristics of the study sample or design of the dietary intervention may influence the ability to detect these 
effects. 
 
3.4.2 Strengths and limitations 
The strengths of these findings included that it used a systematic methodology following current guidelines for 
systematic reviews, including prospective registration and used the Jaded Score to evaluate the quality of 
evidence. The low levels of heterogeneity surrounding the results although each study had its own follow-up 
periods, inclusion criteria, basic health condition, carried periods of life, amounts of nuts and gender. High 
compliance of intervention diets and high retention rate were reported by most trials. Our systematic search 
makes it unlikely that large reports were missed, and error and bias were minimized by independent, duplicate 
decisions on study inclusion and data extraction. Effect sizes were standardized to a common dose. Furthermore, 
the duration of trials (average 14-week) was adequate to achieve changes and stabilization of lipid values (Kris-
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Etherton and Dietschy 1997). We evaluated multiple CVD risk factors, including 28 outcomes; separately 
evaluated 9 types of nuts. These biomarkers were selected to reflect changes in disease progression and 
amelioration to explore mechanisms responsible for the favorable effects of nut consumption on CVD (Luo, 
Zhang et al. 2014) and other chronic conditions (Ibarrola-Jurado, Bullo et al. 2013, Afshin, Micha et al. 2014). 
The identified trial populations were relatively diverse, including differences in age, sex, baseline comorbidity 
status, and background diets, enhancing the generalizability of our findings and make our findings may apply to 
a broad population. In addition, with the intention of identifying the different effects of nuts consumption between 
two ethnicities in all 82 randomized controlled trials, outcomes were compared by two subgroups, which are 
ethnicity and country. This improves the accuracy on identifying different effects of nuts consumption on ethnic 
groups.  
Potential limitations should be considered when the results are interpreted. Compliance which was sometimes 
assessed by self-report in most included RCTs would cause overestimation of effects. There are limitations with 
meta-analysis as well. Primarily, a meta-analysis is limited by the methods, reported outcomes, and quality of 
the individual studies. When individual studies clearly describe their methods, fewer assumptions are made in 
data extraction and analysis when pooling multiple studies together. Nevertheless, larger numbers of trials in an 
analysis make it less likely that such errors could materially alter a final result.  
Publication bias is another concern with meta-analyses. Negative or null findings fail to be submitted and/or 
accepted for publication. Despite extensive literature searches, meta-analysis can include only those studies 
that are published. Given that the pro-inflammatory cytokines such as TNF-α, IL-6 and CRP which 
characteristically induce endothelial cell activation also appeared unchanged, the lack of difference found for 
ICAM-1 and VCAM-1 is perhaps not surprising. There is also a concern that although final results show a 
significant improvement in lipids markers - LDL-C, VLDL-C and HDL-C. Apo A-I, which is the major protein in 
HDL-C, was not shown to increase but remained zero.  
Our subgroup analysis addresses limitations as well. Although in our review we included as many outcomes as 
possible to pool and analyze, there is possibility that inadequate and imbalanced numbers of studies between 
Asian and non-Asian countries leading to no statistical significant difference in the majority of outcomes between 
Asian and non-Asian population.  Two markers – Lag time of LDL and TAC were shown statistically significant 
difference between two ethnicities may be not representative because only two and three studies reported 
respectively.  
 
3.4.3 Scientific analysis of findings 
Frequent nut intake may improve biomarker outcomes via multiple mechanisms. Nuts are rich in unsaturated 
fatty acids and most contain substantial amounts of monounsaturated fatty acids (MUFA), which are important 
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contributors to the beneficial health effects namely prevention from the development of CVDs, lowering blood 
cholesterol and improvement of endothelial function (Ros and Mataix 2006). Specifically, Brazil nuts and pine 
nuts contain similar proportions of MUFAs and PUFAs especially linoleic acid, which is a polyunsaturated 
omega-6 fatty acid. Walnuts are rich in both LA and α-Linolenic acid (ALA), which is the plant n-3 fatty acid. Nuts 
that contain vitamin E include almonds, hazelnuts and peanuts. Walnuts, hazelnuts, pistachios, cashews, 
pecans, pine nuts, macadamias and Brazilian nuts all contained oleic and linoleic acid. Oleic acid is also found 
in almonds. Hazelnuts contain the most oleic acid, while walnuts contain the most linoleic acid. In addition, nuts 
are complex food matrices that also are sources of other bioactive compounds, namely: macronutrients, such 
as vegetable protein and fiber; other nutrients, such as potassium, calcium, magnesium, and tocopherols; and 
phytochemicals, such as phytosterols and phenolic compounds, among other bioactive compounds, such as 
resveratrol and arginine (Kris-Etherton, Yu-Poth et al. 1999). Phytosterols in nuts relate to the LDL-cholesterol 
response observed after nuts consumption (Escurriol, Cofan et al. 2009). 
 
3.4.4 Implications for health and future research 
The results of this review have important public health implications. A significant decline in vascular risk factors 
after average 14-week duration of a variety of nut consumption may potentially have important implications in 
primary prevention of atherosclerosis, cardiovascular diseases and cardiovascular mortality.  
Reduced values of FMD are regarded to be early markers of atherosclerosis (Celermajer, Sorensen et al. 1992) 
as well as a predictor of future CVD events (Celermajer, Sorensen et al. 1992, Inaba, Chen et al. 2010). In 
relation with our findings on FMD, studies showed that increases in FMD of 1% increase, independently of 
confounding factors, are associated with reductions ranging from 10% to 13% in the risk of cardiovascular events 
(Inaba, Chen et al. 2010, Xu, Arora et al. 2014, Matsuzawa, Kwon et al. 2015).  
Apolipoprotein A-I (Apo A-I) and Apolipoprotein B (Apo B) are two important components involved in lipid 
transport and in the processes causing atherosclerosis and CVD. Apo B, as the major protein in VLDL-C, is a 
stronger marker of cardiovascular risk for Caucasian (Sniderman, Islam et al. 2012) and for Chinese (Chien, 
Hsu et al. 2007) across varying age-groups and geographic regions than conventional lipids, lipoproteins 
markers (Schmidt and Bergstrom 2014). Therefore, a significant reduction in Apo B in both ethnicities supported 
healthy benefits with moderate nut intake in the present meta-analysis.  
According to the study (Baigent, Keech et al. 2005), 1 mmol/L decrease in LDL-cholesterol is associated with a 
23% reduction in myocardial infarction or coronary death and 12% reduction in all-cause mortality. Similarly, 
another study showed that 1 mmol/L decrease in LDL-cholesterol equates to a decrease in relative risk for stroke 
of 21.1% (Amarenco and Labreuche 2009). Consequently, in the present meta-analysis, there would be equally 
around a 4.4% reduction in myocardial infraction or coronary death, almost 2.3% decrease in all-cause mortality 
and approximately 4% reduction in risk of stroke after nut consumption.  
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3.4.5 Unanswered questions and future research 
This work has observed the effect of well-established cardiovascular biomarkers such as blood lipids cholesterol, 
Apo B, FMD, with less evidence on inflammatory biomarkers (sICAM-1, sVCAM-1, PECAM-1 and E-selectin). 
ApoB/apoA-I ratio, pro inflammatory cytokines (CRP, TNF-alpha, IL-1 and IL-6), anti-inflammatory cytokines (IL-
4, adiponectin, IL-10), chemokines (IL-8 and MCP-1) antioxidant biomarkers and oxidative stress biomarkers. 
These CV markers should be informative and researched in the near future. Further ongoing trials with 
standardized dosing and more Asian studies are also required to clarify the different effects nuts for the 
prevention of CVD among the Asian and non-Asian population.   
 
3.5 Conclusions 
In conclusion, this systematic review and meta-analysis of controlled trials observed that nuts consumption 
significantly lowers total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides, VLDL-cholesterol, 
Apolipoprotein B (ApoB) and flow-mediated dilatation (FMD). Our findings also highlight the different effects of 
nuts intake between Asian and non-Asian population. This review observed no significant different effects after 
nuts consumption between different ethnicities but showed a valuable tendency of improvement on 
cardiovascular markers after nut intake among Asian and non-Asian population. Overall two ethnicities both 
achieved improvements on inflammatory biomarkers and lipids. Non-Asian population tends to obtain 
improvements on more CV markers than Asian population after nuts consumption. Specifically, non-Asian 
population seem to be more likely to improve better on blood lipids (TC, HDL-C, LDL-C, TG, VLDL-C), 
inflammatory biomarker (sICAM-1, IL-6) and anti-inflammatory cytokines (adiponectin) than Asian population 
after middle-term period of nuts intake while Asian group may also have the likelihood of presenting a better 
improvement on some biomarkers such as apolipoprotein (Apo A-I, Apo B), pro-inflammatory cytokines (CRP), 
inflammatory biomarker (sVCAM-1) and blood pressure (SBP). Although large-scale studies are needed to 
validate and replicate to test the nuts effects on different ethnicities, these results in the present review have 
potential public health implications and support the development of promising individualized nutritional strategies 
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canola oil  
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24wks Walnut diet 46g/d Habitual diet 100 Good 4 


















100 Good 4 




















AAD 100 Good 5 
 
- 115 - 
 



















16wks Almonds diet 60g/d No nuts 83.1 Good 5 

















8wks Walnut diet 43g/d Western-
type diet 
70.2 Good 5 
Zibaeenezhad 























93.8 Good 5 
 
- 116 - 
 























n length  
Intervention  Dose & 
frequenc
y  
















3wks Macadamia nuts 
bread 
10g/d  Coconuts breads 100 
 Iwamoto 






Japanese  23.7±SEM0.9y 50 21.45±SEM0.
5 
Healthy Total n=40 4wks Walnut diet  51g/d Reference diet 100 





Korean 52.4±0.6y 13.1 25.4±0.22 Overweight 





4wks  Roasted 
almonds 
56g/d 70 g/d isocaloric 
home-made cookies 
93 






Korean 35-65y 0 27.1±2.1 MS Nut n=30;  
Control 
n=31 
6wks Mixed nuts 
(walnuts, 
peanuts, and 
pine nuts)  
30g/d Control diet 98.36 






Chinese 58±SEM2y 45 26.0±SEM0.7 T2DM Total n=22 4wks Roasted, 
unsalted whole 
almonds diet 
56g/d Program step II diet 90.90 
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N/A 26.0±SEM0.7 T2DM with 
mild hyper-
lipidemia 
Total n=22 4wks Almond diet 56g/d NCEP step II diet  90.9 






Chinese 48.4±8.2y 56.4 25.4±2.6 MS LCF n=94;        
LCW n=94 




30g/d Flaxseed with LCW  100 
Table 3.2. Pooled estimates of positive effect size for the results of nuts interventions compared to respective controls. 
Outcome Parameter Mean Difference 95% Confidence Interval p-Value No. of Studies Sample Size I2 (%) 
FFA (mmol/L) -0.03 -0.05 to -0.01 P=0.0009 4 156 0 
TC (mg/dl) -7.23 -9.66 to -4.81 P< 0.001 72 3718 59 
HDL-C (mg/dl) 0.9 0.14 to 1.67 P=0.02 73 3760 53 
LDL-C (mg/dl) -6.81 -8.81 to -4.8 P< 0.001 74 3756 68 
TG (mg/dl) -8.66 -12.58 to -4.74 P< 0.001 71 3725 64 
VLDL-C (mg/dl) -1.85 -2.96 to -0.74 P=0.001 15 1127 0 
Apo B (mg/dl) -4.60 -6.87 to -2.34 P< 0.001 27 1299 64 
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Table 3.3 The dose of nuts in this systematic review and meta-analysis 
 Walnuts Almonds Pistachios Brazil nuts Peanuts Macadamia Hazelnuts Cashews Pecans Mixed nuts 
Number of papers 26 20 12 3 4 4 5 4 3 7 
Average dose  
(per day) 
48g/d 54.2g/d 75g/d 25.3g/d 66.5 g/d 26.25g/d 45.7g/d 61.8g/d 60.8g/d 45.8g/d 
Dose range 
(per day) 





















50% total fat 
None None None 
N=1; 7 kCal /kg 
bodyweight 
daily;  
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Table 3.4. Subgroup analysis was undertaken based on the participants’ country as well as ethnicity. East Asian and Non-East Asian population in both ethnicity 
and country were analysed for nuts consumption. 
Outcome 
parameter 




P-value & I2 (%) in 
subgroups 
p-Value and I2 (%) of 
subgroup differences 
TC Ethnicity East Asian -4.74 (95% CI: -10.90 to 1.43) 6 P=0.13; I2=0% P=0.48; I2=0% 
Non-East Asian -7.91 (95% CI: - 13.69 to -2.12) 18 P=0.002; I2=64% 
Country East Asian -4.74 (95% CI: -10.90 to 1.43) 6 P=0.13; I2=0% P=0.42; I2=0% 
Non-East Asian -7.50 (95% CI: -10.10 to -4.91) 67 P<0.00001; I2=59% 
HDL-C Ethnicity East Asian -0.08 (95% CI: -2.29 to 2.14) 6 P=0.94; I2=0% P=0.29; I2=10.2% 
Non-East Asian 1.26 (95% CI: 0.44 to 2.08) 18 P=0.007; I2=7% 
Country East Asian -0.08 (95% CI:- 2.29 to 2.14) 6 P=0.94; I2=0% P=0.38; I2=0% 
Non-East Asian 0.98 (95% CI: 0.17 to 1.79) 67 P=0.02; I2=55% 
LDL-C Ethnicity East Asian -4.77 (95% CI:-10.67 to 1.12) 6 P=0.06; I2=0% P=0.79; I2=0% 
Non-East Asian -5.97 (95% CI: -9.83 to -2.12) 18 P= 0.0004; I2=44% 
Country East Asian -4.78 (95% CI:-9.85 to 0.30) 6 P= 0.06; I2=0% P=0.43; I2=0% 
Non-East Asian -7.0 (95% CI:-9.13 to -4.88) 68 P<0.00001; I2=69% 
TG Ethnicity East Asian -1.16 (95% CI:-9.39 to 7.07) 6 P=0.56; I2=0% P=0.21; I2=36.4% 
Non-East Asian -9.46 (95% CI:-20.54 to 1.61) 18 P=0.04; I2=78% 
Country East Asian -2.10 (95% CI:-9.35 to 5.16) 6 P=0.57; I2=0% P=0.09; I2=64.9% 
Non-East Asian -9.33 (95% CI:-13.56 to -5.10) 66 P<0.0001; I2=63% 
Oxidized-
LDL 
Ethnicity East Asian -6.65 (95% CI:-29.44 to 16.14) 2 P=0.57; I2=81% P=0.73; I2=0% 
Non-East Asian -1.69 (95% CI: -18.34 to 14.96) 1 P=0.84 
Country East Asian -6.65 (95% CI:-29.44 to 16.14) 2 P=0.57; I2=0% P=0.58; I2=0% 
Non-East Asian -0.17 (95% CI:-0.55 to 0.22) 9 P=0.39; I2=81% 
SBP Ethnicity East Asian -4.21 (95% CI:-9.09 to 0.67) 2 P=0.09; I2=0% P=0.25; I2=23.7% 
Non-East Asian -1.69 (95% CI:-3.52 to 0.14) 6 P=0.26; I2=0% 
Country East Asian -0.67 (95% CI:-4.57 to 3.23) 4 P=0.74; I2=30% P=0.36; I2=0% 
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Non-East Asian 1.58 (95% CI:-1.28 to 4.43) 37 P=0.28; I2=90% 
DBP Ethnicity East Asian -2.2 (95% CI:-9.41 to 5.01) 1 P=0.55 P=0.58; I2=0% 
Non-East Asian -0.04 (95% CI: -2.77 to 2.69) 6 P=0.93; I2=53% 
Country East Asian -0.67 (95% CI:-4.57 to 3.23) 4 P=0.74; I2=30% P=0.36; I2=0% 
Non-East Asian 1.58 (95% CI:-1.28 to 4.43) 34 P=0.28; I2=90% 
FFA Ethnicity East Asian 0.00 (95% CI:-0.16 to 0.16) 1 P=1 P=0.67; I2=0% 
Non-East Asian -0.03 (95% CI:-0.06 to -0.01) 2 P=0.0008; I2=0% 
Country East Asian 0.00 (95% CI:-0.16 to 0.16) 1 P=1 P=0.67; I2=0% 
Non-East Asian -0.03 (95% CI:-0.06 to -0.01) 3 P=0.0008; I2=0% 
Adiponectin Ethnicity East Asian 0.02 (95% CI:-4.28 to 4.32) 2 P=0.97; I2=0% P=0.25; I2=25.6% 
Non-East Asian 0.78 (95% CI:-0.1 to 1.46) 3 P=0.02; I2=31% 
Country East Asian -0.03 (95% CI:--1.27 to 1.21) 1 P=0.96 P=0.15; I2=51.7% 
Non-East Asian 0.92 (95% CI: 0.54 to 1.3) 7 P<0.00001; I2=0% 
Lag time of 
LDL 
Ethnicity East Asian 13 (95% CI: 8.57 to 17.43) 1 P<0.00001 Not applicable 
Non-East Asian Not applicable 0 Not applicable 
Country East Asian 13 (95% CI: 8.57 to 17.43) 1 P<0.00001 P=0.0004; I2=92% 
Non-East Asian -8.4 (95% CI:-19.42 to 2.62) 1 P=0.14 
TAC Ethnicity East Asian 0.06 (95% CI:-0.19 to 0.31) 1 P=0.64 Not applicable 
Non-East Asian Not applicable 0 Not applicable 
Country East Asian 0.06 (95% CI:-0.19 to 0.31) 1 P=0.64 P<0.0001; I2=94.8% 
Non-East Asian 2.31 (95% CI: (1.34 to 3.29) 2 P<0.00001; I2=0% 
Apo A Ethnicity East Asian 0.00 (95% CI:--29.97 to 29.97) 2 P=0.56; I2=0% P=0.70; I2=0% 
Non-East Asian -0.85 (95% CI:- -4.89 to 3.19) 5 P=0.68; I2=0% 
Country East Asian -1.4 (95% CI:-8.3 to 5.49) 3 P=0.69;  I2=0% P=0.84; I2=0% 
Non-East Asian -0.64 (95% CI: -3.43 to 2.14) 23 P=0.65; I2=39% 
Apo B Ethnicity East Asian -11.81 (95% CI: -29.66 to 6.04) 2 P=0.19; I2=70% P=0.53; I2=0% 
Non-East Asian -6.05 (95% CI: -8.48 to -3.62) 7 P<0.00001; I2=0% 
Country East Asian -5.91 (95% CI: -16.06 to 4.24) 3 P=0.25; I2=65% P=0.81; I2=0% 
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Non-East Asian -4.61 (95% CI: -6.98 to -2.24) 25 P=0.0001; I2=66% 
Hs-CRP Ethnicity East Asian -0.10 (95% CI: -0.35 to 0.15) 1 P=0.43 P=0.71; I2=0% 
Non-East Asian -0.24 (95% CI: -0.94 to 0.46) 3 P=0.50; I2=14% 
Country East Asian -0.1 (95% CI: -0.35 to 0.15) 1 P=0.43 P=0.19; I2=40.9% 
Non-East Asian -0.36 (95% CI: -0.66 to -0.06) 10 P=0.02; I2=0% 
CRP Ethnicity East Asian -1.29 (95% CI: -2.98 to 0.4) 1 P=0.14 P=0.23; I2=31.8% 
Non-East Asian -0.21 (95% CI: -0.64 to 0.22) 3 P=0.34; I2=0% 
Country East Asian -1.29 (95% CI: -2.98 to 0.4) 1 P=0.14 P=0.14; I2=53.6% 
Non-East Asian -0.02 (95% CI: -0.08 to 0.04) 15 P=0.48; I2=0% 
TNF-a Ethnicity East Asian -0.06 (95% CI: -0.13 to 0.01) 1 P=0.1 P=0.4; I2=0% 
Non-East Asian -1.07 (95% CI: -3.41 to 1.28) 3 P=0.37; I2=60% 
Country East Asian -0.06 (95% CI: -0.13 to 0.01) 1 P=0.1 P=0.77; I2=33% 
Non-East Asian 0.03 (95% CI: -0.25 to 0.31) 8 P=0.85; I2=39% 
IL-6 Ethnicity East Asian 0.29 (95% CI: -0.46 to 1.04) 2 P=0.45; I2=75% P=0.33; I2=0% 
Non-East Asian -0.11 (95% CI: -0.37 to 0.16) 2 P=0.69; I2=48% 
Country East Asian 0.29 (95% CI: -0.46 to 1.04) 2 P=0.45; I2=75% P=0.46; I2=0% 
Non-East Asian 0 (95% CI: -0.09 to 0.1) 11 P=0.92; I2=0% 
sICAM-1 Ethnicity East Asian 0.10 (95% CI: -28.17 to 28.36) 2 P=0.99; I2=0% P=0.76; I2=0% 
Non-East Asian -3.24 (95% CI: -20.49 to 14.02) 3 P=0.71; I2=0% 
Country East Asian 0.1 (95% CI: -28.17 to 28.36) 2 P=0.99; I2=0% P=0.74; I2=0% 
Non-East Asian -4.88 (95% CI: -12.55 to 2.79) 12 P=0.21; I2=0% 
sVCAM-1 Ethnicity East Asian -48.61 (95% CI: -97.96 to 0.74) 2 P=0.05; I2=0% P=0.13; I2=55.8% 
Non-East Asian 14.24 (95% CI: -51.12 to 79.6) 2 P=0.67; I2=0% 
Country East Asian -48.61 (95% CI: -97.96 to 0.74) 2 P=0.05; I2=0% P=0.08; I2=66.9% 
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Table 3.5. Study quality 
References Generation of Random method 
clarification 
Method of monitoring subject 
compliance to nuts consumption 
or/and reference diets 
Drop-outs reasons 
clarification/withdraw reasons 
Allocation concealment of 
treatment 
Agebratt et al., 2016 Canada Not reported Food diary record No dropouts Not reported 
Aronis et al., 2012 Greece Not reported Not reported No dropouts Not reported 
Bamberger, C et al., 2017, 
Germany 
Randomization (blocking of 12; SAS proc 
factex) 
An in-patient setting or a setting where all 
of the meals are provided 
Disease; Medication; Personal 
reason; Protocol violation 
Not reported 
Bento et al., 2014 Brazil Not reported 3-d dietary record Pregnant; personal unforeseen 
circumstances 
Not reported 
Berryman et al., 2015 USA Computer-generated randomization Daily weigh-ins and food logs Diet issues; Time restraints; 
Unrelated illness; Moved out of 
area; Pre-existing metabolic 
condition 
Not reported 
Brennan et al., 2010 USA Not reported Weight foods Not reported Yes: blinded statistician 
assigned diets 
Burns-Whitmore et al., 2014 
USA 
Not reported Daily diary record; Fatty acid composition 
of erythrocyte membranes assessment 
Family or job pressures; 
Allergies unrelated to 
interventions 
Not reported 
Carvalho et al., 2015 Brazil Computer generated random list 
restricted in blocking of participants and 
sequentially numbered labels were 
inserted in sealed containers with nut or 
placebo 
Plasma selenium levels assessment Pleural effusion due to a history 
of CAD 
Not reported 
Casas-Agustench et al., 2011 
Spain 
Not reported Extra packages of nuts were given to the 
rest of family 
Personal reasons Not reported 
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Chen et al., 2015  USA The permuted blocks of size 6 (total 10 
blocks) 
Phone calls; Package bags check Colitis; Body weight Not reported 
Chiang et al., 2012  USA Not reported Direct observation during meal times; 
Dietary diaries check 
Not reported Not reported 
Chisholm et al., 1998 New 
Zealand 
Not reported The relative increases of linoleic acid in 
plasma triacylglycerol and alpha linolenic 
acid assessment; Dietary record check 
No dietary records provide Not reported 
Chisholm et al., 2005 New 
Zealand 
Not reported Not reported Not reported Not reported 
Claesson et al., 2009 Sweden Not reported Not reported Gastrointestinal symptoms; 
Diarrhoea and increased flatus 
Not reported 
Colpo et al., 2014 Brazil Latin squares of 4*4 24-h dietary recall; Food frequency 
questionnaires 
No dropouts Not reported 
Curb et al., 2000 USA Randomizations stratified by sex Telephone screening; Individual and 
group meetings 
Not reported Yes: study personnel involved 
in performing measurements 
and analyses were blinded to 
the diet sequences. 
Damavandi et al., 2013 Iran Not reported Not reported Not reported Not reported 
Davidi et al., 2011 USA Random number generated by SAS Empty packages collection; A log detailing 
the compliance to fill out 
Did not come for end of visit; 
Discontinued intervention due to 
high LDL, high HDL levels and 
was misplaced to the wrong 
treatment group 
Not reported 
de Souza et al., 2018 Brazil Random numbers allocated 
consecutively to the subjects in the order 
that they attended the randomization visit 
Telephone calls and during routine 
monthly consultations 
Pregnancy; Change of address; 
started a physical exercise 
program; missed evaluations 
due to work commitment or 
illness among family members 
Not reported 
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Dhillon et al., 2016 USA Not reported 24-h food recalls; Weight check Illness; Pregnancy; Time 
constraints 
Not reported 
Din et al., 2011  UK Block randomization Food diary record No dropouts Not reported 
Foster et al., 2012 USA Random number generator Not reported Time constraints/work schedule; 
Dissatisfied with program; Life 
stressors; No reason given; 
Pregnancy; Relocation 
Not reported 
Gebauer et al., 2008 USA Not reported Dietary questionnaires No dropouts Yes: study personnel who 
measured outcome variables 
were blinded to the diet 
assignments 
Ghadimi Nouran et al., 2010 
USA 
Not reported An extra coded bag of peanuts to share 
with family and friends; 24h diet recalls 
Lost interest; Unforeseen travel Not reported 
Griel et al., 2008 Canada Not reported The review of daily and weekly monitoring 
forms 
Time constraints Not reported 
Gulati et al., 2014 India Not reported Weekly compliance questionnaires, 
telephone calls, discussion, and 
crosschecking with the spouse or any 
close relative; Empty packets of pistachios 
and pistachio shells; Food-frequency 
questionnaire and 24-h dietary recall 
Not reported Not reported 
Hiraoka-Yamamoto et al., 2004 
Japanese 
Not reported Calculation of percentages of the 
prescribed bread consumed 
No dropouts Not reported 
Huguenin et al., 2015a Brazil The randomization was in blocks of 10 
and based on a table of random numbers 
Not reported Personal reasons; Pulmonary 
edema; Living far; Financial 
reason; Requiring 
accompaniment; Inpatient 
status; Cancer diagnosis 
Yes: the randomization were 
blinded except for one who 
encoded interventions and 
had no contact with the center 
 
- 125 - 
 
at which the study was 
conducted 
Iwamoto et al., 2002 Japan Not reported Tray checks at the meals eaten on site 
and by self-report on standardized forms 
for the packed meals 
No dropouts Not reported 
Jamshed et al., 2015 Pakistan Computer-generated block 
randomization 
Regular phone calls; Dietary diary record Fail to contact; Started using 
nuts; Left the city; Angioplasty; 
Discontinued 
Not reported 
Jenkins, et al., 2018 Canada Randomisation was carried out 
anonymously 
7-day food record Allergy Not reported 
Jenkins et al., 2002 USA Not reported 7-d diet record, a supplement checklist on 
which subjects recorded supplements 
consumed and return of uneaten 
supplements, which were weighed and 
recorded 
Reasons directly related to the 
study: food allergies and 
abdominal discomfort; unrelated 
reasons 
Not reported 
Jung, H et al.,2018 Korean Not reported A diary calendar and counting returned 
packages; 3-day dietary records 
Time commitment; Abdominal 
discomfort 
Not reported 
Kasliwal et al., 2015 India Not reported Monthly visits Participants core laboratory 
results were outside the study 
eligibility criteria 
Not reported 
Katz et al., 2012 USA Not reported 3-day diet record Changes in medication; Inability 
to comply with the protocol; 
Schedule conflicts 
Not reported 
Kay et al., 2010 UK Not reported Food questionnaires Not reported Not reported 
Kendall et al., 2014 Canada Not reported Not reported No dropouts Not reported 
Kocyigit et al., 2006 Turkey Not reported Not reported No dropouts Not reported 
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Kris-Etherton et al., 1999 USA Random, balanced order sequence Body weight measurements; Daily dietary 
questionnaire 
No enthusiasm about the length 
of the study; Different 
geographical areas 
Not reported 
Kurlandsky and Stote, 2006 
USA 
Not reported 3-day diet record Minor illness and a total 
cholesterol level below inclusion 
standards 
Not reported 
Lee et al., 2014 South Korean Not reported Daily dietary self-record Personal reasons Not reported 
Lee et al., 2017 USA Computer-generated randomization 
scheme utilized a Williams design with 
permuted block randomization 
Daily weight logs and daily food logs 
checks 
Not compliant; Food dislikes; 
Time restraints; Relocation; 
Personal reasons 
Not reported 
Li et al., 2011 Taiwan China 1:1 manner using a computerized 
random proportion model 
Daily diet diary to record foods not eaten, 
non-study foods eaten, and beverages 
Noncompliance in consuming 
the study meals 
Not reported 
Li et al., 2010 USA Not reported Meet with research dietitians Noncompliant with the daily 
food log or study visit or lost to 
follow-up and consequently 
drop from the study; Rash 
Not reported 
Liu et al., 2013 Taiwan China Not reported Daily diet diary to record foods not eaten, 
non-study foods eaten, and beverages 
Without full compliance Not reported 
Lopez-Uriarte et al., 2010 
Spain 
Not reported 3-day food record Personal reasons Not reported 
Ma et al., 2010 USA Two possible sequence permutations 3-day diet record Changes in medications; Poor 
compliance with the treatment 
protocol 
Not reported 
Mah et al., 2017 USA Statistician generates the randomization 
for the intervention sequence with the 
use of the SAS PROC PLAN with a 1:1 
allocation ratio 
Returned food items Adverse events; An 
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McKay, et al., 2018 USA Randomization was stratified by gender 
according to a computer-generated list 
Empty containers and unused food return Elevated TC, LDL, SBP,DBP,  
fasting blood glucose levels; low 
HDL, obese 
Study personnel 
were blinded to the treatment 
assignment for the duration of 
the intervention and sample 
analysis 
Mohamedou et al., 2012 
Morocco 
Not reported Not reported Personal reasons Not reported 
Mohan et al., 2018 India Not reported Self-reported dietary intake by 24-h 
dietary recall; face-to-face interview 
Allergy; Personal reasons; Non-
responsive 
Not reported 
Moreira Alves et al., 2014 
Brazil 
Not reported Time records in a notepad daily; 3-day 
food record 
Not reported Not reported 
Morgan et al., 2002 USA Not reported 3-d dietary record Withdrew consent; Intolerance 
to the walnuts 
Not reported 
Morgan and Clayshulte, 2000 
USA 
Not reported 3-day food record; Food frequency 
checklists; Interviewing participants at 
each study visit and inspecting food ration 
boxes 
Unable to confirm the study 
protocols 
Not reported 
Mukuddem-Petersen et al., 
2007 UK 
Randomly drawing numbers by a hat A dietitian supervised mealtimes and 
ensured the complete intake of foods; 
Food diaries of the additional points used 
and possible left-overs were collected and 
weighed 
Work obligations; Unrelated 
medical condition; Holiday 
Not reported 
Nieman et al., 2014 USA Randomized (1:1 allocation, random 
number generator) 
Email check weekly; Empty plastic bags 
check 
Not reported Not reported 
Njike et al., 2015 USA SAS-generated random table (a 
permuted design in a 1:1 ratio) 
Not reported Medical reasons unrelated to 
walnut consumption; 
Relocation; Allergic reaction;  
Inability to comply with the study 
Not reported 
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protocol; Mental and family 
issues 
Olmedilla-Alonso et al., 2008 
Spain 
Not reported Dietary record No dropouts Not reported 
Orem et al., 2013 Turkey Not reported Not reported No dropouts Not reported 




Perez-Martinez et al., 2007 
Spain 
Not reported Not reported No dropouts Not reported 
Rajaram et al., 2001 USA Randomly assigned after stratification 
based on two categories of age, gender 
and screening values of serum 
cholesterol 
Food diary record; Plasma fatty acids 
assessment 
No dropouts Not reported 
Rajaram et al., 2010 USA Random, balanced order sequence Interventions were eaten under the 
supervision of a senior investigator 
Lack of adherence to the study 
protocol 
Not reported 
Rajaram et al., 2009 USA Randomized and stratified on the basis 
of age, gender, and baseline serum TC 
concentration to 1 of 6 possible diet 
sequences 
Foods weight; Daily diary record Time conflicts Not reported 
Ros et al., 2004 Spain Not reported 7-day dietary recalls Personal reasons Not reported 
Ruisinger et al., 2015 USA Not reported 3-day food record The inability to consume foods 
daily and concerns about the 
additional energy intake 
Not reported 
 
- 129 - 
 
Sabate et al., 1993 USA Stratification on the basis of age, base-
line serum cholesterol leel and body 
mass index 
Food diaries record Blood drawing missing Not reported 
Sabate et al., 2003 USA Not reported Not reported Unable to comply with the diet 
protocol 
Not reported 
Sauder et al., 2014 USA Not reported Daily food compliance questionnaires; 
Returned food containers check 
Developed food intolerance; 
Pre-existing medical condition 
revealed 
Not reported 
Sauder et al., 2015 USA Simple randomization Not reported Elevated blood pressure; 
Medication change; No longer 
interested; Developed food 
intolerance; Pre-existing 
medical condition revealed 
Not reported 
Schutte et al., 2006 South 
Africa 
Stratified based on gender and age Weighing returned leftover food portions 
and checking food diaries 
No dropouts Not reported 
Sheridan et al., 2007 USA Not reported Pistachio storage bags return No dropouts Not reported 
Sola et al., 2012 Spain Computer-generated random number 
sequence in gender-stratified blocks. 
Empty wrapper counts and 
any non-consumed doses check 
Low compliance rate (<80%) of 
interventional consumption 
Yes: clinical investigators and 
laboratory personnel were 
blinded with respect to the 
type of cream being 
consumed. 
Somerset et al., 2013 Australia Randomised consecutively as subjects 
entered the trial, in blocks of 10 subjects 
Not reported No dropouts Not reported 
Spiller et al., 1998 Italy Not reported 3-day diet record; 24-hour dietary recalls; 
Verbal reports at the study group 
meetings 
Reasons unrelated to the study; 
Unwilling to follow a diet 
expected not to lower TC 
Not reported 
Sweazea et al., 2014 USA Not reported Not reported Scheduling conflicts Not reported 
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Tamizifar B, 2005 Iran Not reported Food diaries record Pre-existing gastrointestinal 
problems 
Not reported 
Tapsell et al., 2009 Australia Computerized random number generator Biomarker data analysis Work/family time commitments;  
Indigestion problems; Consulted 
naturopath and started fish oil 
capsules; Travelling; Moved out 
of area 
Not reported 
Tapsell et al., 2004 Australia Not reported Not reported Not reported Not reported 
Tey et al., 2011 New Zealand Blocks of size four to allocate and 
incomplete blocks remaining at the 
conclusion of enrolment were randomly 
allocated first using strata based on sex 
and BMI 
Weighing returned serving bags; 3 day 
dietary record 
Dissatisfaction with group 
assignment; Personal issues; 
Adverse events 
Not reported 
Tey et al., 2013 Australia Not reported Weighing bags returned; 3 day dietary 
record 
BMI<25; Pregnant Not reported 




West et al., 2012 USA Not reported Not reported No dropouts Not reported 
West et al., 2010 Canada Randomization table to a 
counterbalanced sequence of diets 
Not reported No dropouts Not reported 
Wien et al., 2010 USA Randomized without stratification using 
computer-generated random integer 
generator software (www. random.org) 
Plasma atocopherol concentrations 
evaulation; Self-reported food dietary 
record 
Work and personal schedule 
conflicts 
Not reported 
Wu et al., 2010 Shanghai 
China 
Block randomized to 1 of the 3 
intervention arms 
The weight of breads consumed divided 
by the prescribed weight of total breads 
throughout the intervention; ALA content 
of erythrocyte membranes assessment 
No dropouts Not reported 
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Wu et al., 2014 USA Complete block design Not reported Protocol violations; Acute 
infection with the use of 
antibiotics>5 days; Cortisone 
injections; Dietary non-
compliance; Abnormal thyroid 
function after subtotal 
thyroidectomy 
Not reported 
Zibaeenezhad et al., 2017 Iran Computer-based random digit generator 
based on the registration number of 
participants 
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CHAPTER 4 
Effects of olive oil on cardiovascular risk factors in different ethnic groups: A 
systematic review and meta-analysis of randomized controlled trials 
Abstract  
Background and aims. Epidemiological evidence suggests an association between 
consumption of olive oil and lower risk for cardiovascular diseases (CVDs). However, how 
factors such as ethnicity plays a role in this association are not well established. Therefore, 
the aim of the present systematic review and meta-analysis was to synthesize data from 
randomized controlled trials (RCTs) investigating the effects of olive oil on markers of 
cardiovascular biomarkers. 
Methods.   Literature search in electronic databases including Medline, Web of Science 
and Scopus were searched from inception to December 2018. Inclusion criteria were: 
intervention RCTs reporting effects of olive oil on CV risk factors among adults. The main 
outcomes of interest included blood lipids (total-, HDL-C, LDL-C, TG, VLDL-C, Apo A-I, Apo 
B, ox-LDL), endothelial function (FMD, PWV, NO), SBP, DBP and inflammatory factors 
(CRP, hs-CRP, IL-6, IL-8, IL-10, sICAM-1, sVCAM-1, TNF-alpha, adiponectin, E-selectin) 
and other biomarkers (VWf; fibrinogen and ET-1). Random-effects models were used to 
determine the pooled effect sizes. Systematic review registration: CRD42018089055. 
Results.   Out of 791 publications identified, 22 randomized controlled trials were included 
in the final selection and were meta-analyzed. Overall, olive oil (with daily consumption 
ranging between 13.3 and 64.8 gram) improve markers such as PAI-1 and tPA although 
tPA were not included into the meta-analysis as the significant result of tPA was only from 
single study.  
Limitations.  The small number of studies/participants limits this review. 
Conclusions.   The available evidence on the effects of olive oil on CV risk factors supports 
the view that variables PAI-1, tPA are shown to be improved after olive oil consumption. 
More studies from Asian and non-Asian countries regarding olive oil intake and 
cardiovascular risk factors need to be researched in the near future. 
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4.1 Introduction  
Consumption of olive oil has almost doubled over the last 25 years with an increase of 73% 
as the growth in global demand for olive oil has been powered in part by the health benefits, 
especially for cardiovascular health. Olive oil has the biggest growth (41%) among all 
products exports to China from Italy (Ylenia 2016). China has imported approximately 12.25 
million tons of olive oil in 2014 while in Britain, olive oil market is estimated around £250M 
(CBI - Ministry of Foreign Affairs 2020). The UK's imports of olive oil exceeded 84 thousand 
tones, at a value of €220 million in 2019.  
The popularity of olive oil consumption is because olive oil contains a complex mixture of 
over 200 compounds which are beneficial for health (Aiello, Guccione et al. 2015). The main 
constituents of olive oil are triglycerides (98-99%) and the three main fatty acids in the 
triglyceride fraction are a monounsaturated fatty acid (MUFA) (oleic acid), a saturated fatty 
acid (palmitic acid) and a polyunsaturated fatty acid (PUFA) (linoleic acid) (Aiello, Guccione 
et al. 2015). Oleic acid represents the topmost MUFA provided in the diet (∼90% of all 
MUFAs) and is the main MUFA of olive oil (55-83%). Oleic acid was shown to enhance the 
resistance of LDL-C to oxidation and therefore, reduces the risk of atherosclerosis (Aiello, 
Guccione et al. 2015). The remaining unsaponifiable fraction (1-2%) contains phenolic 
compounds and the phenolic fraction in olive oil are polyphenols of which there are 7 
different subfamilies. These are anthocyanins, flavonoids, flavones, phenolic acids, 
phenolic alcohols, acids and secoiridoids. Their amount in olive oil is highly affected by the 
variety as well as the geographical origin of the olives (Aiello, Guccione et al. 2015). 
Phenolic compounds have antioxidant, anti-inflammatory and antimicrobial properties, 
which reduce atherosclerotic plaque formation (Cicerale, Lucas et al. 2012, Virruso, Accardi 
et al. 2014). 
Epidemiological research from the Mediterranean basin has suggested a lower incidence 
of coronary heart disease in people from Mediterranean countries where olive oil is the 
primary source of fat (Dontas, Zerefos et al. 2007). Epidemiological research consistently 
showed that the health benefit of olive oil is associated with increased longevity (Buckland 
and Gonzalez 2015) and this benefit is mostly due to the olive oil’s unequivocal cardio-
protective role (Guasch-Ferré, Hu et al. 2014). Beside the fact that MUFA and PUFAs 
benefit blood lipids (Puiggros, Chacon et al. 2002, Chan, Demonty et al. 2007), phenolic 
content in olive oil was also shown to reduce oxidative status, lowers blood pressure (Covas 
2007) and preventing CVD risk factors, including diabetes, metabolic syndrome and obesity 
(Buckland and Gonzalez 2015). 
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Despite considerable evidence on the biological mechanisms involved (Covas, 
Konstantinidou et al. 2009, Estruch 2010, Lopez-Miranda, Perez-Jimenez et al. 2010), only 
up until have epidemiological studies provided direct evidence on the relationship between 
olive oil consumption and primary prevention of CVD (Ruiz-Canela and Martinez-Gonzalez 
2011, Ros 2012). However, the EPIC-Spain cohort study observed a negative association 
between olive oil consumption and coronary heart disease (CHD) (Buckland, Travier et al. 
2012). A three-city large-scale study presented results that intense olive oil consumption for 
dressing or cooking (37% of the cohort) had a 41(95% CI 6, 63) % reduced risk of stroke 
compared with participants who never consume olive oil (23% of the cohort) (Samieri, Feart 
et al. 2011). Additionally, a systematic review showed that incorporating with the 
Mediterranean diet olive oil intake might have a beneficial effect on endothelial function and 
markers of inflammation (Schwingshackl, Christoph et al. 2015). Most recently, new 
research (Xu, Wang et al. 2018) has revealed that unsaturated fats in olive oil promote a 
high level of Apo lipoprotein A-IV which is a protein that inhibits the aggregation of platelets, 
components of the blood that can clump together and form clots within arteries. 
A number of studies supporting the health benefits of olive oil have been carried out among 
Mediterranean populations, such as the PREDIMED study. However, whether studies have 
evaluated the effects of olive oil among difference ethnicity groups is uncertain. Here we 
undertake a systematic review to explore whether studies comparing the effect of olive oil 
supplementation among different ethnic groups are available, with a particular interest on 
East Asian and Caucasians individuals. CV markers such as blood lipids (TC, HDL-C, LDL-
C, TG ox-LDL), markers of endothelial dysfunction (NO, FMD, PWV, PWA), blood markers 
- cell adhesion molecules: VCAM-1, ICAM-1, E-selectin, vWf), oxidative damage (ox-LDL) 
and markers of inflammation (IL-6, IL-1β, CRP, SAA) would also be targeted in this 
systematic review.  
4.2 Materials and Methods 
This systematic review was performed based on the established methods recommended 
by the Cochrane (Higgins, Altman et al. 2011) and the Centre for Reviews and 
Dissemination guidelines  (Tacconelli 2010) (Centre for Reviews and Dissemination 2009). 
This systematic review is also reported with accordance to PRISMA criteria guidelines 
(Moher, Liberati et al. 2009) (Appendix C1). In addition, the protocol of the systematic 
review has been registered with PROSPERO, the International Prospective Register of 
Systematic Reviews (Centre For Reviews and Dissemination 2009), indexed under 
Registration number CRD42018089055. 
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Two researchers (FL and JL) documented the procedures to search and synthesize the 
evidence in accordance with the preferred reporting items for systematic review and meta-
analysis (PRISMA) statement for reporting systematic reviews (Figure. 4.1 and Table 4.1) 
(Liberati, Altman et al. 2009, Higgins, Altman et al. 2011). FL and JL examined and selected 
the studies hierarchically. The decision was made initially on the basis of screening titles 
and abstracts of papers, and later the full text of the study was subsequently assessed to 
reach a decision.  
4.2.1 Data sources and literature search strategy 
Relevant studies were systematically identified by searching three electronic databases, 
including MEDLINE (beginning 1990); Scopus (beginning 1966); Web of Science 
(beginning 1991) through December 2018, with no language restriction.   
The search strategies included the following terms: (“Cardiovascular risk factors” OR 
“Cardiovascular diseases”) AND (“endothelial function” OR “endothelial dysfunction” OR 
“flow-mediated dilation” OR “FMD” OR “arterial stiffness” OR “carotid intima-media 
thickness” OR “intercellular adhesion molecule-1” OR “ICAM-1” OR “vascular cell adhesion 
molecule-1” OR “VCAM-1” OR “e-selectin” OR “p-selectin” OR "dimethylarginine" OR 
“ADMA” OR "oxidized low density lipoprotein" OR "oxidized-LDL" OR “inflammation” OR 
“C-reactive protein” OR “CRP” OR “LDL cholesterol” OR “HDL cholesterol” OR “triglycerides” 
OR “total cholesterol” ) AND (“olive oil” OR “EGCG”) AND (“randomized controlled trial” OR 
“randomized” OR “clinical trial as topic” OR “placebo” OR “randomly” OR “trial”) NOT 
(“animal”). Two investigators reviewed potentially relevant articles independently with 
discrepancies being resolved through consensus (FL). Institutional review board approval 
was not necessary for this systematic review.  
4.2.2 Study selection 
The following inclusion criteria were defined prior to study selection process:  
g) RCTs with either crossover or parallel design; 
h) Nutritional interventions: Interventions supplementing olive oil versus a control or 
placebo group (inactive); 
i) Adults participants more than 18 years of age;  
j) Minimum intervention duration was more than one week;  
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k) Assessment of the “outcome of interest”: RCTs had to assess at least one of these 
primary outcomes. Markers of inflammation (CRP, IL-6, IL-8, TNF-α, adiponectin); 
endothelial function/endothelial dysfunction (sICAM-1, Svcam-1, FMD, PWV, NO); 
Blood lipids (plasma TC, HDL-C, LDL-C, VLDL-C, TG, Apo B and Apo A-I); 
Fibrinolytic variables (tPA, PAI-1); VWf; Fibrinogen and ET-1.  
l) Report of post-intervention mean values (or if not available, change from baseline 
values were used instead) with standard deviation (or basic data which allow to 
calculate these parameters, i.e., standard errors, 95% confidence interval, p-values). 
Exclusion criteria included:  
e)  Non-randomized controlled trials; 
Interventions not involving olive oil or combined interventions in which the effects of olive 
oil cannot singled out;  
 
4.2.3 Data extraction and statistical analysis 
Data extracted from each trial were: study design, year of publication, country of origin, 
randomization, duration and length of follow-up, methods of analysis, completion rates; 
participant characteristics (population, settings of interventions, baseline characteristics); 
outcome measures (dietary and/or nutritional intake, BMI, CV biomarkers); intervention 
details (i.e. olive oil). Study quality was assessed using the Cochrane risk of bias tool 
(Higgins and Green 2011). 
All data were analyzed using the software REVIEW MANAGER 5.3. A random effects model 
accounting for inter-study variation was used, thereby minimizing potential bias due to 
methodological differences between studies. In a random effects model, the post-mean 
values or the changes from baseline values and corresponding standard deviations of 
intervention and control/intervention groups were compared. Pooled results were reported 
as mean differences with 95% CIs and with two-sided P-values. Nevertheless, when 
variables (such as IL-6 or CRP, and ICAM-1) were reported on different scales, mean 
differences (MD) were used as a summary statistic for comparing effect sizes across studies. 
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Multiple dietary intervention arms from three studies were included in the meta-analysis. 
Following previous guidance (Higgins, Altman et al. 2011) excessive weightings from 
“double counts” arising from the “shared” group (in this case, the control group) were 
controlled by splitting the sample size of the shared group into approximately equal smaller 
groups for the comparisons. In this analysis, we sought to extract and analyse adjusted 
results from multivariate models, if reported in the studies. 
Heterogeneity was evaluated using the I2 statistic (Centre for Reviews and Dissemination 
2009, Higgins, Altman et al. 2011) Levels of heterogeneity are commonly regarded as high 
when I2 values are >50%. Publication bias was appraised by visually inspecting the funnel 
plot, and supplemented with calculations of the Egger's regression test (Egger, Davey Smith 
et al. 1997). Quality of studies was assessed using the jaded system (Jadad, Moore et al. 
1996). 
4.2.4 Quality assessment 
The Cochrane collaboration’s tool for assessing risk of bias was utilized to elucidate the risk 
of bias of the included studies attaching either low, unclear or high risk of bias to the seven 
domains (sequence generation, allocation concealment, blinding of participants and 
personnel, blinding of outcome assessment, incomplete outcome data, selective outcome 
reporting) to each study (Higgins, Altman et al. 2011, Higgins and Green 2011). 
4.3. Results 
4.3.1 Literature Search and Study Characteristics 
Searches of the literature identified 791 published studies and the abstracts were reviewed. 
In total, 573 records remained after removing duplicates and 432 did not meet the inclusion 
criteria and were excluded. 141 studies were screened as full text and Figure 4.1. Ultimately, 
22 studies were included in the present systematic review and meta-analysis (Table 4.1) 
(Sirtori, Gatti et al. 1992, Lichtenstein, Ausman et al. 1993, Kris-Etherton, Pearson et al. 
1999, Pedersen, Baumstark et al. 2000, Nielsen, Pedersen et al. 2002, Perona, Canizares 
et al. 2004, Binkoski, Kris-Etherton et al. 2005, Cicero, D'Addato et al. 2009, Jiménez-
Gómez, López-Miranda et al. 2009, Tholstrup, Hjerpsted et al. 2011, Kontogianni, 
Vlassopoulos et al. 2013, Namayandeh, Kaseb et al. 2013, Oliveras-Lopez, Molina et al. 
2013, Engel and Tholstrup 2015, Maki, Lawless et al. 2015, Tong, Rappold et al. 2015, 
Venturini, Simao et al. 2015, Voon, Ng et al. 2015, de Oliveira, Kovacs et al. 2017, Atefi, 
Pishdad et al. 2018, Galvão Cândido, Xavier Valente et al. 2018, Khaw, Sharp et al. 2018). 
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Characteristics of the sample, interventions, outcome assessment and results are shown in 
Table 4.1. In addition, the study selection procedure is shown in Figure 4.1.  
The 22 randomized controlled trials selected, comprised with altogether 860 participants 
who were followed-up for 5.3 weeks on average (range from 3 weeks to 13 weeks). Twelve 
out of 22 RCTs had a crossover design. The ages of the samples in these RCTs ranged 
from 18 to 78 years of age and the mean ± SD of ages is 54.17 ± 6.82. 4 studies recruited 
only male (Pedersen, Baumstark et al. 2000, Nielsen, Pedersen et al. 2002, Jiménez-
Gómez, López-Miranda et al. 2009, Tholstrup, Hjerpsted et al. 2011) while 2 studies (Atefi, 
Pishdad et al. 2018, Galvão Cândido, Xavier Valente et al. 2018) recruited only female, the 
rest of studies involved mixed samples of men and women. Participants had existing 
disease conditions in 36% of all randomized trials; these were most commonly moderate 
hypercholesterolemia (n=5), Type 2 diabetic (n=1), obese or overweight (n=1), hypertensive 
(n=1) while 14 trials targeted at healthy participants (Table 4.1). Overall, 22 studies 
originated from the USA (n=7), Spain (n=3), Italy (n=2), Malaysia (n=1), Denmark (n=2), 
Brazil (n=3), Greece (n=1), UK (n=1) and Iran (n=2).  
Eight studies (Cicero et al., 2009 , Galvão Cândido et al., 2018, Kontogianni et al., 2013, 
Khaw et al., 2018, Maki et al., 2015, Oliveras-Lopez et al., 2013, Pedersen et al., 2000, 
Venturini et al., 2015) which conducted trials by using extra virgin olive oil as interventions 
while the remaining studies used other olive oil such as virgin olive oil, regular olive oil and 
olive oil capsules. The dose of olive oil used in these interventions varied from 13.3 to 64.8 
g/d and the mean dose is 36.71g/d in 14 studies. Two studies (Lichtenstein, Ausman et al. 
1993, Binkoski, Kris-Etherton et al. 2005) reported the percentage of olive oil of the diet.  
4.3.2 Main outcomes 
Only variables including PAI-1 as well as t-PA out of 22 studies are shown to be improved 
after olive oil consumption (Table 4.2). 8 biomarkers including TC, HDL-C, DBP, sICAM-1, 
sVCAM-1, VWf, Apo B and IL-8 tend to be likely to be beneficial from olive oil interventions 
(Appendix C2 – C22). However, another 10 cardiovascular biomarkers including SBP, IL-
6, CRP, adiponectin, TNF-alpha, Fibrinogen, Endothelin 1, plasma E-Selectin, ApoA1 and 
IL-10 show negative effects after olive oil intake (Appendix C2 – C22). LDL-C, TG and hs-
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4.3.2.1 Meta-analysis of studies supplementing olive oil 
Olive oil interventions in two studies (Tholstrup, Hjerpsted et al. 2011, Tong, Rappold et al. 
2015) having 58 participants resulted in a significant decrease in PAI-1 (MD: -1.02ng/mL, 
95% CI: -1.92 to -0.12; p = 0.03, I2 = 0%) (Figure 4.2). Pooled estimates of effects size for 
all markers of inflammation are summarized in Table 4.2. 
Overall, eight biomarkers were improved after olive oil consumption. Blood lipids such as 
TC (Figure C2), HDL-C (Figure C3), DBP (Figure C7), and inflammatory markers such as 
sICAM-1 (Figure C8), sVCAM-1 (Figure C9) and blood glycoprotein such as VWf (Figure 
C15) and apo-lipoprotein such as Apo B (Figure C19) and chemokines such as IL-8 (Figure 
C21) are likely to slightly improve by olive oil consumption.  
However, 10 biomarkers were more likely to present non-significant effect after olive oil 
consumption. These include SBP (Figure C6), pro-inflammatory cytokines such as IL-6 
(Figure C10), CRP (Figure C12), adiponectin (Figure C13), TNF-alpha (Figure C14), 
glycoprotein such as fibrinogen (Figure C16) and endothelin-1 (Figure C17), and 
inflammatory biomarkers such as plasma E-selectin (Figure C18), apolipoprotein such as 
Apo A-I (Figure C20) and anti-inflammatory cytokines such as IL-10 (Figure C22). Hs-CRP 
(Figure C11), LDL-C (Figure C4) and TG (Figure C5) have no change after olive oil 
consumption.  
4.3.2.2 Studies supplementing olive oil 
Study (Tong, Rappold et al. 2015) reported that tissue plasminogen activator (tPA) levels 
were significantly increased immediately after (11.6%; 95% CI: 0.8, 22.2; p = 0.04) and 20 
hours after concentrated ambient particulate exposure in the olive oil group (Tong, Rappold 
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Figure 4.2. Meta-analysis of studies consuming olive oil on plasminogen activator inhibitor-1 
(PAI-1) (ng/mL). 
 
4.3.3. Subgroup analysis 
Subgroup analysis according to ethnicity was undertaken. Due to limited numbers of studies 
included in this review, only one study (Voon, Ng et al. 2015) derived from Malaysia and 
reported that there is no improvement on the cellular adhesion molecule family including E-
selectin, sICAM-1 and sVCAM-1. Other studies are all non-Asian population based.  
4.3.4. Quality of studies 
The methodological quality and risk bias of the RCTs are included in this review. The 
average retention rate for the trials included in this review was 95.9% for all 22 trials (Table 
4.1). The Jadad rating score was used to score the randomized trials from 1 to 5 points 
(Jadad, Moore et al. 1996, Berger and Alperson 2009). Quality scores were assigned with 
one point each for whether randomization and blinding were used, participant withdrawals 
and dropouts, random number generation, and the method of blinding on a scale from 0 to 
5 (Moher, Pham et al. 1998). 15 studies achieved the Jadad score of 5 while 7 studies 
achieved the Jadad score of 4.  
Table 4.3 reported the quality scores of the included RCTs.  All studies were randomized, 
but only two studies presented the appropriate methods such as generated random order 
(Maki, Lawless et al. 2015) and a computer-based randomization (Voon, Ng et al. 2015). 
Most RCTs (n=20) described methods for monitoring or verifying participant compliance. 11 
studies had no dropouts and reasons of the dropouts for other studies were mostly due to 
personal issues except one trial (Kris-Etherton, Pearson et al. 1999) which reported 
dropouts that were due to the long length of the intervention period (Table 4.3). In addition, 
most studies (n=20) did not report allocation concealment of treatments.  
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4.4. Discussion 
4.4.1. Principal findings 
 
Synthesis of data available from 22 RCTs with 860 participants for an average 5 weeks in 
the present systematic review and meta-analysis suggested that the interventions with olive 
oil or olive oil supplementation provide small beneficial effects on three distinct 
cardiovascular risk factors, which are PAI-1 and tPA while other cardiovascular risk factors 
are unaffected by olive oil interventions. However, significant result of tPA was abstracted 
from single study so that the result was not included into the meta-analysis. Overall, the 
presently available data are too small for drawing a solid conclusion.  
4.4.2. Agreements with prior systematic reviews 
PAI-1 is well established as a contributing pro-thrombotic and anti-fibrinolytic factor in CV 
events (Huber, Christ et al. 2001, Tofler, Massaro et al. 2016). t-PA antigen also was more 
convincingly demonstrated than PAI-1 to be an independent risk factor for CVD (Ridker, 
Brown et al. 2004). In this meta-analysis, a decreased PAl-1 (mean difference: -1.02; CI: 
1.92 to -0.12, p=0.03, n=2 trials) or t-PA antigen concentration (mean difference: -5.85; CI: 
-8.72 to -3.43; p<0.001; n=1 trial) were seen indicating that corresponds to an increased 
circulating fibrinolytic activity (Tofler, Massaro et al. 2016). While increasing PAI-1 levels 
(mean: 29.1 ng/ml) with CVD incident were associated with a worse risk factor profile, 
similar differences across quartile of t-PA were observed (mean: 12.0 ng/ml) in the 
Framingham Heart study (Tofler, Massaro et al. 2016). Elevated plasma PAI-1 levels are 
also associated with endothelial dysfunction (Lyon and Hsueh 2003). Notably, factors such 
as levels of TG and VLDL-C stimulate plasma PAI-1 levels (Bilgic Gazioglu, Akan et al. 
2015). In the present meta-analysis, TG was shown to have a tendency of reduction which 
also implied the decrease in PAI-1. However, increased plasma concentrations of TNF-
alpha are not positively associated with the decreased PAI-1 level in the present review.  
4.4.3. Strengths and limitations   
The strengths of the current findings include a rigorous methodology in the systematic 
review of the literature and meta-analysis, including prospective registration and the use of 
the Cochrane Risk of Bias tool to evaluate the quality of evidence. The low levels of 
heterogeneity surround the results. 
The small number of included studies (n=22) limits this meta-analysis in the first instance. 
Most outcome parameters such as SBP, DBP, ApoA-1, Apo B and CRP were collected in 
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a low number of studies with a relatively small sample size except blood lipids outcomes. 
This may at least in part explain the difficulty to model a link between biomarkers of 
cardiovascular via synthesizing the corresponding data from trials with heterogeneous 
designs. As for some outcome variables such as vWf, sICAM-1, sVCAM-1, IL-6, IL-8, 
fibrinogen, ET-1, E-selectin, only one or two studies could be included. A small number of 
participants in total (n = 860) for the 24 risk factors but only three variables are improved 
after olive oil intake. Due to the small numbers, outcome PAI-1 are of considerable 
heterogeneity (0%) and the present of improvements on outcomes are only from one or two 
studies. Since the effect sizes were found to be small, the results should not be over 
interpreted. Neither the risk of bias nor subgroup analysis can be fully assessed because 
of the small number of studies.  
Trials varied regarding study design, e.g., length of intervention, amount and type of olive 
oil used, classification of alternate source of fat (“control”), number of participants. In 
addition, most of study designs prescribed the intake of extra virgin olive oil (EVOO), refined 
olive oil, raw olive oil provided by the investigators or researchers in pre-defined amounts 
(e.g., 13.3 g/day, 15 ml /day) to ensure a regular intake in combination with the habitual 
diets.  
In addition, PAI-1 gene expression in vitro and in vivo is induced by a huge amount of 
triggers including TNF-a and PAI-1 which was found to be correlated positively with TNF-
alpha (Bilgic Gazioglu, Akan et al. 2015). Nevertheless, in the present review TNF-a was 
shown to adversely correlate with PAI-1. This is probably due to lack of adequate studies 
to correctly address the value of both outcomes. Furthermore, changes in hs-CRP, LDL-C 
and TG did not differ between olive oil interventions and respective controls/placebos in the 
present meta-analysis, which might be explained by the low number of study participants 
enrolled in the RCTs assessing these parameters. Taken together, these limitations 
implicate a cautious interpretation of the results of our meta-analyses. 
4.4.4 Scientific analysis of findings 
A number of potential mechanisms are probably responsible for the findings of this review. 
Firstly, vascular reactivity is affected by food consumption (Kay, Kris-Etherton et al. 2006). 
Anti-oxidant compounds in food can limit oxidative damage and restore endothelial function 
making atherosclerotic events slow down (Tousoulis, Psaltopoulou et al. 2015). Therefore, 
polyphenol consumption has been associated with low mortality rates caused by CV events 
(Tresserra-Rimbau, Rimm et al. 2014). Furthermore, endothelial function was shown to be 
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improved by anti-oxidant and anti-inflammatory polyphenols (Zern and Fernandez 2005). 
Hence, the phenolic compounds such as oleuropein, tyrosol and hydroxytyrosol, 
antioxidants present in olive oil might mediate the beneficial effects on FMD in the present 
review. Oleic acid, as another potential health-promoting ingredient of olive oil, in olive oil 
was demonstrated to benefit cardiovascular risk factors (Bermudez, Lopez et al. 2011). 
Beneficial effects of MUFAs such as oleic acid on CV risk factors have been consistently 
reported in meta-analyses and meta-regressions (Schwingshackl and Hoffmann 2012, 
Martinez-Gonzalez, Dominguez et al. 2014, Schwingshackl and Hoffmann 2014) although 
the data available at present are still ambiguous. Polyphenols derived from olive oil are 
characterized as antioxidants, antiplatelet agents, and anti-inflammatory agents. Such 
functions may regulate haemostasis by directly inactivating PAI-1 and the inactivation of 
PAI-1 may contribute to the pro-fibrinolytic effects (Cale, Li et al. 2010).   
4.4.5. Implications for health and future research 
This meta-analysis delivers small evidence for the positive effects of olive oil on markers of 
inflammation and endothelial function including PAI-1, FMD and tPA. Further studies need 
to be found and researched concerning olive oil consumption on different ethnicities.  
4.5. Conclusion 
 
The available evidence on the effects of olive oil on CV risk factors reported that olive oil 
consumption improves biomarkers including PAI-1 and tPA. Further studies regarding olive 
oil consumption and cardiovascular risk factors need to be researched. 
Research questions raised from the present chapter 4: 
The work described in this chapter raised the following questions: 
1. What cardiovascular risk factors and blood biomarkers will be changed after the 
consumption of olive oil consumption among Caucasians, mostly British and East Asians, 
mostly Chinese in Newcastle upon Tyne?  
2.   Dose the effect of olive oil on cardiovascular risk factors similar between different ethnic 
population living in the Northeast England? 
These questions will be addressed in Chapter 5.
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Table 4.2. Pooled estimates of effect size for the results of olive oil interventions compared to respective controls. 
Outcome Parameter Mean Difference 95% Confidence Interval p-Value No. of Studies Sample Size I2 (%) 
PAI-1 (ng/mL) -1.02 1.92 to -0.12 p = 0.03 2 58 0 
FMD (%) 2.3 0.05 to 4.55 p = 0.04 1 26 N/A 
tPA (ng/mL) -5.85 -8.27 to -3.43 P< 0.00001 1 26 N/A 
 
Table 4.3. The quality scores of the included RCTs.   
References Generation of Random 
method clarification 








Atefi et al., 2018 Balanced block method 24-h food records Fail to follow the diet; 
insulin need; need for 
blood lipids lowering drugs 
N/A 
Binkoski et al., 2005 USA Random, balanced order 
sequence 
Body weight measurements 
and a dietary assessment 
questionnaire 
No dropouts N/A 
Cicero et al., 2009 Italy N/A 7-day nutritional diary No dropouts N/A 
de Oliveira et al., 2017 Random: Order of entry N/A N/A N/A 
Engel and Tholstrup, 2015 
Danmark 
Random order 3-d dietary records Personal practical 
problems; Moving to 
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Galvão Cândido et al., 2018 Block randomization The return of the packages Secondary pathological 
events; personal reasons 
N/A 
Jiménez-Gómez et al., 2009 Spain N/A Diary records No dropouts N/A 
Kontogianni et al., 2013  Greece N/A Total fatty acid analysis in 




exacerbation of irritable 
bowel's symptoms; 
protocol misunderstanding 
Yes: a lack of 
blinding due to 
flavour 
Kris-Etherton et al., 1999 USA Random, balanced order 
sequence 
Body weight measurements 
and a dietary assessment 
questionnaire 
Long length of the study; 
relocated to different 
geographical areas 
N/A 




Mind change; personal 
reasons; 
N/A 
Lichtenstein et al., 1993 USA Randomized order Plasma fatty acid check No dropouts Yes 
Maki et al., 2015 USA SAS-generated random 
with the seed number 
recorded 
The returned uneaten portion 
of food items 
An intolerance to eggs; 
financial reasons; the 
investigator’s discretion 
N/A 
Namayandeh et al., 2013 Iran N/A N/A No dropouts N/A 
Nielsen et al., 2002 Denmark N/A Food records and plasma 
analysis of TAG and 
cholesterolfatty acids 
confirmation 
No dropouts N/A 
Oliveras-Lopez et al., 2013 Spain 
(Malaga) 
N/A Semi-quantitative food 
frequency questionnaire 
No dropouts N/A 
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(FFQ); an individual 7-day 
weighed food diary 
Pedersen et al., 2000  USA N/A The fatty acid composition of 
cholesteryl esters in plasma 
No dropouts N/A 
Perona et al., 2004 Spain N/A A 24h recall and food 
frequency questionnaires 
No dropouts N/A 
Sirtori et al., 1992  Italy N/A A 1-week dietary recall No dropouts N/A 
Tholstrup et al., 2011 USA Randomized order 3-d food records A baseline cholesterol 
concentration .5.2 mmol/L 
N/A 
Tong et al., 2015 USA N/A 3-day food records No dropouts N/A 
Venturini et al., 2015 Brazil N/A Boxes of capsules were 
handed out and return to 
count the remaining capsules 
or bottles 
No dropouts N/A 
Voon et al., 2015  Malaysia Computer-based 
procedure 




The effects of extra virgin olive oil or butter on blood pressure and other 
cardiovascular biomarkers In Caucasians and East Asians male adults in the UK: 
A study for a single centre, randomized, controlled, open label, crossover trial 
 
 
5.1 Introduction  
Evidence from prospective studies shows that the Mediterranean diet with olive oil as the 
predominant fat source is associated with numerous health benefits (Visioli, Franco et al. 
2018). These benefits are in part attributed to its high monounsaturated fatty acid content 
as well as to bioactive components found in olive oil. A number of studies have tested the 
effects of consuming olive oil on intervention trials. However, most studies on the 
Mediterranean diet and on the health effects of olive oil have included mostly Caucasian 
individuals (Mazzocchi, Leone et al. 2019). 
Diet-related disparities, reflecting differences in diet, as well as in the incidence, prevalence, 
mortality, and the burden of disease between and within specific population subgroups, 
have been long recognised (Satia 2009). No individual is identical to another; there is 
significant variation in individual constitution, lifestyle, genetics, diet, health, and other 
factors. Ancestry and ethnicity are important determinants of health. Often, the disease risk 
profile of some ethnic groups within a population differs from that of the majority population 
– sometimes in favour, but mostly to the detriment of minority populations. Certain countries 
such as the UK or the USA have become increasingly diverse over the last century; in such 
countries 20-30% of the population make up ethnic minority groups. In spite of the 
importance of ethnicity, a lack of adequate representation of racial and ethnic minority 
populations in intervention trials has been identified; this is recognised as a limitation of the 
generalizability and potential public health impact of these interventions (Haughton, Silfee 
et al. 2018). Therefore, caution against generalising results from predominantly white study 
populations to other racial/ethnic populations should be emphasised since ethnicity is a 
well-known effect modifier, this is a variable for which the effect of the intervention varies 
across different levels of the variable (Kris‐Etherton, Petersen et al. 2020). In the UK the 
Chinese ethnic group or “British Chinese” migrated from former British colonies, such as: 
Hong Kong, Malaysia, Singapore, Canada, Australia, New Zealand and Mauritius, with 
lower numbers from mainland China and Taiwan. Chinese communities are found in many 
major cities such as London, Glasgow, Manchester and Newcastle. There are well 
established Chinatowns in London, Manchester, Birmingham, Newcastle and Liverpool.  
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The North East of England, is characterised by high rates of obesity, poor health (NHS 
2020), especially cardiovascular disease, which account for 24% of all deaths (Public Health 
England 2019). Cardiovascular risk factors such as overweight and obesity levels in the 
North East currently rank third lowest for men but second highest for women. 
Cardiovascular diseases including heart disease, strokes and other related conditions are 
one of the biggest causes of ill health and early deaths in the North East of England. Each 
year over 6,700 people die from CVD across the region, representing one quarter of all 
deaths (Public Health England 2019). Approximately 2000 of these deaths occur in people 
under 75 years of age. Many of the risk factors for CVD including high blood pressure, 
obesity, smoking, physical inactivity, excessive alcohol consumption and poor diet, are 
more common in the North East region. In 2015 and 2017, the rate of premature CVD 
mortality in the North East was the second highest of all the English regions and significantly 
higher than the national rate (Public Health England 2019). There is an imperative need to 
reduce the risk of developing cardiovascular diseases by developing strategies to promote 
healthy eating, physical activity, smoking cessation and weight loss.  
A study reported that there was much lower prevalence and mortality of stroke, and higher 
prevalence and higher mortality rates from CHD among Chinese immigration (Gong and 
Zhao 2016). For Chinese immigrants in the North East of England, however, there is a lack 
of literature of evidence exploring and showing whether or not Chinese citizens, or East 
Asians population living in the North East of England experience either cardiovascular 
diseases or cardiovascular risk factors.  
 
5.2 Rationale of the clinical trial 
No dietary interventional studies have directly compared different ethnic groups such as 
Caucasians and East Asians although a number of studies have been undertaken to 
evaluate the impact of olive oil in a number of cardiovascular risk markers. In addition, few 
studies have evaluated blood pressure, one of the most important risk factors of 
cardiovascular disease, using ambulatory blood pressure measures which have a stronger 
association with CVD outcomes than clinic blood pressure (Piper, Evans et al. 2015). 
Similarly, few studies have reported on the impact of olive oil on blood markers of 
endothelial function.  
The evidence from the survey study undertaken as part of this PhD and reported in Chapter 
2 suggested that olive oil (OO) intake is positively associated with PREDIMED score (MDPS) 
as well as MD acceptability and inversely associated with perceived barriers to healthy 
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eating (PBHE). OO is less popular among Asians than Caucasians, however the 
acceptability of OO consumption is relatively high in both ethnicities.  
Systematic reviews and meta-analysis of the relevant literature were undertaken to inform 
the design of this olive oil human trial. The evidence from the systematic reviews and meta-
analyses of relevant literature (Chapter 4) suggested that olive oil consumption with daily 
consumption ranging between 13.3 and 64.8 g, significantly reduced important biomarkers 
of cardiovascular function such as PAI-1 and tPA. There was no significant evidence of a 
reduction on TC, LDL and BP. However, DBP and TC are more likely to be improved by 
olive oil consumption. Only few studies, however, have assessed 24-hour BP after extra 
virgin olive oil intake between Caucasians and East Asians. However, the evidence of 
different effects of OO consumption on emergent circulating biomarkers such as CRP, 
sICAM-1, sVCAM-1, PAI-1, sP-selectin, sE-selectin and IL-6, in East Asians and 
Caucasians is currently less examined in the literature. Novel biomarkers such as 
syndecan-1 in the present study have not been studied in relation to whether they are 
improved by olive oil consumption. Furthermore, levels of circulating markers of 
inflammation and atherosclerosis including interleukin 6 (IL-6), soluble intercellular 
adhesion molecules (sICAM-1), soluble vascular adhesion molecules (sVCAM-1), E-
selectin and P-selectin have been only scarcely studied on the impact of the effects of extra 
virgin olive oil between Caucasians and East Asians too. 
On the basis of these results, therefore, this study aims to determine and compare the 
beneficial effects of extra virgin olive oil (EVOO) and butter after 6-week interventions on 
resting blood pressure, 24 hours ambulatory blood pressure, blood lipid profile including TG, 
TC, LDL-cholesterol, HDL-cholesterol, circulating markers of inflammatory cytokines 
including CRP, IL-6, PAI-1, adhesion molecules such as sE-selectin, sP-selectin, sICAM-1, 
and sVCAM-1, as well as novel biomarkers such as syndecan-1 in Caucasians and East 
Asians who live in the North East of England.  
The hypothesis of this human clinical trial chapter is to test if the cardiovascular risk factors 
will be positively effective by EVOO intake in healthy participants both ethnicities and EVOO 
will have different levels of positive effects on cardiovascular risk factors between healthy 
Caucasians and East Asians. A comprehensive study examining liquid extra virgin olive oil 
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5.3 Method and Materials 
The study was subject to ethical review by the Northumbria University Ethics Committee 
(Project ref: 10527) and was given a favourable ethical opinion to proceed. Informed 
signed consent was sought from each participant.  
The study protocol was written in accordance with the Standard Protocol Items: 
Recommendations for Interventional Trials (SPIRIT) guidelines (Chan, Tetzlaff et al. 2013) 
and Consolidated Standards of Reporting Trials (CONSORT) guidelines (Figure 5.1 and 
Appendix D8) (Dwan, Li et al. 2019). The study was conducted at Northumbria University 
facilities. In total 34 male participants who live in Newcastle upon Tyne of the North East of 
England completed the intervention, the participants were statistically analysed as a full 
sample size as well as being split into Caucasians (n=18) and East Asians (n=14). In 
addition to traditional biomarkers, there are a number of novel biomarkers that have shown 
clinical potential to predict the incidence of CVDs. These novel biomarkers are involved at 
various stages of the atherosclerosis process.  
 




            
Figure 5.1 CONSORT Flow diagram for reporting of the results of the human clinical trial
CONSORT 2010 Flow diagram 
Assessed for eligibility (n=52) 
Caucasians (n=32) 
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5.3.1 Trial design 
This study is a single-centre, two-arms, crossover randomised controlled superiority trial. A 
crossover design was chosen in order to evaluate within- and between-subject effects of 
the interventions tested so as to eliminate between‐subject variability. A crossover design 
offers two advantages over a parallel-group RCT: (1) the influence of confounding 
covariates are reduced because each participant serves as their own control; and (2) 
statistical power is higher and required sample size to detect meaningful effects is lower 
(Stephen 2002). The protocol for this trial has been registered at Clinical Trials 
(https://clinicaltrials.gov/) registration: NCT04187638).  
This study involved 4 study visits over a 6‐week period plus a screening visit prior to the 
study visit 1. During the pre‐screening visit, participants received a participant information 
sheet, consent form, a physical activity questionnaire, plus a medical and lifestyle 
questionnaire. Two questions in the lifestyle questionnaire were related to OO intake (use 
of OO as a main fat for cooking or dressing and using how many tablespoons of OO. 
Participants were asked to complete a 3‐day dietary record including 2 weekdays and 1 
weekend day to take into account any differences in nutrient intakes during weekdays and 
weekends at pre‐screening visit prior to future visit 1. Participants were recommended to 
record their dietary intake with the instructions attached by researcher during the first two-
week intervention period and were asked to repeat their own habitual dietary pattern (on 
breakfast and evening meals) to match up the nutrition intake and energy intake, and to 
maintain physical activity pattern throughout the rest of the whole study in order to limit 
dietary intake as well as body weight variability to remain unchanged during the whole 
clinical study. OO and butter dose was designed to provide approximately 8% to 11% of 
energy from fat. A comparable energy level was maintained during the two subsequent 
phases and a 3-day food record was completed before bringing along with to future visits. 
 
On each study visit, participants’ blood pressure, anthropometric of body composition and 
physical strength measurements were collected. In addition, fasting urine and venous blood 
samples were obtained. Body mass index (BMI) was calculated as weight (kg) divided by 
height squared (m2), grip strength, body fat and resting blood pressure, ambulatory blood 
pressure monitoring were obtained following standard protocols (i.e., without shoes or 
wearing heavy garments) and a fasting venous blood sample (18ml in each visit) was 
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collected by trained researchers. Therefore, a total of 72ml of blood per individual was 
collected throughout the entire study. Fasting spot urine samples were also collected into a 
flask. The outcomes for this study included both resting and 24‐hour ambulatory systolic 
(SBP) and diastolic blood pressure (DBP); urine samples to assess nitric oxide production; 
blood biomarkers such as cholesterol, triglycerides, LDL, HDL, sICAM‐1, sVCAM‐1, CRP 
and IL‐6 were analysed from the blood plasma samples. The plasma and urine collected 
was also used to identify novel markers of dietary intake. Plasma and urine analyses did 
not commence until the full intervention study was complete, and all samples from each 
subject were analysed within one batch to reduce inter‐batch variation.  
 
Butter was chosen to be the control group since butter is one of the most common fat-based 
foods that British citizens consume daily. The same brand of butter and extra virgin olive oil 
were purchased from Tesco - unsalted Block Butter (0.03g of salt/30g butter) and Filippo 
Berio Organic Extra Virgin Olive Oil were chosen throughout the trial to prevent confounding 
effects from butter containing salt (0.45g of salt/30g butter). Over‐consumption of salt 
causes raised blood pressure and consume less than 6g (0.2oz) of salt a day, which is 
about a teaspoonful was the goal to reduce blood pressure (NHS 2019). The researcher 
instructed each participant to measure the dose of extra virgin olive oil (EVOO) to be 
consumed per day by spoon as well as the amount of unsalted block butter mixing with the 
can of soup consumed at lunchtime as a lunch meal replacement. During two-week washout 
period, participants were asked not to consume the olive oil and butter provided or any other 
types of olive oil.  
 
5.3.2 Participants eligibility criteria and study settings 
Adult, self-reported healthy, adult men (20-64 years of age), of two different ethnicities - 
Caucasians mostly British and East Asians mostly Chinese, participated in this study. East 
Asians (including Chinese, Hong Kong, Korean, and Malaysia Chinese) and Caucasians 
(including local British and Western Europeans such as Croatian, Irish) aged 20-64 years 
were included and studied. Only male individuals took part in the study. Women were not 
included as controlling for the potential influence of menstrual cycle would increase the 
length of this study, making it thus unfeasible within this PhD project. Although the lack of 
diversity of gender remained an issue in general CVD clinical trials, it is of vital importance 
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to notice that this trial was conducted among only 34 participants with two ethnicities and a 
large age range within a limited period of time, which lasts around ten months, therefore in 
order to complete this trial in a practical way, it is necessary to maintain other controllable 
aspects (e.g. gender) the same is to keep consistency of the subjects in order to reduce the 
compounding factors which potentially complex the design of the intervention and affect the 
trial results.       
Participants were volunteers living around Newcastle upon Tyne, Northeast England, UK. 
Subjects were excluded if they are taking antioxidant supplements; diagnosed and/or taking 
medications for hypertension (>140/90mmHg), diabetes, high blood cholesterol and heart 
problems; diagnosed lactose intolerance; taking omega-3 supplements regularly in the last 
six months, or if they reported being allergic to olive oil.  
Participants were recruited via social media including Facebook, LinkedIn and Twitter and 
other reachable forms of community recruitment including web advertisements, and flyers 
and posters in local venues from January until November 2019. Participants were asked to 
attend 1 screening visit and 4 study visits over a 6‐week study period held in 
Northumberland building (NB425) at Northumbria University. These visits were scheduled 
in the morning and lasted around 30 minutes to one hour. During the study days, 
participants were asked to refrain from strenuous exercise. Participants returned at the 
same time point for the study visit every 2 weeks and repeated all of the measurements 
mentioned above.  
 
5.3.3 Interventions 
Participants received two treatments incorporated into their usual diet. In the intervention 
arm, participants were supplemented with at least 30 ml/day of extra virgin olive oil (EVOO) 
for two weeks. The control arm received 30 g/day of butter for two weeks. A washout period 
of 2 weeks in between which participants restrained from consuming either extra virgin olive 
oil (EVOO) and the butter block followed the intervention arms (Figure 5.2). 2-week time of 
washout period is the minimum washout period which is effective to eliminate the “order 
“effects which potentially affects the outcome due to the nature of this EVOO intervention. 
Based on the systematic review of meta-analysis of olive oil in Chapter 4, 2-week washout 
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period was also shown to be sufficiently enough to eliminate the issue of “carry-over” effects 
between treatments.  
 The amount of olive oil provided in this study was informed by the systematic review in 
Chapter 4. It was estimated that 30 ml of olive oil for a minimum of 2-weeks would be 
enough to show effects on the cardiovascular biomarkers.  
The nutritional composition of Filippo Berio Extra Virgin Olive Oil (500ml) and Tesco British 
Unsalted Butter (250g) obtained from Tesco product description and USDA Food 
Composition Databases is presented in Table 5.2. Participants were instructed to replace 
their usual lunch meal with the OO or butter plus one can of Heinz Cream of Vegetable 
Soup (400g) or Heinz Potato and Leek soup (400g). In addition, participants also were 
recommended to eat a piece of fruit (e.g., one banana: 30.75kcal or one gala apple: 
70.89kcal) and one slice of white medium bread (90kcal) so that the total calorie intake of 
the entire lunch meal is similar as the total calorie intake of usual lunch meal. The total 
energy intake of the provided lunch meal is approximately 600kcal. 
Compliance and adverse effects with interventions were assessed by self-report using daily 
checklists. In addition, body weight and body composition, and handgrip strength were 
measured on each study-visit as indicators of evidence of maintenance of lifestyles. 
Participants were also contacted regularly to discuss any problems relating to the 
supplementation of olive oil and to provide encouragement and support by either emailing 
or phone call usually at the midpoint of each round of intervention. Self-reported daily 
checklist of extra virgin olive oil showed a good acceptability and compliance with EVOO. 
No side-effects of the intervention were reported regarding EVOO and butter consumption. 
 
5.3.4. Randomization and Allocation 
Participants were assigned a unique study identification number (ID). Participants were 
randomized using computer-generated random integer generator software 
(http://www.randomization.com) in blocks of 4, with a 1:1 ratio by the principal supervisor, 
Dr Jose Lara. This ensured a balanced design with half the sample starting with butter and 
the other half with olive interventions. A randomisation list was produced for each ethnic 
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group to minimise potential confounding. The allocation sequence was concealed from the 
researcher (Fan Liang) using sequentially numbered, opaque and sealed envelopes.  
Participants were unaware of the randomization sequence; but given the nature of it, they 
were not blind to the intervention, once they began each phase of the intervention, they 
were aware of either the extra virgin olive oil (EVOO) or butter to be consumed.  
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Figure 5.2 Flow diagram of olive oil intervention.
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5.4 Outcome measures  
The outcome measures of this study are listed in Table 5.1. The primary outcome measure 
of this study is ambulatory blood pressure based on the results of olive oil systematic review 
and meta-analysis in Chapter 4 as these outcomes were the most common, representative 
and typical outcomes assessing the effectiveness of olive oil interventions, while other 
biomarkers such as these related to endothelial function were poorly studied. Thus, novel 
biomarkers need to be evaluated in response to the interventions in the clinical trial study.   
 Secondary outcomes included traditional and novel CV biomarkers (Table 5.1). To 
minimize inter-observer variability all outcome measures in this study were measured by 
the researcher (Fan Liang) every time. All measurements were carried in a temperature-
controlled room in which the ambient temperature was 23±1oC. To minimize inter-observer 
variability all outcome measures in this clinical trial were measured by the researcher every 
time.  
Table 5.1.  Outcome measures evaluated at baseline, 2, 4 and 6 weeks. 
Primary Outcome Measures 
Blood pressure 1. Resting (Laboratory) Blood pressure 
2. 24hr ambulatory blood pressure 




5. NHDLC  
New established biomarker 1. sP-selectin (ng/mL) 
2. sE-Selectin (ng/mL) 
3. Interleukin 6 (ng/mL) 
4. PAI-1 (ng/mL) 
5. CRP (pg/mL) 
6. sVCAM1 (ng/mL) 
7. sICAM1 (ng/mL) 
8. Syndecan-1 (ng/mL) 
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Table 5.2 Nutrient Content 30 ml of extra virgin olive oil, 30 g of butter, 400g of soup 
respectively; Data obtained from USDA Food Composition Databases and Tesco product 
description. 
Nutrient (unit) EVOO  Butter  Heinz Vegetable 
Soup  
Heinz Potato and 
Leek soup  
Total Fat (g) 27.39 2.46  3.4 7.4 
Saturated Fat (g) 4.65 1.56  0.2 4.4 
Trans Fat (g) 0  0  0 0 
Polyunsaturated Fat (g) 3.21 0  0 0 
Monounsaturated Fat (g) 19.53 0  0 0 
Cholesterol (mg) 0 0  0 0 
Iron (mg) 0.07 (0) 0  0 0 
Energy (kJ) 1013.4 kJ-246.6 
kcal 
918.6 kJ – 223.5 
kcal 
792 kJ-188kcal 832 kJ-196kcal 
Carbohydrate (g) 0  0.18 33.2 28.6 
Sugars (g) 0  0.18 13 0 
Fibre (g) 0  0 3.6 2.2 
Salt (g) 0  0.03 2.4 2.4 
Protein (g) 0  0.18 4.4 3.2 
 
5.4.1 Resting blood pressure and 24-hour ambulatory blood pressure (ABP) 
Resting blood pressure was measured in a quiet room after participants rested for 15 
minutes in a seated position with arm resting on a firm surface and feet flat on the floor, 
using a non-invasive digital automatic blood pressure monitor (Carescape™ V100: GE 
Healthcare, UK). Blood pressure measurements were taken in the non-dominant upper arm 
in triplicate, and the average of the last two measurements was used for subsequent 
analyses.  
A non-invasive ABP device (Medical 90217-1Q: Spacelabs, Inc. Richmond, Washington, 
USA) was utilized to record and measure 24-hour ABP. An ABP cuff were fitted by the 
researcher, and participants were asked to wear the monitors for a period of 24 hours after 
completing all other measurements. The ABP blood pressure device that is attached to a 
belt around participants’ bodies, which is connected to a cuff around the upper arm. 
All readings were performed on the non-dominant upper arm of the participant on each 
study day. The monitor was programmed (ABP Report Management System version 3.0.3 
Spacelabs, Inc. Richmond, Washington, USA) to inflate automatically, at 30-min intervals 
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during 0800-2200 and 60-min intervals during 2200-0800, for a total period of 24-hours. 
Mean daytime and night-time blood pressure were calculated based on measurements 
taken while participants were awake and asleep, respectively (Yano, Tanner et al. 2019). 
Throughout the 24-hours period, participants were instructed to maintain their arm relaxed 
down the side of their body and kept still until the end of each subsequent measurement. 
While walking, the participants were required to stop and stand still for a minute until the 
measurement completed.  
 
5.4.2 Fasting blood sample and urine collection  
Fasting blood samples were collected using a BD Vacutainer® Safety-Lok™ blood 
collection set inserted into the antecubital vein in right arm; blood was drawn into separate 
6 mL BD Vacutainer® Heparin Tube tubes (Becton Dickinson). Tubes were inverted 10 
times to mix the blood and anticoagulant inside the tube and centrifuged immediately for 15 
min at 1500rpm. Plasma samples were instantaneously stored at -80 ℃ until analysis. 
Analyses of plasma samples were undertaken after the intervention study was completed 
and all samples for each participant were analysed without knowledge of the treatments, 
within one batch to reduce inter-batch variation. Fasting plasma samples (3 x 6ml Li‐Heparin 
tubes) were collected before and after each arm of intervention. A spot (20ml each of spot) 
urine was obtained in each of the 4 visits in order to assess metabolites (Four in total 
throughout the study).  
 
5.4.3 Plasma analysis 
Plasma samples were used for analysis of cardiovascular biomarkers using commercial 
Elisa kits according to the manufacturer’s specifications. A microplate spectrofluorometric 
reader (Tecan Spark®) was used to measure absorbance at 492 nm on a plate reader 
(Tecan Spark, Tecan, Switzerland) on each ELISA plate. Viability was calculated and 
expressed as percent of control. Due to limits in budget, eight biomarkers including P-
selectin, interleukin-6, PAI-1, CRP, sVCAM-1, sICAM-1, sE-selectin and syndecan-1, were 
analysed only at post-intervention, which include study visit 2 and visit 4.  
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Cardiovascular biomarkers measures included: 
Soluble vascular and intracellular adhesion molecules (sVCAM-1 and sICAM-1). sVCAM-
1 (Product number: RAB0505; Lot number: 1222D0195) (Appendix D13) and human 
sICAM-1 (Product number: RAB0219; Lot number: 0528F0185) (Sigma-Aldrich, St Louis, 
MO, USA) (Appendix D14).  
Plasma soluble E-selectin and P-selectin. Human sE-selectin (Cat. No.: RAB0422; Lot 
number: 0410F0118) (Appendix D15) and sP-selectin (Cat. No.: RAB0426; Lot number: 
0509F0217) (Sigma-Aldrich, St Louis, MO, USA) (Appendix D9). 
Plasma pro- and anti-inflammatory cytokines. IL-6 (Product number: RAB0306; Lot number: 
0424F0140) (Sigma-Aldrich, St Louis, MO, USA) (Appendix D10).  
Plasma concentrations of plasminogen activator inhibitor (PAI)-1. (Product number: 
RAB0429; Lot number: 1016F0312) (Sigma-Aldrich, St Louis, MO, USA) (Appendix D11). 
C-reactive protein (CRP). CRP (Product number: RAB0096; Lot number: 0925F0283) 
(Sigma-Aldrich, St Louis, MO, USA) (Appendix D12). 
Syndecan-1. Human SDC1/syndecan-1 (Product number: RAB0736; Lot number: 
0612F0035) (Sigma-Aldrich, St Louis, MO, USA) (Appendix D16). 
Lipid profile, (including TC, TG, HDL-C as well as LDL-C) content in plasma was measured 
by The Laboratories of the Integrated Laboratory Medicine in Freeman Hospital at 
Newcastle Upon Tyne.  
 
5.4.4 Other measures and data collected 
5.4.4.1 Anthropometric measurements  
Anthropometric measurements were taken including height and weight without shoes, 
which were then used to calculate BMI by dividing body mass (kg) by body height2 (m) 
(kg/m2) (World Health Organization 1995, Madden and Smith 2016)  
A stadiometer was used to measure height to the nearest centimetre (cm). Participants were 
asked to remove their shoes and position their head in the Frankfurt plane position. 
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Participants were positioned looking straight ahead with the lower border of the left orbit 
and the tragus of the ear lying on the horizontal plane (Raine and Twomey 1994). 
Body weight was measured using Tanita scales after participants removed outer garments 
and any personal objects affecting body weight (keys, coins, jewellery etc.). Participants 
were barefoot for both height and weight measurements (Kuriyan 2018). 
 
5.4.4.2 Body composition assessment  
Bioelectrical impedance analysis (BIA) was performed using a single frequency (50 kHz) 
device (Body stat 1500, Body stat Ltd; Isle of Man, UK). Estimations of fat in percentage (%) 
and in weight (kg), lean weight in percentage (%) and (kg), total water in percentage (%) 
and litre (L) were recorded. Before measurement, participants rested in the supine position 
and have their limbs abducted to avoid current shunting. Body stat electrode pads was 
placed in the middle of the dorsal surface of the left hand just proximal to the 
metacarpophalangeal joints and left foot proximal to the metatarsophalangeal joints; a 
second set of electrodes were placed between the distal prominence of the radius and the 
ulnar styloid and between the medial and lateral malleoli at the ankle.  
 
5.4.4.3 Handgrip strength 
Handgrip strength was measured using a CAMRY-EH101 hand dynamometer (range 0 to 
90kg; accuracy 0.1 kg) (EH101; Camry, Guangdong Province, China). In a standing position, 
participants hold the dynamometer in their dominant hand (Meng, Wu et al. 2015). The 
handle of the dynamometer was adjusted if required. When ready, participants were 
instructed to squeeze the dynamometer with maximum effort and hold for approximately 5 
seconds without other body movements (McGrath, Kraemer et al. 2018). The participants 
were strongly encouraged by the researcher to give a maximum effort. Handgrip strength 
was assessed in triplicate and the average of all readings were taken as the final score (Lee, 
Peng et al. 2016, McGrath, Kraemer et al. 2018). 
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5.4.4.4 Dietary assessment and nutritional analysis  
Participants were asked to record their dietary intake for 3 non-consecutive days (i.e., type 
of foods, preparation and amount of food/drink consumed), two weekdays and one weekend 
day. The 3-day dietary record was estimated by providing guidance on the estimation of 
household measures, and food intake record from each participant allowed a nutritional 
analysis with the aid of the ‘‘Micro-diet’’ software (Micro-diet System, Version 6.4, Salford 
University, UK) (Rosa, Carmen et al. 2015). 
 
5.4.4.5 Sample size 
This study was powered based on a sample size calculation on the number of participants. 
Sample size is calculated using G*Power (http://www.gpower.hhu.de/en.html) version 3.1.3 
(Program written, concept and design by Franz, Universitat Kiel, Germany) (Faul et al., 
2009). T-test for differences between two dependent means was used. Calculations 
considered a prior power of 0.8, a 0.05 significance level and a 0.5 correlation coefficient 
between groups.  
Sample size calculations were performed for the primary endpoint; this is, change in SBP 
response. The estimated participants required to allow detection a difference of 6 mmHg 
between the responses to the intervention and control, based on the systematic review in 
Chapter 4. T-test, difference between two dependent means (matched pairs), a priori: 
compute required sample size and two tails were chosen. At a power of 0.80, a 0.05 
significance level, a sample of 12 in a crossover study allowed to detect a difference of 
approximately 0.5 standard deviations in SBP (graph shown in Appendix D17). We 
proposed recruiting 15 male adults within each ethnic group in order to allow for a 20% 
drop‐out rate. This sample size is a conservative one, given that in a cross-over study 
design, the correlation between the groups would be higher which lower the sample size. 
Therefore, over‐recruitment (at least 30 participants) was acceptable and feasible to add 
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5.5 Statistical analysis 
An intention-to-treat analysis was performed (Montori and Guyatt 2001) in accordance with 
CONSORT guidelines (Dwan, Li et al. 2019) to provide an assessment of the practical 
impact of a treatment.  
All statistical analyses were carried out using IBM SPSS Statistics version 24. Data was 
evaluated for normality of distribution using the Shapiro-Wilk test. 
The General Linear Model (GLM) for repeated measures were used to compare within-
subject treatment effects. In addition, analysis of variance (GLM univariate) was used to 
test between subject comparisons. Results (unadjusted and adjusted for covariates) are 
presented as means (or marginal means) ± SEM. Adjustment for covariates includes 
baseline and washout values, the results for blood pressure as well as blood lipids were 
obtained after baseline, washout, BMI (kg/m2), age (years), sodium (mg/day) intake and 
energy intake (kcals/day) value. Results for novel biomarkers were achieved after washout, 
BMI (kg/m2), age (years), energy intake, saturated fatty acids (mg/day) and dietary 
cholesterol (mg/day) values. Bonferroni correction test for multiple comparisons were 
implemented. Paired t-tests were used to compare changes from baseline. Analysis was 
run on the participants as a whole as well as grouped by ethnicity: A p value less than 0.05 




5.6. Results  
The study was completed during early December 2019. Recruitment for this study was 
successful and a total of 32 participants took part (Figure 5.1). 32 participants completed 
the entire trial after baseline assessment with a high retention rate (94.2%) and good 
adherence to the treatments (Figure 5.1). The participants reported 100% compliance with 
interventions, i.e., extra virgin olive oil (EVOO) and butter consumption. Neither body weight, 
nor other demographic and clinical characteristics changed significantly over the periods of 
intervention. Research participants experience questionnaire reported that participants 
either strongly agree or agree with feeling being valued as a participant. No participants 
reported negative feedback and no adverse effect overall. All but one Caucasian participant 
reported to be sure they would continue using extra virgin olive oil (EVOO) in the near future 
after taking part in the study and apart from this participant.  
 
5.6.1 Participants baseline characteristic  
The demographic and anthropometric characteristics of the sample studied are shown in 
Table 5.3. In total 32 participants completed the interventional study, age ranged from 20 
to 64 years old. The baseline characteristics of participants are presented for the full sample 
size as well as when these were divided according to their ethnicity into Caucasians (n=18) 
and East Asians (n=14). Overall, no significant differences were observed between groups 
at baseline on any of the variables presented in Table 5.3. The results shown indicate a 
sample of mature adults, on average of a normal weight, normal blood pressure and body 
composition, although some spread was observed, for example in BMI values ranging from 
17.7 kg/m2 to 31.6 kg/m2. Statistical analysis comparing Caucasians versus Asians revealed 
that these groups were comparable.
 




Table 5.3 Participants (n=32) baseline characteristic 
Baseline 
characteristics 
All participants (n=32)  *Caucasians (n=18)  **East Asians (n=14)   
Mean SEM STD Mean SEM STD Mean SEM STD P-value (Sig. 2-tailed) 
Age (year) 31.22 1.83 10.33 33.72 2.97 12.60 28.00 1.39 5.20 0.122 
BMI (kg/m2) 24.11 0.63 3.59 24.64 0.79 3.36 23.44 1.04 3.87 0.355 
Resting SBP (mmHg) 117.60 1.76 9.97 120.32 2.02 8.58 114.09 2.89 10.82 0.079 
Resting DBP (mmHg) 68.60 1.95 11.03 67.28 2.38 10.11 70.30 3.29 12.30 0.451 
Resting HR (bpm) 69.20 1.77 10.03 67.98 2.37 10.05 70.77 2.71 10.14 0.443 
24-hour SBP (mmHg) 120.70 1.37 7.78 122.13 2.16 9.16 118.86 1.41 5.29 0.215 
24-hour DBP (mmHg) 68.94 1.32 7.45 68.74 2.06 8.75 69.20 1.52 5.68 0.865 
24-hour MAP (mmHg) 86.22 1.15 6.5 86.54 1.88 7.99 85.81 1.10 4.13 0.758 
  Daytime BP     
 SBP (mmHg)  126.18 1.53 8.66 128.79 2.26 9.60 122.81 1.62 6.06 0.051 
 DBP (mmHg) 71.96 1.54 8.73 72.47 2.34 9.93 71.30 1.93 7.20 0.714 
 MAP (mmHg) 89.86 1.31 7.39 91.01 2.04 8.65 88.38 1.42 5.31 0.326 
  Nighttime BP (n=30; Caucasians n=17; East Asians n=13)   
 SBP (mmHg) 114.58 1.64 8.98 115.99 2.54 10.47 112.75 1.81 6.51 0.336 
 DBP (mmHg) 65.20 1.27 6.93 65.17 2.13 8.77 65.32 1.02 3.66 0.98 
 MAP (mmHg) 81.80 1.23 6.71 82.12 2.06 8.51 81.38 0.96 3.47 0.749 
  Body composition     
 




All participants (n=32)  *Caucasians (n=18)  **East Asians (n=14)   
Mean SEM STD Mean SEM STD Mean SEM STD P-value (Sig. 2-tailed) 
 Grip strength mean (kg) 40.41 1.14 6.45 40.19 1.76 7.48 40.69 1.36 5.10 0.833 
 Grip strength max (kg) 42.77 1.18 6.68 42.43 1.82 7.71 43.21 1.42 5.33 0.749 
 Body fat (%) 16.37 0.91 5.16 17.09 1.28 5.42 15.44 1.29 4.84 0.379 
 Body fat (kg) 12.62 1.00 5.67 13.64 1.45 6.17 11.31 1.30 4.86 0.254 
 Lean (%) 83.36 1.19 5.56 82.57 1.62 5.60 84.31 1.79 5.66 0.478 
 Lean (kg) 61.88 1.14 6.47 63.40 1.46 6.18 59.92 1.75 6.53 0.134 
 Total (kg) 74.25 1.96 11.08 76.60 2.75 11.68 71.23 2.63 9.86 0.178 
 Dry lean weight (kg) 18.03 0.52 2.94 18.31 0.67 2.85 17.67 0.83 3.12 0.553 
 Water (%) 59.63 0.94 5.32 59.49 1.36 5.76 59.81 1.31 4.91 0.87 
 Water (It) 43.85 0.76 4.27 45.09 1.01 4.27 42.25 1.03 3.85 0.061 
 Impedance 50KHz 490.13 18.48 104.54 463.94 28.97 122.91 523.79 17.19 64.31 0.109 
*Caucasians: Normal BMI = 18.50 – 24.99 kg/m2; Underweight BMI:- < 18.5 kg/m2 ; Overweight BMI: = 25.0 – 29.99 kg/m2 ; Obese BMI: > = 30.00 kg/m2 





5.6.2 Nutritional intakes of participants  
The average energy intake of participants, recorded from 3-day dietary diaries by each participant, are presented in Table 5.4. Table 5.4 showed that there 
is no statistically significant difference of nutritional intake of Caucasians and East Asians as p-value are all higher than 0.05. Reported energy intake (EI) 
was related to estimated basal metabolic rate (BMR) based on self-reported body weight and age. As reported in Table 5.4, EI:BMR ratios of both ethnicities 
(Caucasians: 1.23; East Asians: 1.15) are lower than 1.35, which is likely to reflect the presence of underreporting of energy intake (Table 5.4).  
 
- 177 - 
 
Table 5.4 Daily intakes of nutrients by Caucasians and East Asians from 3-d dietary records 
Baseline 
characteristics 
Caucasians  East Asians   
Mean SEM STD Range N Mean SEM STD Range N P-value 
Protein (g) 101.24 8.77 37.21 (55.3, 181.3) 18 93.05 6.47 24.20 (47.8, 127.7) 14 0.481 
Fat (g) 81.40 7.31 31.01 (28.0, 152.3) 18 84.31 6.83 25.56 (40.2, 131.8) 14 0.778 
Carbohydrate (g) 253.15 26.60 112.86 (132.3,562.5) 18 231.49 13.80 51.62 (156.9, 330.3) 14 0.476 
Energy intake (EI) (kcal) 2148.98 148.00 627.92 (1194.6, 3934.1) 18 1966.20 90.16 337.33 (1214.9, 2635.3) 14 0.334 
Energy intake (EI) (kJ) 8977.63 614.65 2607.75 (5051.8, 16553.6) 18 8346.21 401.51 1502.32 (5125.4, 11047.3) 14 0.427 
Total Saturates (g) 28.84 3.02 12.80 (8.2, 61.1) 18 28.81 2.23 8.35 (12.9, 44.5) 14 0.995 
Total monounsaturate (g) 29.09 3.36 14.25 (7.9, 59.8) 18 30.67 3.00 11.24 (13.4, 51.8) 14 0.736 
Total polyunsaturate (g) 12.89 1.52 6.44 (4.0, 28.3) 18 16.70 2.05 7.67 (8.4, 32.5) 14 0.137 
Cholesterol (mg) 389.83 53.12 225.39 (51.1, 776.8) 18 374.23 52.39 196.03 (127.6, 711.5) 14 0.839 
Total trans fatty acid (g) 1.60 0.34 1.44 (0.4, 5.9) 18 1.47 0.29 1.08 (0.3, 4.4) 14 0.781 
Total n-3 fatty acid (g) 0.94 0.48 2.04 (0.08, 8.75) 18 0.78 0.21 0.79 (0.03, 2.78) 14 0.789 
Total n-6 fatty acid (g) 3.47 0.86 3.64 (0.37, 13.69) 18 4.78 1.09 4.09 (0.36, 14.86) 14 0.345 
EI/BMR ratio 1.23 0.10 0.41 (0.75, 2.46) 18 1.15 0.06 0.24 (0.64, 1.48) 14 0.543 
Sodium 2841.47 305.68 1296.91 (1186.80, 6565.71) 18 12597.16 9756.05 36503.78 (1352.75,139251.89) 14 0.336 
Data are presented as mean ± STD, mean ± SEM or range (minimum, maximum); 
An EI:BMR < 1.35 was considered to represent underreporting and an EI:BMR ≥2.4 as overreporting of EI; 
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5.6.3. Anthropometric data of participants  
The weight, BMI, handgrip strength and body composition of the participants, including body fat, water mass and impedance did not differ significantly between 
baseline, washout period and after consumption of extra virgin olive oil (EVOO) and butter (Table 5.5). These are suggestive of good compliance with 
instructions to not change lifestyle habits (diet, physical activity) during the intervention.  
 
Table 5.5 Effects of extra virgin olive oil and butter on anthropometric data in total participants (n=32). 
 Unadjusted Adjustment for baseline and 
washout 
Variable N Olive Oil  Butter P Olive Oil Butter P** 
Mean SEM Mean SEM LSM SEM LSM SEM 
Grip strength mean (kg) 32 41.46 1.29 40.43 1.25 0.20 41.46 0.77 40.43 0.50 0.20 
Grip strength maximum (kg) 32 43.69 1.37 42.94 1.28 0.35 43.69 0.78 42.94 0.63 0.37 
Body fat (%) 32 16.45 1.00 16.93 0.96 0.26 16.45 0.41 16.93 0.37 0.27 
Body fat (kg) 32 12.79 1.08 13.30 1.08 0.20 12.79 0.36 13.30 0.33 0.21 
Lean (kg) 32 61.95 1.22 62.31 1.22 0.36 61.95 0.30 62.31 0.35 0.36 
Total (kg) 32 74.52 2.08 75.39 2.09 0.09 74.52 0.47 75.39 0.39 0.09 
Dry lean weight (kg) 32 18.12 0.61 18.31 0.57 0.35 18.12 0.17 18.31 0.14 0.34 
Water (%) 32 59.35 1.01 58.68 0.87 0.22 59.35 0.53 58.68 0.44 0.23 
Water (It) 32 43.77 0.76 43.67 0.67 0.78 43.67 0.23 43.77 0.31 0.37 
Basal MET.RATE (kcal) 32 1904.22 32.21 1892.34 33.49 0.26 1904.22 8.83 1892.34 10.63 0.27 
*BMR (kcal/kg) 32 25.43 0.35 25.66 0.36 0.06 25.43 0.17 25.66 0.17 0.07 
EST.AVERAGE REQ: (kcal) 32 2772.31 107.11 2897.25 63.20 0.12 2772.31 79.74 2897.25 24.73 0.12 
Impedance 50KHz 32 497.41 11.63 505.44 10.58 0.37 497.41 10.42 505.44 8.62 0.39 
 




5.6.4 Blood Pressure 
5.6.4.1   Resting Blood Pressure and 24 - hour/Ambulatory Blood Pressure 
Results analysed for the total sample showed no significant difference in resting blood 
pressure when comparing interventions; however, statistically significant differences on 24 
hours SBP, daytime SBP, night-time DBP and night-time MAP were observed as shown in 
Table 5.6. Overall, after 30ml of EVOO consumption, the 24-hour systolic blood pressure 
was significantly reduced by 4.23 mmHg (p = 0.02) in unadjusted comparisons, 4.23 mmHg 
(p*=0.021) with adjustment for baseline and washout period and 4.23 mmHg (p**=0.032) 
with adjustment for baseline, washout, BMI, age, sodium intake and energy intake 
respectively (Table 5.6). Also, followed by EVOO consumption compared with butter in the 
group of all participants, the daytime SBP was significantly reduced by 5.13 mmHg 
(p=0.008), 5.13 mmHg (p*=0.01) and 5.13 mmHg (p**=0.014) respectively (Table 5.6). 
Finally, after EVOO consumption, the night-time DBP was significantly decreased by 
3.81mmHg (p = 0.023), 3.98 mmHg (p* = 0.021) and 3.98 mmHg (p** = 0.017) respectively 
while the night-time MAP was significantly reduced by 3.73 mmHg (p=0.019), 3.82 mmHg 
(p*=0.024) and 3.82 mmHg (p**=0.02) respectively (Table 5.6). 
Results comparing the effect of interventions only on Caucasian individuals are shown in 
Table 5.7. Finding indicated that night-time DBP and night-time MAP was significantly 
reduced by 4.436 mmHg (P**=0.042) with adjustment for baseline, washout, BMI, age. 
Sodium and energy intake and 4.124 mmHg (P**=0.042) with adjustment for baseline, 
washout, BMI, age. Sodium and energy intake respectively after EVOO consumption 
compared with butter intake.  
Table 5.8 presents the results for only East Asians participants; the 24-hour systolic blood 
pressure was significantly reduced after EVOO by 5.91 mmHg (p = 0.017) without 
adjustment, 5.91 mmHg (p*= 0.015) with adjustment for baseline and washout period and 
5.91 mmHg (p** = 0.045) with adjustment for baseline, washout, BMI, age, sodium and 
energy intake after extra virgin olive oil consumption respectively. Furthermore, daytime 
SBP was significantly reduced by 8.18 mmHg (p= 0.004), 8.18 mmHg (P** = 0.007) and 
8.18 mmHg (P** = 0.021) after extra virgin olive oil consumption (Table 5.8). Daytime MAP 
was significantly reduced by 5.22 mmHg (p=0.03), 0.039 (p*=0.039) and 0.039 (p**=0.032) 
respectively after extra virgin olive oil intake too (Table 5.8).
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Table 5.6 Effects of extra virgin olive oil and butter on blood pressure in Caucasians and East Asian healthy men of all participants (n=32). 
 Unadjusted Adjustment for baseline and 
washout 
Adjustment for baseline, washout, BMI, 
age, sodium intake and energy intake 
Variable N Olive Oil Butter P Olive Oil Butter P* Olive Oil Butter P** 
Mean SEM Mean SEM LSM SEM LSM SEM LSM SEM LSM SEM 
Resting SBP (mmHg) 32 116.866 1.797 118.525 1.810 0.358 116.866 1.566 118.525 1.517 0.361 116.87 1.64 118.53 1.41 0.335 
Resting DBP (mmHg) 32 69.3344 1.613 68.366 1.650 0.535 69.334 1.191 68.366 1.153 0.543 68.217 1.724 68.394 0.953 0.937 
Resting HR 32 72.447 2.144 72.616 1.924 0.935 72.447 1.739 72.616 1.232 0.937 69.706 2.056 72.922 1.373 0.190 
24-Hour ABP N Olive Oil Butter P Olive Oil Butter P* Olive Oil Butter P** 
Mean SEM Mean SEM LSM SEM LSM SEM LSM SEM LSM SEM 
 SBP (mmHg) 32 117.81 1.47 122.04 1.52 0.020 117.81 1.196 122.04 1.344 0.021 117.81 1.28 122.04 1.42 0.032 
 DBP (mmHg) 32 68.519 1.324 70.553 1.296 0.179 68.519 1.046 70.553 1.017 0.123 68.519 1.008 70.553 1.041 0.114 
 MAP (mmHg) 32 85.469 1.181 87.863 1.221 0.086 85.469 0.875 87.863 1.036 0.056 85.469 0.905 87.863 1.075 0.064 
Daytime ABP N Olive Oil Butter P Olive Oil Butter P* Olive Oil Butter P** 
Mean SEM Mean SEM LSM SEM LSM SEM LSM SEM LSM SEM 
 SBP (mmHg) 32 123.20 1.693 128.33 1.433 0.008 123.20 1.411 128.33 1.086 0.01 123.20 1.48 128.33 1.12 0.014 
 DBP (mmHg) 32 72.637 1.527 74.184 1.375 0.388 72.638 1.299 74.184 1.025 0.346 72.673 1.304 74.184 1.034 0.350 
 MAP (mmHg) 32 90.006 1.444 92.241 1.165 0.170 90.006 1.234 92.241 0.910 0.155 90.006 1.258 92.241 0.928 0.168 
Nighttime ABP N Olive Oil Butter P Olive Oil Butter P** Olive Oil Butter P*** 
Mean SEM Mean SEM LSM SEM LSM SEM LSM SEM LSM SEM 
 SBP (mmHg) 32 111.452 1.494 115.084 1.711 0.057 111.680 1.230 115.353 1.685 0.068 111.68 1.187 115.353 1.749 0.068 
 DBP (mmHg) 32 62.98 1.317 66.79 1.505 0.023 62.997 1.108 66.98 1.362 0.021 63.00 0.991 66.98 1.46 0.017 
 MAP (mmHg) 32 79.57 1.149 83.30 1.509 0.019 79.65 0.955 83.470 1.405 0.024 79.65 0.91 83.470 1.49 0.02 
* Estimated from repeated measures ANOVA of the Olive Oil and Butter with baseline and washout value as covariate. 
**Estimated from repeated measures ANOVA of the Olive Oil and Butter with baseline, washout, BMI, age, sodium intake and energy intake value as covariate. 




- 181 - 
 
 
Table 5.7 Effects of Extra virgin olive oil and Butter on blood pressure in Caucasians participants (n=18). 
  Unadjusted Adjustment for baseline and 
washout  
Adjustment for baseline, washout, BMI, age, 
sodium intake and energy intake 
Variable N Olive Oil Butter P Olive Oil Butter P* Olive Oil Butter P** 
Mean SEM Mean SEM LSM SEM LSM SEM LSM SEM LSM SEM 
Resting SBP (mmHg) 18 118.10 2.29 119.13 2.56 0.712 118.10 2.14 119.13 2.02 0.704 120.211 1.469 123.139 2.072 0.302 
Resting DBP (mmHg) 18 68.22 2.08 68.39 2.29 0.933 68.22 1.59 68.39 1.19 0.934 68.378 1.337 69.761 0.989 0.346 
Resting HR 18 69.71 2.33 72.92 2.86 0.226 69.71 1.81 72.92 1.54 0.201 69.706 2.056 72.922 1.373 0.19 
24-Hour ABP 
 SBP (mmHg) 18 120.21  2.05  123.14  2.07  0.269 120.21  1.36  123.14  1.98  0.263 120.21 1.49 123.14 2.11 0.322 
 DBP (mmHg) 18 68.38  1.96  69.76  1.56  0.489 68.38  1.41  69.76  1.08  0.418 68.378 1.337 69.761 0.989 0.346 
 MAP (mmHg) 18 86.26  1.82  87.52  1.47  0.508 86.26  1.13  87.52  1.23  0.418 86.256 1.019 87.522 1.032 0.384 
Daytime ABP  
 SBP (mmHg) 18 127.23  1.98  129.98  1.93  0.3 127.23  1.81  129.98  1.67  0.329 127.23 1.86 129.98 1.83 0.352 
 DBP (mmHg) 18 73.79  2.14  73.66  1.72  0.956 73.79  1.56  73.66  1.13  0.948 73.789 1.616 73.656 0.889 0.948 
 MAP (mmHg) 18 92.22  2.03  92.13  1.38  0.97 92.22  1.62  92.13  0.98  0.967 92.22 1.56 92.13 0.83 0.967 
Nighttime ABP 
 SBP (mmHg) 18 112.37  2.20  116.59  2.22  0.147 112.82  1.23  117.16  2.33  0.148 112.824 1.418 117.159 2.045 0.139 
 DBP (mmHg) 18 62.33  2.05  66.42  1.92  0.078 62.29  1.63  66.72  1.79  0.082 62.288 1.416 66.724 1.413 0.042 
 MAP (mmHg) 18 79.47  1.80  83.40  1.96  0.079 79.59  1.30  83.71  1.83  0.101 79.588 1.177 83.712 1.236 0.042 
*Estimated from repeated measures ANOVA of the Olive Oil and Butter with baseline and washout value as covariate. 
**Estimated from repeated measures ANOVA of the Olive Oil and Butter with baseline, washout, BMI, age, sodium intake and energy intake value as covariate. 
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Table 5.8 Effects of extra virgin olive oil and Butter on blood pressure in East Asians participants (n=14). 
East Asians  Unadjusted Adjustment for baseline and 
washout  
Adjustment for baseline, washout, BMI, age, 
sodium intake and energy intake 
Variable N Olive Oil Butter P Olive Oil Butter P* Olive Oil Butter P** 
Mean SEM Mean SEM LSM SEM LSM SEM LSM SEM LSM SEM 
Resting SBP (mmHg) 14 115.28 0.91 117.75 2.60 0.264 115.28  2.51  117.75  2.41  0.298 114.721 2.245 120.629 1.778 0.047 
Resting DBP (mmHg) 14 70.77 2.57 68.33 2.45 0.308 70.77  1.95  68.33  2.24  0.333 68.700 1.764 71.571 2.103 0.197 
Resting HR 14 75.97 3.77 72.22 2.54 0.260 75.97  2.98  72.22  1.91  0.283 75.971 2.142 72.221 2.163 0.296 
24-Hour ABP  
 SBP (mmHg) 14 114.72 1.84 120.63 2.27 0.017 114.72 1.80 120.63 1.58 0.015 114.72 2.22 120.63 1.62 0.045 
 DBP (mmHg) 14 68.70 1.77 71.57 2.22 0.239 68.7 1.68 71.57 1.91 0.22 68.700 1.764 71.571 2.103 0.197 
 MAP (mmHg) 14 84.46 1.37 88.30 2.11 0.067 84.46 1.33 88.30 1.80 0.072 84.457 1.601 88.300 1.847 0.076 
Daytime ABP   
 SBP (mmHg) 14 118.02 2.32 126.20 2.07 0.004 118.02  2.07  126.20  1.14  0.007 118.02 2.59 126.20 0.96 0.021 
 DBP (mmHg) 14 71.16 2.18 74.86 2.30 0.175 71.16  2.15  74.86  1.93  0.195 71.157 2.296 74.864 1.910 0.095 
 MAP (mmHg) 14 87.16 1.83 92.38 2.05 0.030 87.16  1.80  92.38  1.67  0.039 87.16 2.14 92.38 1.49 0.032 
Nighttime ABP   
 SBP (mmHg) 14 110.19  1.90  112.99  2.67  0.224 110.19  1.43  112.99  1.82  0.178 110.185 1.766 112.992 2.146 0.246 
 DBP (mmHg) 14 63.92  1.42  67.31  2.50  0.179 63.92  1.51  67.31  1.88  0.122 63.923 1.385 67.308 1.609 0.081 
 MAP (mmHg) 14 79.72  1.23  83.15  2.45  0.142 79.72  1.15  83.15  1.88  0.105 79.723 1.321 83.154 1.982 0.129 
*Estimated from repeated measures ANOVA of the Olive Oil and Butter with baseline and washout value as covariate. 
**Estimated from repeated measures ANOVA of the Olive Oil and Butter with baseline, washout, BMI, age, sodium intake and energy intake value as covariate. 
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5.6.4.2 Blood lipid profile & Novel Circulating biomarkers 
Results analysed for the total sample showed no significant differences in most blood lipid 
profile as well as inflammatory biomarkers when comparing interventions; however, 
statistically significant differences between East Asians and Caucasians for sVCAM-1 
(p=0.003) were observed (Table 5.9). After EVOO, TC was significantly reduced by 0.216 
(p=0.005) with unadjustment, 0.209 (p*=0.008) with adjustment for baseline and washout, 
and 0.209 (p**=0.011) with adjustment for baseline, washout, BMI, age, energy intake, 
saturated fatty acids and cholesterol respectively in the group of all participants after extra 
virgin olive oil intake (Table 5.10). LDL-C was significantly reduced by 0.18 mmol/L (p = 
0.011), 0.18 mmol/L (p*= 0.012) and 0.18 mmol/L (p**= 0.016) after EVOO respectively in 
the group of all participants (Table 5.10).  
In Caucasians, EVOO significantly reduced LDL-C by 0.217 mmol/L (p=0.039) without 
adjustment, 0.217 mmol/L (p*= 0.046) with adjustment for baseline and washout and 0.217 
mmol/L (p**= 0.048) with adjustment for baseline, washout, BMI, age, energy intake, 
saturated fatty acids and cholesterol (Table 5.11). In the group of East Asians (Table 5.12), 
TC was significantly decreased by 0.207 mmol/L (p=0.03). However, the significance 
remained robust after both adjustments as covariates. Among the East Asian participants, 
E-selectin was significantly increased by 17.21 ng/mL (p=0.004) and 17.21 ng/mL 
(p***=0.012) (Table 5.12.1).
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Table 5.9 Participants baseline characteristic of blood-borne biomarkers. 
Baseline 
characteristics 
Caucasians   East Asians    
Mean SEM N Mean SEM N P-value 
TC (mmol/L) 4.23 0.25 18 4.49 0.19 13 0.449 
HDL-C (mmol/L) 1.34 0.08 18 1.32 0.11 13 0.859 
LDL-C (mmol/L) 2.48 0.24 18 2.72 0.16 13 0.445 
Triglycerides (mmol/L) 0.89 0.09 18 0.90 0.09 14 0.965 
Caucasians including British, Italian, Croatian, Irish, American; East Asians including Chinese, Hong Kong China, Malaysians. 
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Table 5.10 Effects of Extra Virgin Olive oil and butter on blood-borne biomarkers in all Caucasians and East Asian male participants (n=32). 
  Unadjusted Adjustment for baseline and 
washout 
Adjustment for baseline, washout, BMI, 
age, energy intake, saturated fatty acids 
and cholesterol 
Variable N Olive oil Butter P Olive oil Butter P* Olive oil Butter P** 
 Mean SEM Mean SEM LSM SEM LSM SEM LSM SEM SEM SEM 
TC (mmol/L) 31 4.28 0.15 4.49 0.15 0.005 4.23 0.06 4.44 0.06 0.008 4.226 0.052 4.435 0.063 0.011 
HDL (mmol/L) 31 1.30 0.66 1.34 0.07 0.172 1.33 0.02 1.36 0.03 0.274 1.329 0.016 1.358 0.024 0.277 
LDL (mmol/L) 31 2.48 0.12 2.66 0.13 0.011 2.48 0.04 2.66 0.06 0.012 2.477 0.035 2.657 0.063 0.016 
Triglycerides (mmol/L) 32 1.35 0.30 1.13 0.10 0.371 1.35 0.29 1.13 0.10 0.331 1.347 0.292 1.128 0.088 0.349 
IL-6 (pg/mL) 32 292.75 3.69 289.46 2.92 0.543 290.71 7.89 295.71 2.95 0.581 290.71 11.70 295.71 1.76 0.733 
sICAM-1 (ng/mL) 32 318.58 17.36 347.41 22.05 0.298 318.58 28.55 356.02 32.49 0.466 318.58 34.10 356.02 20.87 0.391 
sVCAM-1 (ng/mL) 32 101.13 5.57 98.70 8.14 0.764 104.83 12.57 109.63 16.40 0.788 104.83 15.86 109.63 15.51 0.787 
P-selectin (ng/mL) 32 613.14 67.58 525.93 40.84 0.318 498.90 66.78 570.76 71.13 0.448 498.90 74.10 570.76 92.20 0.376 
E-selectin (ng/mL) 32 
58.50 9.03 57.98 8.83 
0.936 










Syndecan-1 (pg/mL) 32 
20.02 4.52 19.721 4.334 
0.92 










PAI-1 (ng/mL) 32 148.36 13.26 151.79 12.74 0.855 146.52 21.54 160.42 19.55 0.698 146.52 29.71 160.42 23.75 0.767 
CRP (pg/mL) 32 
36.23 4.12 36.50 2.508 
0.958 










*Estimated from repeated measures ANOVA of olive oil with baseline value as covariate. 
**Estimated from repeated measures ANOVA of olive oil with baseline, washout, BMI, age, energy intake, saturated fatty acids and dietary cholesterol value as covariate. 
LSM = Least Squared Means (Marginal means). 
 
 




Table 5.11 Effects of Extra Virgin Olive oil on blood-borne biomarkers in Caucasians male participants (n=18). 
  Unadjusted Adjustment for baseline and 
washout  
Adjustment for baseline, washout, BMI, 
age, energy intake, saturated fatty acids 
and cholesterol 
Variable N Olive oil Butter P Olive oil Butter P* Olive oil Butter P** 
Mean SEM Mean SEM LSM SEM LSM SEM LSM SEM LSM SEM 
TC (mmol/L) 18 4.13 0.20 4.36 0.21 0.059 4.13 0.08 4.36 0.07 0.056 4.133 0.065 4.356 0.076 0.082 
HDL (mmol/L) 18 1.36 0.08 1.37 0.08 0.767 1.36 0.02 1.38 0.04 0.764 1.356 0.025 1.367 0.039 0.782 
LDL (mmol/L) 18 2.47 0.18 2.69 0.19 0.039 2.47 0.06 2.69 0.07 0.048 2.471 0.046 2.688 0.076 0.072 
Non-HDL (mmol/L) 18 2.78 0.22 3.04 0.23 0.037 2.78 0.08 3.04 0.09 0.042 2.778 0.06 3.039 0.103 0.065 
Triglycerides (mmol/L) 18 0.92 0.10 0.93 0.08 0.958 0.92 0.10 0.93 0.06 0.959 0.922 0.075 0.928 0.055 0.946 
*Estimated from repeated measures ANOVA of olive oil and butter with baseline and washout value as covariate. 
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Table 5.11.1 Effects of Extra Virgin Olive oil on blood-borne biomarkers in Caucasians male participants (n=18). 
  
Unadjusted 
Adjustment for washout, BMI, age, energy intake, saturated fatty 
acids and cholesterol 
Variable N Olive oil Butter P Olive oil Butter P*** 
Mean SEM Mean SEM LSM SEM LSM SEM 
IL-6 (pg/mL) 18 296.40 3.27 291.83 3.30 0.338 296.40 2.584 291.83 3.039 0.348 
PAI-1 (ng/mL) 18 153.47 17.85 145.88 14.82 0.763 153.47 20.18 145.87 15.30 0.779 
sICAM-1 (ng/mL) 18 325.74 24.63 384.12 32.96 0.142 325.74 25.14 384.12 26.50 0.131 
sVCAM-1 (ng/mL) 18 102.31 8.30 107.29 10.90 0.654 102.31 8.48 107.29 8.407 0.596 
P-selectin (ng/mL) 18 593.25 49.24 567.97 42.73 0.67 593.24 50.07 567.97 42.05 0.667 
E-selectin (ng/mL) 18 73.860 12.186 59.552 11.355 0.159 73.86 12.382 59.552 11.73 0.205 
Syndecan-1 (pg/mL) 18 14.088 5.704 13.484 5.146 0.678 14.088 5.328 1.3484 50.80 0.669 
CRP (pg/mL) 18 34.901 7.017 36.879 3.530 0.815 34.901 6.677 36.879 27.43 0.773 
*Estimated from repeated measures ANOVA of olive oil and butter with baseline and washout value as covariate. 
**Estimated from repeated measures ANOVA of olive oil and butter with baseline, washout, BMI, age, energy intake, saturated fatty acids and cholesterol value as covariate. 
*** Estimated from repeated measures ANOVA of olive oil and butter with washout, BMI, age, energy intake, saturated fatty acids and cholesterol value as covariate. 
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Table 5.12. Effects of extra virgin olive oil and butter on blood-borne biomarkers in men of East Asians (n=14). 
  Unadjusted Adjustment for baseline and 
washout  
Adjustment for baseline, washout, BMI, 
age, energy intake, saturated fatty acids 
and cholesterol 
Variable N Olive oil Butter P Olive oil Butter P* Olive oil Butter P** 
Mean SEM Mean SEM  LSM SEM LSM SEM  LSM SEM LSM SEM  
TC (mmol/L) 14 4.46 0.21 4.66 0.22 0.03 4.35 0.08 4.55 0.10 0.079 4.354 0.065 4.546 0.111 0.113 
HDL (mmol/L) 14 1.24 0.11 1.31 0.12 0.086 1.29 0.03 1.35 0.04 0.161 1.292 0.017 1.346 0.026 0.136 
LDL (mmol/L) 13 2.49 0.15 2.62 0.19 0.16 2.49 0.07 2.62 0.10 0.181 2.485 0.044 2.615 0.103 0.323 
Non-HDL (mmol/L) 13 3.29 0.24 3.36 0.24 0.561 3.13 0.13 3.20 0.09 0.632 3.131 0.105 3.200 0.108 0.65 
Triglycerides (mmol/L) 14 1.89 0.65 1.39 0.18 0.361 1.89 0.57 1.39 0.16 0.271 1.893 0.508 1.386 0.128 0.276 
*Estimated from repeated measures ANOVA of olive oil and butter with baseline and washout value as covariate. 
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Table 5.12.1 Effects of extra virgin olive oil and butter on blood-borne biomarkers in men of East Asians (n=14). 
  
Unadjusted 
Adjustment for washout, BMI, age, energy intake, saturated fatty 
acids and cholesterol 
Variable N Olive oil Butter P Olive oil Butter P*** 
Mean SEM Mean SEM  LSM SEM LSM SEM  
IL-6 (pg/mL) 14 288.06 7.30 286.41 5.18 0.882 288.06 7.883 286.414 5.107 0.891 
Human PAI-1 (ng/mL) 14 141.78 20.39 159.39 22.53 0.549 141.783 21.020 159.389 21.903 0.573 
sICAM-1 (ng/mL) 14 309.37 24.71 300.21 22.77 0.812 309.366 25.475 300.205 25.225 0.815 
sVCAM-1 (ng/mL) 14 99.62 7.29 87.66 12.03 0.33 99.621 7.026 87.656 13.344 0.403 
P-selectin (ng/mL) 14 638.72 143.98 471.88 74.97 0.38 638.717 166.474 471.88 82.988 0.443 
E-selectin (ng/mL) 14 38.75 11.89 55.96 14.41 0.004 38.75 9.707 55.96 11.763 0.012 
Syndecan-1 (pg/mL) 14 27.6520 6.9609 27.7397 7.0036 0.99 27.652 62.595 27.740 74.180 0.989 
CRP (pg/mL) 14 37.9361 3.0298 36.002 3.647 0.671 37.938 27.723 36.002 30.856 0.692 
*Estimated from repeated measures ANOVA of olive oil and butter with baseline and washout value as covariate. 
*** Estimated from repeated measures ANOVA of olive oil and butter with washout, BMI, age, energy intake, saturated fatty acids and cholesterol value as covariate. 
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5.7.  Discussion  
Despite the recent proliferation of research on the health benefits of olive oil, few trials have 
been carried out in Asian individuals. To the best of our knowledge, this is the first trial 
assessing the impact of olive oil comparing two ethnic groups. Data from this study will 
substantiate our evidence on the efficacy of olive oil in improving cardiovascular risk 
biomarkers. 
5.7.1 Principal findings 
In the present study the benefits of dietary supplementation with extra virgin olive oil (EVOO) 
on serum inflammatory markers and lipid profile were explored, in a sample of healthy adults 
of two ethnicities. 30ml of EVOO effects were tested against 30g of butter and the results 
are significant difference between the two intervention periods in all participants.  
The present study found that the consumption of 30 ml of EVOO over a 2-week period 
produced a positive effect on 24-hour SBP including daytime SBP, night-time DBP and MAP 
and TC, LDL-C for all participants. For East Asians participants, olive oil consumption exerts 
a beneficial effect on 24-hour SBP and daytime SBP, MAP while night-time DBP was 
improved among Caucasians after EVOO intake. EVOO intake also has a positive effect on 
blood lipids such as TC and circulating biomarkers such as E-selectin in East Asians while 
LDL-C and non-HDL-C are improved among Caucasians after EVOO intake. 
Overall, night-time BP (night-time DBP, night-time MAP) were shown to be improved by 
Caucasians while day-time BP (daytime SBP, daytime MAP) were shown to be improved 
by East Asians after EVOO consumption. However, 24-hour BP were significantly improved 
in East Asians while no changes in 24-hour BP in Caucasians. This shows that EVOO 
intervention presents a better overall improvement on BP in East Asians than Caucasians.  
East Asians shows a significant improvement on E-selectin after EVOO intake while total-
cholesterol is improved among East Asians and LDL-cholesterol is improved among 
Caucasians. East Asians show a better outcome in terms of cardiovascular biomarkers.  
These results indicate that consuming EVOO as part of an overall diet brings benefits that 
in the long term may translate into reducing the risk of CVDs. These results are significant 
given the fact that high BP remains ranked 1st among the leading 30 level-3 global risk 
factors for DALYs (Zhou, Wang et al. 2019). Importantly, these effects were unrelated to 
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differences and changes in body fats and BMI. These results support the recommendation 
of EVOO to decrease some cardiovascular risk factors in both Caucasians and East Asians;  
this is particularly important for East Asian individuals and populations whose 
cardiovascular risk may be present at lower BMIs (WHO Expert Consultation 2004). 
 
5.7.2 Meaning of the current findings 
The results of this dietary intervention indicated that 30ml intake of extra virgin olive oil 
(EVOO) daily with two weeks was associated with leading a significant improvement in 24-
hour blood pressure for both Caucasians and East Asians in general. While night-time DBP 
as well as night-time MAP were achieved significant improvement among Caucasians male 
participants, daytime SBP and daytime MAP were gained significant improvement among 
East Asian male participants. In addition, sE-selectin was significantly improved among only 
East Asian participants after EVOO consumption. Therefore, if extra virgin olive oil (EVOO) 
is included in habitual diet regularly, it could help to prevent BP related conditions and in 
the long term reduce the levels of CV mortality and morbidity. 
 
5.7.2.1 Possible mechanisms and implications for clinicians or policymakers. 
The cardiovascular beneficial effects of EVOO are mainly attributed to its high content on 
MUFAs but also minor phenolic compounds act as antioxidants in EVOO, with the phenols 
oleuropein and hydroxytyrosol (HT) standing out nutritionally, HT represents one of the main 
polyphenol contents of EVOO and has anti-inflammatory and anti-teratogenic activity, 
improving the lipid profile, reducing oxidative stress, and activating inflammatory cells 
(Marcelino, Hiane et al. 2019).  
Consuming EVOO increases the postprandial concentration of phenolic compounds in the 
plasma and in LDL-C and hydroxytyrosol and oleuropein, dose-dependently inhibit LDL 
oxidation in vitro and in vivo, repress superoxide-driven reactions, and break the chain-like 
propagation of lipid peroxides (Berrougui, Ikhlef et al. 2015). A study (Gimeno, Fitó et al. 
2002) indicated that olive oil phenols are able to bind to LDL-C in vitro which are significantly 
associated with the delay in LDL oxidation. In this report it was suggested that olive oil 
phenols protect other phenols bound to LDL from oxidation. Similar results for mechanism 
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of action showed that the lower LDL oxidation rate, as well as the reduced uptake of oxidized 
LDL by macrophages after olive oil, may be due to the high concentration of both phenolic 
compounds as well as other unsaponifiable compounds present in extra-virgin olive oil. 
Furthermore, flavonoids and isoflavonoids as well as other linear isoprenoids exhibiting in 
vitro antioxidant activity could help limit LDL peroxidation (Ramirez-Tortosa, Urbano et al. 
1999). 
The mechanism of absorption of olive oil phenols is different and inadequate research 
among different ethnicities, let alone different polarity of oleuropein-glycoside, oleuropein- 
and ligstroside-aglycones, and tyrosol and hydroxytyrosol probably results in different 
mechanisms of absorption in different ethnicities (Maud et al., 2002). Furthermore, a study 
(Siefer et al, 2018) investigating the lipid-lowering effect of 30 mg/day hydroxytyrosol from 
different sources (a pure, synthetic product and an olive extract) in comparison to placebo 
in a healthy population showed that neither total cholesterol levels nor HDL-cholesterol 
levels were significantly affected by the absorption of hydroxytyrosol, yet, a significant LDL-
cholesterol reduction was observed after intervention with the pure, synthetic hydroxytyrosol 
in comparison to placebo (p = 0.0003).This could potentially explain the outcome that a 
decrease in LDL-cholesterol in Caucasians was observed.  
Antihypertensive mechanisms might be proposed for the fat component oleic acid (OA), 
which is the main fatty acid present in EVOO and minor constituents, most of which feature 
marked antioxidant properties. The MUFAs OA induced a marked and significant decrease 
in systolic BP, and the dose of MUFAs administered was closely correlated with the 
reduction in BP (Terés, Barceló-Coblijn et al. 2008). Evidence showed that the potential 
mechanisms for EVOO to positively impact on hypertension is via bioactive minor 
components, mainly antioxidant polyphenolic components (oleuropein, hydroxytyrosol) 
(Duansak and Schmid-Schönbein 2013). Investigated antihypertensive mechanisms of 
action range across anti-oxidative activities, changes of aminopeptidase activities favouring 
the production of Ang 2-10 and the clearance of Ang III and Ang IV increase in the 
endothelial nitric oxide synthase (eNOS) expression, and reduction of plasma Ang II 
(Massaro, Scoditti et al. 2020). In addition, phenolic compounds, including the secoiridoids 
oleocanthal and oleacein in EVOO, help to stabilize atherosclerotic plaques in hypertensive 
patients by modulating the expression of mitochondrial membrane potential (MMPs) (Filipek, 
Czerwińska et al. 2017). 
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The expression of cell adhesion molecules, such as E-selectin are crucial for endothelial 
activation and regulate the inflammatory process. E-selectin was significantly reduced as 
consumption of high MUFAs (65.1%) rich in EVOO (Vafeiadou, Weech et al. 2015). It 
suggests a positive correlations between circulating E-selectin and blood pressure and the 
reduction in E-selectin may have contributed to the observed decrease in night SBP on 
human (Rao, Gurumurthy et al. 2011). 
Overall, the excellent nutritional composition of EVOO, which includes a high content of 
monounsaturated fatty acids (oleic fatty acid) and minor phenolic compounds such as 
polyphenols (oleuropein and hydroxytyrosol) benefits risk factors on cardiovascular health. 
Despite so many positive effects of EVOO, still not enough is known about the mechanisms 
involved in these processes, especially the isolated actions of the components as well as 
the possible synergistic effects or antagonistic interactions with other components of the 
diet or medicine. Study (Osman et al, 2017) showed that the usage of EVOO with the 
therapeutic dose of ibuprofen presented synergistic effect in controlling the cardinal signs 
of acute inflammation rather than using nonsteroidal anti-inflammatory medication alone. 
Study (Natarajan et al., 2019) also indicated that tomatoes contain carotenoids which are 
fat soluble, and hence, absorption is increased with a fat medium such as EVOO. 
From a nutrient perspective, this has been known for some time, e.g., with enhanced 
absorption of nonheme iron in the presence of vitamin C, and competitive inhibition of zinc 
absorption by iron (Maria and Hajo, 2020). From the perspective of dietary patterns, 
however, focusing on isolated nutrients cannot account for all interactions, and may result 
in erroneous conclusions. Important associations may be missed, or effects may be 
assumed in which none exist (Tapsell et al, 2016). 
 
5.7.2.2. Comparison to previous studies 
The current study results did not support the previous finding reported in Chapter 4, but 
DBP and TC are likely to be improved by olive oil intake. However, there is no significant 
reduction on TC, LDL and BP.  
However, previous research supports the beneficial effect of olive oil on different vascular 
risk factors. A acute cross-over study on healthy men and women (Violi, Loffredo et al. 
2015), the consumption of the Mediterranean meal supplemented with either 10 g of olive 
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or 10 g of corn oil reported significant (P=0,014) reductions of LDL-C after 2-hours of 
consumption; The changes in LDL-C before and after these meals were (olive oil before 
meal 67.9±15.0mg/dL and after 73.0± 18.0 mg/dL, P<0.05; corn oil before meal 68.6±19.2 
and after meal 90.5±13.1, P=0.001). In addition, significant improvements on LDL (P<0.001) 
but no significant changes were reported on triglycerides or HDL-C.   
In agreement with the results in this study, other evidence suggested that diastolic blood 
pressure decreases after the olive oil consumption, -0.73 mm Hg, 95% CI (-1.07, -0.40); p 
< 0.001, I2 = 86.9%, with high heterogeneity among the included studies. This reduction 
was mainly due to EVOO from 10 ml to 50 ml/day: -1.44 mm Hg, 95% CI (-1.89, -1.00); p < 
0.001 (Zamora-Zamora, Martínez-Galiano et al. 2018). Similarly, a 2-month crossover 
human trial in young women with mild hypertension reported that the consumption of a diet 
containing polyphenol-rich olive oil can decrease BP and lead to a significant (P < 0.01) 
decrease of 7.91 mm Hg in systolic and 6.65 mm Hg of diastolic BP compared with the 
baseline value (Moreno-Luna, Muñoz-Hernandez et al. 2012). 
The regular consumption of EVOO (25 ml/day) by healthy individuals has been found to 
reduce the total cholesterol (n=13; SMD: -4.7; p<0.05), systolic blood pressure (n=13; SMD: 
-5; P<0.05) and diastolic blood pressure (n=13; SMD: -6; P<0.05), by means of the negative 
regulation in the ACE (angiotensin I) and NR1H2 genes (Martín-Peláez, Castañer et al. 
2017). 
Another systematic review has also reported medium effects after high phenolic olive oil for 
lowering systolic blood pressure (n = 69; SMD −0.52; CI −0.77/−0.27; p < 0.01 (Hohmann, 
Cramer et al. 2015). Nevertheless, in disagreement of the present clinical study, no effects 
were found for diastolic blood pressure (n = 69; SMD −0.20; CI −1.01/0.62; p = 0.64); TC 
(n = 400; SMD −0.05; CI: −0.16/0.05; p = 0.33); LDL-C (n = 400; SMD −0.03; CI :−0.15/0.09; 
p = 0.61) (Hohmann, Cramer et al. 2015). A recent randomized trial in middle-aged Chinese 
individuals also showed that olive oil consumption had not significantly effect on serum total 
cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein 
cholesterol (HDL-C), or triacylglycerol (TG) (Sun, Xia et al. 2018). This study (Sun, Xia et 
al. 2018) was conducted in Yixing city, China, with participants for both gender, which was 
potentially the reason why there was no significant effect.  
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The inflammatory process is regulated by the expression of cell adhesion molecules, such 
as sE-selectin, which in this case is increased, and the consumption of EVOO, which has 
also been shown to be a factor responsible for the diminished sE-selectin when compared 
with the consumption of high-cholesterol diet. Such reduction might be also related as much 
to the presence of oleic fatty acid as to polyphenols (Katsarou, Kaliora et al. 2015). 
Olive oil consumption shows a greater impact on people who are at high risk of 
cardiovascular factors, people experience vascular diseases and any cardiovascular risk 
factor than on healthy participants.  
During 24 years of follow-up, among 10,240 incident cases of CVD, including 6,270 CHD 
cases and 3,970 stroke cases. After adjusting for major diet and lifestyle factors, compared 
with non-consumers, those with higher olive oil intake (>1/2 tablespoon/d or > 7g/d) had 
15% lower risk of total CVD [pooled hazard ratio (95% confidence interval): 0.85 (0.77, 0.93)] 
and 21% lower risk of CHD [pooled hazard ratio (95% CI): 0.79 (0.70, 0.89)]. It estimated 
that replacing 5g of margarine, butter, mayonnaise, or dairy fat with the equivalent amount 
of olive oil was associated with 5-7% lower risk of total CVD and CHD (Guasch et al, 2020). 
Subjects undergoing coronary angiography experienced a significant decrease in plasma 
LDL-cholesterol (-9.52 ± 20.44 mg/dL, p = .007), a significant reduction in plasma CRP (-
0.40 ± 0.52 mg/L, p = .01) after 25ml EVOO consumption (Khandouzi et al. 2021). 
Individuals at high cardiovascular risk in EVOO consumption had 39% (HR: 0.61; 95% CI: 
0.44 to 0.85) CVD risk reduction, for each 10 g/d increase in EVOO consumption, CVD and 
mortality risk decreased by 10% and 7%, respectively (Guasch-Ferré et al., 2014).  
In healthy male subjects, increase in high-density lipoprotein cholesterol levels was 
observed for low-, medium-, and high-polyphenol olive oil: mean change, 0.025 mmol/L 
(95% CI, 0.003 to 0.05 mmol/L), 0.032 mmol/L (CI, 0.005 to 0.05 mmol/L), and 0.045 mmol/L 
(CI, 0.02 to 0.06 mmol/L), respectively. Triglyceride levels decreased by an average of 0.05 
mmol/L for all olive oils. Oxidative stress markers decreased linearly with increasing 
phenolic content. (Covas et al., 2006). In healthy English men and women subjects, LDL-C 
concentrations were significantly increased on olive oil (+0.38, 95% CI 0.16 to 0.60 mmol/L, 
P<0.0001), Study showed that high phenolic extra virgin OO slightly reduce LDL-cholesterol 
compared to low phenolic (extra) virgin OO (mean difference [MD]: −0.14 mmol/L, 95%–CI: 
−0.28, −0.01) in healthy subjects (Schwingshackl et al., 2019). 
 
- 196 - 
 
5.7.2.3 Strengths  
This study has a number of strengths. Firstly, the improvements observed in BP reported 
in this study were documented using robust methodology. BP changes were 
documented using ambulatory 24-hour BP rather than resting BP (more likely to be 
affected by external factors to the intervention). Secondly, self -reported daily checklist 
of EVOO showed a good acceptability and compliance with both EVOO and butter intake. 
No side-effect of interventions was reported. The fact that BMI, body composition and 
handgrip strength remained unchanged during the whole clinical trial, supports the 
presence of good compliance with maintaining usual diet and physical activity patterns.  
Another strength of the present study is its crossover design, which permitted the same 
participants to receive all olive oils and thereby minimized interferences with confounding 
variables. Furthermore, the dose of EVOO to be consumed in this study was accurately 
guided and explained by the researcher and provided as single bottle with graduated spoon, 
and the fact that the Filippo Berio Organic Extra Virgin Olive Oil (500ml) was of the same 
brand thereby reducing the risk of variability in consumption and composition of the olive oil. 
In addition, the measurements were all taken by the same researcher, so it would be 
consistent for every visit and reduce the possibility of bias. 
In addition, this study also does not focus on single nutrients but EVOO food itself when it 
replaces participants’ lunch meals. Assessing one single nutrient have had negative 
consequences as it often fails to consider substitution effects and associated foods. There 
is no effect of a nutrient in an absolute sense because this may change based on the 
replacement nutrient and the foods that deliver them.  
The last advantage that only men were studied, excludes the confounding associated with 
hormonal changes during menstrual cycles affecting outcome measures in women. Based 
on the outcome of survey chapter, which constitute mostly female, thus male becomes the 
main target in this trial study. Males are not subject to frequent hormonal changes. 
Fluctuating hormones and differences between male and female study subjects could all 
complicate the design of the study and the interpretation of the results. For instance, female 
participants would be asked to postpone or be extend their EVOO/butter intervention or 
washout period for at least one week if female participants start their menstrual cycle in the 
middle of the trial due to irregular menstrual cycle. In addition, 30ml extra virgin olive oil 
daily intake, containing vitamin E, helps to promote the formation of estrogen in female body. 
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Evidence showed that hormones changes and endocrine disorders could alter plasma lipid 
levels, which may confound the outcome of EVOO intake (Gaforio et al, 2019). 
Results regarding recruiting female participants was widespread safety concerns for 
pregnant women and women who might become pregnant, resulting in women being left 
out of studies (Sabine 2011).Female and male differ, too, in terms of body weight and size, 
therefore dosing is also an critical consideration. Although it is less likely to affect the results 
in crossover trial study, women and men still have different levels or separate thresholds of 
certain biomarkers. In addition, there are also differences in the ways that men and women 
potentially experience many health conditions in terms of prevalence, symptoms, age at 
onset, and severity, including in the case of autoimmune diseases, such as lupus and 
multiple sclerosis and psychological disorders, such as depression and schizophrenia.  
 
5.7.2.4 Limitations  
This study is, however, not without limitations. Firstly, this study was an “open label” study 
that could not blind participants. However, this is a common situation in dietary interventions. 
Self-reporting may be another potential limitation since participants evidently underreported 
their food intake at baseline. However, good self-reported compliance together with 
changes in the outcomes of interest indicate that during the study this is likely to have been 
minimised. Thirdly, the dietary pattern between Caucasians and East Asians is likely to be 
culturally varying, especially for habitual dietary intake (Leung and Stanner 2011). Due to 
cultural differences between Western and Eastern diets, background usual diet has been 
recognized as a potential factor affecting the effectiveness of EVOO interventions, with most 
British following a westernized, rich in saturated fat diet while most East Asians following 
an Eastern diet with unhealthy oils into cooking, such as those containing trans-fat and 
animal fat (Chan, Malik et al. 2009). Evidence observed that the consumption of a high-
cholesterol diet (HCD) with EVOO was responsible for increasing the TC and LDL-C when 
compared with the group receiving only HCD without the addition of another lipid source 
(Venturini, Simão et al. 2015). The inability to assess potential interactions between EVOO 
and other diet components that might affect the generalizability of the outcomes because 
of dietary differences among ethnicities as synergistic or antagonistic interactions existing 
between nutrients within dietary patterns (Tapsell, Neale et al. 2016).  
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It might exist slight bias regarding food intake reports from participants as EI:BMR ratio < 
1.35 is shown underreporting for both ethnicities (1.23 for Caucasians; 1.15 for East Asians; 
p=0.543) (Table 5.4). Under-reporting of energy intake might affect estimates of nutrient 
intakes. Under-reporters are shown to consume fewer foods rich in fat, energy and all other 
nutrients than did the subjects whose EI:BMR within the normal range (Mirmiran et al, 2006).  
However, no statistically significant difference of weight, BMI, handgrip strength and body 
composition, nutritional intake between Caucasians and East Asians (p<0.05) during 
washout, interventional period (Table 5.4; Table 5.5) suggesting of good compliance during 
the whole intervention showed that EI:BMR ratio does not affect the outcomes of the trial.  
Although male only recruitment simplifies the design of the clinical trial, excluding female 
participants can be considered as a limitation since the awareness in order to reduce gender 
disparities in research and clinical care has been arising (Mosca, Barrett-Connor et al. 2011). 
The lack of inclusion of women in CVD trials has already been highlighted as a barrier to 
making clinical recommendations in the initial AHA evidence-based guidelines for the 
prevention of CVD in women (Mosca, Barrett-Connor et al. 2011). Evidence presented by 
(Mosca, Barrett-Connor et al. 2011) reported that the absolute numbers of female living with 
and dying of CVD and stroke exceed those of men, as does the number of hospital 
discharges for heart failure and stroke, although for both women and men, coronary heart 
disease is the largest contributor to CVD morbidity and mortality.  
Study (Galiuto 2015) showed that while menopause, and some major cardiovascular risk 
factors such as systolic arterial hypertension, smoking, diabetes, TG and HDL-C levels 
mainly act in women. In males, cardiovascular risk profile linearly increases over time, along 
with atherosclerotic process continuously develops. On the contrary, females are protected 
from atherosclerosis in the fertile age, since estrogens exert beneficial effects on 
cardiovascular system, by acting via genomic and non-genomic mechanisms (Galiuto 2015). 
After menopause, estrogen deficiency leads to exponential increase of cardiovascular risk, 
as it induces structural and functional changes including endothelial dysfunction, imbalance 
of autonomic activity towards an increased adrenergic status, visceral adiposity, and 
enhanced systemic inflammation in cardiovascular system (Galiuto 2015). All these factors 
contribute to the development of systemic hypertension, abnormal lipid profile and insulin 
resistance. By this point of view, menopause itself can be represented as an independent 
predictor of CVD (Galiuto 2015) thus female participants should be recruited and targeted 
 
- 199 - 
 
for the future CVD clinical trials. Last limitation of the study is that the beneficial effect 
obtained in a group of healthy Caucasians and East Asians adults with low cardiovascular 
risk score, may be meaningless in other groups of risk.  
 
5.7.3 Unanswered questions and future research 
In this human trial study, bottles of EVOO was used for the dietary intervention, rather than 
olives products, or other grades (e.g., refined olive oil, virgin olive oil) or forms of olive oil 
(e.g. capsules), which are associated with different acceptability of daily intake and different 
bioavailability of MUFAs, PUFAs, and other minor phenolic compounds including phenols 
oleuropein and hydroxytyrosol (Marcelino, Hiane et al. 2019). The way of usage of liquid 
olive oil, such as cooking, dipping, marinading and baking, which are associated with 
different feasibility of daily olive oil consumption can be changed in future trial too (e.g. OO 
incorporated into buns) (Tholstrup, Hjerpsted et al. 2012). These different forms of olive oil 
could be evaluated and ascertain the effects of varying healthy fats does and their effects 
on both traditional and novel cardiovascular biomarkers and both resting BP and 24-hour 
BP. Further research could alter the length of intervention (e.g. 6 weeks to 9 weeks) 
(Oliveras-López, Molina et al. 2013, Galvão Cândido, Xavier Valente et al. 2018) and 
change the dose of EVOO intake (e.g. 50g; 60g) (Oliveras-López, Molina et al. 2013, Khaw, 
Sharp et al. 2018). 
As already stated above, this study was conducted with male participants only, and so there 
would be room for future research to address whether the findings of this study could be 
replicated in women. Similarly, future research could investigate the impact of these 
intervention in middle-age groups from Caucasians and East Asians, at risk of, or affected 
by, cardiovascular disease or cardiovascular risk factors. The potential explanation for the 
difference of ambulatory BP and inflammatory biomarkers between East Asians and 
Caucasians after EVOO consumption would be worth to be explored. The further study will 
be expected to be determined by the different degree of digestion of tyrosol (T) and 
hydroxytyrosol (HT) from EVOO in urine samples of two ethnicities. 
This study was designed to test a dose of EVOO that is commonly observed among 
individuals in Mediterranean countries, however it is uncertain whether such level of 
consumption (ie. 30 ml/day) could be sustainable in the long term, future research could 
 
- 200 - 
 
evaluate the effect of lower doses that are likely to be more acceptable and sustainable in 
the long term. 
5.8 Conclusion  
In conclusion, this study provided evidence on the benefits of the consumption of consistent 
habitual diet except standardising their lunch with extra virgin olive oil 30 ml compared with 
butter, for two weeks, has a significant impact on reducing TC, LDL-C, 24-hour SBP 
including daytime SBP, night-time DBP and night-time MAP in both Caucasians and East 
Asians participants with no risk of cardiovascular disease. However, total cholesterol, E-
selectin, 24-hour SBP, daytime SBP and daytime MAP were improved among East Asians 
participants after EVOO intake while LDL-cholesterol, non-HDL cholesterol and night-time 
DBP was improved only among Caucasians. TC was improved after olive oil intake for all 
participants. Based on these findings, consumption of EVOO should be advocated to 
improve the cardiovascular health of Caucasians and East Asian individuals.  
 




6.1 Thesis Summary 
The biological ageing process is influenced by lifestyle factors (75% contribution) and 
genetic factors (25% contribution) which accounts for a fact that dietary intake in lifestyle 
aspects, plays a critical role in determining healthy ageing (Passarino, De Rango et al. 
2016). People become more dissimilar from their contemporaries of the same chronological 
age as they become older mostly due to dietary factors, so that personalized dietary 
interventions alongside recommendations is of vital important (Passarino, De Rango et al. 
2016). Among the physiological and metabolic changes occurring with ageing, the ageing 
of heart function is the key determinant of health. The Mediterranean dietary pattern is well 
recognised as one of the main contributors related to improve cardiovascular health, which 
is one of the leading cause of mortality and mobility (Anand, Hawkes et al. 2015), even 
during recent years, a high prevalence of cardiovascular disease among people who 
experienced COVID-19 are reported (Bansal 2020, Clerkin, Fried et al. 2020) and pre-
existing CVD is associated with worse outcomes among patients with COVID-19 (Aggarwal, 
Cheruiyot et al. 2020),  
As for tackling cardiovascular health problems, DASH diet trials was not designed for CVD 
clinical events (Kwan, Wong et al. 2013) and there is no RCT which has evaluated the 
impact of the Portfolio Diet on CVD clinical events (Anand, Hawkes et al. 2015). Low-fat-
high-carb (LFHC) diet unfortunately result in such a high glycaemic load on HDL-C and 
glucose metabolism (Scholl 2012). Additionally, there is insufficient research of meta-
analysis on the Japanese diet regarding cardio-protective effects (Teramoto 2017) while the 
DASH diet was reported as having a poor compliance among a Western population (Kwan, 
Wong et al. 2013). Therefore, choosing the Mediterranean diet as the worldwide dietary 
recommendation amongst various dietary patterns is becoming the most popular and is 
being promoted in improving vascular health. The Mediterranean diet (Ruiz-Canela and 
Martínez-González 2011), which is characterised by high intake of vegetables, grain, nuts 
and especially olive oil, has received the most attention in relation to chronic disease 
prevalence, especially cardiovascular disease (Ruiz-Canela and Martínez-González 2011) 
as PREDIMED study suggested that a MD supplemented with either extra virgin olive oil or 
mixed nuts cut the risk of CVD events by as much as 30% in subjects at high risk of 
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developing heart diseases after 5-year follow-up (Estruch, Ros et al. 2013). Extra virgin 
olive oil, characterized as the main component of MD, is responsible for a large part of 
cardio benefits associated to the Mediterranean diet (Mazzocchi, Leone et al. 2019), in their 
randomized trial (Casas, Sacanella et al. 2014) reported that high adherence to a MD 
intervention supplemented with 50ml/d EVOO for 12-month period was associated with a 
significant decrease in inflammatory markers (C-reactive protein and interleukin-6), a 
reduction in SBP, DBP and plasma LDL-C concentration.  
The main aim of this thesis was to investigate the effectiveness of extra virgin olive oil with 
habitual diet on cardiovascular biomarkers and cardiovascular risk factors in two ethnicities 
- East Asians and Caucasians living in the UK. This novel thesis topic was originating from 
the interest on evaluating the response to dietary interventions among different ethnic 
groups. This thesis followed a series of logical steps presented in separate chapters and is 
summarised in Figure 6.1.  
In Figure 6.1, phase one of the present PhD programme involved an overview of the topic. 
In phase two, the acceptability, feasibility and frequency of olive oil consumption in 
Caucasians and East Asians based in Newcastle upon Tyne UK by Online Survey was 
researched. In phase three, the literature of systematic review and meta-analysis on the 
association between olive oil and nuts (two major components in the Mediterranean diet) 
and cardiovascular health in different ethnicities was researched. 
In the survey chapter (Chapter 2), the response from East Asians overall reported a better 
health and the acceptability and the frequency of olive oil consumption in East Asians is 
better than Caucasians. Olive oil consumption in both ethnicities - 142 Caucasians (87.3% 
female; mean age: 32.8±SD12.2; BMI: 22.8±SD2.8) and 142 East Asians (78.2%; mean 
age: 32.8±SD10.9; BMI: 22.4±SD2.7), was closely positively associated with older age, 
higher MD score, higher MD acceptability and lower PBHE. 
Healthy eating habits - the Mediterranean-style diet, emphasizing in extra virgin olive oil, 
nuts consumption, have given increasingly attention by global population as the benefits of 
olive oil and nuts intake on cardiovascular health have been evidenced numerously. The 
next step of this thesis was to evaluate the evidence from previous RCTs on the effects of 
olive oil and nuts on cardiovascular risk factors and cardiovascular biomarkers. Systematic 
review and meta-analysis in Chapter 3 reported that nuts consumption significantly improve 
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biomarkers including TC, HDL-C, LDL-C, TG, VLDL-C, Apo B, FMD and FFA. The 
systematic review and meta-analysis on Chapter 4 reported that olive oil significantly 
improve biomarkers such as PAI-1 and tPA.  
Our systematic review and meta-analysis found that olive oil intake had beneficial effects 
on cardiovascular health. These results suggested the fact that such dietary habit could be 
one of the important modifiable factors affecting the maintenance of a healthy phenotype, 
which is low risk of any cardiovascular diseases and cardiovascular risk factors including 
hypertension, obesity, diabetes and high cholesterol. However, what cardiovascular 
biomarkers and risk factors would be changed/improved by daily olive oil intake in East 
Asians and Caucasians are worth of future clinical research.  
Phase four of the present PhD programme was the development of dietary intervention on 
comparing EVOO and butter on cardiovascular risk factors in Caucasians and East Asians 
(Figure 6.1). In Chapter 4 of systematic reviews and meta-analysis of the scientific 
literature reported that previous interventions on olive oil or olive oil capsules spending 
average duration about 5 weeks and olive oil doses were with daily consumption ranging 
between 13.3 and 64.8 grams. The results from systematic review, as a knowledge basis, 
help researchers to identify clinical outcome measures relevant to cardiovascular risk 
factors. In adherence to the gained knowledge, the selection criteria for the measures 
included biomarkers that responded to dietary interventions in my designed trial, particularly 
to EVOO. Thus, a tentative panel of traditional lipids profiles and inflammatory biomarkers 
were potentially selected to be tested in two ethnicities in our clinical trial.  
Therefore, phase four of the present PhD programme was reported in Chapter 5 (Figure 
6.1), our crossover randomised controlled trial aimed to investigate the impact of extra virgin 
olive oil intervention on risk factors of cardiovascular health as well as markers of 
inflammatory biomarkers, blood lipids and other novel biomarkers have not been previously 
investigated. In addition, this RCT is novel since there are no previous RCTs investigating 
and comparing the effects of extra virgin olive oil and butter intake among East Asians and 
Caucasians living in Northeast England, UK.  
The results of the extra virgin olive oil (EVOO) intervention on BP, blood lipids profiles and 
several inflammatory as well as novelty biomarkers were examined in Chapter 5 and 
consumption of 30 ml of EVOO over a 2-week period produced a positive effect on 24-hour 
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SBP including daytime SBP, night-time DBP and MAP and TC, LDL-C for all participants. 
Furthermore, there is different effect between East Asians and Caucasians. East Asians 
participants showed a better effect on 24-hour SBP and daytime SBP, MAP while night-
time DBP was improved among Caucasians after EVOO intake. EVOO intake also has a 
positive effect on blood lipids such as TC, circulating biomarkers such as E-selectin in East 
Asians while LDL-C and non-HDL are improved among Caucasians after EVOO intake. 
Further investigation and research are still warranted since whether different types of olive 
oil containing different levels of nutritional benefits exert the same beneficial effect as EVOO 
remain unknown. For example, EVOO is not the only olive oil form available for consumption. 
The share of ordinary (not virgin) olive oil imported by the UK among the total British olive 
oil imports was 33%, followed by EVOO (28%) and VOO (19%) (CBI - Ministry of Foreign 
Affairs 2020). Two distinct types including refined and unrefined olive oil are widely 
distributed into the worldwide marketing could be studied in the near future. Moreover, it 
was believed that fish oil with dietary ω-3 PUFAs intake have beneficial effects on the 
decrease in TG levels (Belalcazar, David et al. 2010) and olive oil may act synergistically 
with fish oil by increasing the incorporation of ω-3 fatty acids in cell membranes (Crawford, 
Galli et al. 2000) as evidence showed that middle-aged individuals (mean age 51.45±8.27y) 
receiving 10 ml/day of EVOO plus 3 g/day of fish oil exert beneficial synergistic effects on 
lipid metabolism (Venturini, Simão et al. 2015).  
 
6.2 Novelty and strength of the present thesis  
The work presented in this thesis contributes to our understanding of the impact of food and 
diet on cardiovascular health. This work is novel in several ways and has a number of 
strengths. Strengths of this work include, adopting a rigorous methodology and a series of 
logical steps on investigating the effect of extra virgin olive oil on cardiovascular health. The 
design of the clinical trial presented here was developed based on evidence from previous 
relevant literature of systematic review and meta-analyses. Previous RCTs focused on 
investigating the effects of extra virgin olive oil (EVOO) intake on markers of cardiovascular 
risk but not been evaluated previously among two ethnicities – East Asians and Caucasians. 
The present work thus fills a gap in the literature by reporting results comparing the cardio 
health impacts between two ethnicities living near northeast of the UK. The result of the 
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clinical trial was consistent with previous evidence. In addition, this is the first clinical trial 
investigating the effects of liquid extra virgin olive oil (rich in MUFAs and phenolic 
compounds such ashydroxytyrosol, tyrosol, and oleuropein) on 24-hour BP plus novel 
biomarker such as syndcan-1, as well as other cardiovascular risk factors which have been 
less studied and published such as PAI-1, sICAM-1, sVCAM-1, sE-selectin and sP-selectin 
between Caucasians and East Asians. However, compliance, albeit good, was self-reported 
and there were no objective methods in place to measure compliance. Further research 
could determine tyrosol (T) and hydroxytyrosol (HT) in urine samples by gas 
chromatography-mass spectrometry, alongside self-report checklists to measure 
compliance (Miro-Casas et al, 2001).  
 
6.3 Relevance for Stakeholders  
The results of the present human trial are of relevance to healthcare professional such as 
nutritionists and dietitians who could possibly use these to encourage the adoption of a diet 
with an increased extra virgin olive oil intake to reduce BP and further reduce the risk of 
CVD. These may be useful specially for people with hypertension or borderline hypertension 
for East Asians and Caucasians, the intake of extra virgin olive oil (EVOO) should be 
encouraged and the positive effects of EVOO consumption should be highlighted. 
 
6.4 Future work and public health implications for clinicians or policymakers 
To the best of our knowledge, no previous RCTs have tested and compared the effect of 
EVOO on two different ethnicities living around Northeast England. The positive impacts of 
EVOO on resting blood pressure, 24-hour/ambulatory blood pressure, blood lipids and 
inflammatory biomarkers encourage further studies with a larger population to investigate 
the effects of EVOO consumption, as well as the influence of micro-components present in 
EVOO, such as fat component oleic acid (OA), polyphenols (oleuropein and hydroxytyrosol) 
and phenolic compounds, including the secoiridoids oleocanthal and oleacein in EVOO, 
which could act in a synergistic/antagonistic approach regulating the activity of these 
molecules.  
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The current evidence supports medium-term incorporation of 30ml of liquid EVOO daily into 
habitual diets is highly likely to reduce cardiovascular risk in the primary preventions of 
cardiovascular diseases in healthy individuals. Either healthy individuals with normal blood 
pressure or patients with high blood pressure who substitute 30ml of EVOO consumption 
known as antioxidant polyphenols in their diets replacing with other types of fat can help to 
keep blood pressure healthy or reduce the amount of medication. 
The current clinical trial provides evidence to confirm and strengthen dietary 
recommendations to increase liquid EVOO in the diet as emphasised in Mediterranean diet 
recommendations (Martínez-González et al., 2019; Ditano-Vázquez, et al.,2019). The 
present work does not put restrictions on specific age range, the majority of healthy 
participants, however, are young-aged university students. Evidence suggested 
metabolism slows down around age 60 years as being less active, losing muscle mass, 
higher possibility of experiencing diseases, slower process of digestion and absorption of 
certain nutrients in EVOO, thus results in different effects after EVOO intake. Young aged 
(18-44 years old), middle-aged (45-65 years old) and older adults (aged 65 and above) will 
be targeted to compare and determine whether ambulatory blood pressure, blood lipids and 
biomarkers change with age, and whether or not moderate or high amounts of EVOO intake 
(30-35ml or more amounts) would improve blood lipids profiles as well as inflammatory 
biomarkers such as PAI-1, IL-6, sICAM-1, sVCAM-1 and CRP.   
However, this clinical trial finding highlights the need for further elucidation of the more 
nuanced relationships between EVOO and cardiovascular health. In particular, a future 
human trial study on dietary interventions could target female individuals as well as 
individuals of both gender at high CVD risk. It would also be useful to evaluate other foods 
known to reduce CVD risks. The effects of other forms and types of olive oil with different 
doses (e.g., higher doses 40ml) on cardiovascular risk factors require further investigation. 
The findings cannot be extrapolated to all liquid olive oil products such as olive pomace oil, 
frylight olive oil spray. Further research is needed to determine the effects of EVOO on the 
cardiovascular health of different ethnicity in a larger number with high CVDs risk and 
female participants should also be included too. 
The positive impacts of MUFAs, omega-3 PUFAs and phenolic compounds on 24-hour 
blood pressure, blood lipids levels and inflammatory biomarkers encourage further research 
with a larger population of both Caucasians and East Asians who live in the UK to 
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investigate the influence of EVOO alongside MUFA OA, phenolic compounds such as 
hydroxytyrosol, oleuropein, secoiridoids oleocanthal and oleacein, which could act in a 
synergistic/antagonistic way regulating the activity of these molecules.  
6.5 Conclusion 
As a conclusion, current human clinical trial supports the 30 ml of liquid EVOO improves 
cardiovascular health in East Asians and Caucasians, particularly in 24-hour BP and LDL-
cholesterol, future clinical trial design will be highlighted in both genders, comparing 
different age groups and larger dose of EVOO cooperating with habitual diets in East Asians 
and Caucasians.  
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                                             Figure 6.1 Overview of this PhD programme
Phase One 
Preliminary work  
Survey: Nuts and olive oil intake among 142 East Asians and 
142 Caucasians and their association with PREDIMED score, 
perceived barriers and acceptability of the Mediterranean 
diet. 
Systematic reviews of RCT studies on olive oil, nuts and risk of 










- 209 - 
 
References 
Acar, B., E. Gucuk Ipek, S. Unal, C. Yayla, M. Karanfil, C. Burak, M. Kara, F. Bayraktar, M. S. Kuyumcu 
and S. Aydogdu (2018). "Evaluation of Mediterranean diet adherence in patients with a history of 
coronary revascularization." Rev Clin Esp 218(5): 215-222. 
Adams, J., L. Goffe, A. J. Adamson, J. Halligan, O’Brien, N., R. Purves and M. White (2015). "Prevalence 
and socio-demographic correlates of cooking skills in UK adults: cross-sectional analysis of data from 
the UK National Diet and Nutrition Survey." International Journal of Behavioral Nutrition and Physical 
Activity 12 (99). 
Afshin, A., R. Micha, S. Khatibzadeh and D. Mozaffarian (2014). "Consumption of nuts and legumes and 
risk of incident ischemic heart disease, stroke, and diabetes: a systematic review and meta-analysis." 
Am J Clin Nutr 100(1): 278-288. 
Agebratt, C., E. Ström, T. Romu, O. Dahlqvist-Leinhard, M. Borga, P. Leandersson and F. H. Nystrom 
(2016). "A Randomized Study of the Effects of Additional Fruit and Nuts Consumption on Hepatic Fat 
Content, Cardiovascular Risk Factors and Basal Metabolic Rate." Plos One 11(1): e0147149-e0147149. 
Aggarwal, G., I. Cheruiyot, S. Aggarwal, J. Wong, G. Lippi, C. J. Lavie, B. M. Henry and F. Sanchis-
Gomar (2020). "Association of Cardiovascular Disease With Coronavirus Disease 2019 (COVID-19) 
Severity: A Meta-Analysis." Current Problems in Cardiology 45(8): 100617. 
Aiello, A., G. D. Guccione, G. Accardi and C. Caruso (2015). "What olive oil for healthy ageing?" 
Maturitas 80(2): 117-118. 
Alves-Bezerra, M. and D. E. Cohen (2017). "Triglyceride Metabolism in the Liver." Comprehensive 
Physiology 8(1): 1-8. 
Amarenco, P. and J. Labreuche (2009). "Lipid management in the prevention of stroke: review and 
updated meta-analysis of statins for stroke prevention." The Lancet Neurology 8(5): 453-463. 
American Heart Association (2019). A Public Health Action Plan to Prevent Heart Disease and Stroke. 
T. G. T. U.S. Department Of Health And Human Services Centers For Disease Control And Prevention. 
Amirabdollahian, F. and F. Haghighatdoost (2018). "Anthropometric Indicators of Adiposity Related to 
Body Weight and Body Shape as Cardiometabolic Risk Predictors in British Young Adults: Superiority of 
Waist-to-Height Ratio." Journal of obesity 2018: 8370304-8370304. 
Ana Z., Miriam S., Rosario F., Eva M., Ana L., Lorena R., (2020). Front. 
Nutr.,https://doi.org/10.3389/fnut.2021.683261 
Anand, S. S., C. Hawkes, R. J. de Souza, A. Mente, M. Dehghan, R. Nugent, M. A. Zulyniak, T. Weis, A. 
M. Bernstein, R. M. Krauss, D. Kromhout, D. J. A. Jenkins, V. Malik, M. A. Martinez-Gonzalez, D. 
Mozaffarian, S. Yusuf, W. C. Willett and B. M. Popkin (2015). "Food Consumption and its Impact on 
Cardiovascular Disease: Importance of Solutions Focused on the Globalized Food System: A Report 
From the Workshop Convened by the World Heart Federation." Journal of the American College of 
Cardiology 66(14): 1590-1614. 
Angeliki M. A., Alexander K., Eleftheria K., Emilio R., Christos S. M (2020) . “Mediterranean diet as a 
nutritional approach for COVID-19.” The Journal of Metabolism, Clinical and Experimental 114 (154407); 
DOI:https://doi.org/10.1016/j.metabol.2020.154407 
Appel, L. J., F. M. Sacks, V. J. Carey, E. Obarzanek and J. F. Swain (2005). "Effects of protein, 
monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids: results of the 
OmniHeart randomized trial." National Library of Medicine 16(19): 2455-2464. 
 
- 210 - 
 
Appleton, K., R. McGill, C. Neville and J. Woodside (2010). Barriers to increasing fruit and vegetable 
intakes in the older population of Northern Ireland: Low levels of liking and low awareness of current 
recommendations. 
Aronis, K. N., M. T. Vamvini, J. P. Chamberland, L. L. Sweeney, A. M. Brennan, F. Magkos and C. S. 
Mantzoros (2012). "Short-term walnut consumption increases circulating total adiponectin and 
apolipoprotein A concentrations, but does not affect markers of inflammation or vascular injury in obese 
humans with the metabolic syndrome: data from a double-blinded, randomized, placebo-controlled 
study." Metabolism: Clinical And Experimental 61(4): 577-582. 
Atefi, M., G. R. Pishdad and S. Faghih (2018). "The effects of canola and olive oils on insulin resistance, 
inflammation and oxidative stress in women with type 2 diabetes: a randomized and controlled trial." 
Journal of Diabetes and Metabolic Disorders: 1-7. 
Aune, D., N. Keum, E. Giovannucci, L. T. Fadnes, P. Boffetta, D. C. Greenwood, S. Tonstad, L. J. Vatten, 
E. Riboli and T. Norat (2016). "Nut consumption and risk of cardiovascular disease, total cancer, all-
cause and cause-specific mortality: a systematic review and dose-response meta-analysis of prospective 
studies." BMC Med 14(1): 207. 
Bacchiega, B. C., A. B. Bacchiega, M. J. G. Usnayo, R. Bedirian, G. Singh and G. d. R. C. Pinheiro 
(2017). "Interleukin 6 Inhibition and Coronary Artery Disease in a High-Risk Population: A Prospective 
Community-Based Clinical Study." Journal of the American Heart Association 6(3): e005038. 
Badimon, L., T. Padró and G. Vilahur (2012). "Atherosclerosis, platelets and thrombosis in acute 
ischaemic heart disease." European heart journal. Acute cardiovascular care 1(1): 60-74. 
Baigent, C., A. Keech, P. M. Kearney, L. Blackwell, G. Buck, C. Pollicino, A. Kirby, T. Sourjina, R. Peto, 
R. Collins and R. Simes (2005). "Efficacy and safety of cholesterol-lowering treatment: prospective meta-
analysis of data from 90,056 participants in 14 randomised trials of statins." Lancet 366(9493): 1267-
1278. 
Bamberger, C., A. Rossmeier, K. Lechner, L. Wu, E. Waldmann, R. G. Stark, J. Altenhofer, K. Henze 
and K. G. Parhofer (2017). "A walnut-enriched diet reduces lipids in healthy caucasian subjects, 
independent of recommended macronutrient replacement and time point of consumption: A prospective, 
randomized, controlled trial." Nutrients 9(10). 
Banel, D. K. and F. B. Hu (2009). "Effects of walnut consumption on blood lipids and other cardiovascular 
risk factors: a meta-analysis and systematic review." Am J Clin Nutr 90(1): 56-63. 
Bansal, M. (2020). "Cardiovascular disease and COVID-19." Diabetes & Metabolic Syndrome: Clinical 
Research & Reviews 14(3): 247-250. 
Bansal, N., C. M. Fischbacher, R. S. Bhopal, H. Brown, M. F. C. Steiner and S. Capewell (2013). 
"Myocardial infarction incidence and survival by ethnic group: Scottish Health and Ethnicity Linkage 
retrospective cohort study." BMJ Open 3(9). 
Bao, Y., J. Han, F. B. Hu, E. L. Giovannucci, M. J. Stampfer, W. C. Willett and C. S. Fuchs (2013). 
"Association of nut consumption with total and cause-specific mortality." N Engl J Med 369(21): 2001-
2011. 
Barba, C., T. Cavalli-Sforza, J. Cutter, I. Darnton-Hill, P. Deurenberg, M. Yap, T. Gill, P. James, G. Ko, 
A. H. Miu, V. Kosulwat, S. Kumanyika, A. Kurpad, N. Mascie-Taylor, H. K. Moon, C. Nishida, M. Ismail, 
K. S. Reddy, E. Rush and P. Zimmet (2004). Appropriate Body Mass Index for Asian Populations and 
Its Implications for Policy and Intervention Strategies. 
Bärebring, L., Palmqvist, M., Winkvist, A. (2020). Gender differences in perceived food healthiness and 
food avoidance in a Swedish population-based survey: a cross sectional study. Nutr J 19, 140 (2020). 
https://doi.org/10.1186/s12937-020-00659-0 
 
- 211 - 
 
Barron, E., J. Lara, M. White and J. C. Mathers (2015). "Blood-borne biomarkers of mortality risk: 
systematic review of cohort studies." PloS one 10(6): e0127550-e0127550. 
Bary, S. (2017). Asian consumers more interested in nutrition and healthy eating than westerners: survey. 
Belalcazar, L. M., M. R. David and M. H. Steven (2010). "Marine ω-3 Fatty Acid Intake - Associations 
with cardiometabolic risk and response to weight loss intervention in the Look AHEAD (Action for Health 
in Diabetes) study." American Diabetes Association 33: 197-199. 
Bell, S., M. Daskalopoulou, E. Rapsomaniki, J. George, A. Britton, M. Bobak, J. P. Casas, C. E. Dale, S. 
Denaxas, A. D. Shah and H. Hemingway (2017). "Association between clinically recorded alcohol 
consumption and initial presentation of 12 cardiovascular diseases: population based cohort study using 
linked health records." BMJ 356: j909. 
Benjamin Emelia, J., P. Muntner, A. Alonso, S. Bittencourt Marcio, W. Callaway Clifton, P. Carson April, 
M. Chamberlain Alanna, R. Chang Alexander, S. Cheng, R. Das Sandeep, N. Delling Francesca, L. 
Djousse, S. V. Elkind Mitchell, F. Ferguson Jane, M. Fornage, C. Jordan Lori, S. Khan Sadiya, M. Kissela 
Brett, L. Knutson Kristen, W. Kwan Tak, T. Lackland Daniel, T. Lewis Tené, H. Lichtman Judith, T. 
Longenecker Chris, S. Loop Matthew, L. Lutsey Pamela, S. Martin Seth, K. Matsushita, E. Moran Andrew, 
E. Mussolino Michael, M. O’Flaherty, A. Pandey, M. Perak Amanda, D. Rosamond Wayne, A. Roth 
Gregory, K. A. Sampson Uchechukwu, M. Satou Gary, B. Schroeder Emily, H. Shah Svati, L. Spartano 
Nicole, A. Stokes, L. Tirschwell David, W. Tsao Connie, P. Turakhia Mintu, B. VanWagner Lisa, T. 
Wilkins John, S. Wong Sally, S. Virani Salim and n. null (2019). "Heart Disease and Stroke Statistics—
2019 Update: A Report From the American Heart Association." Circulation 139(10): e56-e528. 
Bento, A. P. N., C. Cominetti, A. Simões Filho and M. M. V. Naves (2014). "Baru almond improves lipid 
profile in mildly hypercholesterolemic subjects: a randomized, controlled, crossover study." Nutrition, 
Metabolism, And Cardiovascular Diseases: NMCD 24(12): 1330-1336. 
Berger, V. W. and S. Y. Alperson (2009). "A general framework for the evaluation of clinical trial quality." 
Rev Recent Clin Trials 4(2): 79-88. 
Bermudez, B., S. Lopez, A. Ortega, L. M. Varela, Y. M. Pacheco, R. Abia and F. J. Muriana (2011). 
"Oleic acid in olive oil: from a metabolic framework toward a clinical perspective." Curr Pharm Des 17(8): 
831-843. 
Berrougui, H., S. Ikhlef and A. Khalil (2015). "Extra Virgin Olive Oil Polyphenols Promote Cholesterol 
Efflux and Improve HDL Functionality." Evidence-based complementary and alternative medicine : 
eCAM 2015: 208062-208062. 
Berryman, C. E., S. G. West, J. A. Fleming, P. L. Bordi and P. M. Kris-Etherton (2015). "Effects of Daily 
Almond Consumption on Cardiometabolic Risk and Abdominal Adiposity in Healthy Adults With Elevated 
LDL-Cholesterol: A Randomized Controlled Trial." Journal of the American Heart Association 4(1). 
Beyer, S. E., M. M. Sanghvi, N. Aung, A. Hosking, J. A. Cooper, J. M. Paiva, A. M. Lee, K. Fung, E. 
Lukaschuk, V. Carapella, M. A. Mittleman, S. Brage, S. K. Piechnik, S. Neubauer and S. E. Petersen 
(2018). "Prospective association between handgrip strength and cardiac structure and function in UK 
adults." PloS one 13(3): e0193124-e0193124. 
Bielinski, S. J., C. Berardi, P. A. Decker, P. S. Kirsch, N. B. Larson, J. S. Pankow, M. Sale, M. de Andrade, 
H. Sicotte, W. Tang, N. Q. Hanson, C. L. Wassel, J. F. Polak and M. Y. Tsai (2015). "P-selectin and 
subclinical and clinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis (MESA)." 
Atherosclerosis 240(1): 3-9. 
Bilgic G, S., G. Akan, F. Atalar and G. Erten (2015). "PAI-1 and TNF-α profiles of adipose tissue in obese 
cardiovascular disease patients." International Journal of Clinical and Experimental Pathology 8(12): 
15919-15925. 
 
- 212 - 
 
Binkoski, A. E., P. M. Kris-Etherton, T. A. Wilson, M. L. Mountain and R. J. Nicolosi (2005). "Balance of 
unsaturated fatty acids is important to a cholesterol-lowering diet: comparison of mid-oleic sunflower oil 
and olive oil on cardiovascular disease risk factors." Journal Of The American Dietetic Association 105(7): 
1080-1086. 
Deng, B, Luo,T., Huang,Y., Shen,T., and Jing Ma (2012). “Prevalence and Determinants of 
Hyperlipidemia in Moderate Altitude Areas of the Yunnan-Kweichow Plateau in Southwestern China” 
High Altitude Medicine & Biology 13:1, 13-21 
Blankenberg, S., J. Rupprecht Hans, C. Bickel, D. Peetz, G. Hafner, L. Tiret, J. Meyer and n. null (2001). 
"Circulating Cell Adhesion Molecules and Death in Patients With Coronary Artery Disease." Circulation 
104(12): 1336-1342. 
Blomhoff, R., Carlsen, M. H., Andersen, L. F., & Jacobs, D. R., Jr (2006). Health benefits of nuts: potential 
role of antioxidants. The British journal of nutrition, 96 Suppl 2, S52–S60. 
https://doi.org/10.1017/bjn20061864 
Boehme, A. K., C. Esenwa and M. S. V. Elkind (2017). "Stroke Risk Factors, Genetics, and Prevention." 
Circulation research 120(3): 472-495. 
Bots, S. H., S. A. E. Peters and M. Woodward (2017). "Sex differences in coronary heart disease and 
stroke mortality: a global assessment of the effect of ageing between 1980 and 2010." BMJ Global Health 
2(2): e000298. 
Brennan, A. M., L. L. Sweeney, X. Liu and C. S. Mantzoros (2010). "Walnut consumption increases 
satiation but has no effect on insulin resistance or the metabolic profile over a 4-day period." Obesity 
(Silver Spring) 18(6): 1176-1182. 
British Heart Foundation (2021). Coronavirus and Heart & Circulatory Diseases Factsheet. 
British Heart Foundation (2021). UK Factsheet. 
Brown, I. J., I. Tzoulaki, V. Candeias and P. Elliott (2009). "Salt intakes around the world: implications 
for public health." International Journal of Epidemiology 38(3): 791-813. 
Buchan, D. S., N. E. Thomas and J. S. Baker (2012). "Novel risk factors of cardiovascular disease and 
their associations between obesity, physical activity and physical fitness." Journal of public health 
research 1(1): 59-66. 
Buckland, G. and C. A. Gonzalez (2015). "The role of olive oil in disease prevention: A focus on the 
recent epidemiological evidence from cohort studies and dietary intervention trials." British Journal of 
Nutrition 113(S2): S94-S101. 
Buckland, G., A. Agudo, N. Travier, J. M. Huerta, L. Cirera, M. J. Tormo, C. Navarro, M. D. Chirlaque, C. 
Moreno-Iribas, E. Ardanaz, A. Barricarte, J. Etxeberria, P. Marin, J. R. Quirós, M. L. Redondo, N. 
Larrañaga, P. Amiano, M. Dorronsoro, L. Arriola, M. Basterretxea, M. J. Sanchez, E. Molina and C. A. 
González (2011). "Adherence to the Mediterranean diet reduces mortality in the Spanish cohort of the 
European Prospective Investigation into Cancer and Nutrition (EPIC-Spain)." Br J Nutr 106(10): 1581-
1591. 
Buckland, G., N. Travier, A. Barricarte, E. Ardanaz, C. Moreno-Iribas, M.-J. Sanchez, E. Molina-Montes, 
M.-D. Chirlaque, J. Huerta, C. Navarro, M. Luisa Redondo, P. Amiano, M. Dorronsoro, N. Larrañaga and 
C. A. Gonzalez (2012). Olive oil intake and CHD in the European Prospective Investigation into Cancer 
and Nutrition Spanish cohort. 
Buckley, D. I., R. Fu, M. Freeman, K. Rogers and M. Helfand (2009). "C-Reactive Protein as a Risk 
Factor for Coronary Heart Disease: A Systematic Review and Meta-analyses for the U.S. Preventive 
Services Task Force." Annals of Internal Medicine 151(7): 483-495. 
 
- 213 - 
 
Burns-Whitmore, B., E. Haddad, J. Sabaté and S. Rajaram (2014). "Effects of supplementing n-3 fatty 
acid enriched eggs and walnuts on cardiovascular disease risk markers in healthy free-living lacto-ovo-
vegetarians: a randomized, crossover, free-living intervention study." Nutrition Journal 13: 29-29. 
Buttar, H. S., T. Li and N. Ravi (2005). "Prevention of cardiovascular diseases: Role of exercise, dietary 
interventions, obesity and smoking cessation." Experimental and clinical cardiology 10(4): 229-249. 
Cale, J. M., S. H. Li, M. Warnock, E. J. Su, P. R. North, K. L. Sanders, M. M. Puscau, C. D. Emal and D. 
A. Lawrence (2010). "Characterization of a novel class of polyphenolic inhibitors of plasminogen activator 
inhibitor-1." J Biol Chem 285(11): 7892-7902. 
Cappuccio, F. P. (2004). "Commentary: Epidemiological transition, migration, and cardiovascular 
disease." International Journal of Epidemiology 33(2): 387-388. 
Carpenter, C. (2010). A Meta-Analysis of the Effectiveness of Health Belief Model Variables in Predicting 
Behavior. 
Carvalho, R. F., G. V. B. Huguenin, R. R. Luiz, A. S. B. Moreira, G. M. M. Oliveira and G. Rosa (2015). 
"Intake of partially defatted Brazil nut flour reduces serum cholesterol in hypercholesterolemic patients--
a randomized controlled trial." Nutrition Journal 14: 59-59. 
Casas, R., E. Sacanella, M. Urpí-Sardà, G. Chiva-Blanch, E. Ros, M. A. Martínez-González, M. I. Covas, 
J. Salas-Salvadó, M. Fiol, F. Arós and R. Estruch (2014). "The effects of the mediterranean diet on 
biomarkers of vascular wall inflammation and plaque vulnerability in subjects with high risk for 
cardiovascular disease. A randomized trial." PLoS One 9(6): e100084. 
Casas-Agustench, P., P. López-Uriarte, M. Bulló, E. Ros, J. J. Cabré-Vila and J. Salas-Salvadó (2011). 
"Effects of one serving of mixed nuts on serum lipids, insulin resistance and inflammatory markers in 
patients with the metabolic syndrome." Nutrition, Metabolism, And Cardiovascular Diseases: NMCD 
21(2): 126-135. 
Cavallo, C. (2015). Evaluation of healthiness perception and authenticity of olive oil: Role of product 
packaging and consumer attitudes. Master Master Management, Economics and Consumer Studies. 
CBI - Ministry of Foreign Affairs (2020). The European market potential for olive oil. 
Celermajer, D. S., K. E. Sorensen, V. M. Gooch, D. J. Spiegelhalter, O. I. Miller, I. D. Sullivan, J. K. Lloyd 
and J. E. Deanfield (1992). "Non-invasive detection of endothelial dysfunction in children and adults at 
risk of atherosclerosis." The Lancet 340(8828): 1111-1115. 
Centre for Reviews and Dissemination (2009). Systematic Reviews: CRD’s guidance for undertaking 
reviews in health care. York Publishing Services Ltd, 64 Hallfi eld Road, Layerthorpe, York, UK, Centre 
for Reviews and Dissemination, University of York. 
Chan, A. W., J. M. Tetzlaff, D. G. Altman, A. Laupacis, P. C. Gøtzsche, K. Krleža-Jerić, A. Hróbjartsson, 
H. Mann, K. Dickersin, J. A. Berlin, C. J. Doré, W. R. Parulekar, W. S. Summerskill, T. Groves, K. F. 
Schulz, H. C. Sox, F. W. Rockhold, D. Rennie and D. Moher (2013). "SPIRIT 2013 statement: defining 
standard protocol items for clinical trials." Ann Intern Med 158(3): 200-207. 
Chan, J. C. N., V. Malik, W. Jia, T. Kadowaki, C. S. Yajnik, K.-H. Yoon and F. B. Hu (2009). "Diabetes 
in Asia: Epidemiology, Risk Factors, and Pathophysiology." JAMA 301(20): 2129-2140. 
Chan, Y.-M., I. Demonty, D. Pelled and P. Jones (2007). Olive oil containing olive oil fatty acid esters of 
plant sterols and dietary diacylglycerol reduces low-density lipoprotein cholesterol and decreases the 
tendency for peroxidation in hypercholesterolemic subjects. 
Chang, S. K., C. Alasalvar, B. W. Bolling and F. Shahidi (2016). "Nuts and their co-products: The impact 
of processing (roasting) on phenolics, bioavailability, and health benefits – A comprehensive review." 
Journal of Functional Foods 26: 88-122. 
 
- 214 - 
 
Chen, C. Y. O., M. Holbrook, M.-A. Duess, M. M. Dohadwala, N. M. Hamburg, B. F. Asztalos, P. E. 
Milbury, J. B. Blumberg and J. A. Vita (2015). "Effect of almond consumption on vascular function in 
patients with coronary artery disease: a randomized, controlled, cross-over trial." Nutrition Journal 14: 
61-61. 
Chen, J., D. Gu, J. Huang, D. C. Rao, C. E. Jaquish, J. E. Hixson, C.-S. Chen, J. Chen, F. Lu, D. Hu, T. 
Rice, T. N. Kelly, L. L. Hamm, P. K. Whelton and J. He (2009). "Metabolic syndrome and salt sensitivity 
of blood pressure in non-diabetic people in China: a dietary intervention study." The Lancet 373(9666): 
829-835. 
Chen, Y., W. K. Copeland, R. Vedanthan, E. Grant, J. E. Lee, D. Gu, P. C. Gupta, K. Ramadas, M. Inoue, 
S. Tsugane, A. Tamakoshi, Y.-T. Gao, J.-M. Yuan, X.-O. Shu, K. Ozasa, I. Tsuji, M. Kakizaki, H. Tanaka, 
Y. Nishino, C.-J. Chen, R. Wang, K.-Y. Yoo, Y.-O. Ahn, H. Ahsan, W.-H. Pan, C.-S. Chen, M. S. 
Pednekar, C. Sauvaget, S. Sasazuki, G. Yang, W.-P. Koh, Y.-B. Xiang, W. Ohishi, T. Watanabe, Y. 
Sugawara, K. Matsuo, S.-L. You, S. K. Park, D.-H. Kim, F. Parvez, S.-Y. Chuang, W. Ge, B. Rolland, D. 
McLerran, R. Sinha, M. Thornquist, D. Kang, Z. Feng, P. Boffetta, W. Zheng, J. He and J. D. Potter 
(2013). "Association between body mass index and cardiovascular disease mortality in east Asians and 
south Asians: pooled analysis of prospective data from the Asia Cohort Consortium." BMJ : British 
Medical Journal 347: f5446. 
Chen, C. Y., Milbury, P. E., Lapsley, K., & Blumberg, J. B. (2005). Flavonoids from almond skins are 
bioavailable and act synergistically with vitamins C and E to enhance hamster and human LDL resistance 
to oxidation. The Journal of nutrition, 135(6), 1366–1373. https://doi.org/10.1093/jn/135.6.1366 
Chiang, Y.-L., E. Haddad, S. Rajaram, D. Shavlik and J. Sabaté (2012). "The effect of dietary walnuts 
compared to fatty fish on eicosanoids, cytokines, soluble endothelial adhesion molecules and 
lymphocyte subsets: a randomized, controlled crossover trial." Prostaglandins, Leukotrienes, And 
Essential Fatty Acids 87(4-5): 111-117. 
Chien, K. L., H. C. Hsu, T. C. Su, M. F. Chen, Y. T. Lee and F. B. Hu (2007). "Apolipoprotein B and non-
high density lipoprotein cholesterol and the risk of coronary heart disease in Chinese." J Lipid Res 48(11): 
2499-2505. 
Chisholm, A., J. Mann, M. Skeaff, C. Frampton, W. Sutherland, A. Duncan and S. Tiszavari (1998). "A 
diet rich in walnuts favourably influences plasma fatty acid profile in moderately hyperlipidaemic 
subjects." European Journal of Clinical Nutrition 52(1): 12-16. 
Chisholm, A., K. Mc Auley, J. Mann, S. Williams and M. Skeaff (2005). "Cholesterol lowering effects of 
nuts compared with a Canola oil enriched cereal of similar fat composition." Nutrition, Metabolism and 
Cardiovascular Diseases 15(4): 284-292. 
Chobanian, A. V., G. L. Bakris, H. R. Black, W. C. Cushman, L. A. Green, J. L. Izzo, Jr., D. W. Jones, B. 
J. Materson, S. Oparil, J. T. Wright, Jr. and E. J. Roccella (2003). "The Seventh Report of the Joint 
National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the 
JNC 7 report." Jama 289(19): 2560-2572. 
Cicerale, S., L. J. Lucas and R. S. Keast (2012). "Antimicrobial, antioxidant and anti-inflammatory 
phenolic activities in extra virgin olive oil." Curr Opin Biotechnol 23(2): 129-135. 
Cicero, A. F. G., S. D'Addato, A. Fiorito, A. Poli and A. V. Gaddi (2009). "Plasma lipid effects of corn oil 
and extra-virgin olive oil in hypercholesterolaemic subjects: A randomised, controlled trial." 
Mediterranean Journal of Nutrition and Metabolism 1(3): 187-192. 
Claesson, A.-L., G. Holm, A. Ernersson, T. Lindström and F. H. Nystrom (2009). "Two weeks of 
overfeeding with candy, but not peanuts, increases insulin levels and body weight." Scandinavian Journal 
Of Clinical And Laboratory Investigation 69(5): 598-605. 
 
- 215 - 
 
Clark, H. D., G. A. Wells, C. Huët, F. A. McAlister, L. R. Salmi, D. Fergusson and A. Laupacis (1999). 
"Assessing the Quality of Randomized Trials: Reliability of the Jadad Scale." Controlled Clinical Trials 
20(5): 448-452. 
Clerkin, K. J., J. A. Fried, J. Raikhelkar, G. Sayer, J. M. Griffin, A. Masoumi, S. S. Jain, D. Burkhoff, D. 
Kumaraiah, L. Rabbani, A. Schwartz and N. Uriel (2020). "COVID-19 and Cardiovascular Disease." 
Circulation 141(20): 1648-1655. 
Colpo, E., C. Vilanova, L. G. B. Reetz, M. Duarte, I. L. G. Farias, D. E. Meinerz, D. O. C. Mariano, R. G. 
Vendrusculo, A. A. Boligon, C. L. D. Corte, R. Wagner, M. L. Athayde and J. B. T. Da Rocha (2014). 
"Brazilian nut consumption by healthy volunteers improves inflammatory parameters." Nutrition 30(4): 
459-465. 
Costantino, S., F. Paneni and F. Cosentino (2016). "Ageing, metabolism and cardiovascular disease." 
The Journal of Physiology 594(8): 2061-2073. 
Cordain, L., Eaton, S. B., Sebastian, A., Mann, N., Lindeberg, S., Watkins, B. A., O'Keefe, J. H., & Brand-
Miller, J. (2005). Origins and evolution of the Western diet: health implications for the 21st century. The 
American journal of clinical nutrition, 81(2), 341–354. 
Covas MI, Nyyssönen K, Poulsen HE, Kaikkonen J, Zunft HJ, Kiesewetter H, Gaddi A, de la Torre R, 
Mursu J, Bäumler H, Nascetti S, Salonen JT, Fitó M, Virtanen J, Marrugat J; EUROLIVE Study Group. 
The effect of polyphenols in olive oil on heart disease risk factors: a randomized trial. Ann Intern Med. 
2006 Sep 5;145(5):333-41. doi: 10.7326/0003-4819-145-5-200609050-00006. PMID: 16954359. 
Covas, M. I., V. Konstantinidou and M. Fito (2009). "Olive oil and cardiovascular health." J Cardiovasc 
Pharmacol 54(6): 477-482. 
Covas, M.-I. (2007). "Olive oil and the cardiovascular system." Pharmacological Research 55(3): 175-
186. 
Crawford, M., C. Galli, F. Visioli, S. Renaud, A. P. Simopoulos and A. A. Spector (2000). "Role of Plant-
Derived Omega–3 Fatty Acids in Human Nutrition." (44): 263–265. 
Cuevas-Ramos, D., P. Almeda-Valdes, E. Chavez-Manzanera, C. E. Meza-Arana, G. Brito-Cordova, R. 
Mehta, O. Perez-Mendez and F. J. Gomez-Perez (2013). "Effect of tomato consumption on high-density 
lipoprotein cholesterol level: a randomized, single-blinded, controlled clinical trial." Diabetes Metab Syndr 
Obes 6: 263-273. 
Curb, J. D., G. Wergowske, J. C. Dobbs, R. D. Abbott and B. J. Huang (2000). "Serum lipid effects of a 
high-monounsaturated fat diet based on macadamia nuts." Archives of Internal Medicine 160(8): 1154-
1158. 
Dadlani, A., K. Madan and J. P. S. Sawhney (2019). "Ambulatory blood pressure monitoring in clinical 
practice." Indian heart journal 71(1): 91-97. 
Dan, S., Pant, M., & Upadhyay, S. K. (2020). The Case Fatality Rate in COVID-19 Patients With 
Cardiovascular Disease: Global Health Challenge and Paradigm in the Current Pandemic. Current 
pharmacology reports, 1–10. Advance online publication. https://doi.org/10.1007/s40495-020-00239-0. 
Damasceno, N. R. T., A. Sala-Vila, M. Cofan, A. M. Perez-Heras, M. Fito, V. Ruiz-Gutierrez, M. A. 
Martinez-Gonzalez, D. Corella, F. Aros, R. Estruch and E. Ros (2013). "Mediterranean diet 
supplemented with nuts reduces waist circumference and shifts lipoprotein subfractions to a less 
atherogenic pattern in subjects at high cardiovascular risk." Atherosclerosis 230(2): 347-353. 
Dassanayake, J., L. Gurrin, W. R. Payne, V. Sundararajan and S. C. Dharmage (2011). "Cardiovascular 
disease risk in immigrants: what is the evidence and where are the gaps?" Asia Pac J Public Health 
23(6): 882-895. 
 
- 216 - 
 
Davidi, A., J. Reynolds, V. Y. Njike, Y. Ma, K. Doughty and D. L. Katz (2011). "The effect of the addition 
of daily fruit and nut bars to diet on weight, and cardiac risk profile, in overweight adults." Journal of 
Human Nutrition and Dietetics 24(6): 543-551. 
Davis, C., J. Hodgson, J. Bryan, M. Garg, R. Woodman and K. Murphy (2017). "Older Australians Can 
Achieve High Adherence to the Mediterranean Diet during a 6 Month Randomised Intervention; Results 
from the Medley Study." Nutrients 9(6). 
de Oliveira, P. A., C. Kovacs, P. Moreira, D. Magnoni, M. H. Saleh and J. Faintuch (2017). "Unsaturated 
Fatty Acids Improve Atherosclerosis Markers in Obese and Overweight Non-diabetic Elderly Patients." 
Obes Surg 27(10): 2663-2671. 
de Souza, R. G. M., A. C. Gomes, I. A. de Castro and J. F. Mota (2018). "A baru almond–enriched diet 
reduces abdominal adiposity and improves high-density lipoprotein concentrations: A randomized, 
placebo-controlled trial." Nutrition 55-56: 154-160. 
Del Carlo, M., G. Sacchetti, C. Di Mattia, D. Compagnone, D. Mastrocola, L. Liberatore and A. Cichelli 
(2004). "Contribution of the phenolic fraction to the antioxidant activity and oxidative stability of olive oil." 
J Agric Food Chem 52(13): 4072-4079. 
Del Gobbo, L. C., M. C. Falk, R. Feldman, K. Lewis and D. Mozaffarian (2015). "Effects of tree nuts on 
blood lipids, apolipoproteins, and blood pressure: systematic review, meta-analysis, and dose-response 
of 61 controlled intervention trials." Am J Clin Nutr 102(6): 1347-1356. 
Demerath, E., B. Towne, J. Blangero and R. M. Siervogel (2001). "The relationship of soluble ICAM-1, 
VCAM-1, P-selectin and E-selectin to cardiovascular disease risk factors in healthy men and women." 
Annals of Human Biology 28(6): 664-678. 
Demonty, I., R. T. Ras, H. C. van der Knaap, G. S. Duchateau, L. Meijer, P. L. Zock, J. M. Geleijnse and 
E. A. Trautwein (2009). "Continuous dose-response relationship of the LDL-cholesterol-lowering effect 
of phytosterol intake." J Nutr 139(2): 271-284. 
Deng, Y., E. Foley, J. Gonzales, P. Gordts, Y.-L. Li and J. Esko (2012). "Shedding of syndecan-1 from 
human hepatocytes alters very low density lipoprotein clearance." Hepatology (Baltimore, Md.) 55: 277-
286. 
Department for Environment, F. a. R. A. (2015). Food Statistics Pocketbook. 
Dhaka, V., N. Gulia, K. S. Ahlawat and B. S. Khatkar (2011). "Trans fats-sources, health risks and 
alternative approach - A review." Journal of food science and technology 48(5): 534-541. 
Dhillon, J., S. Y. Tan and R. D. Mattes (2016). "Almond Consumption during Energy Restriction Lowers 
Truncal Fat and Blood Pressure in Compliant Overweight or Obese Adults." Journal of Nutrition 146(12): 
2513-2519. 
Din, J. N., S. M. Aftab, A. W. Jubb, F. H. Carnegy, K. Lyall, J. Sarma, D. E. Newby and A. D. Flapan 
(2011). "Effect of moderate walnut consumption on lipid profile, arterial stiffness and platelet activation 
in humans." European Journal Of Clinical Nutrition 65(2): 234-239. 
Ditano-Vázquez, P., Torres-Peña, J. D., Galeano-Valle, F., Pérez-Caballero, A. I., Demelo-Rodríguez, 
P., Lopez-Miranda, J., Katsiki, N., Delgado-Lista, J., & Alvarez-Sala-Walther, L. A. (2019). The Fluid 
Aspect of the Mediterranean Diet in the Prevention and Management of Cardiovascular Disease and 
Diabetes: The Role of Polyphenol Content in Moderate Consumption of Wine and Olive 
Oil. Nutrients, 11(11), 2833. https://doi.org/10.3390/nu11112833 
Donato Anthony, J., R. Machin Daniel and A. Lesniewski Lisa (2018). "Mechanisms of Dysfunction in the 
Aging Vasculature and Role in Age-Related Disease." Circulation Research 123(7): 825-848. 
 
- 217 - 
 
Dontas, A. S., N. S. Zerefos, D. B. Panagiotakos, C. Vlachou and D. A. Valis (2007). "Mediterranean diet 
and prevention of coronary heart disease in the elderly." Clinical interventions in aging 2(1): 109-115. 
Duansak, N. and G. W. Schmid-Schönbein (2013). "The oxygen free radicals control MMP-9 and 
transcription factors expression in the spontaneously hypertensive rat." Microvasc Res 90: 154-161. 
Durstine, J. L. and P. W. Grandjean (2001). "Blood Lipid and Lipoprotein Adaptations to Exercise:A 
Quantitative Analysis." Sports Medicine 31: 1033–1062. 
Dwan, K., T. Li, D. G. Altman and D. Elbourne (2019). "CONSORT 2010 statement: extension to 
randomised crossover trials." BMJ 366: l4378. 
Egger, M., G. Davey Smith, M. Schneider and C. Minder (1997). "Bias in meta-analysis detected by a 
simple, graphical test." Bmj 315(7109): 629-634. 
Eguchi, K., T. G. Pickering, S. Hoshide, J. Ishikawa, S. Ishikawa, J. E. Schwartz, K. Shimada and K. 
Kario (2008). "Ambulatory Blood Pressure Is a Better Marker Than Clinic Blood Pressure in Predicting 
Cardiovascular Events in Patients With/Without Type 2 Diabetes." American Journal of Hypertension 
21(4): 443-450. 
Emerging Risk Factors, C., S. Kaptoge, E. Di Angelantonio, G. Lowe, M. B. Pepys, S. G. Thompson, R. 
Collins and J. Danesh (2010). "C-reactive protein concentration and risk of coronary heart disease, 
stroke, and mortality: an individual participant meta-analysis." Lancet (London, England) 375(9709): 132-
140. 
Engel, S. and T. Tholstrup (2015). "Butter increased total and LDL cholesterol compared with olive oil 
but resulted in higher HDL cholesterol compared with a habitual diet." The American Journal of Clinical 
Nutrition 102(2): 309-315. 
England, P. H. (2016). The Eatwell Guide - Helping you eat a healthy, balanced diet. Protecting and 
improving the nation’s health. 
Eric, J. S. and L. I-Min (2010). "Physical Activity and Cardiovascular Health -Lessons Learned From 
Epidemiological Studies Across Age, Gender, and Race/Ethnicity." Circulation 122: 743–752. 
Escurriol, V., M. Cofan, M. Serra, M. Bullo, J. Basora, J. Salas-Salvado, D. Corella, I. Zazpe, M. A. 
Martinez-Gonzalez, V. Ruiz-Gutierrez, R. Estruch and E. Ros (2009). "Serum sterol responses to 
increasing plant sterol intake from natural foods in the Mediterranean diet." Eur J Nutr 48(6): 373-382. 
Estruch, R. (2010). "Anti-inflammatory effects of the Mediterranean diet: the experience of the 
PREDIMED study." Proc Nutr Soc 69(3): 333-340. 
Estruch, R., E. Ros, J. Salas-Salvadó, M.-I. Covas, D. Corella, F. Arós, E. Gómez-Gracia, V. Ruiz-
Gutiérrez, M. Fiol, J. Lapetra, R. M. Lamuela-Raventos, L. Serra-Majem, X. Pintó, J. Basora, M. A. 
Muñoz, J. V. Sorlí, J. A. Martínez, M. Fitó, A. Gea, M. A. Hernán and M. A. Martínez-González (2018). 
"Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-
Virgin Olive Oil or Nuts." New England Journal of Medicine 378(25): e34. 
Estruch, R., E. Ros, J. Salas-Salvadó, M.-I. Covas, D. Corella, F. Arós, E. Gómez-Gracia, V. Ruiz-
Gutiérrez, M. Fiol, J. Lapetra, R. M. Lamuela-Raventos, L. Serra-Majem, X. Pintó, J. Basora, M. A. 
Muñoz, J. V. Sorlí, J. A. Martínez and M. A. Martínez-González (2013). "Primary Prevention of 
Cardiovascular Disease with a Mediterranean Diet." New England Journal of Medicine 368(14): 1279-
1290. 
European Commission (2011). Trans fats in foods and in the overall diet of the Union population. 
Eysenbach, G. (2004). "Improving the quality of Web surveys: the Checklist for Reporting Results of 
Internet E-Surveys (CHERRIES)." J Med Internet Res 6(3): e34. 
 
- 218 - 
 
Fajemiroye, J. O., L. C. da Cunha, R. Saavedra-Rodríguez, K. L. Rodrigues, L. M. Naves, A. A. Mourão, 
E. F. da Silva, N. E. E. Williams, J. L. R. Martins, R. B. Sousa, A. C. S. Rebelo, A. A. d. S. Reis, R. d. S. 
Santos, M. L. Ferreira-Neto and G. R. Pedrino (2018). "Aging-Induced Biological Changes and 
Cardiovascular Diseases." BioMed research international 2018: 7156435-7156435. 
Faul, F., Erdfelder, E., Buchner, A. et al. (2009). Statistical power analyses using G*Power 3.1: Tests for 
correlation and regression analyses. Behavior Research Methods 41, 1149–1160. 
https://doi.org/10.3758/BRM.41.4.1149 
Feingold, K. R. and C. Grunfeld (2000). Introduction to Lipids and Lipoproteins. Endotext. K. R. Feingold, 
B. Anawalt, A. Boyce et al. South Dartmouth (MA), MDText.com, Inc. 
Fernández-Castillejo, S., R. M. Valls, O. Castañer, L. Rubió, Ú. Catalán, A. Pedret, A. Macià, M. L. 
Sampson, M. I. Covas, M. Fitó, M. J. Motilva, A. T. Remaley and R. Solà (2016). "Polyphenol rich olive 
oils improve lipoprotein particle atherogenic ratios and subclasses profile: A randomized, crossover, 
controlled trial." Mol Nutr Food Res 60(7): 1544-1554. 
Filipek, A., M. E. Czerwińska, A. K. Kiss, J. A. Polański and M. Naruszewicz (2017). "Oleacein may inhibit 
destabilization of carotid plaques from hypertensive patients. Impact on high mobility group protein-1." 
Phytomedicine 32: 68-73. 
Fisman, E. Z., M. Benderly, R. J. Esper, S. Behar, V. Boyko, Y. Adler, D. Tanne, Z. Matas and A. 
Tenenbaum (2006). "Interleukin-6 and the risk of future cardiovascular events in patients with angina 
pectoris and/or healed myocardial infarction." Am J Cardiol 98(1): 14-18. 
Forouhi, N. G. and N. Sattar (2006). "CVD risk factors and ethnicity—A homogeneous relationship?" 
Atherosclerosis Supplements 7(1): 11-19. 
Forouzanfar, M. H., A. Afshin and L. T. Alexander (2016). "Global, regional, and national comparative 
risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of 
risks: a systematic analysis for the Global Burden of Disease Study 2015." The Lancet 388(10053): 
1659-1724. 
Forouzanfar, M. H., P. Liu and G. A. Roth (2017). "Global Burden of Hypertension and Systolic Blood 
Pressure of at Least 110 to 115 mm Hg, 1990-2015." JAMA 317(2): 165-182. 
Foster, G. D., K. L. Shantz, S. S. Vander Veur, T. L. Oliver, M. R. Lent, A. Virus, P. O. Szapary, D. J. 
Rader, B. S. Zemel and A. Gilden-Tsai (2012). "A randomized trial of the effects of an almond-enriched, 
hypocaloric diet in the treatment of obesity." The American Journal Of Clinical Nutrition 96(2): 249-254. 
Francis, L., J. Young and J. Lara (2018). "Adherence to and acceptability of the Mediterranean diet 
amongst young adults in the North East of England." Proceedings of the Nutrition Society 77(OCE4): 
E214. 
Freitas, I. A. d., N. d. A. Lima, G. B. d. Silva Jr, R. L. d. Castro Jr, P. Patel, C. C. d. V. Lima and D. O. d. 
C. Lino (2020). "Novel biomarkers in the prognosis of patients with atherosclerotic coronary artery 
disease." Revista Portuguesa de Cardiologia (English Edition) 39(11): 667-672. 
Frostegård, J. (2013). "Immunity, atherosclerosis and cardiovascular disease." BMC medicine 11: 117-
117. 
Fuchs, F. D. and P. K. Whelton (2020). "High Blood Pressure and Cardiovascular Disease." 
Hypertension 75(2): 285-292. 
Fuchs, J., C. Scheidt-Nave, T. Hinrichs, A. Mergenthaler, J. Stein, S. G. Riedel-Heller and E. Grill (2013). 
"Indicators for healthy ageing--a debate." International journal of environmental research and public 
health 10(12): 6630-6644. 
 
- 219 - 
 
G., L. and S. S. (2011). "Diets of minority ethnic groups in the UK: influence on chronic disease risk and 
implications for prevention." Nutrition Bulletin 36(2): 161-198. 
Gaforio, J. J., Visioli, F., Alarcón-de-la-Lastra, C., Castañer, O., Delgado-Rodríguez, M., Fitó, M., 
Hernández, A. F., Huertas, J. R., Martínez-González, M. A., Menendez, J. A., Osada, J., Papadaki, A., 
Parrón, T., Pereira, J. E., Rosillo, M. A., Sánchez-Quesada, C., Schwingshackl, L., Toledo, E., & 
Tsatsakis, A. M. (2019). Virgin Olive Oil and Health: Summary of the III International Conference on 
Virgin Olive Oil and Health Consensus Report, JAEN (Spain) 2018. Nutrients, 11(9), 2039. 
https://doi.org/10.3390/nu11092039 
Galiuto, L. (2015). "Gender differences in cardiovascular disease." https://www.oatext.com/Gender-
differences-in-cardiovascular-disease.php 
Galvão Cândido, F., F. Xavier Valente, L. E. da Silva, O. Gonçalves Leão Coelho, M. D. C. Gouveia 
Peluzio and R. C. Gonçalves Alfenas (2018). "Consumption of extra virgin olive oil improves body 
composition and blood pressure in women with excess body fat: a randomized, double-blinded, placebo-
controlled clinical trial." Eur J Nutr 57(7): 2445-2455. 
Gámbaro, A., A. Ellis and L. Raggio (2013). "Virgin Olive Oil Acceptability in Emerging Olive Oil-
Producing Countries." Food and Nutrition Sciences 4(10): 1060-1068. 
Gao, Z., Z. Chen, A. Sun and X. Deng (2019). "Gender differences in cardiovascular disease." Medicine 
in Novel Technology and Devices 4: 100025. 
Garcia, M., Z. Aragonés and N. Poole (2002). "A repositioning strategy for olive oil in the UK market." 
Agribusiness 18: 163-180. 
Gebauer, S. K., S. G. West, C. D. Kay, P. Alaupovic, D. Bagshaw and P. M. Kris-Etherton (2008). "Effects 
of pistachios on cardiovascular disease risk factors and potential mechanisms of action: A dose-
response study." American Journal of Clinical Nutrition 88(3): 651-659. 
George, E. S., S. Marshall, H. L. Mayr, G. L. Trakman, O. A. Tatucu-Babet, A.-C. M. Lassemillante, A. 
Bramley, A. J. Reddy, A. Forsyth, A. C. Tierney, C. J. Thomas, C. Itsiopoulos and W. Marx (2019). "The 
effect of high-polyphenol extra virgin olive oil on cardiovascular risk factors: A systematic review and 
meta-analysis." Critical Reviews in Food Science and Nutrition 59(17): 2772-2795. 
Ghadimi Nouran, M., M. Kimiagar, A. Abadi, M. Mirzazadeh and G. Harrison (2010). "Peanut 
consumption and cardiovascular risk." Public Health Nutr 13(10): 1581-1586. 
Gidding Samuel, S. and B. Allen Norrina (2019). "Cholesterol and Atherosclerotic Cardiovascular 
Disease: A Lifelong Problem." Journal of the American Heart Association 8(11): e012924. 
Gimeno, E., M. Fitó, R. M. Lamuela-Raventós, A. I. Castellote, M. Covas, M. Farré, M. C. de la Torre-
Boronat and M. C. López-Sabater (2002). "Effect of ingestion of virgin olive oil on human low-density 
lipoprotein composition." European Journal of Clinical Nutrition 56(2): 114-120. 
Global Data - Research And Markets (2020). Nuts and Seeds (Savory Snacks) Market in United Kingdom 
- Outlook to 2023: Market Size, Growth and Forecast Analytics. 
Gokce, N., J. F. Keaney, L. M. Hunter, M. T. Watkins, Z. S. Nedeljkovic, J. O. Menzoian and J. A. Vita 
(2003). "Predictive value of noninvasivelydetermined endothelial dysfunction for long-term 
cardiovascular events inpatients with peripheral vascular disease." Journal of the American College of 
Cardiology 41(10): 1769-1775. 
Gong, Z. and D. Zhao (2015). "Cardiovascular diseases and risk factors among Chinese immigrants." 
Internal and emergency medicine 11. 
Gong, Z. and D. Zhao (2016). "Cardiovascular diseases and risk factors among Chinese immigrants." 
Internal and Emergency Medicine 11(3): 307-318. 
 
- 220 - 
 
Goss, A. M., L. L. Goree, A. C. Ellis, P. C. Chandler-Laney, K. Casazza, M. E. Lockhart and B. A. Gower 
(2013). "Effects of diet macronutrient composition on body composition and fat distribution during weight 
maintenance and weight loss." Obesity (Silver Spring, Md.) 21(6): 1139-1142. 
Gov.UK (2020). Chinese ethnic group: facts and figures. Ethnicity facts and figures. 
Gowing, L. R., R. L. Ali, S. Allsop, J. Marsden, E. E. Turf, R. West and J. Witton (2015). "Global statistics 
on addictive behaviours: 2014 status report." Addiction 110(6): 904-919. 
Griel, A. E., Y. Cao, D. D. Bagshaw, A. M. Cifelli, B. Holub and P. M. Kris-Etherton (2008). "A macadamia 
nut-rich diet reduces total and LDL-cholesterol in mildly hypercholesterolemic men and women." The 
Journal Of Nutrition 138(4): 761-767. 
Griffith, R., M. O'Connell and K. Smith (2015). "Food expenditure and nutritional quality over the Great 
Recession." Institute for Fiscal Studies Briefing Note BN143. 
Grundy Scott, M., J. Stone Neil and L. Bailey Alison (2019). "Guideline on the Management of Blood 
Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on 
Clinical Practice Guidelines." Circulation 139(25): e1082-e1143. 
Guasch-Ferré, M., F. B. Hu, M. A. Martínez-González, M. Fitó, M. Bulló, R. Estruch, E. Ros, D. Corella, 
J. Recondo, E. Gómez-Gracia, M. Fiol, J. Lapetra, L. Serra-Majem, M. A. Muñoz, X. Pintó, R. M. 
Lamuela-Raventós, J. Basora, P. Buil-Cosiales, J. V. Sorlí, V. Ruiz-Gutiérrez, J. A. Martínez and J. 
Salas-Salvadó (2014). "Olive oil intake and risk of cardiovascular disease and mortality in the 
PREDIMED Study." BMC medicine 12: 78-78. 
Gulati, S., A. Misra, R. M. Pandey, S. P. Bhatt and S. Saluja (2014). "Effects of pistachio nuts on body 
composition, metabolic, inflammatory and oxidative stress parameters in Asian Indians with metabolic 
syndrome: a 24-wk, randomized control trial." Nutrition (Burbank, Los Angeles County, Calif.) 30(2): 192-
197. 
Gupta, R., N. Gupta and R. S. Khedar (2013). "Smokeless tobacco and cardiovascular disease in low 
and middle income countries." Indian Heart Journal 65(4): 369-377. 
Gylling, H., J. Plat, S. Turley, H. N. Ginsberg, L. Ellegård, W. Jessup, P. J. Jones, D. Lütjohann, W. 
Maerz, L. Masana, G. Silbernagel, B. Staels, J. Borén, A. L. Catapano, G. De Backer, J. Deanfield, O. 
S. Descamps, P. T. Kovanen, G. Riccardi, L. Tokgözoglu and M. J. Chapman (2014). "Plant sterols and 
plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease." 
Atherosclerosis 232(2): 346-360. 
Haim, M., D. Tanne, V. Boyko, T. Reshef, U. Goldbourt, J. Leor, Y. A. Mekori and S. Behar (2002). 
"Soluble intercellular adhesion molecule-1 and long-term risk of acute coronary events in patients with 
chronic coronary heart disease. Data from the Bezafibrate Infarction Prevention (BIP) Study." J Am Coll 
Cardiol 39(7): 1133-1138. 
Haldar, S., C. Siok Ching and J. Henry (2015). "Body Composition in Asians and Caucasians: 
Comparative Analyses and Influences on Cardiometabolic Outcomes." Advances in food and nutrition 
research 75: 97-154. 
Harland, J. O., N. Unwin, R. S. Bhopal, M. White, B. Watson, M. Laker and K. G. Alberti (1997). "Low 
levels of cardiovascular risk factors and coronary heart disease in a UK Chinese population." Journal of 
epidemiology and community health 51(6): 636-642. 
Harvard T.H. Chan (2020). Ethnic Differences in BMI and Disease Risk. 
Harvard T.H. Chan (2021). Ethnic Differences in BMI and Disease Risk. Obesity Prevention Source. 
Haring, B., Misialek, J. R., Rebholz, C. M., Petruski-Ivleva, N., Gottesman, R. F., Mosley, T. H., & Alonso, 
A. (2015). Association of Dietary Protein Consumption With Incident Silent Cerebral Infarcts and Stroke: 
 
- 221 - 
 
The Atherosclerosis Risk in Communities (ARIC) Study. Stroke, 46(12), 3443–3450. 
https://doi.org/10.1161/STROKEAHA.115.010693 
Haughton, C. F., V. J. Silfee, M. L. Wang, A. C. Lopez-Cepero, D. P. Estabrook, C. Frisard, M. C. Rosal, 
S. L. Pagoto and S. C. Lemon (2018). "Racial/ethnic representation in lifestyle weight loss intervention 
studies in the United States: A systematic review." Prev Med Rep 9: 131-137. 
Havranek Edward, P., S. Mujahid Mahasin, A. Barr Donald, V. Blair Irene, S. Cohen Meryl, S. Cruz-
Flores, G. Davey-Smith, R. Dennison-Himmelfarb Cheryl, S. Lauer Michael, W. Lockwood Debra, M. 
Rosal and W. Yancy Clyde (2015). "Social Determinants of Risk and Outcomes for Cardiovascular 
Disease." Circulation 132(9): 873-898. 
Heart UK (2019). Triglycerides. https://www.heartuk.org.uk/cholesterol/triglycerides 
Heim, D. and S. MacAskill (2006). Black and minority ethnic health in Greater Glasgow: a comparative 
report on the health and well-being of African & Caribbean, Chinese, Indian and Pakistani people and 
the general population, NHS Greater Glasgow. 
Henry, C. J. (2005). "Basal metabolic rate studies in humans: measurement and development of new 
equations." Public Health Nutr 8(7a): 1133-1152. 
Hermida, R. C., J. J. Crespo, M. Domínguez-Sardiña, A. Otero, A. Moyá, M. T. Ríos, E. Sineiro, M. C. 
Castiñeira, P. A. Callejas, L. Pousa, J. L. Salgado, C. Durán, J. J. Sánchez, J. R. Fernández, A. Mojón, 
D. E. Ayala and H. P. Investigators (2019). "Bedtime hypertension treatment improves cardiovascular 
risk reduction: the Hygia Chronotherapy Trial." European Heart Journal. 
Hernáez, Á., S. Fernández-Castillejo, M. Farràs, Ú. Catalán, I. Subirana, R. Montes, R. Solà, D. Muñoz-
Aguayo, A. Gelabert-Gorgues, Ó. Díaz-Gil, K. Nyyssönen, H. J. Zunft, R. de la Torre, S. Martín-Peláez, 
A. Pedret, A. T. Remaley, M. I. Covas and M. Fitó (2014). "Olive oil polyphenols enhance high-density 
lipoprotein function in humans: a randomized controlled trial." Arterioscler Thromb Vasc Biol 34(9): 2115-
2119. 
Higgins JP and G. S (2008). Assessing Risk of Bias in Included Studies. Cochrane Handbook for 
Systematic Reviews of Interventions. 
Higgins, J. and S. Green, Eds. (2011). Cochrane Handbook for Systematic Reviews of Interventions 
Version 5.1.0 The Cochrane Collaboration, 2011. 
Higgins, J. P. and S. Green (2011). Assessing risk of bias in included studies. Cochrane Handbook for 
Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. J. P. G. Higgins, S, The 
Cochrane Collaboration. 
Higgins, J. P., D. G. Altman, P. C. Gotzsche, P. Juni, D. Moher, A. D. Oxman, J. Savovic, K. F. Schulz, 
L. Weeks and J. A. Sterne (2011). "The Cochrane Collaboration's tool for assessing risk of bias in 
randomised trials." Bmj 343: d5928. 
Hiraoka-Yamamoto, J., K. Ikeda, H. Negishi, M. Mori, A. Hirose, S. Sawada, Y. Onobayashi, K. Kitamori, 
S. Kitano, M. Tashiro, T. Miki and Y. Yamori (2004). "Serum lipid effects of a monounsaturated 
(palmitoleic) fatty acid-rich diet based on macadamia nuts in healthy, young japanese women." Clinical 
and Experimental Pharmacology and Physiology 31(SUPPL.2): S37-S38. 
Hoffman, R. and M. Gerber (2013). "Evaluating and adapting the Mediterranean diet for non-
Mediterranean populations: A critical appraisal." Nutrition Reviews 71(9): 573-584. 
Hohmann, C. D., H. Cramer, A. Michalsen, C. Kessler, N. Steckhan, K. Choi and G. Dobos (2015). 
"Effects of high phenolic olive oil on cardiovascular risk factors: A systematic review and meta-analysis." 
Phytomedicine 22(6): 631-640. 
 
- 222 - 
 
Hollis, B., R. Newson, B. Su, S. Onida, A. Davies, A. Majeed and M. Soljak (2016). "Peripheral arterial 
disease prevalence model for small populations." Risk 3: 4. 
Howard Barbara, V., C. Robbins David, L. Sievers Maurice, T. Lee Elisa, D. Rhoades, B. Devereux 
Richard, D. Cowan Linda, R. S. Gray, K. Welty Thomas, T. Go Oscar and J. Howard Wm (2000). "LDL 
Cholesterol as a Strong Predictor of Coronary Heart Disease in Diabetic Individuals With Insulin 
Resistance and Low LDL." Arteriosclerosis, Thrombosis, and Vascular Biology 20(3): 830-835. 
Hu, F. B., Y. Liu and W. C. Willett (2011). "Preventing chronic diseases by promoting healthy diet and 
lifestyle: public policy implications for China." Obesity Reviews 12(7): 552-559. 
Huber, K., G. Christ, J. Wojta and D. Gulba (2001). "Plasminogen Activator Inhibitor Type-1 in 
Cardiovascular Disease: Status Report 2001." Thrombosis Research 103: S7-S19. 
Huguenin, G. V. B., A. S. B. Moreira, T. D. Siant'Pierre, R. A. Goncalves, G. Rosa, G. M. M. Oliveira, R. 
R. Luiz and E. Tibirica (2015). "Effects of Dietary Supplementation with Brazil Nuts on Microvascular 
Endothelial Function in Hypertensive and Dyslipidemic Patients: A Randomized Crossover Placebo-
Controlled Trial." Microcirculation 22(8): 687-699. 
Huo, R., T. Du, Y. Xu, W. Xu, X. Chen, K. Sun and X. Yu (2015). "Effects of Mediterranean-style diet on 
glycemic control, weight loss and cardiovascular risk factors among type 2 diabetes individuals: a meta-
analysis." Eur J Clin Nutr 69(11): 1200-1208. 
Ibarrola-Jurado, N., M. Bullo, M. Guasch-Ferre, E. Ros, M. A. Martinez-Gonzalez, D. Corella, M. Fiol, J. 
Warnberg, R. Estruch, P. Roman, F. Aros, E. Vinyoles, L. Serra-Majem, X. Pinto, M. I. Covas, J. Basora 
and J. Salas-Salvado (2013). "Cross-sectional assessment of nut consumption and obesity, metabolic 
syndrome and other cardiometabolic risk factors: the PREDIMED study." PLoS One 8(2): e57367. 
Inaba, Y., J. A. Chen and S. R. Bergmann (2010). "Prediction of future cardiovascular outcomes by flow-
mediated vasodilatation of brachial artery: a meta-analysis." The International Journal of Cardiovascular 
Imaging 26(6): 631-640. 
International Nuts & Dried Fruit (2016). Nuts & Fried Fruits - global statistical review. 2015/2016. Spain, 
The International Nut and Dried Fruit Council Foundation (INC). 
Iwamoto, M., K. Imaizumi, M. Sato, Y. Hirooka, K. Sakai, A. Takeshita and M. Kono (2002). "Serum lipid 
profiles in Japanese women and men during consumption of walnuts." European Journal Of Clinical 
Nutrition 56(7): 629-637. 
Jaana, K., V. Hanna, J. Jari and L. Kari (2015). "Cardiovascular disease risk factors in relation to smoking 
behaviour and history: a population-based cohort study." Division of Clinical Epidemiology and Aging 
Research. 
Jadad, A. R., R. A. Moore, D. Carroll, C. Jenkinson, D. J. Reynolds, D. J. Gavaghan and H. J. McQuay 
(1996). "Assessing the quality of reports of randomized clinical trials: is blinding necessary?" Control Clin 
Trials 17(1): 1-12. 
Jager, A., V. W. van Hinsbergh, P. J. Kostense, J. J. Emeis, G. Nijpels, J. M. Dekker, R. J. Heine, L. M. 
Bouter and C. D. Stehouwer (2000). "Increased levels of soluble vascular cell adhesion molecule 1 are 
associated with risk of cardiovascular mortality in type 2 diabetes: the Hoorn study." Diabetes 49(3): 485-
491. 
Jamshed, H., F. A. T. Sultan, R. Iqbal and A. H. Gilani (2015). "Dietary Almonds Increase Serum HDL 
Cholesterol in Coronary Artery Disease Patients in a Randomized Controlled Trial." The Journal Of 
Nutrition 145(10): 2287-2292. 
 
- 223 - 
 
Jarbøl, D. E., P. V. Larsen, D. Gyrd-Hansen, J. Søndergaard, C. Brandt, A. Leppin, B. L. Barfoed and J. 
B. Nielsen (2017). "Determinants of preferences for lifestyle changes versus medication and beliefs in 
ability to maintain lifestyle changes. A population-based survey." Preventive Medicine Reports 6: 66-73. 
Jenkins, D. J. A., C. W. C. Kendall, B. Lamarche, M. S. Banach, K. Srichaikul, E. Vidgen, S. Mitchell, T. 
Parker, S. Nishi, B. Bashyam, R. J. de Souza, C. Ireland, S. C. Pichika, J. Beyene, J. L. Sievenpiper and 
R. G. Josse (2018). "Nuts as a replacement for carbohydrates in the diabetic diet: a reanalysis of a 
randomised controlled trial." Diabetologia 61(8): 1734-1747. 
Jenkins, D. J., Kendall, C. W., Marchie, A., Josse, A. R., Nguyen, T. H., Faulkner, D. A., Lapsley, K. G., 
& Blumberg, J. (2008). Almonds reduce biomarkers of lipid peroxidation in older hyperlipidemic 
subjects. The Journal of nutrition, 138(5), 908–913. https://doi.org/10.1093/jn/138.5.908 
Jiang, Y. R., S. H. Xia, Y. Q. Zhang, J. G. Yu and P. Hu (2013). Trans Fatty acid content of foods in 
China. Your Global Fats and Oils Connection. The American Oil Chemists' Society. 
Jiménez-Gómez, Y., J. López-Miranda, L. M. Blanco-Colio, C. Marín, P. Pérez-Martínez, J. Ruano, J. A. 
Paniagua, F. Rodríguez, J. Egido and F. Pérez-Jiménez (2009). "Olive oil and walnut breakfasts reduce 
the postprandial inflammatory response in mononuclear cells compared with a butter breakfast in healthy 
men." Atherosclerosis 204(2): e70-e76. 
Jimenez-Lopez, C., M. Carpena, C. Lourenço-Lopes, M. Gallardo-Gomez, J. M. Lorenzo, F. J. Barba, 
M. A. Prieto and J. Simal-Gandara (2020). "Bioactive Compounds and Quality of Extra Virgin Olive Oil." 
Foods 9(8): 1014. 
Jin, K., D. Ding, J. Gullick, F. Koo and L. Neubeck (2015). "A Chinese Immigrant Paradox? Low Coronary 
Heart Disease Incidence but Higher Short-Term Mortality in Western-Dwelling Chinese Immigrants: A 
Systematic Review and Meta-Analysis." J Am Heart Assoc 4(12). 
Jung, H., C. Y. O. Chen, J. B. Blumberg and H. K. Kwak (2018). "The effect of almonds on vitamin E 
status and cardiovascular risk factors in Korean adults: a randomized clinical trial." European Journal of 
Nutrition 57(6): 2069-2079. 
Jung, R. G., P. Motazedian, F. D. Ramirez, T. Simard, P. Di Santo, S. Visintini, M. A. Faraz, A. Labinaz, 
Y. Jung and B. Hibbert (2018). "Association between plasminogen activator inhibitor-1 and 
cardiovascular events: a systematic review and meta-analysis." Thrombosis journal 16: 12-12. 
Karlsson, S., Nånberg, E., Fjaeraa, C., & Wijkander, J. (2010). Ellagic acid inhibits lipopolysaccharide-
induced expression of enzymes involved in the synthesis of prostaglandin E2 in human monocytes. The 
British journal of nutrition, 103(8), 1102–1109. https://doi.org/10.1017/S0007114509992935 
Kastorini, C. M., H. J. Milionis, K. Esposito, D. Giugliano, J. A. Goudevenos and D. B. Panagiotakos 
(2011). "The effect of Mediterranean diet on metabolic syndrome and its components: a meta-analysis 
of 50 studies and 534,906 individuals." J Am Coll Cardiol 57(11): 1299-1313. 
Katsarou, A. I., A. C. Kaliora, A. Papalois, A. Chiou, N. Kalogeropoulos, G. Agrogiannis and N. K. 
Andrikopoulos (2015). "Serum lipid profile and inflammatory markers in the aorta of cholesterol-fed rats 
supplemented with extra virgin olive oil, sunflower oils and oil-products." Int J Food Sci Nutr 66(7): 766-
773. 
Kay, C. D., P. M. Kris-Etherton and S. G. West (2006). "Effects of antioxidant-rich foods on vascular 
reactivity: Review of the clinical evidence." Current Atherosclerosis Reports 8(6): 510. 
Kearney, J. M. and S. McElhone (2007). "Perceived barriers in trying to eat healthier – results of a pan-
EU consumer attitudinal survey." British Journal of Nutrition 81(S1): S133-S137. 
 
- 224 - 
 
Kelishadi, R. and P. Poursafa (2014). "A Review on the Genetic, Environmental, and Lifestyle Aspects 
of the Early-Life Origins of Cardiovascular Disease." Current Problems in Pediatric and Adolescent 
Health Care 44(3): 54-72. 
Kelly R. B. (2010). Diet and exercise in the management of hyperlipidemia. American family 
physician, 81(9), 1097–1102. 
Khaw, K. T., S. J. Sharp, L. Finikarides, I. Afzal, M. Lentjes, R. Luben and N. G. Forouhi (2018). 
"Randomised trial of coconut oil, olive oil or butter on blood lipids and other cardiovascular risk factors 
in healthy men and women." BMJ Open 8(3): e020167. 
Khoramdad, M., A. Vahedian-azimi, L. Karimi, F. Rahimi-Bashar, H. Amini and A. Sahebkar (2020). 
"Association between passive smoking and cardiovascular disease: A systematic review and meta-
analysis." IUBMB Life 72(4): 677-686. 
Khandouzi N, Zahedmehr A, Nasrollahzadeh J. Effect of polyphenol-rich extra-virgin olive oil on lipid 
profile and inflammatory biomarkers in patients undergoing coronary angiography: a randomised, 
controlled, clinical trial. Int J Food Sci Nutr. 2021 Jun;72(4):548-558. doi: 
10.1080/09637486.2020.1841123. Epub 2020 Oct 29. PMID: 33121297. 
Kiechl, S., G. Paré, M. Barbalic, L. Qi, J. Dupuis, A. Dehghan, C. Bis Joshua, C. Laxton Ross, Q. Xiao, 
E. Bonora, J. Willeit, Q. Xu, C. M. Witteman Jacqueline, D. Chasman, P. Tracy Russell, M. Ballantyne 
Christie, M. Ridker Paul, J. Benjamin Emelia and S. Ye (2011). "Association of Variation at the ABO 
Locus With Circulating Levels of Soluble Intercellular Adhesion Molecule-1, Soluble P-selectin, and 
Soluble E-selectin." Circulation: Cardiovascular Genetics 4(6): 681-686. 
Kilic, I. D., G. Findikoglu, Y. I. Alihanoglu, B. S. Yildiz, S. Uslu, S. Rota and H. Evrengul (2015). 
"Circulating adhesion molecules and arterial stiffness." Cardiovascular journal of Africa 26(1): 21-24. 
Kocyigit, A., A. A. Koylu and H. Keles (2006). "Effects of pistachio nuts consumption on plasma lipid 
profile and oxidative status in healthy volunteers." Nutrition, Metabolism, And Cardiovascular Diseases: 
NMCD 16(3): 202-209. 
Kollias, A., Kyriakoulis, K. G., Stambolliu, E., Ntineri, A., Anagnostopoulos, I., & Stergiou, G. S. (2020). 
Seasonal blood pressure variation assessed by different measurement methods: systematic review and 
meta-analysis. Journal of hypertension, 38(5), 791–798. 
https://doi.org/10.1097/HJH.0000000000002355 
Kontogianni, M. D., A. Vlassopoulos, A. Gatzieva, A.-E. Farmaki, S. Katsiougiannis, D. B. Panagiotakos, 
N. Kalogeropoulos and F. N. Skopouli (2013). "Flaxseed oil does not affect inflammatory markers and 
lipid profile compared to olive oil, in young, healthy, normal weight adults." Metabolism: Clinical And 
Experimental 62(5): 686-693. 
Kreatsoulas, C. and S. S. Anand (2010). "The impact of social determinants on cardiovascular disease." 
The Canadian journal of cardiology 26 Suppl C(Suppl C): 8C-13C. 
Kris-Etherton, P. M. and J. Dietschy (1997). "Design criteria for studies examining individual fatty acid 
effects on cardiovascular disease risk factors: human and animal studies." Am J Clin Nutr 65(5 Suppl): 
1590s-1596s. 
Kris‐Etherton, P. M., K. S. Petersen, G. Velarde, N. D. Barnard, M. Miller, E. Ros, J. H. O'Keefe, K. 
Williams, L. V. Horn, M. Na, C. Shay, P. Douglass, D. L. Katz and A. M. Freeman (2020). "Barriers, 
Opportunities, and Challenges in Addressing Disparities in Diet 2010; Related Cardiovascular Disease 
in the United States." Journal of the American Heart Association 9(7): e014433. 
 
- 225 - 
 
Kris-Etherton, P. M., S. Yu-Poth, J. Sabate, H. E. Ratcliffe, G. Zhao and T. D. Etherton (1999). "Nuts and 
their bioactive constituents: effects on serum lipids and other factors that affect disease risk." Am J Clin 
Nutr 70(3 Suppl): 504s-511s. 
Kris-Etherton, P. M., T. A. Pearson, Y. Wan, R. L. Hargrove, K. Moriarty, V. Fishell and T. D. Etherton 
(1999). "High-monounsaturated fatty acid diets lower both plasma cholesterol and triacylglycerol 
concentrations." The American Journal Of Clinical Nutrition 70(6): 1009-1015. 
Krishnamoorthy, S., C. W. Khoo, H. S. Lim, D. A. Lane, P. Pignatelli, S. Basili, F. Violi and G. Y. H. Lip 
(2013). "Prognostic role of plasma von Willebrand factor and soluble E-selectin levels for future 
cardiovascular events in a ‘real-world’ community cohort of patients with atrial fibrillation." European 
Journal of Clinical Investigation 43(10): 1032-1038. 
Kumar, S. (2017). "Cardiovascular Disease and Its Determinants: Public Health Issue." Journal of 
Clinical Medicine and Therapeutics. 
Kunutsor, S. K., S. J. L. Bakker and R. P. F. Dullaart (2017). "Soluble Vascular Cell Adhesion Molecules 
May be Protective of Future Cardiovascular Disease Risk: Findings from the PREVEND Prospective 
Cohort Study." Journal of Atherosclerosis and Thrombosis advpub. 
Kuriyan, R. (2018). "Body composition techniques." The Indian journal of medical research 148(5): 648-
658. 
Kurlandsky, S. B. and K. S. Stote (2006). "Cardioprotective effects of chocolate and almond consumption 
in healthy women." Nutrition Research 26(10): 509-516. 
Kwan, M. W.-M., M. C.-S. Wong, H. H.-X. Wang, K. Q.-L. Liu, C. L.-S. Lee, B. P.-Y. Yan, C.-M. Yu and 
S. M. Griffiths (2013). "Compliance with the Dietary Approaches to Stop Hypertension (DASH) Diet: A 
Systematic Review." PLOS ONE 8(10): e78412. 
Kyçyk, O., M. Aguilera, J. Gaforio, A. Jiménez Marquez and G. Beltrán (2016). "Sterol composition of 
virgin olive oil of forty three olive cultivars from the World Olive Germplasm Bank Collection." Journal of 
the science of food and agriculture 96. 
Lăcătușu, C.-M., E.-D. Grigorescu, M. Floria, A. Onofriescu and B.-M. Mihai (2019). "The Mediterranean 
Diet: From an Environment-Driven Food Culture to an Emerging Medical Prescription." International 
journal of environmental research and public health 16(6): 942. 
Lachat C, Nago E, Verstraeten R, Roberfroid D, Van Camp J, Kolsteren P. Eating out of home and its 
association with dietary intake: a systematic review of the evidence. Obes Rev. 2011 Nov 23. 
Lam, F. W., K. V. Vijayan and R. E. Rumbaut (2015). "Platelets and Their Interactions with Other Immune 
Cells." Comprehensive Physiology 5(3): 1265-1280. 
Lam, M. C. L. and J. Adams (2017). "Association between home food preparation skills and behaviour, 
and consumption of ultra-processed foods: Cross-sectional analysis of the UK National Diet and nutrition 
survey (2008-2009)." Int J Behav Nutr Phys Act 14(1): 68. 
Landman, J. and J. K. Cruickshank (2001). "A review of ethnicity, health and nutrition-related diseases 
in relation to migration in the United Kingdom." Public Health Nutrition 4(2b): 647-657. 
Lara, J. J., J. A. Scott and M. E. Lean (2004). "Intentional mis-reporting of food consumption and its 
relationship with body mass index and psychological scores in women." J Hum Nutr Diet 17(3): 209-218. 
Lara, J., E. Turbett, A. McKevic, K. Rudgard, H. Hearth and J. Mathers (2015). "The Mediterranean diet 
among British older adults: Its understanding, acceptability and the feasibility of a randomised brief 
intervention with two levels of dietary advice." Maturitas 82. 
 
- 226 - 
 
Lara, J., L. A. McCrum and J. C. Mathers (2014). "Association of Mediterranean diet and other health 
behaviours with barriers to healthy eating and perceived health among British adults of retirement age." 
Maturitas 79(3): 292-298. 
Lavie Carl, J., C. Ozemek, S. Carbone, T. Katzmarzyk Peter and N. Blair Steven (2019). "Sedentary 
Behavior, Exercise, and Cardiovascular Health." Circulation Research 124(5): 799-815. 
Lear, S. A., W. Hu, S. Rangarajan, D. Gasevic, D. Leong, R. Iqbal, A. Casanova, S. Swaminathan, R. M. 
Anjana, R. Kumar, A. Rosengren, L. Wei, W. Yang, W. Chuangshi, L. Huaxing, S. Nair, R. Diaz, H. 
Swidon, R. Gupta, N. Mohammadifard, P. Lopez-Jaramillo, A. Oguz, K. Zatonska, P. Seron, A. Avezum, 
P. Poirier, K. Teo and S. Yusuf (2017). "The effect of physical activity on mortality and cardiovascular 
disease in 130 000 people from 17 high-income, middle-income, and low-income countries: the PURE 
study." Lancet 390(10113): 2643-2654. 
Lee, H., S. S. Kim, K. S. You, W. Park, J. H. Yang, M. Kim and L. L. Hayman (2014). "Asian flushing: 
genetic and sociocultural factors of alcoholism among East asians." Gastroenterol Nurs 37(5): 327-336. 
Lee, J. S., P.-Y. Chang, Y. Zhang, J. R. Kizer, L. G. Best and B. V. Howard (2017). "Triglyceride and 
HDL-C Dyslipidemia and Risks of Coronary Heart Disease and Ischemic Stroke by Glycemic 
Dysregulation Status: The Strong Heart Study." Diabetes Care 40(4): 529-537. 
Lee, W.-J., L.-N. Peng, S.-T. Chiou and L.-K. Chen (2016). "Relative Handgrip Strength Is a Simple 
Indicator of Cardiometabolic Risk among Middle-Aged and Older People: A Nationwide Population-
Based Study in Taiwan." PLOS ONE 11(8): e0160876. 
Lee, Y. J., C. E. Berryman, S. G. West, C. Y. O. Chen, J. B. Blumberg, K. G. Lapsley, A. G. Preston, J. 
A. Fleming and P. M. Kris-Etherton (2017). "Effects of Dark Chocolate and Almonds on Cardiovascular 
Risk Factors in Overweight and Obese Individuals: A Randomized Controlled-Feeding Trial." Journal of 
the American Heart Association 6(12). 
Lee, Y. J., G. E. Nam, J. A. Seo, T. Yoon, I. Seo, J. H. Lee, D. Im, K. N. Bahn, S. A. Jeong, T. S. Kang, 
J. H. Ahn, D. H. Kim and N. H. Kim (2014). "Nut consumption has favorable effects on lipid profiles of 
Korean women with metabolic syndrome." Nutrition Research 34(9): 814-820. 
Leu, H.-B., C.-M. Chung, J.-W. Chen and W.-H. Pan (2019). "The Mediterranean diet reduces the genetic 
risk of chromosome for myocardial infarction in an Asian population community cohort." Scientific 
Reports 9(1): 18405. 
Leung, G. and S. Stanner (2011). "Diets of minority ethnic groups in the UK: influence on chronic disease 
risk and implications for prevention." Nutrition Bulletin 36(2): 161-198. 
Lewington, S. and R. Clarke (2005). "Combined Effects of Systolic Blood Pressure and Total Cholesterol 
on Cardiovascular Disease Risk." Circulation 112(22): 3373-3374. 
Lewington, S., G. Whitlock, R. Clarke, P. Sherliker, J. Emberson, J. Halsey, N. Qizilbash, R. Peto and R. 
Collins (2007). "Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-
analysis of individual data from 61 prospective studies with 55,000 vascular deaths." Lancet 370(9602): 
1829-1839. 
Levine ME, Lu AT, Quach A, Chen BH, Assimes TL, Bandinelli S, Hou L, Baccarelli AA, Stewart JD, Li 
Y, Whitsel EA, Wilson JG, Reiner AP, Aviv A, Lohman K, Liu Y, Ferrucci L, Horvath S. An epigenetic 
biomarker of aging for lifespan and healthspan. Aging (Albany NY). 2018 Apr 18;10(4):573-591. doi: 
10.18632/aging.101414. PMID: 29676998; PMCID: PMC5940111. 
Li, D., J. Lv, F. Liu, P. Liu, X. Yang, Y. Feng, G. Chen and M. Hao (2015). "Hypertension burden and 
control in mainland China: Analysis of nationwide data 2003-2012." Int J Cardiol 184: 637-644. 
 
- 227 - 
 
Li, H. and J. Ge (2015). "Cardiovascular diseases in China: Current status and future perspectives." 
International journal of cardiology. Heart & vasculature 6: 25-31. 
Li, H., K. Sun, R. Zhao, J. Hu, Z. Hao, F. Wang, Y. Lu, F. Liu and Y. Zhang (2017) "Inflammatory 
biomarkers of coronary heart disease." Frontiers in bioscience (Landmark edition) 22, 504-515 DOI: 
10.2741/4498. 
Li, S. C., Y. H. Liu, J. F. Liu, W. H. Chang, C. M. Chen and C. Y. Chen (2011). "Almond consumption 
improved glycemic control and lipid profiles in patients with type 2 diabetes mellitus." Metabolism 60(4): 
474-479. 
Li, Z., Y. Bai, X. Guo, L. Zheng, Y. Sun and A. M. Roselle (2016). "Alcohol consumption and 
cardiovascular diseases in rural China." International Journal of Cardiology 215: 257-262. 
Liberati, A., D. G. Altman, J. Tetzlaff, C. Mulrow, P. C. Gøtzsche, J. P. A. Ioannidis, M. Clarke, P. J. 
Devereaux, J. Kleijnen and D. Moher (2009). "The PRISMA statement for reporting systematic reviews 
and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration." BMJ 
339. 
Liberato, S. C., L. Maple-Brown, J. Bressan and A. P. Hills (2013). "The relationships between body 
composition and cardiovascular risk factors in young Australian men." Nutrition journal 12: 108-108. 
Lichtenstein, A. H., L. M. Ausman, W. Carrasco, J. L. Jenner, L. J. Gualtieri, B. R. Goldin, J. M. Ordovas 
and E. J. Schaefer (1993). "Effects of canola, corn, and olive oils on fasting and postprandial plasma 
lipoproteins in humans as part of a National Cholesterol Education Program Step 2 diet." Arteriosclerosis 
And Thrombosis: A Journal Of Vascular Biology 13(10): 1533-1542. 
Lionakis, N., D. Mendrinos, E. Sanidas, G. Favatas and M. Georgopoulou (2012). "Hypertension in the 
elderly." World journal of cardiology 4(5): 135-147. 
Liu, J.-F., Y.-H. Liu, C.-M. Chen, W.-H. Chang and C. Y. O. Chen (2013). "The effect of almonds on 
inflammation and oxidative stress in Chinese patients with type 2 diabetes mellitus: a randomized 
crossover controlled feeding trial." European Journal Of Nutrition 52(3): 927-935. 
Liu, Q., F. C. Liu, K. Y. Huang and J. X. Li (2020). "Beneficial effects of moderate to vigorous physical 
activity on cardiovascular disease among Chinese adults." Jonrnal of Geriatric Cardiology 17: 85–95. 
Liu, W., Y. Wang, J. Zheng, D. Song, S. Zheng, L. Ren, Y. Wang, Y. Yao, Y. Wang, Y. Liu, R. Bai, J. 
Dong and T. Liu (2019). "Syndecan-1 as an independent risk factor for the incidence of adverse 
cardiovascular events in patients having stage C and D heart failure with non-ischemic dilated 
cardiomyopathy." Clin Chim Acta 490: 63-68. 
Liyanage, T., T. Ninomiya, A. Wang, B. Neal, M. Jun, M. G. Wong, M. Jardine, G. S. Hillis and V. Perkovic 
(2016). "Effects of the Mediterranean Diet on Cardiovascular Outcomes-A Systematic Review and Meta-
Analysis." PLoS One 11(8): e0159252. 
Logan, K. J., J. V. Woodside and I. S. Young (2010). "Adoption and maintenance of a Mediterranean 
diet in patients with coronary heart disease from a Northern European population: a pilot randomised 
trial of different methods of delivering Mediterranean diet advice." J Hum Nutr Diet. 23(1): 30-37. 
Lombardo, L., F. Grasso, F. Lanciano, S. Loria and E. Monetti (2018). Chapter 2 - Broad-Spectrum 
Health Protection of Extra Virgin Olive Oil Compounds. Studies in Natural Products Chemistry. R. Atta 
ur, Elsevier. 57: 41-77. 
Lopez-Miranda, J., F. Perez-Jimenez, E. Ros, R. De Caterina, L. Badimon, M. I. Covas, E. Escrich, J. M. 
Ordovas, F. Soriguer, R. Abia, C. A. de la Lastra, M. Battino, D. Corella, J. Chamorro-Quiros, J. Delgado-
Lista, D. Giugliano, K. Esposito, R. Estruch, J. M. Fernandez-Real, J. J. Gaforio, C. La Vecchia, D. Lairon, 
F. Lopez-Segura, P. Mata, J. A. Menendez, F. J. Muriana, J. Osada, D. B. Panagiotakos, J. A. Paniagua, 
 
- 228 - 
 
P. Perez-Martinez, J. Perona, M. A. Peinado, M. Pineda-Priego, H. E. Poulsen, J. L. Quiles, M. C. 
Ramirez-Tortosa, J. Ruano, L. Serra-Majem, R. Sola, M. Solanas, V. Solfrizzi, R. de la Torre-Fornell, A. 
Trichopoulou, M. Uceda, J. M. Villalba-Montoro, J. R. Villar-Ortiz, F. Visioli and N. Yiannakouris (2010). 
"Olive oil and health: summary of the II international conference on olive oil and health consensus report, 
Jaen and Cordoba (Spain) 2008." Nutr Metab Cardiovasc Dis 20(4): 284-294. 
Lopez-Uriarte, P., R. Nogues, G. Saez, M. Bullo, M. Romeu, L. Masana, C. Tormos, P. Casas-Agustench 
and J. Salas-Salvado (2010). "Effect of nut consumption on oxidative stress and the endothelial function 
in metabolic syndrome." Clinical Nutrition 29(3): 373-380. 
Lokko, P., Lartey, A., Armar-Klemesu, M., & Mattes, R. D. (2007). Regular peanut consumption improves 
plasma lipid levels in healthy Ghanaians. International journal of food sciences and nutrition, 58(3), 190–
200. https://doi.org/10.1080/09637480701198067 
Lou, H., Yuan, H., Ma, B., Ren, D., Ji, M., & Oka, S. (2004). Polyphenols from peanut skins and their 
free radical-scavenging effects. Phytochemistry, 65(16), 2391–2399. 
https://doi.org/10.1016/j.phytochem.2004.06.026 
Lu, X., L. Wang, S. Chen, L. He, X. Yang, Y. Shi, J. Cheng, L. Zhang, C. C. Gu, J. Huang, T. Wu, Y. Ma, 
J. Li, J. Cao, J. Chen, D. Ge, Z. Fan, Y. Li, L. Zhao, H. Li, X. Zhou, L. Chen, D. Liu, J. Chen, X. Duan, Y. 
Hao, L. Wang, F. Lu, Z. Liu, C. Yao, C. Shen, X. Pu, L. Yu, X. Fang, L. Xu, J. Mu, X. Wu, R. Zheng, N. 
Wu, Q. Zhao, Y. Li, X. Liu, M. Wang, D. Yu, D. Hu, X. Ji, D. Guo, D. Sun, Q. Wang, Y. Yang, F. Liu, Q. 
Mao, X. Liang, J. Ji, P. Chen, X. Mo, D. Li, G. Chai, Y. Tang, X. Li, Z. Du, X. Liu, C. Dou, Z. Yang, Q. 
Meng, D. Wang, R. Wang, J. Yang, H. Schunkert, N. J. Samani, S. Kathiresan, M. P. Reilly, J. Erdmann, 
X. Peng, X. Wu, D. Liu, Y. Yang, R. Chen, B. Qiang, D. Gu, A. D. G.-W. R. The Coronary and C. Meta-
Analysis (2012). "Genome-wide association study in Han Chinese identifies four new susceptibility loci 
for coronary artery disease." Nature Genetics 44(8): 890-894. 
Luo, C., Y. Zhang, Y. Ding, Z. Shan, S. Chen, M. Yu, F. B. Hu and L. Liu (2014). "Nut consumption and 
risk of type 2 diabetes, cardiovascular disease, and all-cause mortality: a systematic review and meta-
analysis." Am J Clin Nutr 100(1): 256-269. 
Lusis A. J. (2000). Atherosclerosis. Nature, 407(6801), 233–241. https://doi.org/10.1038/35025203 
Lyon, C. J. and W. A. Hsueh (2003). "Effect of plasminogen activator inhibitor-1 in diabetes mellitus and 
cardiovascular disease." The American Journal of Medicine 115(8): 62-68. 
Ma, Y., V. Y. Njike, J. Millet, S. Dutta, K. Doughty, J. A. Treu and D. L. Katz (2010). "Effects of walnut 
consumption on endothelial function in type 2 diabetic subjects: a randomized controlled crossover trial." 
Diabetes Care 33(2): 227-232. 
Ma, G, S (2015). “Food, eating behavior, and culture in Chinese society”. Journal of Ethnic Foods. 2(4): 
195-199.  
Maares, M., & Haase, H. (2020). A Guide to Human Zinc Absorption: General Overview and Recent 
Advances of In Vitro Intestinal Models. Nutrients, 12(3), 762. https://doi.org/10.3390/nu12030762 
Macdiarmid, J., J. Loe, J. Kyle and G. McNeill (2013). "It was an education in portion size". Experience 
of eating a healthy diet and barriers to long term dietary change. 
Mackenbach, J. P., A. E. Cavelaars, A. E. Kunst and F. Groenhof (2000). "Socioeconomic inequalities 
in cardiovascular disease mortality; an international study." Eur Heart J 21(14): 1141-1151. 
Madden, A. M. and S. Smith (2016). "Body composition and morphological assessment of nutritional 
status in adults: a review of anthropometric variables." Journal of Human Nutrition and Dietetics 29(1): 
7-25. 
 
- 229 - 
 
Mah, E., J. A. Schulz, V. N. Kaden, A. L. Lawless, J. Rotor, L. B. Mantilla and D. J. Liska (2017). "Cashew 
consumption reduces total and LDL cholesterol: a randomized, crossover, controlled-feeding trial." The 
American Journal Of Clinical Nutrition 105(5): 1070-1078. 
Mahdy Ali, K., A. Wonnerth, K. Huber and J. Wojta (2012). "Cardiovascular disease risk reduction by 
raising HDL cholesterol--current therapies and future opportunities." British journal of pharmacology 
167(6): 1177-1194. 
Maki, K. C., A. L. Lawless, K. M. Kelley, V. N. Kaden, C. J. Geiger and M. R. Dicklin (2015). "Corn oil 
improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and 
women with elevated cholesterol: results from a randomized controlled feeding trial." Journal Of Clinical 
Lipidology 9(1): 49-57. 
Marcelino, G., P. A. Hiane, K. d. C. Freitas, L. F. Santana, A. Pott, J. R. Donadon and R. d. C. A. 
Guimarães (2019). "Effects of Olive Oil and Its Minor Components on Cardiovascular Diseases, 
Inflammation, and Gut Microbiota." Nutrients 11(8): 1826. 
Marsman, D., D. W. Belsky, D. Gregori, M. A. Johnson, T. Low Dog, S. Meydani, S. Pigat, R. Sadana, 
A. Shao and J. C. Griffiths (2018). "Healthy ageing: the natural consequences of good nutrition-a 
conference report." European journal of nutrition 57(Suppl 2): 15-34. 
Marta G; Gang L; Yanping L; Laura S; Joann E M; Jordi S; Miguel A M; Meir J S; Walter W; Qi S; Frank 
B Hu (2020) Olive Oil Consumption and Risk of Cardiovascular Disease; 
https://doi.org/10.1161/circ.141.suppl_1.P509Circulation. 2020; 141:  
Martínez-González, M. A., Gea, A., & Ruiz-Canela, M. (2019). The Mediterranean Diet and 
Cardiovascular Health. Circulation research, 124(5), 779–798. 
https://doi.org/10.1161/CIRCRESAHA.118.313348 
Martínez-González, M. A., A. García-Arellano, E. Toledo, J. Salas-Salvadó, P. Buil-Cosiales, D. Corella, 
M. I. Covas, H. Schröder, F. Arós, E. Gómez-Gracia, M. Fiol, V. Ruiz-Gutiérrez, J. Lapetra, R. M. 
Lamuela-Raventos, L. Serra-Majem, X. Pintó, M. A. Muñoz, J. Wärnberg, E. Ros, R. Estruch and P. S. 
I. for the (2012). "A 14-Item Mediterranean Diet Assessment Tool and Obesity Indexes among High-Risk 
Subjects: The PREDIMED Trial." PLoS ONE 7(8): e43134. 
Martinez-Gonzalez, M. A., L. J. Dominguez and M. Delgado-Rodriguez (2014). "Olive oil consumption 
and risk of CHD and/or stroke: a meta-analysis of case-control, cohort and intervention studies." Br J 
Nutr 112(2): 248-259. 
Martín-Peláez, S., O. Castañer, V. Konstantinidou, I. Subirana, D. Muñoz-Aguayo, G. Blanchart, S. 
Gaixas, R. de la Torre, M. Farré, G. T. Sáez, K. Nyyssönen, H. J. Zunft, M. I. Covas and M. Fitó (2017). 
"Effect of olive oil phenolic compounds on the expression of blood pressure-related genes in healthy 
individuals." Eur J Nutr 56(2): 663-670. 
Maria Ida M., Giuseppe B., Miriam L., Paola C., Katherine E., (2020) "Mediterranean Diet and COVID-
19: Hypothesizing Potential Benefits in People With Diabetes". Front. Endocrinol. 11:574315. doi: 
10.3389/fendo.2020.574315 
Massaro, M., E. Scoditti, M. A. Carluccio, N. Calabriso, G. Santarpino, T. Verri and R. De Caterina (2020). 
"Effects of Olive Oil on Blood Pressure: Epidemiological, Clinical, and Mechanistic Evidence." Nutrients 
12(6): 1548. 
Matsuzawa, Y., T.-G. Kwon, R. J. Lennon, L. O. Lerman and A. Lerman (2015) "Prognostic Value of 
Flow-Mediated Vasodilation in Brachial Artery and Fingertip Artery for Cardiovascular Events: A 
Systematic Review and Meta-Analysis." Journal of the American Heart Association 4 DOI: 
10.1161/jaha.115.002270. 
 
- 230 - 
 
Maud, N., Peter, L., Zock J., Roodenburg, C., Martijn, B (2002) “Olive Oil Phenols Are Absorbed in 
Humans” The Journal of Nutrition, 132(3): 409-417. https://doi.org/10.1093/jn/132.3.409 
Mazidi, M., P. Rezaie, G. A. Ferns and H. K. Gao (2016). "Impact of different types of tree nut, peanut, 
and soy nut consumption on serum C-reactive protein (CRP): A systematic review and meta-analysis of 
randomized controlled clinical trials." Medicine (Baltimore) 95(44): e5165. 
Mazzocchi, A., L. Leone, C. Agostoni and I. Pali-Schöll (2019). "The Secrets of the Mediterranean Diet. 
Does [Only] Olive Oil Matter?" Nutrients 11(12). 
McGrath, R. P., W. J. Kraemer, S. A. Snih and M. D. Peterson (2018). "Handgrip Strength and Health in 
Aging Adults." Sports Medicine 48(9): 1993-2000. 
McKay, D., M. Eliasziw, C. Chen and J. Blumberg (2018). "A Pecan-Rich Diet Improves Cardiometabolic 
Risk Factors in Overweight and Obese Adults: A Randomized Controlled Trial." Nutrients 10(3): 339. 
McPhee, J. S., D. P. French, D. Jackson, J. Nazroo, N. Pendleton and H. Degens (2016). "Physical 
activity in older age: perspectives for healthy ageing and frailty." Biogerontology 17(3): 567-580. 
Meng, Y., H. Wu, Y. Yang, H. Du, Y. Xia, X. Guo, X. Liu, C. Li and K. Niu (2015). "Relationship of anabolic 
and catabolic biomarkers with muscle strength and physical performance in older adults: a population-
based cross-sectional study." BMC Musculoskeletal Disorders 16: 202. 
Mente, A., L. Koning, H. S. Shannon and S. S. Anand (2009). "A systematic review of the evidence 
supporting a causal link between dietary factors and coronary heart disease." Arch Intern Med 13(7): 
659-669. 
Mercanligil, S. M., Arslan, P., Alasalvar, C., Okut, E., Akgül, E., Pinar, A., Geyik, P. O., Tokgözoğlu, L., 
& Shahidi, F. (2007). Effects of hazelnut-enriched diet on plasma cholesterol and lipoprotein profiles in 
hypercholesterolemic adult men. European journal of clinical nutrition, 61(2), 212–220. 
https://doi.org/10.1038/sj.ejcn.1602518 
Mertens, E., O. Markey, J. M. Geleijnse, D. I. Givens and J. A. Lovegrove (2017). "Dietary Patterns in 
Relation to Cardiovascular Disease Incidence and Risk Markers in a Middle-Aged British Male 
Population: Data from the Caerphilly Prospective Study." Nutrients 9(1): 75. 
Miftode, R.-S., I.-L. Şerban, A.-S. Timpau, I.-L. Miftode, A. Ion, A.-M. Buburuz, A.-D. Costache and I.-I. 
Costache (2019). "Syndecan-1: A Review on Its Role in Heart Failure and Chronic Liver Disease Patients’ 
Assessment." Cardiology Research and Practice 2019: 4750580. 
Millett, E. R. C., S. A. E. Peters and M. Woodward (2018). "Sex differences in risk factors for myocardial 
infarction: cohort study of UK Biobank participants." BMJ 363: k4247. 
Mirmiran, P., Esmaillzadeh, A., & Azizi, F. (2006). Under-reporting of energy intake affects estimates of 
nutrient intakes. Asia Pacific journal of clinical nutrition, 15(4), 459–464. 
Miró-Casas, E., Farré Albaladejo, M., Covas, M. I., Rodriguez, J. O., Menoyo Colomer, E., Lamuela 
Raventós, R. M., & de la Torre, R. (2001). Capillary gas chromatography-mass spectrometry quantitative 
determination of hydroxytyrosol and tyrosol in human urine after olive oil intake. Analytical biochemistry, 
294(1), 63–72. https://doi.org/10.1006/abio.2001.5160 
Mohamedou, M. M. O., A. Tacha, M. E. Messal, M. S. E. Kebbaj, A. Chraibi and A. Adlouni (2012). "The 
consumption of argan oil induces a lipid-lowering effect in dyslipidemic patients." Mediterranean Journal 
of Nutrition and Metabolism 5(2): 143-147. 
Mohan, V., R. Gayathri, L. M. Jaacks, N. Lakshmipriya, R. M. Anjana, D. Spiegelman, R. G. Jeevan, K. 
K. Balasubramaniam, S. Shobana, M. Jayanthan, V. Gopinath, S. Divya, V. Kavitha, P. Vijayalakshmi, 
M. R. Bai R, R. Unnikrishnan, V. Sudha, K. Krishnaswamy, J. Salas-Salvadó and W. C. Willett (2018). 
"Cashew Nut Consumption Increases HDL Cholesterol and Reduces Systolic Blood Pressure in Asian 
 
- 231 - 
 
Indians with Type 2 Diabetes: A 12-Week Randomized Controlled Trial." The Journal of Nutrition 148(1): 
63-69. 
Moher, D., A. Liberati, J. Tetzlaff, D. G. Altman and P. G. The (2009). "Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses: The PRISMA Statement." PLOS Medicine 6(7): e1000097. 
Moher, D., B. Pham, A. Jones, D. J. Cook, A. R. Jadad, M. Moher, P. Tugwell and T. P. Klassen (1998). 
"Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-
analyses?" The Lancet 352(9128): 609-613. 
Montori, V. M. and G. H. Guyatt (2001). "Intention-to-treat principle." Canadian Medical Association 
Journal 165(10): 1339. 
Mooney, K. M. and M. T. Mc Auley (2016). "Cardiovascular disease and healthy ageing." 
Moore, S. E., C. T. McEvoy, L. Prior, J. Lawton, C. C. Patterson, F. Kee, M. Cupples, I. S. Young, K. 
Appleton, M. C. McKinley and J. V. Woodside (2018). "Barriers to adopting a Mediterranean diet in 
Northern European adults at high risk of developing cardiovascular disease." Journal of Human Nutrition 
and Dietetics 31(4): 451-462. 
Moreira Alves, R. D., A. P. Boroni Moreira, V. S. Macedo, J. Bressan, R. de Cassia Goncalves Alfenas, 
R. Mattes and N. M. Brunoro Costa (2014). "High-oleic peanuts: new perspective to attenuate glucose 
homeostasis disruption and inflammation related obesity." Obesity (Silver Spring) 22(9): 1981-1988. 
Moreno-Luna, R., R. Muñoz-Hernandez, M. L. Miranda, A. F. Costa, L. Jimenez-Jimenez, A. J. Vallejo-
Vaz, F. J. G. Muriana, J. Villar and P. Stiefel (2012). "Olive Oil Polyphenols Decrease Blood Pressure 
and Improve Endothelial Function in Young Women with Mild Hypertension." American Journal of 
Hypertension 25(12): 1299-1304. 
Mosca, L., E. Barrett-Connor and N. K. Wenger (2011). "Sex/Gender Differences in Cardiovascular 
Disease Prevention." Circulation 124(19): 2145-2154. 
Mozaffarian, D. (2016). "Dietary and Policy Priorities for Cardiovascular Disease, Diabetes, and Obesity: 
A Comprehensive Review." Circulation 133(2): 187-225. 
Mozaffarian, D. and J. H. Y. Wu (2018). "Flavonoids, Dairy Foods, and Cardiovascular and Metabolic 
Health: A Review of Emerging Biologic Pathways." Circ Res 122(2): 369-384. 
Muntner, P., D. F. Gu and R. P. Wildman (2011). "Prevalence of Physical Activity Among Chinese Adults: 
Results From the International Collaborative Study of Cardiovascular Disease in Asia." American Public 
Health Association. 
Murman, D. L. (2015). "The Impact of Age on Cognition." Seminars in hearing 36(3): 111-121. 
Murphy, K. J. and N. Parletta (2018). "Implementing a Mediterranean-Style Diet Outside the 
Mediterranean Region." Curr Atheroscler Rep 20(6): 28. 
Murphy, M., W. Robertson and O. Oyebode (2017). "Obesity in International Migrant Populations." 
Current obesity reports 6(3): 314-323. 
Namayandeh, S. M., F. Kaseb and S. Lesan (2013). "Olive and sesame oil effect on lipid profile in 
hypercholesterolemic patients, which better?" International journal of preventive medicine 4(9): 1059-
1062. 
Natarajan, T.D., Ramasamy, J.R. & Palanisamy, K. Nutraceutical potentials of synergic foods: a 
systematic review. J. Ethn. Food 6, 27 (2019). https://doi.org/10.1186/s42779-019-0033-3 
 
- 232 - 
 
Neale, E. P., L. C. Tapsell, V. Guan and M. J. Batterham (2017). "The effect of nut consumption on 
markers of inflammation and endothelial function: a systematic review and meta-analysis of randomised 
controlled trials." BMJ Open 7(11): e016863. 
Neves, F. M. d. O., G. C. Meneses, N. E. A. Sousa, R. R. P. Pessoa Bezerra de Menezes, M. C. 
Parahyba, A. M. C. Martins and A. B. Libório (2015). "Syndecan-1 in Acute Decompensated Heart Failure 
– Association With Renal Function and Mortality –." Circulation Journal 79(7): 1511-1519. 
NHS (2019). The Eatwell Guide - Eat well. 
NHS (2020). Statistics on Obesity, Physical Activity and Diet, England, 2020. England. 
NHS (2020). Binge drinking - Alcohol Support. 
Nichols, G. A., S. Philip, K. Reynolds, C. B. Granowitz and S. Fazio (2019). "Increased residual 
cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statin-controlled 
LDL cholesterol." Diabetes, Obesity and Metabolism 21(2): 366-371. 
Nielsen, N. S., A. Pedersen, B. Sandström, P. Marckmann and C. E. Høy (2002). "Different effects of 
diets rich in olive oil, rapeseed oil and sunflower-seed oil on postprandial lipid and lipoprotein 
concentrations and on lipoprotein oxidation susceptibility." British Journal of Nutrition 87(5): 489-499. 
Nils-Gerrit, W. (2020). Statistics and facts on Food & Nutrition. Fruit and nuts: Weekly UK household 
consumption 2018/19  
Njike, V. Y., R. Ayettey, P. Petraro, J. A. Treu and D. L. Katz (2015). "Walnut ingestion in adults at risk 
for diabetes: effects on body composition, diet quality, and cardiac risk measures." BMJ Open Diabetes 
Research & Care 3(1): e000115-e000115. 
Nocella, C., V. Cammisotto, L. Fianchini, A. D'Amico, M. Novo, V. Castellani, L. Stefanini, F. Violi and R. 
Carnevale (2018). "Extra Virgin Olive Oil and Cardiovascular Diseases: Benefits for Human Health." 
Endocrine, Metabolic & Immune Disorders - Drug Targets (Formerly Current Drug Targets - Immune, 
Endocrine & Metabolic Disorders) 18(1): 4-13. 
Nocon, M., T. Hiemann, F. Müller-Riemenschneider, F. Thalau, S. Roll and S. N. Willich (2008). 
"Association of physical activity with all-cause and cardiovascular mortality: a systematic review and 
meta-analysis." Eur J Cardiovasc Prev Rehabil 15(3): 239-246. 
North, B. J. and D. A. Sinclair (2012). "The intersection between aging and cardiovascular disease." 
Circulation research 110(8): 1097-1108. 
Oda, E. (2017). "LDL cholesterol was more strongly associated with percent body fat than body mass 
index and waist circumference in a health screening population." Obesity Research & Clinical Practice 
12. 
O'Doherty, M. G., K. Cairns, V. O'Neill, F. Lamrock, T. Jørgensen, H. Brenner, B. Schöttker, T. Wilsgaard, 
G. Siganos, K. Kuulasmaa, P. Boffetta, A. Trichopoulou and F. Kee (2016). "Effect of major lifestyle risk 
factors, independent and jointly, on life expectancy with and without cardiovascular disease: results from 
the Consortium on Health and Ageing Network of Cohorts in Europe and the United States (CHANCES)." 
European journal of epidemiology 31(5): 455-468. 
Ohmura, H. (2019). "Triglycerides as Residual Risk for Atherosclerotic Cardiovascular Disease." Circ J 
83(5): 969-970. 
Oliveras-López, M. J., J. J. Molina, M. V. Mir, E. F. Rey, F. Martín and H. L. de la Serrana (2013). "Extra 
virgin olive oil (EVOO) consumption and antioxidant status in healthy institutionalized elderly humans." 
Arch Gerontol Geriatr 57(2): 234-242. 
 
- 233 - 
 
Olmedilla-Alonso, B., F. Granado-Lorencio, C. Herrero-Barbudo, I. Blanco-Navarro, S. Blázquez-García 
and B. Pérez-Sacristán (2008). "Consumption of Restructured Meat Products with Added Walnuts Has 
a Cholesterol-Lowering Effect in Subjects at High Cardiovascular Risk: A Randomised, Crossover, 
Placebo-Controlled Study." Journal of the American College of Nutrition 27(2): 342-348. 
O'Neil, C. E., D. R. Keast, T. A. Nicklas and V. L. Fulgoni (2011). "Nut Consumption Is Associated with 
Decreased Health Risk Factors for Cardiovascular Disease and Metabolic Syndrome in U.S. Adults: 
NHANES 1999–2004." Journal of the American College of Nutrition 30(6): 502-510. 
Orem, A., F. B. Yucesan, C. Orem, B. Akcan, B. V. Kural, C. Alasalvar and F. Shahidi (2013). "Hazelnut-
enriched diet improves cardiovascular risk biomarkers beyond a lipid-lowering effect in 
hypercholesterolemic subjects." Journal of Clinical Lipidology 7(2): 123-131. 
Orozco-Beltran, D., V. F. Gil-Guillen, J. Redon, J. M. Martin-Moreno, V. Pallares-Carratala, J. Navarro-
Perez, F. Valls-Roca, C. Sanchis-Domenech, A. Fernandez-Gimenez, A. Perez-Navarro, V. Bertomeu-
Martinez, V. Bertomeu-Gonzalez, A. Cordero, M. Pascual de la Torre, J. L. Trillo, C. Carratala-Munuera, 
S. Pita-Fernandez, R. Uso, R. Durazo-Arvizu, R. Cooper, G. Sanz, J. M. Castellano, J. F. Ascaso, R. 
Carmena, M. Tellez-Plaza and E. S. G. on behalf of (2017). "Lipid profile, cardiovascular disease and 
mortality in a Mediterranean high-risk population: The ESCARVAL-RISK study." PLOS ONE 12(10): 
e0186196. 
Osman, W.A., Labib, D.A., Abdelhalim, M.O. and Elrokh, E.M. (2017), Synergistic analgesic, anti-pyretic 
and anti-inflammatory effects of extra virgin olive oil and ibuprofen in different experimental models of 
albino mice. Int J Rheum Dis, 20: 1326-1336. https://doi.org/10.1111/1756-185X.13105. 
Palmefors, H., S. DuttaRoy, B. Rundqvist and M. Börjesson (2014). "The effect of physical activity or 
exercise on key biomarkers in atherosclerosis--a systematic review." Atherosclerosis 235(1): 150-161. 
Pan, A., M. Chen, R. Chowdhury, J. H. Wu, Q. Sun, H. Campos, D. Mozaffarian and F. B. Hu (2012). "α-
Linolenic acid and risk of cardiovascular disease: a systematic review and meta-analysis." The American 
journal of clinical nutrition 96(6): 1262-1273. 
Pan, W. H., K. M. Flegal, H. Y. Chang, W. T. Yeh, C. J. Yeh and W. C. Lee (2004). "Body mass index 
and obesity-related metabolic disorders in Taiwanese and US whites and blacks: implications for 
definitions of overweight and obesity for Asians." Am J Clin Nutr 79(1): 31-39. 
Papoutsi, Z., Kassi, E., Chinou, I., Halabalaki, M., Skaltsounis, L. A., & Moutsatsou, P. (2008). Walnut 
extract (Juglans regia L.) and its component ellagic acid exhibit anti-inflammatory activity in human aorta 
endothelial cells and osteoblastic activity in the cell line KS483. The British journal of nutrition, 99(4), 
715–722. https://doi.org/10.1017/S0007114507837421 
Papadaki, A. and J. A. Scott (2002). "The impact on eating habits of temporary translocation from a 
Mediterranean to a Northern European environment." Eur J Clin Nutr 5(5): 455-461. 
Papadaki, A. and J. A. Scott (2008). "Follow-up of a web-based tailored intervention promoting the 
Mediterranean diet in Scotland." Patient Educ Couns 73(2): 256-263. 
Papadaki, A., A. Thanasoulias, R. Pound, S. J. Sebire and R. Jago (2016). "Employees' Expectations of 
Internet-Based, Workplace Interventions Promoting the Mediterranean Diet: A Qualitative Study." J Nutr 
Educ Behav 48(10): 706-715. 
Papadaki, A., L. Wood, S. J. Sebire and R. Jago (2015). "Adherence to the Mediterranean diet among 
employees in South West England: Formative research to inform a web-based, work-place nutrition 
intervention." Prev Med Rep 2: 223-228. 
Parekh, T., R. Desai, S. Pemmasani and A. Cuellar (2020). "IMPACT OF SOCIAL DETERMINANTS OF 
HEALTH ON CARDIOVASCULAR DISEASES." Journal of the American College of Cardiology 75(11 
Supplement 2): 1989. 
 
- 234 - 
 
Parham, M., S. Heidari, A. Khorramirad, M. Hozoori, F. Hosseinzadeh, L. Bakhtyari and J. Vafaeimanesh 
(2014). "Effects of pistachio nut supplementation on blood glucose in patients with type 2 diabetes: a 
randomized crossover trial." The Review Of Diabetic Studies: RDS 11(2): 190-196. 
Passarino, G., F. De Rango and A. Montesanto (2016). "Human longevity: Genetics or Lifestyle? It takes 
two to tango." Immunity & ageing : I & A 13: 12-12. 
Patel, A., F. Barzi, K. Jamrozik, T. H. Lam, H. Ueshima, G. Whitlock and M. Woodward (2004). "Serum 
triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region." Circulation 110(17): 
2678-2686. 
Pawelczyk, M., B. Kaczorowska and Z. Baj (2017). "The impact of hyperglycemia and hyperlipidemia on 
plasma P-selectin and platelet markers after ischemic stroke." Archives of medical science : AMS 13(5): 
1049-1056. 
Payne, R. A. (2012). "Cardiovascular risk." British journal of clinical pharmacology 74(3): 396-410. 
Pedersen, A., M. W. Baumstark, P. Marckmann, H. Gylling and B. Sandström (2000). "An olive oil-rich 
diet results in higher concentrations of LDL cholesterol and a higher number of LDL subfraction particles 
than rapeseed oil and sunflower oil diets." Journal Of Lipid Research 41(12): 1901-1911. 
Perez-Martinez, P., J. Lopez-Miranda, L. Blanco-Colio, C. Bellido, Y. Jimenez, J. A. Moreno, J. Delgado-
Lista, J. Egido and F. Perez-Jimenez (2007). "The chronic intake of a Mediterranean diet enriched in 
virgin olive oil, decreases nuclear transcription factor κB activation in peripheral blood mononuclear cells 
from healthy men." Atherosclerosis 194(2): e141-e146. 
Perona, J. S., J. Canizares, E. Montero, J. M. Sanchez-Dominguez, A. Catala and V. Ruiz-Gutierrez 
(2004). "Virgin olive oil reduces blood pressure in hypertensive elderly subjects." Clinical Nutrition 23(5): 
1113-1121. 
Peters, S. A., Y. Singhateh, D. Mackay, R. R. Huxley and M. Woodward (2016). "Total cholesterol as a 
risk factor for coronary heart disease and stroke in women compared with men: A systematic review and 
meta-analysis." Atherosclerosis 248: 123-131. 
Philip, Q. (2018). Olive oil market in China - How to sell olive oil to Chinese distrubutors. Marketing To 
China. Shanghai. 
Piper, M. A., C. V. Evans, B. U. Burda, K. L. Margolis, E. O'Connor and E. P. Whitlock (2015). "Diagnostic 
and predictive accuracy of blood pressure screening methods with consideration of rescreening intervals: 
a systematic review for the U.S. Preventive Services Task Force." Ann Intern Med 162(3): 192-204. 
Pletsch-Borba, L., C. Watzinger, R. Turzanski Fortner, V. Katzke, L. Schwingshackl, S. A. Sowah, A. 
Hüsing, T. Johnson, M.-L. Groß, S. González Maldonado, M. Hoffmeister, P. Bugert, R. Kaaks, M. 
Grafetstätter and T. Kühn (2019). "Biomarkers of Vascular Injury and Type 2 Diabetes: A Prospective 
Study, Systematic Review and Meta-Analysis." Journal of Clinical Medicine 8(12): 2075. 
Public Health England (2019). Health matters: preventing cardiovascular disease. GOV.UK. 
Public Health England (2019). State of the North East 2019: Cardiovascular disease prevention. 
Wellington House 
Puiggros, C., P. Chacon, L. I. Armadans, J. Clapes and M. Planas (2002). "Effects of oleic-rich and 
omega-3-rich diets on serum lipid pattern and lipid oxidation in mildly hypercholesterolemic patients." 
Clin Nutr 21(1): 79-87. 
Raggi, P., J. Genest, J. T. Giles, K. J. Rayner, G. Dwivedi, R. S. Beanlands and M. Gupta (2018). "Role 
of inflammation in the pathogenesis of atherosclerosis and therapeutic interventions." Atherosclerosis 
276: 98-108. 
 
- 235 - 
 
Rahman, M. S., & Woollard, K. (2017). Atherosclerosis. Advances in experimental medicine and 
biology, 1003, 121–144. https://doi.org/10.1007/978-3-319-57613-8_7 
Raine, S. and L. Twomey (1994). "Posture of the head, shoulders and thoracic spine in comfortable erect 
standing." Aust J Physiother 40(1): 25-32. 
Rajaram, S., E. H. Haddad, A. Mejia and J. Sabaté (2009). "Walnuts and fatty fish influence different 
serum lipid fractions in normal to mildly hyperlipidemic individuals: a randomized controlled study." The 
American Journal Of Clinical Nutrition 89(5): 1657S-1663S. 
Rajaram, S., K. Burke, B. Connell, T. Myint and J. Sabate (2001). "A monounsaturated fatty acid-rich 
pecan-enriched diet favorably alters the serum lipid profile of healthy men and women." Journal of 
Nutrition 131(9): 2275-2279. 
Rajaram, S., K. M. Connell and J. Sabaté (2010). "Effect of almond-enriched high-monounsaturated fat 
diet on selected markers of inflammation: A randomised, controlled, crossover study." British Journal of 
Nutrition 103(6): 907-912. 
Ramirez-Tortosa, M. C., G. Urbano, M. a. López-Jurado, T. Nestares, M. a. C. Gomez, A. Mir, E. Ros, 
J. Mataix and A. Gil (1999). "Extra-Virgin Olive Oil Increases the Resistance of LDL to Oxidation More 
than Refined Olive Oil in Free-Living Men with Peripheral Vascular Disease." The Journal of Nutrition 
129(12): 2177-2183. 
Rao, G. S., P. Gurumurthy, P. Gururajan, R. Saibabu and K. M. Cherian (2011). "Serum E-selectin levels 
in Indian children and adolescents: relation to clinical and biochemical parameters." Pediatr Int 53(1): 
40-45. 
Ravera, A., V. Carubelli, E. Sciatti, I. Bonadei, E. Gorga, D. Cani, E. Vizzardi, M. Metra and C. Lombardi 
(2016). "Nutrition and Cardiovascular Disease: Finding the Perfect Recipe for Cardiovascular Health." 
Nutrients 8(6). 
Rees, K., L. Hartley, N. Flowers, A. Clarke, L. Hooper, M. Thorogood and S. Stranges (2012). 
"Mediterranean’dietary pattern for the primary prevention of cardiovascular disease." Cochrane 
Database Syst Rev 8. 
Reiss, A. B., N. M. Siegart and J. De Leon (2017). "Interleukin-6 in atherosclerosis: atherogenic or 
atheroprotective?" Clinical Lipidology 12(1): 14-23. 
Ren, Y., Q. Ren, J. Lu, X. Guo, X. Huo, L. Ji and X. Yang (2018). "Low triglyceride as a marker for 
increased risk of cardiovascular diseases in patients with long-term type 2 diabetes: A cross-sectional 
survey in China." Diabetes/Metabolism Research and Reviews 34(2): e2960. 
Ridker, P. M., N. J. Brown, D. E. Vaughan, D. G. Harrison and J. L. Mehta (2004). "Established and 
emerging plasma biomarkers in the prediction of first atherothrombotic events." Circulation 
109(25_suppl_1): IV-6-IV-19. 
Rizwan, S., C. Benincasa, K. Mahmood, S. Anjum, Z. Mehmood, G. Alizai, M. Azam, E. Perri and A. 
Sajjad (2018). "Fatty Acids and Phenolic Profiles of Extravirgin Olive Oils from Selected Italian Cultivars 
Introduced in Southwestern Province of Pakistan." Journal of Oleo Science 68. 
Rocha, V. Z., R. T. Ras, A. C. Gagliardi, L. C. Mangili, E. A. Trautwein and R. D. Santos (2016). "Effects 
of phytosterols on markers of inflammation: A systematic review and meta-analysis." Atherosclerosis 
248: 76-83. 
Ros, E., & Mataix, J. (2006). Fatty acid composition of nuts--implications for cardiovascular health. The 
British journal of nutrition, 96 Suppl 2, S29–S35. https://doi.org/10.1017/bjn20061861 
Ros, E. (2009). "Nuts and novel biomarkers of cardiovascular disease." The American Journal of Clinical 
Nutrition 89(5): 1649S-1656S. 
 
- 236 - 
 
Ros E. (2010). Health benefits of nut consumption. Nutrients, 2(7), 652–682. 
https://doi.org/10.3390/nu2070652 
Ros, E. (2012). "Olive oil and CVD: accruing evidence of a protective effect." Br J Nutr 108(11): 1931-
1933. 
Ros, E. and J. Mataix (2006). "Fatty acid composition of nuts - Implications for cardiovascular health." 
British Journal of Nutrition 96(SUPPL. 2): S29-S35. 
Ros, E., I. Nunez, A. Perez-Heras, M. Serra, R. Gilabert, E. Casals and R. Deulofeu (2004). "A walnut 
diet improves endothelial function in hypercholesterolemic subjects - A randomized crossover trial." 
Circulation 109(13): 1609-1614. 
Ros, E., M. A. Martínez-González, R. Estruch, J. Salas-Salvadó, M. Fitó, J. A. Martínez and D. Corella 
(2014). "Mediterranean Diet and Cardiovascular Health: Teachings of the PREDIMED Study." Advances 
in Nutrition 5(3): 330S-336S. 
Rosa, M., P. Carmen and L. Ana M (2015). "Dietary assessment methods: dietary records." Nutricion 
Hospitalaria 31(3): 38-45. 
Rosato, V., N. J. Temple, C. La Vecchia, G. Castellan, A. Tavani and V. Guercio (2019). "Mediterranean 
diet and cardiovascular disease: a systematic review and meta-analysis of observational studies." Eur J 
Nutr 58(1): 173-191. 
Rosengren, A., A. Smyth, S. Rangarajan, C. Ramasundarahettige, S. I. Bangdiwala, K. F. AlHabib, A. 
Avezum, K. Bengtsson Boström, J. Chifamba, S. Gulec, R. Gupta, E. U. Igumbor, R. Iqbal, N. Ismail, P. 
Joseph, M. Kaur, R. Khatib, I. M. Kruger, P. Lamelas, F. Lanas, S. A. Lear, W. Li, C. Wang, D. Quiang, 
Y. Wang, P. Lopez-Jaramillo, N. Mohammadifard, V. Mohan, P. K. Mony, P. Poirier, S. Srilatha, A. Szuba, 
K. Teo, A. Wielgosz, K. E. Yeates, K. Yusoff, R. Yusuf, A. H. Yusufali, M. W. Attaei, M. McKee and S. 
Yusuf (2019). "Socioeconomic status and risk of cardiovascular disease in 20 low-income, middle-
income, and high-income countries: the Prospective Urban Rural Epidemiologic (PURE) study." The 
Lancet Global Health 7(6): e748-e760. 
Ruisinger, J. F., C. A. Gibson, J. M. Backes, B. K. Smith, D. K. Sullivan, P. M. Moriarty and P. Kris-
Etherton (2015). "Statins and almonds to lower lipoproteins (the STALL Study)." Journal Of Clinical 
Lipidology 9(1): 58-64. 
Ruiz-Canela, M. and M. A. Martinez-Gonzalez (2011). "Olive oil in the primary prevention of 
cardiovascular disease." Maturitas 68(3): 245-250. 
Sabate, J., E. Haddad, J. S. Tanzman, P. Jambazian and S. Rajaram (2003). "Serum lipid response to 
the graduated enrichment of a Step I diet with almonds: a randomized feeding trial." American Journal 
of Clinical Nutrition 77(6): 1379-1384. 
Sabate, J., G. E. Fraser, K. Burke, S. F. Knutsen, H. Bennett and K. D. Lindsted (1993). "Effects of 
walnuts on serum lipid levels and blood pressure in normal men." N Engl J Med 328(9): 603-607. 
Sabate, J., K. Oda and E. Ros (2010). "Nut consumption and blood lipid levels: a pooled analysis of 25 
intervention trials." Arch Intern Med 170(9): 821-827. 
Sabine, O. P. (2011). "Gender differences and clinical trial design." Clinical Investigation 1(2). 
Saiz, L. C., J. Gorricho, J. Garjón, M. C. Celaya, J. Erviti and L. Leache (2018). "Blood pressure targets 
for the treatment of people with hypertension and cardiovascular disease." Cochrane Database of 
Systematic Reviews (7). 
Salas-Salvadó, J., M. Bulló, N. Babio, M. Á. Martínez-González, N. Ibarrola-Jurado, J. Basora, R. Estruch, 
M. I. Covas, D. Corella, F. Arós, V. Ruiz-Gutiérrez and E. Ros (2011). "Reduction in the Incidence of 
Type 2 Diabetes With the Mediterranean Diet." Diabetes Care 34(1): 14. 
 
- 237 - 
 
Samieri, C., C. Feart, C. Proust-Lima, E. Peuchant, C. Tzourio, C. Stapf, C. Berr and P. Barberger-
Gateau (2011). "Olive oil consumption, plasma oleic acid, and stroke incidence: the Three-City Study." 
Neurology 77(5): 418-425. 
Sarwar, N., J. Danesh, G. Eiriksdottir, G. Sigurdsson, N. Wareham, S. Bingham, S. M. Boekholdt, K. T. 
Khaw and V. Gudnason (2007). "Triglycerides and the risk of coronary heart disease: 10,158 incident 
cases among 262,525 participants in 29 Western prospective studies." Circulation 115(4): 450-458. 
Satia, J. A. (2009). "Diet-related disparities: understanding the problem and accelerating solutions." 
Journal of the American Dietetic Association 109(4): 610-615. 
Sauder, K. A., C. E. McCrea, J. S. Ulbrecht, P. M. Kris-Etherton and S. G. West (2014). "Pistachio nut 
consumption modifies systemic hemodynamics, increases heart rate variability, and reduces ambulatory 
blood pressure in well-controlled type 2 diabetes: a randomized trial." Journal Of The American Heart 
Association 3(4). 
Sauder, K. A., C. E. McCrea, J. S. Ulbrecht, P. M. Kris-Etherton and S. G. West (2015). "Effects of 
pistachios on the lipid/lipoprotein profile, glycemic control, inflammation, and endothelial function in type 
2 diabetes: A randomized trial." Metabolism: Clinical And Experimental 64(11): 1521-1529. 
Schmidt, C. & Bergstrom, G. 2014. Apolipoprotein B and apolipopotein A-I in vascular risk prediction - a 
review. Curr Pharm Des, 20, 6289-98. 
Scholl, J. (2012). "Traditional dietary recommendations for the prevention of cardiovascular disease: do 
they meet the needs of our patients?" Cholesterol 2012: 367898-367898. 
Schroder, H., M. Fitó, R. Estruch, M. Martínez-González, D. Corella, J. Salas-Salvadó, R. M. Lamuela-
Raventós, E. Ros, I. Salaverría, M. Fiol, J. Lapetra, E. Vinyoles, E. Gómez-Gracia, C. Lahoz, L. Serra-
Majem, X. Pinto, V. Ruiz-Gutierrez and M.-I. Covas (2011). A Short Screener Is Valid for Assessing 
Mediterranean Diet Adherence among Older Spanish Men and Women. 
Schroeder, S., M. Enderle, R. Ossen, C. Meisner, A. Baumbach, M. Pfohl, C. Herdeg, M. Oberhoff, H. 
U. Haering and K. R. Karsch (1999). Noninvasive determination of endothelium-mediated vasodilation 
as a screening test for coronary artery disease: Pilot study to assess the predictive value in comparison 
with angina pectoris, exercise electrocardiography, and myocardial perfusion imaging. 
Schultz, W. M., H. M. Kelli, J. C. Lisko, T. Varghese, J. Shen, P. Sandesara, A. A. Quyyumi, H. A. Taylor, 
M. Gulati, J. G. Harold, J. H. Mieres, K. C. Ferdinand, G. A. Mensah and L. S. Sperling (2018). 
"Socioeconomic Status and Cardiovascular Outcomes: Challenges and Interventions." Circulation 
137(20): 2166-2178. 
Schutte, A. E., J. M. Van Rooyen, H. W. Huisman, J. Mukuddem-Petersen, W. Oosthuizen, S. M. 
Hanekom and J. C. Jerling (2006). "Modulation of baroreflex sensitivity by walnuts versus cashew nuts 
in subjects with metabolic syndrome." American Journal Of Hypertension 19(6): 629-636. 
Schwingshackl, L. and G. Hoffmann (2012). "Monounsaturated fatty acids and risk of cardiovascular 
disease: synopsis of the evidence available from systematic reviews and meta-analyses." Nutrients 4(12): 
1989-2007. 
Schwingshackl, L. and G. Hoffmann (2014). "Monounsaturated fatty acids, olive oil and health status: a 
systematic review and meta-analysis of cohort studies." Lipids Health Dis 13: 154. 
Schwingshackl, L., M. Christoph and G. Hoffmann (2015). "Effects of Olive Oil on Markers of 
Inflammation and Endothelial Function—A Systematic Review and Meta-Analysis." Nutrients 7(9): 5356. 
Schwingshackl, L., M. Krause, C. Schmucker, G. Hoffmann, G. Rücker and J. J. Meerpohl (2019). 
"Impact of different types of olive oil on cardiovascular risk factors: A systematic review and network 
meta-analysis." Nutrition, Metabolism and Cardiovascular Diseases 29(10): 1030-1039. 
 
- 238 - 
 
Seamus, P. and A. C. Whelton (2002). "Effect of Aerobic Exercise on Blood Pressure: A Meta-Analysis 
of Randomized, Controlled Trials." Annals of Internal Medicine. 
Seguin, R., L. Connor, M. Nelson, A. LaCroix and G. Eldridge (2014). "Understanding barriers and 
facilitators to healthy eating and active living in rural communities." Journal of nutrition and metabolism 
2014: 146502-146502. 
Segura, R., Javierre, C., Lizarraga, M. A., & Ros, E. (2006). Other relevant components of nuts: 
phytosterols, folate and minerals. The British journal of nutrition, 96 Suppl 2, S36–S44. 
https://doi.org/10.1017/bjn20061862 
Shahidi, F. and P. Ambigaipalan (2018). "Omega-3 Polyunsaturated Fatty Acids and Their Health 
Benefits." Annu Rev Food Sci Technol 9: 345-381. 
Sheridan, M. J., J. N. Cooper, M. Erario and C. E. Cheifetz (2007). "Pistachio Nut Consumption and 
Serum Lipid Levels." Journal of the American College of Nutrition 26(2): 141-148. 
Shrivastava, A. K., H. V. Singh, A. Raizada and S. K. Singh (2015). "C-reactive protein, inflammation 
and coronary heart disease." The Egyptian Heart Journal 67(2): 89-97. 
Siervo, M., J. Lara, S. Chowdhury, A. Ashor, C. Oggioni and J. C. Mathers (2015). "Effects of the Dietary 
Approach to Stop Hypertension (DASH) diet on cardiovascular risk factors: a systematic review and 
meta-analysis." Br J Nutr 113(1): 1-15. 
Siefer, S., Wacker, R., Wilhelm, M., Schoen, C (2018). “Absorption of Hydroxytyrosol from Different 
Sources and its Impact on Lipid Status in Human Subjects” Journal of Nutritional Medicine and Diet Care 
4(1): 2572-3278 
Sirtori, C. R., E. Gatti, E. Tremoli, C. Galli, G. Gianfranceschi, G. Franceschini, S. Colli, P. Maderna, F. 
Marangoni, P. Perego and E. Stragliotto (1992). "Olive oil, corn oil, and n - 3 fatty acids differently affect 
lipids, lipoproteins, platelets, and Superoxide formation in type II hypercholesterolemia." American 
Journal of Clinical Nutrition 56(1): 113-122. 
Smith, R. D., C. N. Kelly, B. A. Fielding, D. Hauton, K. R. R. Silva, M. C. Nydahl, G. J. Miller and C. M. 
Williams (2003). "Long-term monounsaturated fatty acid diets reduce platelet aggregation in healthy 
young subjects." British Journal of Nutrition 90(3): 597-606. 
Smoking, A. o. and Health (2015). Smoking statistics, ASH London. 
Sniderman, A. D., S. Islam, S. Yusuf and M. J. McQueen (2012). "Discordance analysis of apolipoprotein 
B and non-high density lipoprotein cholesterol as markers of cardiovascular risk in the INTERHEART 
study." Atherosclerosis 225(2): 444-449. 
Sofi, F. (2009). "The Mediterranean diet revisited: evidence of its effectiveness grows." Curr Opin Cardiol 
24(5): 442-446. 
Sofi, F., F. Cesari, R. Abbate, G. F. Gensini and A. Casini (2008). "Adherence to Mediterranean diet and 
health status: meta-analysis." BMJ 337. 
Sofi, F., R. Abbate, G. F. Gensini and A. Casini (2009). "Evidences on the relationship between 
Mediterranean diet and health status." Recenti Prog Med 100(3): 127-131. 
Sofi, F., R. Abbate, G. F. Gensini and A. Casini (2010). "Accruing evidence on benefits of adherence to 
the Mediterranean diet on health: an updated systematic review and meta-analysis." The American 
Journal of Clinical Nutrition 92(5): 1189-1196. 
Sokoła-Wysoczańska, E., T. Wysoczański, J. Wagner, K. Czyż, R. Bodkowski, S. Lochyński and B. 
Patkowska-Sokoła (2018). "Polyunsaturated Fatty Acids and Their Potential Therapeutic Role in 
Cardiovascular System Disorders-A Review." Nutrients 10(10): 1561. 
 
- 239 - 
 
Sola, R., M. Fito, R. Estruch, J. Salas-Salvado, D. Corella, R. de la Torre, M. A. Munoz, M. D. Lopez-
Sabater, M. A. Martinez-Gonzalez, F. Aros, V. Ruiz-Gutierrez, M. Fiol, E. Casals, J. Warnberg, P. Buil-
Cosiales, E. Ros, V. Konstantinidou, J. Lapetra, L. Serra-Majem, M. I. Covas and P. S. Investigators 
(2011). "Effect of a traditional Mediterranean diet on apolipoproteins B, A-I, and their ratio: A randomized, 
controlled trial." Atherosclerosis 218(1): 174-180. 
Sola, R., R. M. Valls, G. Godas, G. Perez-Busquets, J. Ribalta, J. Girona, M. Heras, A. Cabre, A. Castro, 
G. Domenech, F. Torres, L. Masana, N. Angles, J. Reguant, B. Ramirez and J. M. Barriach (2012). 
"Cocoa, hazelnuts, sterols and soluble fiber cream reduces lipids and inflammation biomarkers in 
hypertensive patients: a randomized controlled trial." PLoS One 7(2): e31103. 
Somerset, S. M., L. Graham and K. Markwell (2013). "Isoenergetic replacement of dietary saturated with 
monounsaturated fat via macadamia nuts enhances endothelial function in overweight subjects." e-
SPEN Journal 8(3): e113-e119. 
Song, C., S. Burgess, J. D. Eicher, C. J. O'Donnell and A. D. Johnson (2017). "Causal Effect of 
Plasminogen Activator Inhibitor Type 1 on Coronary Heart Disease." Journal of the American Heart 
Association 6(6): e004918. 
Souza, P. A. L. d., A. Marcadenti and V. L. Portal (2017). "Effects of Olive Oil Phenolic Compounds on 
Inflammation in the Prevention and Treatment of Coronary Artery Disease." Nutrients 9(10): 1087. 
Sözmen, K., Ü. Belgin, S. Sakarya, D. Gönül, N. YARDIM, B. KESKİNKILIÇ and G. Ergör (2016). 
"Association of anthropometric measurement methods with cardiovascular disease risk in Turkey." Dicle 
Tıp Dergisi 43(1): 99-106. 
Speed, C. (2004). "The transposability of the Mediterranean-type diet in non-Mediterranean regions: 
application to the physician/allied health team." Eur J Cancer Prev 13(6): 529-534. 
Spiller, G. A., Gates, J. E., Cragen, L. N., Bruce, B., Jenkins, D. A. J. & Bosello, O. 1998. Nuts and 
plasma lipids: An almond-based diet lowers ldl-c while preserving hdl-C. Journal of the American College 
of Nutrition, 17, 285-290. 
Sproston, N. R. and J. J. Ashworth (2018). "Role of C-Reactive Protein at Sites of Inflammation and 
Infection." Frontiers in immunology 9: 754-754. 
Stephen, S. (2002). Cross-over Trials in Clinical Research. 
Stoner, L., A. A. Lucero, B. R. Palmer, L. M. Jones, J. M. Young and J. Faulkner (2013). "Inflammatory 
biomarkers for predicting cardiovascular disease." Clinical Biochemistry 46(15): 1353-1371. 
Storey, B. C., N. Staplin, R. Haynes, C. Reith, J. Emberson, W. G. Herrington, D. C. Wheeler, R. Walker, 
B. Fellström, C. Wanner, M. J. Landray, C. Baigent and S. C. Group (2018). "Lowering LDL cholesterol 
reduces cardiovascular risk independently of presence of inflammation." Kidney international 93(4): 
1000-1007. 
Strait, J. B. and E. G. Lakatta (2012). "Aging-associated cardiovascular changes and their relationship 
to heart failure." Heart failure clinics 8(1): 143-164. 
Su, C., J. Sun, W. Zhu and L. Peng (2018). "History, Distribution, and Potential of the Olive Industry in 
China: A Review." Sustainability 10(5): 1426. 
Sun, G., H. Xia, Y. Yang, S. Ma, H. Zhou, G. Shu, S. Wang, X. Yang, H. Tang, F. Wang, Y. He, R. Ding, 
H. Yin, Y. Wang, Y. Yang, H. Zhu and L. Yang (2018). "Effects of palm olein and olive oil on serum lipids 
in a Chinese population: a randomized, double-blind, cross-over trial." Asia Pac J Clin Nutr 27(3): 572-
580. 
Swartzberg, J. and S. Margen (2001). "Eat, Drink, and Be Healthy: The Harvard Medical School Guide 
to Healthy Eating." American Journal of Epidemiology 154(12): 1160-1160. 
 
- 240 - 
 
Sweazea, K. L., C. S. Johnston, K. D. Ricklefs and K. N. Petersen (2014). "Almond supplementation in 
the absence of dietary advice significantly reduces C-reactive protein in subjects with type 2 diabetes." 
Journal of Functional Foods 10: 252-259. 
T.H.Chan. (2018, 27 May). "Asian Diabetes Prevention Initiative." Asian Diets: Health Benefits and Risks 
Retrieved 27 May, 2018, from http://www.asiandiabetesprevention.org/how-to-reduce-your-risk/asian-
diets-benefits-risks. 
Tacconelli, E. (2010). "Systematic reviews: CRD's guidance for undertaking reviews in health care." The 
Lancet Infectious Diseases 10(4): 226. 
Tamizifar B, R. M., Vosoughi A, Rafieeyan M, Tamizifar B, Aminzade A. (2005). "A low-dose almond-
based diet decreases LDL-C while preserving HDL-C." Arch Iraian Med(8): 45-51. 
Tapsell, L. C., L. J. Gillen, C. S. Patch, M. Batterham, A. Owen, M. Bare and M. Kennedy (2004). 
"Including walnuts in a low-fat/modified-fat diet improves HDL cholesterol-to-total cholesterol ratios in 
patients with type 2 diabetes." Diabetes Care 27(12): 2777-2783. 
Tapsell, L. C., M. J. Batterham, G. Teuss, S. Y. Tan, S. Dalton, C. J. Quick, L. J. Gillen and K. E. Charlton 
(2009). "Long-term effects of increased dietary polyunsaturated fat from walnuts on metabolic 
parameters in type II diabetes." Eur J Clin Nutr 63(8): 1008-1015. 
Tapsell, L., E. Neale, A. Satija and F. Hu (2016). "Foods, Nutrients, and Dietary Patterns: 
Interconnections and Implications for Dietary Guidelines." Advances in Nutrition: An International Review 
Journal 7: 445-454. 
Tchalla, A. E., G. A. Wellenius, T. G. Travison, M. Gagnon, I. Iloputaife, T. Dantoine, F. A. Sorond and 
L. A. Lipsitz (2015). "Circulating vascular cell adhesion molecule-1 is associated with cerebral blood flow 
dysregulation, mobility impairment, and falls in older adults." Hypertension (Dallas, Tex. : 1979) 66(2): 
340-346. 
Teramoto, T. (2017). "Is "The Japan Diet" Cardioprotective?" Journal of atherosclerosis and thrombosis 
24(4): 388-389. 
Terés, S., G. Barceló-Coblijn, M. Benet, R. Alvarez, R. Bressani, J. E. Halver and P. V. Escribá (2008). 
"Oleic acid content is responsible for the reduction in blood pressure induced by olive oil." Proceedings 
of the National Academy of Sciences of the United States of America 105(37): 13811-13816. 
Tey, S. L., A. R. Gray, A. W. Chisholm, C. M. Delahunty and R. C. Brown (2013). "The dose of hazelnuts 
influences acceptance and diet quality but not inflammatory markers and body composition in overweight 
and obese individuals." The Journal Of Nutrition 143(8): 1254-1262. 
Tey, S. L., R. Brown, A. Gray, A. Chisholm and C. Delahunty (2011). "Nuts improve diet quality compared 
to other energy-dense snacks while maintaining body weight." J Nutr Metab 2011: 357350. 
Tholstrup, T., J. Hjerpsted and M. Raff (2011). "Palm olein increases plasma cholesterol moderately 
compared with olive oil in healthy individuals." The American Journal Of Clinical Nutrition 94(6): 1426-
1432. 
Tholstrup, T., J. Hjerpsted and M. Raff (2012). "Palm olein increases plasma cholesterol moderately 
compared with olive oil in healthy individuals." The FASEB Journal 26(S1): 1015.1012-1015.1012. 
Thomas, M. R. and G. Y. Lip (2017). "Novel Risk Markers and Risk Assessments for Cardiovascular 
Disease." Circ Res 120(1): 133-149. 
Tofler, G. H., J. Massaro, C. J. O'Donnell, P. W. F. Wilson, R. S. Vasan, P. A. Sutherland, J. B. Meigs, 
D. Levy and R. B. D'Agostino (2016). "Plasminogen activator inhibitor and the risk of cardiovascular 
disease: The Framingham Heart Study." Thrombosis Research 140: 30-35. 
 
- 241 - 
 
Toma, A., G. Paré and D. P. Leong (2017). "Alcohol and Cardiovascular Disease: How Much is Too 
Much?" Curr Atheroscler Rep 19(3): 13. 
Tong, H., A. G. Rappold, M. Caughey, A. L. Hinderliter, M. Bassett, T. Montilla, M. W. Case, J. Berntsen, 
P. A. Bromberg, W. E. Cascio, D. Diaz-Sanchez, R. B. Devlin and J. M. Samet (2015). "Dietary 
supplementation with olive oil or fish oil and vascular effects of concentrated ambient particulate matter 
exposure in human volunteers." Environmental Health Perspectives 123(11): 1173-1179. 
Torabian, S., E. Haddad, Z. Cordero-MacIntyre, J. Tanzman, M. L. Fernandez and J. Sabate (2010). 
"Long-term walnut supplementation without dietary advice induces favorable serum lipid changes in free-
living individuals." European Journal Of Clinical Nutrition 64(3): 274-279. 
Tousoulis, D., T. Psaltopoulou, E. Androulakis, N. Papageorgiou, S. Papaioannou, E. Oikonomou, A. 
Synetos and C. Stefanadis (2015). "Oxidative Stress and Early Atherosclerosis: Novel Antioxidant 
Treatment." Cardiovascular Drugs and Therapy 29(1): 75-88. 
Townsend N, Bhatnagar P, Wilkins E, Wickramasinghe K and R. M (2015). "Cardiovascular Disease 
Statsitics 2015." British Heart Foundation. 
Townsend, N., L. Wilson, P. Bhatnagar, K. Wickramasinghe, M. Rayner and M. Nichols (2016). 
"Cardiovascular disease in Europe: epidemiological update 2016." European Heart Journal 37(42): 
3232-3245. 
Tracy, R. P., R. N. Lemaitre, B. M. Psaty, D. G. Ives, R. W. Evans, M. Cushman, E. N. Meilahn and L. 
H. Kuller (1997). "Relationship of C-reactive protein to risk of cardiovascular disease in the elderly: 
Results from the Cardiovascular Health Study and the Rural Health Promotion Project." Arteriosclerosis, 
Thrombosis, and Vascular Biology 17(6): 1121-1127. 
Tresserra-Rimbau, A., E. B. Rimm, A. Medina-Remón, M. A. Martínez-González, M. C. López-Sabater, 
M. I. Covas, D. Corella, J. Salas-Salvadó, E. Gómez-Gracia, J. Lapetra, F. Arós, M. Fiol, E. Ros, L. 
Serra-Majem, X. Pintó, M. A. Muñoz, A. Gea, V. Ruiz-Gutiérrez, R. Estruch and R. M. Lamuela-Raventós 
(2014). "Polyphenol intake and mortality risk: a re-analysis of the PREDIMED trial." BMC Medicine 12(1): 
77. 
Tromp, J., A. Van Der Pol, I. T. Klip, R. A. De Boer, T. Jaarsma, W. H. Van Gilst, A. A. Voors, D. J. Van 
Veldhuisen and P. Van Der Meer (2014). "Fibrosis marker syndecan-1 and outcome in patients with 
heart failure with reduced and preserved ejection fraction." Circulation: Heart Failure 7(3): 457-462. 
Tsartsou, E., N. Proutsos, E. Castanas and M. Kampa (2019). "Network Meta-Analysis of Metabolic 
Effects of Olive-Oil in Humans Shows the Importance of Olive Oil Consumption With Moderate 
Polyphenol Levels as Part of the Mediterranean Diet." Frontiers in Nutrition 6: 6. 
Turner, J. R., A. J. Viera and D. Shimbo (2015). "Ambulatory Blood Pressure Monitoring in Clinical 
Practice: A Review." The American Journal of Medicine 128(1): 14-20. 
Tuttolomondo, A., I. Simonetta, M. Daidone, A. Mogavero, A. Ortello and A. Pinto (2019). "Metabolic and 
Vascular Effect of the Mediterranean Diet." International journal of molecular sciences 20(19): 4716. 
UK Parliament (2016). Barriers to Healthy Food. https://post.parliament.uk/research-briefings/post-pn-
0522/ 
Upadhyay, R. K. (2015). "Emerging risk biomarkers in cardiovascular diseases and disorders." Journal 
of lipids 2015: 971453-971453. 
Vafeiadou, K., M. Weech, H. Altowaijri, S. Todd, P. Yaqoob, K. G. Jackson and J. A. Lovegrove (2015). 
"Replacement of saturated with unsaturated fats had no impact on vascular function but beneficial effects 
on lipid biomarkers, E-selectin, and blood pressure: results from the randomized, controlled Dietary 
 
- 242 - 
 
Intervention and VAScular function (DIVAS) study." The American Journal of Clinical Nutrition 102(1): 
40-48. 
Valerie C, (2020), Health inequalities are worsening in the North East of England, British Medical Bulletin, 
Volume 134, Issue 1, June 2020, Pages 63-72, https://doi.org/10.1093/bmb/ldaa008 
Vélez-Toral, M., C. Rodríguez-Reinado, A. Ramallo-Espinosa and M. Andrés-Villas (2020). "“It’s 
Important but, on What Level?”: Healthy Cooking Meanings and Barriers to Healthy Eating among 
University Students." Nutrients 12(8): 2309. 
Venturini, D., A. N. C. Simao, M. R. Urbano and I. Dichi (2015). "Effects of extra virgin olive oil and fish 
oil on lipid profile and oxidative stress in patients with metabolic syndrome." Nutrition 31(6): 834-840. 
Vidyasagaran, A. L., K. Siddiqi and M. Kanaan (2016). "Use of smokeless tobacco and risk of 
cardiovascular disease: A systematic review and meta-analysis." European Journal of Preventive 
Cardiology 23(18): 1970-1981. 
Vijg, J. and E. Le Bourg (2017). "Aging and the Inevitable Limit to Human Life Span." Gerontology 63(5): 
432-434. 
Violi, F., L. Loffredo, P. Pignatelli, F. Angelico, S. Bartimoccia, C. Nocella, R. Cangemi, A. Petruccioli, R. 
Monticolo, D. Pastori and R. Carnevale (2015). "Extra virgin olive oil use is associated with improved 
post-prandial blood glucose and LDL cholesterol in healthy subjects." Nutr Diabetes. 20(5): 172. 
Virruso, C., G. Accardi, G. Colonna-Romano, G. Candore, S. Vasto and C. Caruso (2014). "Nutraceutical 
properties of extra-virgin olive oil: a natural remedy for age-related disease?" Rejuvenation Res 17(2): 
217-220. 
Visioli, F., M. Franco, E. Toledo, J. Luchsinger, W. C. Willett, F. B. Hu and M. A. Martinez-Gonzalez 
(2018). "Olive oil and prevention of chronic diseases: Summary of an International conference." Nutrition, 
Metabolism and Cardiovascular Diseases 28(7): 649-656. 
Vitaglione, P., M. Savarese, A. Paduano, L. Scalfi, V. Fogliano and R. Sacchi (2015). "Healthy Virgin 
Olive Oil: A Matter of Bitterness." Critical Reviews in Food Science and Nutrition 55(13): 1808-1818. 
von Elm, E., D. G. Altman, M. Egger, S. J. Pocock, P. C. Gotzsche and J. P. Vandenbroucke (2007). 
"Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines 
for reporting observational studies." Bmj 335(7624): 806-808. 
Voon, P. T., T. K. W. Ng, V. K. M. Lee and K. Nesaretnam (2015). "Virgin olive oil, palm olein and coconut 
oil diets do not raise cell adhesion molecules and thrombogenicity indices in healthy Malaysian adults." 
European Journal of Clinical Nutrition 69(6): 712-716. 
Wang, D., Y. Li, S. G. Lee, L. Wang, J. Fan, G. Zhang, J. Wu, Y. Ji and S. Li (2011). "Ethnic differences 
in body composition and obesity related risk factors: study in Chinese and white males living in China." 
PloS one 6(5): e19835-e19835. 
Wang, J., X. Lin, Z. T. Bloomgarden and G. Ning (2020). "The Jiangnan diet, a healthy diet pattern for 
Chinese." Journal of Diabetes 12(5): 365-371. 
Wang, Q., X. Liang, L. Wang, X. Lu, J. Huang, J. Cao, H. Li and D. Gu (2012). "Effect of omega-3 fatty 
acids supplementation on endothelial function: a meta-analysis of randomized controlled trials." 
Atherosclerosis 221(2): 536-543. 
Wang, S.-s., S. Lay, H.-n. Yu and S.-r. Shen (2016). "Dietary Guidelines for Chinese Residents (2016): 
comments and comparisons." Journal of Zhejiang University. Science. B 17(9): 649-656. 
 
- 243 - 
 
Wang, X. and T. M. Connolly (2010). Chapter 1 - Biomarkers of Vulnerable Atheromatous Plaques: 
Translational Medicine Perspectives. Advances in Clinical Chemistry. G. S. Makowski, Elsevier. 50: 1-
22. 
Wagner, K. H., Kamal-Eldin, A., & Elmadfa, I. (2004). Gamma-tocopherol--an underestimated 
vitamin?. Annals of nutrition & metabolism, 48(3), 169–188. https://doi.org/10.1159/000079555 
Waterall, J. (2015). High cholesterol: beating the build-up during Cholesterol Month. Public Health 
Matters. Public Health Matters. 
Weissglas-Volkov, D. and P. Pajukanta (2010). "Genetic causes of high and low serum HDL-cholesterol." 
Journal of lipid research 51(8): 2032-2057. 
Wen, C. P., T. Y. David Cheng, S. P. Tsai, H. T. Chan, H. L. Hsu, C. C. Hsu and M. P. Eriksen (2009). 
"Are Asians at greater mortality risks for being overweight than Caucasians? Redefining obesity for 
Asians." Public Health Nutr 12(4): 497-506. 
West, R. (2017). "Tobacco smoking: Health impact, prevalence, correlates and interventions." 
Psychology & health 32(8): 1018-1036. 
West, S. G., A. L. Krick, L. C. Klein, G. Zhao, T. F. Wojtowicz, M. McGuiness, D. M. Bagshaw, P. Wagner, 
R. M. Ceballos, B. J. Holub and P. M. Kris-Etherton (2010). "Effects of diets high in walnuts and flax oil 
on hemodynamic responses to stress and vascular endothelial function." Journal Of The American 
College Of Nutrition 29(6): 595-603. 
West, S. G., S. K. Gebauer, C. D. Kay, D. M. Bagshaw, D. M. Savastano, C. Diefenbach and P. M. Kris-
Etherton (2012). "Diets containing pistachios reduce systolic blood pressure and peripheral vascular 
responses to stress in adults with dyslipidemia." Hypertension 60(1): 58-63. 
Whitman, I. R., V. Agarwal, G. Nah, J. W. Dukes, E. Vittinghoff, T. A. Dewland and G. M. Marcus (2017). 
"Alcohol Abuse and Cardiac Disease." Journal of the American College of Cardiology 69(1): 13-24. 
WHO Expert Consultation (2004). "Appropriate body-mass index for Asian populations and its 
implications for policy and intervention strategies." Lancet 10(9403): 157-163. 
Widmer, R. J., Flammer, A. J., Lerman, L. O., & Lerman, A. (2015). The Mediterranean diet, its 
components, and cardiovascular disease. The American journal of medicine, 128(3), 229–238. 
https://doi.org/10.1016/j.amjmed.2014.10.014 
Wien, M., D. Bleich, M. Raghuwanshi, S. Gould-Forgerite, J. Gomes, L. Monahan-Couch and K. Oda 
(2010). "Almond consumption and cardiovascular risk factors in adults with prediabetes." Journal Of The 
American College Of Nutrition 29(3): 189-197. 
Wongwarawipat, T., N. Papageorgiou, D. Bertsias, G. Siasos and D. Tousoulis (2018). "Olive Oil-related 
Anti-inflammatory Effects on Atherosclerosis: Potential Clinical Implications." Endocr Metab Immune 
Disord Drug Targets 18(1): 51-62. 
Woo, J., K. S. Woo, S. S. F. Leung, P. Chook, B. Liu, R. Ip, S. C. Ho, S. W. Chan, J. Z. Feng and D. S. 
Celermajer (2001). "The Mediterranean score of dietary habits in Chinese populations in four different 
geographical areas." European Journal of Clinical Nutrition 55(3): 215-220. 
World Health Organization (2014). C-reactive protein concentrations as a marker of inflammation or 
infection for interpreting biomarkers of micronutrient status, World Health Organization. 
World Health Organization (2015). Q&As on hypertension. 
World Health Organization (2016). Global NCD Target: Reduce High Blood Pressure. 
World Health Organization (2018). Physical activity. 
 
- 244 - 
 
World Health Organization (2019). Hypertension. 
World Health Organization (2020). Cardiovascular disease. 
Wu, H., A. Pan, Z. Yu, Q. Qi, L. Lu, G. Zhang, D. Yu, G. Zong, Y. Zhou, X. Chen, L. Tang, Y. Feng, H. 
Zhou, X. Chen, H. Li, W. Demark-Wahnefried, F. B. Hu and X. Lin (2010). "Lifestyle counseling and 
supplementation with flaxseed or walnuts influence the management of metabolic syndrome." The 
Journal Of Nutrition 140(11): 1937-1942. 
Wu, X., B. Zhu, S. Xu, Y. Bi, Y. Liu and J. Shi (2020). "A cross country comparison for the burden of 
cardiovascular disease attributable to tobacco exposure in China, Japan, USA and world." BMC Public 
Health 20(1): 888. 
Wulan, S. N., K. R. Westerterp and G. Plasqui (2010). "Ethnic differences in body composition and the 
associated metabolic profile: A comparative study between Asians and Caucasians." Maturitas 65(4): 
315-319. 
Xiao, Y., W. Huang, C. Peng, J. Zhang, C. Wong, J. H. Kim, E. K. Yeoh and X. Su (2017). "Effect of nut 
consumption on vascular endothelial function: A systematic review and meta-analysis of randomized 
controlled trials." Clin Nutr. 
Xiao, R.L., Marta, G.F., Jean, P.C., Deirdre, K.T., Shilpa, N. B., Kathryn, M. R., Walter, C.W., Qi, S., Yan, 
P.L.,(2020). Changes in Nut Consumption and Subsequent Cardiovascular Disease Risk Among US 
Men and Women: 3 Large Prospective Cohort Studies. Journal of the American Heart Association, 9(7), 
https://doi.org/10.1161/JAHA.119.013877 
Xu, X. R., Y. Wang, R. Adili, L. Ju, C. M. Spring, J. W. Jin, H. Yang, M. A. D. Neves, P. Chen, Y. Yang, 
X. Lei, Y. Chen, R. C. Gallant, M. Xu, H. Zhang, J. Song, P. Ke, D. Zhang, N. Carrim, S.-Y. Yu, G. Zhu, 
Y.-M. She, T. Cyr, W. Fu, G. Liu, P. W. Connelly, M. L. Rand, K. Adeli, J. Freedman, J. E. Lee, P. Tso, 
P. Marchese, W. S. Davidson, S. P. Jackson, C. Zhu, Z. M. Ruggeri and H. Ni (2018). "Apolipoprotein 
A-IV binds αIIbβ3 integrin and inhibits thrombosis." Nature Communications 9(1): 3608. 
Xu, Y., R. C. Arora, B. M. Hiebert, B. Lerner, A. Szwajcer, K. McDonald, C. Rigatto, P. Komenda, M. M. 
Sood and N. Tangri (2014). "Non-invasive endothelial function testing and the risk of adverse outcomes: 
a systematic review and meta-analysis." Eur Heart J Cardiovasc Imaging 15(7): 736-746. 
Yano, Y., R. M. Tanner, S. Sakhuja, B. C. Jaeger, J. N. Booth, III, M. Abdalla, D. Pugliese, S. R. Seals, 
G. Ogedegbe, D. W. Jones, P. Muntner and D. Shimbo (2019). "Association of Daytime and Nighttime 
Blood Pressure With Cardiovascular Disease Events Among African American Individuals." JAMA 
Cardiology 4(9): 910-917. 
Yeboah, J., A. R. Folsom, G. L. Burke, C. Johnson, J. F. Polak, W. Post, J. A. Lima, J. R. Crouse and D. 
M. Herrington (2009). "Predictive value of brachial flow-mediated dilation for incident cardiovascular 
events in a population-based study: the multi-ethnic study of atherosclerosis." Circulation 120(6): 502-
509. 
Yi, S.-W., D.-H. Shin, H. Kim, J.-J. Yi and H. Ohrr (2018). "Total cholesterol and stroke mortality in middle-
aged and elderly adults: A prospective cohort study." Atherosclerosis 270: 211-217. 
Ylenia, G. (2016). World Olive Oil Consumption Increased by 73 Percent Over a Generation. 
Zamora-Zamora, F., J. M. Martínez-Galiano, J. J. Gaforio and M. Delgado-Rodríguez (2018). "Effects of 
olive oil on blood pressure: A systematic review and meta-analysis." Grasas y Aceites 69(4): e272. 
Zern, T. L. and M. L. Fernandez (2005). "Cardioprotective effects of dietary polyphenols." J Nutr 135(10): 
2291-2294. 
 
- 245 - 
 
Zhang, F.-L., Y.-Q. Xing, Y.-H. Wu, H.-Y. Liu, Y. Luo, M.-S. Sun, Z.-N. Guo and Y. Yang (2017). "The 
prevalence, awareness, treatment, and control of dyslipidemia in northeast China: a population-based 
cross-sectional survey." Lipids in Health and Disease 16(1): 61. 
Zhang, R., Z. Wang, Y. Fei, B. Zhou, S. Zheng, L. Wang, L. Huang, S. Jiang, Z. Liu, J. Jiang and Y. Yu 
(2015). "The Difference in Nutrient Intakes between Chinese and Mediterranean, Japanese and 
American Diets." Nutrients 7(6): 4661-4688. 
Zhang, Y., Y. a. Gu, N. Wang, Q. Zhao, N. Ng, R. Wang, X. Zhou, Y. Jiang, W. Wang and G. Zhao (2019). 
"Association between anthropometric indicators of obesity and cardiovascular risk factors among adults 
in Shanghai, China." BMC public health 19(1): 1035-1035. 
Zhao, S. W., H. Y. Chong and Z. Dong (2001). "Sino-MONICA Project: A Collaborative Study on Trends 
and Determinants in Cardiovascular Diseases in China, Part I: Morbidity and Mortality Monitoring." 
Circulation 103: 462–468. 
Zhou, B. F., J. Stamler, B. Dennis, A. Moag-Stahlberg, N. Okuda, C. Robertson, L. Zhao, Q. Chan and 
P. Elliott (2003). "Nutrient intakes of middle-aged men and women in China, Japan, United Kingdom, 
and United States in the late 1990s: the INTERMAP study." J Hum Hypertens 17(9): 623-630. 
Zhou, B., J. Bentham and M. Di Cesare (2017). "Worldwide trends in blood pressure from 1975 to 2015: 
a pooled analysis of 1479 population-based measurement studies with 19·1 million participants." The 
Lancet 389(10064): 37-55. 
Zhou, M., H. Wang, X. Zeng, P. Yin, J. Zhu, W. Chen, X. Li, L. Wang, L. Wang, Y. Liu, J. Liu, M. Zhang, 
J. Qi, S. Yu, A. Afshin, E. Gakidou, S. Glenn, V. S. Krish, M. K. Miller-Petrie, W. C. Mountjoy-Venning, 
E. C. Mullany, S. B. Redford, H. Liu, M. Naghavi, S. I. Hay, L. Wang, C. J. L. Murray and X. Liang (2019). 
"Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for 
the Global Burden of Disease Study 2017." Lancet (London, England) 394(10204): 1145-1158. 
Zhu, H., Y. Xi, H. Bao, X. Xu, L. Niu, Y. Tao, N. Cao, W. Wang and X. Zhang (2020). "Assessment of 
cardiovascular disease risk in Northern China: a cross-sectional study." Annals of Human Biology 47(5): 
498-503. 
Zhu, Y., J.-M. Lu, Z.-B. Yu, D. Li, M.-Y. Wu, P. Shen, H.-B. Lin and J.-B. Wang (2019). "Intra-individual 
variability of total cholesterol is associated with cardiovascular disease mortality: A cohort study." 
Nutrition, Metabolism and Cardiovascular Diseases 29. 
Zibaeenezhad, M. J., P. Farhadi, A. Attar, A. Mosleh, F. Amirmoezi and A. Azimi (2017). "Effects of 
walnut oil on lipid profiles in hyperlipidemic type 2 diabetic patients: A randomized, double-blind, placebo-



















Supplementary information for Chapter 2 
 
- 247 - 
 
Appendix A1. Ethical Approval of the survey 
Submission Ref: 892 
Following independent peer review of the above proposal, I am pleased to inform you that 
APPROVAL has been granted on the basis of this proposal and subject to continued 
compliance with the University policies on ethics, informed consent, and any other policies 
applicable to your individual research.  You should also have current Disclosure & Barring 
Service (DBS) clearance if your research involves working with children and/or vulnerable 
adults.    
The University’s Policies and Procedures are here 
All researchers must also notify this office of the following: 
• Any significant changes to the study design, by submitting an ‘Ethics 
Amendment Form’ 
• Any incidents which have an adverse effect on participants, researchers 
or study outcomes, by submitting an ‘Ethical incident Form’ 
• Any suspension or abandonment of the study. 
Please check your approved proposal for any Approval Conditions upon which approval 
has been made.  
Use this link to view the submission: View Submission 
Research Ethics Home: Research Ethics Home 
Please do not reply to this email. This is an unmonitored mailbox. Queries should be 
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Appendix A2. Email recruitment  
Hello, 
We're currently looking for male and female volunteers above 18 years of age who aren’t 
full-time students. 
 
Our PhD students, Louise Francis and Fan Liang in the department of Applied Sciences at 
Northumbria University is currently recruiting participants for an online survey about weight loss 
attempts and adherence to the Mediterranean diet among adults in Northeast England. 
This study has been reviewed and received full ethical approval from the Faculty of Health and 
Life Sciences/Northumbria University Research Ethics Committee. 
The survey involves completing a questionnaire on basic background information about eating 
habits and it should take no longer than 15 minutes to complete. 
If you would like to take part, please visit the following link: 
https://northumbria.onlinesurveys.ac.uk/public-opinions-of-the-mediterranean-diet-copy 
 
Public opinions of the Mediterranean diet 
northumbria.onlinesurveys.ac.uk 
Online survey BOS 
  
However, if you wish to discuss any aspect of this study before taking part in it please 
contact Louise Francis and Fan Liang at louise.francis@northumbria.ac.uk; 
fan.liang@northumbria.ac.uk 
Please feel free to forward this email to anyone that you think might be interested in taking part 
in this study. 
 
Best wishes, 
Louise Francis, Fan Liang and Jose Lara
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  Appendix A3. Survey  
  Public opinions of the Mediterranean diet  (Asian) (copy) 
 
  INFORMATION SHEET 
 
Researchers: Louise Francis, Fan Liang 
 
Contact details: louise.francis@northumbria.ac.uk, fan.liang@northumbria.ac.uk 
Supervisor: Dr Jose Lara 
Contact details: jose.lara@northumbria.ac.uk 
 
What is the purpose of this project? 
 
This research forms part of a PhD project looking at the feasibility and acceptability of the 
Mediterranean diet in the UK. It is therefore important to assess the views of the public on 
this dietary pattern. This information will inform future clinical trials aiming to assess the 
impact of a combination of Mediterranean diet consumption and intermittent fasting on 
weight loss and cardiovascular biomarkers. 
 
Why have I been selected to take part? 
 
You have been invited to complete an online survey as you are meet the following inclusion 
criteria: above 18 years of age, a UK resident and an English-speaker as the survey is written 
in English and no translational facilities are available. 
 
What will I have to do? 
 
You will be asked to complete an anonymous online survey which should take around 15 
minutes. The survey will involve questions about background information such as age and 
height, questions about your opinions of a novel diet, and questions about how often you 
eat certain foods. You can save the survey part way through and complete it at another 
time. 
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Will my participation involve any physical or psychological discomfort?  
Participating in this research should not involve any physical or psychological discomfort. 
How will confidentiality be assured? 
In order to maintain anonymity, an online survey is used which does not collect any personal 
data such as your name or home address. All data will be treated in accordance with the 
Data Protection Act, and data will only be used by members of the research team for reasons 
appropriate to the research question. 
 
Has this research received appropriate ethical clearance? 
 
This study has been given full ethical approval by the Northumbria University Ethics 
Committee. 
 
Will I receive any financial reward for taking part? 
 
No financial rewards are offered for participating in this study. 
 
How can I withdraw from the project? 
 
Participants are not able to withdraw from the project after their survey has been 
submitted as the software used does not allow identification of specific participants' data.  
However if you choose to withdraw from the study before the survey has been submitted, 
closing the browser window in which the survey is open will terminate the survey and no 
data will be collected. 
 
I would like further information or to ask a question. Who do I contact and how? 
 
For any further information, do not hesitate to contact the investigator (Louise Francis and 
Fan Liang) or the project supervisor (Dr Jose Lara) using the email addresses at the top of 
this information sheet. 
 
 
If you have any questions, please click 'Finish later' and return to this survey once your 
questions have been answered. 
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         CONSENT FORM 
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         BACKGROUND QUESTIONS 
 









      What is your ethnicity?    Required 
 
 
       If you selected Other, please specify: 
 
 
        
Male 
Female 
Prefer not to say 
Caucasian 
East Asian (Chinese origin)  
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       Where in the UK do you currently reside?  Required 
 
 















North East England 
North West England 
South East England 




















Prefer Not to say 
Other 
 









      What is your employment status?  Required 
 
 





      What is your highest education level?  Required 
Unemployed 
Working part-time (less than 30 hours per week) 
Working full-time (more than 30 hours per week) 
Carer/Housewife/Househusband 
Retired 






























 What is your weight in kilograms? Click here to open a unit conversion website in a new window - you may  
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      What is your height in metres? Click here to open a unit conversion website in a new window - you may find 
it useful   if you need to convert your height from feet and inches to metres.  Required 
 
 
 Do you have a current diagnosis for any of the following? 
 
  Required 
Yes No 



















       Do you follow a special diet because of a medical condition?  Required 
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        WEIGHING YOURSELF 
 




      How often do you weigh yourself/have somebody else weigh you?  Required 
 
 
       If you selected Other, please specify: 
 
 
      At the present time, are you trying to lose weight, trying to gain weight, or not trying to change your weight?  









Trying to lose weight 
Trying to gain weight 
Not trying to change weight 
 
 




         YOUR WEIGHT LOSS EXPERIENCE 
 
       How many separate weight loss attempts have you made in the past?  Required 
 
 




Have you used any of the following in your attempt(s) to lose weight? 
 
 Yes No 
































     YOUR OWN DIET 
 
    How many times do you usually eat out per month? (i.e. consume food not cooked at home). Please give a    
number   Required 
 
 
     When eating out, which of the following cuisines do you prefer? (Please choose one)  
     Required 
 
 




      Do you ever use olive oil in your diet?  Required 
 
 

















Do you preferentially consume chicken, turkey, or rabbit meat instead of veal, pork, beef or other red meats?   
 
 
How many servings of the following foodstuffs do you consume per day? 
 

















More than 7 
Vegetables (excluding white 
potatoes) (1 serving = 80g, or 2 
broccoli florets, three heaped 
tablespoons of cooked vegetables 























































Fruit (1 serving = 80g, or 1 
banana, 2 kiwis, or 1 heaped 




























Butter, margarine, or cream (1 


























Please enter a number. 
Yes, I eat more white meats than red meats 




How many servings of the following foodstuffs do you consume per week? 

















More than 7 
Red meat (1 serving = 70g, or 









































































Legumes (e.g., kidney beans, lentils 

















































Cakes, pastries or sweets, 





































Other unsalted nuts including 



















A meal containing vegetables, 
pasta, rice, or other dishes seasoned 
with sauces made with tomato and 
















































        THE MEDITERRANEAN DIET 
 
       Which of the following statements is most true for you?  Required 
 
 
      If you selected Other, please specify: 
 
 
      Do you believe that your usual diet is healthy?  Required 
 
 
       If you selected Other, please specify: 
 
 
 Are any of the following factors barriers to your healthy eating? 
 
 Please don't select more than 1 answer(s) per row. Please select 
at least 20 answer(s). 
 Yes No 
 
I've never heard of the Mediterranean diet 
I know a little bit about the Mediterranean diet I 
know quite a bit about the Mediterranean diet 
I fully understand the concept of the Mediterranean diet Other 
Yes 
No 






















































































   THE MEDITERRANEAN DIET 
 
 Would you find the following Mediterranean dietary guidelines acceptable? (if you don't eat or drink 
something, e.g. meat or wine, please just click 'no') 
 
 Yes No I don't know 












Red meat should only be consumed a maximum of twice per week (1 serving = 70g, or 













Sweets such as desserts, chocolate and anything else high in refined sugars 


















A minimum of 2 servings of vegetables (excluding white potatoes) should be eaten 
per day (1 serving = 80g, or 2 broccoli florets, three heaped tablespoons of cooked 













A minimum of 3 servings of fruit should be eaten per day (1 serving 





















More than 3 servings of legumes (e.g. kidney beans, lentils or chickpeas) should be 










More than 3 servings of fish or shellfish should be consumed per week (1 serving of 









More than 3 servings of unsalted nuts should be consumed per week (1 serving = 







A meal containing vegetables, pasta or rice served with a sauce made using tomato, 















Researcher: Louise Francis, Fan Liang 
Contact details: louise.francis@northumbria.ac.uk, fan.liang@northumbria.ac.uk 
Supervisor: Dr Jose Lara 
Contact details: jose.lara@northumbria.ac.uk 
 
What was the aim of this project? 
 
This project aimed to investigate the opinions of the public on the acceptability and feasibility 
of the Mediterranean diet in the UK. 
 
Have I been deceived in any way during the study? 
 
No deception was used in this study. 
 
How will I find out about the results? 
 
Should you wish to receive information on the results of this study, please email one of the 
research team using the above email addresses. 
 
What will happen to the information I have provided? 
 
All data will be stored securely and confidentially until a certain time after the study has 
finished, when it will be destroyed. 
 
How will the results be disseminated? 
 
This research is intended for a PhD project and therefore results may be disseminated in a 
scientific journal. 
 
How would I withdraw my information after finishing the study? 
 
Participants are not able to withdraw from the project after their survey has been submitted 
as the software used does not allow identification of specific participants' data.  However if 
you choose to withdraw from the study before the survey has been submitted, closing the 





How can I register a complaint about this research? 
 
If you have any worries about the way this study was carried out please do not hesitate to 
contact one of the research team using the provided email addresses. 
THANK YOU 
 
Thank you for your participation. 
 
If you would like to be contacted about future related studies, please email 
louise.francis@northumbria.ac.uk or jose.lara@northumbria.ac.uk or 
fan.liang@northumbria.ac.uk
 




STROBE Statement— STROBE 2007 (v4) checklist of items to be included in reports of observational studies in Survey* Checklist for cohort, case‐control, and 
cross‐sectional studies (combined). 
Section/Topic Item #  Recommendation Reported 
on page # 
Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the title or the abstract 54 
(b) Provide in the abstract an informative and balanced summary of what was done and what was found 54 
Introduction    
Background/rationale 2 Explain the scientific background and rationale for the investigation being reported 55-59 
Objectives 3 State specific objectives, including any prespecified hypotheses 60-61 
Methods    
Study design 4 Present key elements of study design early in the paper 61 
Setting 5 Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data 
collection 
61 
Participants 6 (a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods 
of follow-up 
Case-control study—Give the eligibility criteria, and the sources and methods of case ascertainment and control 
selection. Give the rationale for the choice of cases and controls 
Cross-sectional study—Give the eligibility criteria, and the sources and methods of selection of participants 
61 
(b) Cohort study—For matched studies, give matching criteria and number of exposed and unexposed 
Case-control study—For matched studies, give matching criteria and the number of controls per case 
N/A 
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, 
if applicable 
61-63 
Data sources/ measurement 8* For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe 
comparability of assessment methods if there is more than one group 
62 
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Bias 9 Describe any efforts to address potential sources of bias N/A 
Study size 10 Explain how the study size was arrived at 61 
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen 
and why 
62-63 
Statistical methods 12 (a) Describe all statistical methods, including those used to control for confounding N/A 
(b) Describe any methods used to examine subgroups and interactions N/A 
(c) Explain how missing data were addressed N/A 
(d) Cohort study—If applicable, explain how loss to follow-up was addressed 
Case-control study—If applicable, explain how matching of cases and controls was addressed 
Cross-sectional study—If applicable, describe analytical methods taking account of sampling strategy 
N/A 
(e) Describe any sensitivity analyses 63 
 
Results Item #  Recommendation Reported 
on page # 
Participants 13* (a) Report numbers of individuals at each stage of study — e.g., numbers potentially eligible, examined for 
eligibility, confirmed eligible, included in the study, completing follow-up, and analysed 
63 
(b) Give reasons for non-participation at each stage N/A 
(c) Consider use of a flow diagram N/A 
Descriptive data 14* (a) Give characteristics of study participants (e.g., demographic, clinical, social) and information on exposures 
and potential confounders 
63 
(b) Indicate number of participants with missing data for each variable of interest N/A 
(c) Cohort study—Summarise follow-up time (e.g., average and total amount) N/A 
Outcome data 15* Cohort study—Report numbers of outcome events or summary measures over time 63-72 
Case-control study—Report numbers in each exposure category, or summary measures of exposure N/A 
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Cross-sectional study—Report numbers of outcome events or summary measures N/A 
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% 
confidence interval). Make clear which confounders were adjusted for and why they were included 
64-72 
(b) Report category boundaries when continuous variables were categorized N/A 
(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period N/A 
Other analyses 17 Report other analyses done— e.g., analyses of subgroups and interactions, and sensitivity analyses N/A 
Discussion    
Key results 18 Summarise key results with reference to study objectives 72-76 
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both 
direction and magnitude of any potential bias 
N/A 
Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, 
results from similar studies, and other relevant evidence 
72-77 
Generalisability 21 Discuss the generalisability (external validity) of the study results 72-77 
Other information    
Funding 22 Give the source of funding and the role of the funders for the present study and, if applicable, for the original 
study on which the present article is based 
N/A 
 
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is 
best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and 
Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org. 
 




Checklist for Reporting Results of Internet E-Surveys (CHERRIES) 
Item Category  Checklist Item  Explanation  
Design  
 Describe survey 
design 
142 Caucasian and 142 Asian responses from UK and Shanghai, China were recruited and analysed in 
this online survey study. Participants have regular access to internet and email and, no other 
inclusion/exclusion criteria were employed. Recruitment was supported by Northumbria University. This 
online survey was advertised among staffs and students at Northumbria University. A “snowball” 
sampling procedure was attempted by requesting participants to forward the invitation to join the study 
to others. Participants of this study were recruited in a wide range of individuals in terms of education, 
residence, marital and socioeconomic status, age and ethnicity. 
IRB (Institutional Review Board) approval and informed consent process  
 IRB approval This study was approved by the Northumbria University ethics committee (Registration no. 000892) 
 Informed consent Researchers Louise Francis, Fan Liang and Jose Lara created this survey for academic research purpose 
of the feasibility and acceptability of the Mediterranean diet in the UK. After people click on the link of 
this online survey, the first page is the consent form alongside with the information sheet, and this online 
survey takes no longer than 15 minutes to complete.  
 Data protection In order to maintain anonymity, an online survey is used which does not collect any personal data such 
as your name or home address. All data will be treated in accordance with the Data Protection Act, and 
data will only be used by members of the research team for reasons appropriate to the research question. 
Development and pre-testing  
 Development and 
testing 
All questions in this online survey were discussed and created by researchers Louise, Fan and our 
supervisor Jose Lara. Few tempts of pilot survey responses send to lecturers and friends prior to 
publishing to the public in order to gain feedbacks.  
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Recruitment process and description of the sample having access to the questionnaire  
 Open survey versus 
closed survey 
Our online survey is an open survey, which only need participants to be above 18 years of age, a UK 
resident and an English-speaker as the survey is written in English and no translational facilities are 
available. 
 Contact mode The initial contact with the potential participants was made on the Internet and also by Northumbria 
university email.  
 Advertising the 
survey 
Recruitment was supported by Northumbria University. The study was also advertised among staffs and 
students at Northumbria University. A “snowball” sampling procedure was attempted by requesting 
participants to forward the invitation to join the study to others. 
Survey administration  
 Web/E-mail All Online data from all responses in this online survey were put manually into an Excel database by 
researchers. After cleaning all the database in excel, all data were input into SPSS to analyse.  
 Context Online surveys (formerly BOS) is regarded as a powerful, flexible online survey which is an tool designed 
for Academic Research, Education and Public Sector organisations.  
 Mandatory/voluntary This online survey is a voluntary survey to be filled by every visitor who clicked “yes” in the consent 
form page on the website.  
 Incentives None 
 Time/Date The data was collected from August 2017 to April 2018 
 Randomization of 
items or 
questionnaires 
No randomisation of items was used. 
 Adaptive questioning Certain items were populated based on previous responses. The questionnaire online survey was shown 
in Appendix A3.  
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 Number of Items This online questionnaire survey has 1-3 items per page.  
 
 Number of screens 
(pages) 
This online questionnaire survey was distributed by 16 pages. 
 Completeness check All survey items were deemed to be mandatory, and respondents prompted to complete 
outstanding items before leaving the survey page on which the item was contained. This online survey 
technically had been done the consistency or completeness checks before the questionnaire is 
submitted. All items provide a non-response option such as “not applicable” or “rather not say”, and 
selection of one response option should be enforced (Appendix A3). 
 Review step Respondents were able to review and change their answers through a back button which displays a 
summary of the responses and asks the respondents if they are correct. 
Response rates  
 Unique site visitor Determination of unique visitors was handled by the research team. Digital fingerprinting for geo-IP 
ensure that respondents only compete the survey once. 





 Participation rate 
(Ratio of unique 
visitors who agreed 
to participate/unique 
first survey page 
visitors) 
All participants (n=284) visited the survey informed consent page and started to do the online survey 
questionnaire. The recruitment rate is 100%. 
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 Completion rate 
(Ratio of users who 
finished the 
survey/users who 
agreed to participate) 
All participants (n=284) completed this questionnaire online survey. The completion rate is 100%. 
Preventing multiple entries from the same individual  
 Cookies used N/A 
 IP check Digital fingerprinting for geo-IP ensure that respondents only compete the survey once. 
 Log file analysis N/A 
 Registration N/A 
Analysis  
 Handling of 
incomplete 
questionnaires 
All questionnaires had been completed and analysed.  
 Questionnaires 
submitted with an 
atypical timestamp 
N/A 
 Statistical correction All data collected from the Online survey were input into the SPSS to analyse.  
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Appendix A7. 
2.3.5. The association between foods consumption and socio-demographic 
characteristics in East Asians and Caucasians 
There is no statistically significant difference of marital status between both Caucasians and 
East Asians consume either walnuts or olive oil as p value are more than 0.05 (Table 2.6; 
Table 2.6.1). As shown in Table 2.6.2, the majority of Caucasians who resided in North 
East England are not walnuts consumers (p=0.005). Northeast English are not walnuts 
consumers compared to other regions (p=0.005). In Table 2.6.4, there is no significant 
difference between people who consume walnuts and people who do not consume walnuts 
concerning their education level as p-value are both higher than 0.05. There is no significant 
difference between either Caucasians or East Asians who consume olive oil and people 
who do not consume olive oil concerning their education level as p-value are both higher 
than 0.05. 
Table 2.6 The association between walnuts intake and marital status in East Asians and 
Caucasians 
Ethnicity Walnuts Total  





Marital Single 77 8 85 .594 
Married 29 7 36 
Divorced/widowe
d/separated 
10 2 12 
Prefer not to say 2 0 2 
Other 6 1 7 
Total 124 18 142  
East 
Asian 
Marital Single 30 22 52 .885 
Married 35 21 56 
Divorced/widowe
d/separated 
3 3 6 
Prefer not to say 6 3 9 
Other 13 6 19 
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Table 2.6.1 The association between olive oil consumption and marital status in 
East Asians and Caucasians 
Ethnicity Olive oil Total  
No Yes  Asymptotic 
Significance 
(2-sided) 
Caucasian Marital Single 26 59 85 .061 
Married 4 32 36 
Divorced/widowed
/separated 
3 9 12 
Prefer not to say 1 1 2 
Other 4 3 7 
Total 38 104 142  
East Asian Marital Single 35 17 52 .981 
Married 39 17 56 
Divorced/widowed
/separated 
4 2 6 
Prefer not to say 7 2 9 
Other 13 6 19 
Total 98 44 142  
Chi-Square Tests 
 
Table 2.6.2 The association between walnuts intake and geography in East Asians 
and Caucasians 






Caucasian Residence North East England 112 12 124 0.005 
Other 12 6 18 
Total 124 18 142  
East Asian Residence North East England 25 12 37 0.360 
Other 62 43 105 
Total 87 55 142  









Caucasian Residence North East England 31 93 124 .214 
Other 7 11 18 
Total 38 104 142  
East Asian Residence North East England 21 16 37 .061 
Other 77 28 105 
Total 98 44 142  
Chi-Square Tests 
 
Table 2.6.3 The association between walnuts and olive oil intake and employment 
status in East Asians and Caucasians 







Caucasian Employment Unemployed 2 1 3 .081 
Working part-time 28 10 38 
Working full-time 16 2 18 
Carer/housewife/hou
sehusband 
1 0 1 
Full-time student 69 5 74 
Part-time student 5 0 5 
Other 3 0 3 
Total 124 18 142  
East Asian Employment Working part-time 4 1 5 .382 
Working full-time 51 29 80 
Carer/housewife/hou
sehusband 
5 4 9 
Retired 3 6 9 
Full-time student 20 10 30 
Part-time student 1 0 1 
Prefer not to say 2 2 4 
Other 1 3 4 
Total 87 55 142  
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Caucasian Employment Unemployed 0 3 3  
.331 Working part-time 8 30 38 
Working full-time 5 13 18 
Carer/housewife/hou
sehusband 
0 1 1 
Full-time student 25 49 74 
Part-time student 0 5 5 
Other 0 3 3 
Total 38 104 142  
East Asian Employment Working part-time 3 2 5 .561 
Working full-time 58 22 80 
Carer/housewife/hou
sehusband 
7 2 9 
Retired 6 3 9 
Full-time student 20 10 30 
Part-time student 1 0 1 
Prefer not to say 1 3 4 
Other 2 2 4 
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Table 2.6.4 The association between walnuts and olive oil consumption and 
educational level in East Asians and Caucasians 









None 1 0 1 0.939 
Secondary school 20 2 22 
University 101 16 117 
Prefer not to say 1 0 1 
Other 1 0 1 
Total 124 18 142  
East Asian Coded 
Education 
University 84 55 139 0.380 
Prefer not to say 2 0 2 
Other 1 0 1 
Total 87 55 142  









None 1 0 1 .174 
Secondary school 7 15 22 
University 29 88 117 
Prefer not to say 0 1 1 
Other 1 0 1 
Total 38 104 142 .210 
East Asian Coded 
Education 
University 96 43 139 
Prefer not to say 2 0 2 
Other 0 1 1 
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Table B1: PRISMA Checklist 
Section/topic  # Checklist item  Reported 
on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  78 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; 
study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; 
results; limitations; conclusions and implications of key findings; systematic review registration 
number.  
78 - 79 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  80 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, 
interventions, comparisons, outcomes, and study design (PICOS).  
81 - 82 
METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if 
available, provide registration information including registration number.  
82 - 83 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., 
years considered, language, publication status) used as criteria for eligibility, giving rationale.  
83 - 84 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study 
authors to identify additional studies) in the search and date last searched.  
83 - 84 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such 
that it could be repeated.  
82 - 83 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, 
and, if applicable, included in the meta-analysis).  
82 - 83 
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Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) 
and any processes for obtaining and confirming data from investigators.  
84 - 85 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any 
assumptions and simplifications made.  
86 - 87 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of 
whether this was done at the study or outcome level), and how this information is to be used in any 
data synthesis.  
87 - 97 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  87 - 97 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including 
measures of consistency (e.g., I2) for each meta-analysis.  






                                                                                                                                                                                                 
- 293 - 
 
Figure B2. Meta-analysis of studies consuming nuts on FMD (%). 
Ten studies, including 377 participants, evaluated the impact of nut consumption on FMD. Overall, 
nut consumption significantly increased FMD by 0.74 (95% CI 0.09 to 1.39; p = 0.03). Heterogeneity 
levels assessed by the I² test were low at 5%. 
 
 
Figure B3. Meta-analysis of studies consuming nuts on adiponectin (ug/ml) 
 
 
Figure B4. Meta-analysis of studies consuming nuts on oxidized-LDL (mg/dl). 
 
 
Figure B5. Meta-analysis of studies consuming nuts on Lag time of LDL. 
 
 
                                                                                                                                                                                                 




















                                                                                                                                                                                                 





Figure B7. Meta-analysis of studies consuming nuts on DBP (mmHg). 
 
 
Figure B8. Meta-analysis of studies consuming nuts on Pulse BP (mmHg). 
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Figure B11. Meta-analysis of studies consuming nuts on ApoA-1 (mg/dl). 
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Figure B13. Meta-analysis of studies consuming nuts on hs-CRP (pg/mL). 
 
Figure B14. Meta-analysis of studies consuming nuts on CRP (ug/mL). 
 
Figure B15. Meta-analysis of studies consuming nuts on TNF-a (pg/mL). 
 
 
Figure B16. Meta-analysis of studies consuming nuts on IL-10 (pg/mL). 
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Figure B17. Meta-analysis of studies consuming nuts on IL-8 (pg/mL). 
 
 
Figure B18. Meta-analysis of studies consuming nuts on IL-6 (pg/mL). 
 
Figure B19. Meta-analysis of studies consuming nuts on IL-1 (pg/mL). 
 
Figure B20.  Meta-analysis of studies consuming nuts on IL-18 (pg/mL). 
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Figure B22. Meta-analysis of studies consuming nuts on sICAM-1 (ng/mL). 
 
 
Figure B23. Meta-analysis of studies consuming nuts on sVCAM-1 (ng/mL). 
 
Figure B24. Meta-analysis of studies consuming nuts on sICAM-3 (ng/mL). 
 
Figure B25. Meta-analysis of studies consuming nuts on SAA (ug/mL). 
 
Figure B26. Meta-analysis of studies consuming nuts on plasma E-Selectin (ng/mL). 
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Figure B27. Meta-analysis of studies consuming nuts on P-Selectin (ng/mL). 
 
Figure B28. Meta-analysis of studies consuming nuts on Thrombmodulin-1 (ng/mL). 
 
 
Figure B29. Meta-analysis of studies consuming nuts on PAI-1 (ng/mL). 
 
 
Figure B30. Meta-analysis of studies consuming nuts on MCP-1 (pg/mL). 
 
 
Figure B31. Meta-analysis of studies consuming nuts on PWV (m/s). 
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Figure B32. Meta-analysis of studies consuming nuts on Hyperemic blood flow (mL/min). 
 
Figure B33. Meta-analysis of studies consuming nuts on Post- velocity (cm/s). 
 
 
Figure B34. Meta-analysis of studies consuming nuts on plasma nitric oxide (NO) (umol/L). 
 
 
Figure B35. Meta-analysis of studies consuming nuts on TBARS (uM). 
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Figure B38. Meta-analysis of studies consuming nuts on Fibrinogen (g/L). 
 
 
Figure B39. Meta-analysis of studies consuming nuts on Endothelial-1 (fmol/ml).
 
Figure B40. Meta-analysis of studies consuming nuts on endothelium-independent 
vasodilation (EIV) (%). 
 
Figure B41. Meta-analysis of studies consuming nuts on endothelium-dependent vasodilation 
(EDV) (%).  
 
 
Figure B42. Meta-analysis of studies consuming nuts on RHI.  
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 Figure B43. Meta-analysis of studies consuming nuts on Augmentation Index (AI).  
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Thank you for submitting your Original Communication(s) for consideration by the selection panel for 
presentation at the Nutrition Society Student Conference 2016. 
  
I am delighted to tell you that your Original Communication (OC) has been accepted for lightening 
presentation at the meeting.  Attached to this message you will find the running order. Please look 
carefully through the document to find your OC. We have done our very best to accommodate 
preferences for Oral, Poster and Lightening presentations although this has not always been possible 
- as ever we have tried to produce a balanced programme which will be of interest to the 
delegates. The running order highlights if you will be presenting a poster, oral or lightening 
session. Please ensure to check the presentation format and follow the appropriate 
instructions below. 
  
The University of Chester uses PowerPoint 2010 and facilities will be available for standard 
PowerPoint presentations using PC format. 
Save presentations in this format and email to Barbara at 1324743@chester.ac.uk 
A back-up copy should be saved onto a memory stick and brought to the meeting. 
  
Finally, authors are reminded that they MUST register to attend the meeting. To register for the 
conference, please see: https://www.eventbrite.co.uk/e/student-conference-2016-tickets-
25717026318?ref=ebtn 
Student Conference 2016 Tickets, Thu, 8 Sep 2016 at 09:00 ... 
www.eventbrite.co.uk 
Eventbrite - The Nutrition Society presents Student Conference 2016 - Thursday, 8 September 2016 
| Friday, 9 September 2016 at Riverside Innovation Centre. 
I very much look forward to seeing you at the meeting in Chester. 
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Appendix B46. 
Publication bias assessed by funnel plot of seven parameter outcomes (over or equal to 10 
studies included in each outcome) that have positive effects in the meta-analysis. Funnel plot 
showing study precision against the mean differences effect estimate with 95% confidence 
intervals (CI) for TC, HDL-C, LDL-C, TG, VLDL-C and Apo B on intervention supplementing 
nuts. SE = Standard error.  
 
Figure 3.9. Funnel plot of SE for the effect of interventions supplementing nuts on TC (mg/dl) was 
not completely symmetrical, suggesting that the present study has some slight publication bias. 
However, the Egger tests (p=0.28754) did not give sufficient evidence that the present study had 
publication bias. 
 
The intercept: -0.25207, 95% CI (-0.72098, 0.21685), with t=1.07135, d.f=73. The 1-tailed p-value (recommended) is 0.14377, 
































Funnel Plot of Standard Error by Difference in means
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Figure 3.10. Funnel plot of SE for the effect of interventions supplementing nuts on HDL-C (mg/dl) 
was not completely symmetrical, suggesting that the present study has some slight publication bias. 
However, the Egger tests (p=0.23298) did not give sufficient evidence that the present study had 
publication bias. 
 
The intercept: 0.27444, 95% CI (-0.18024, 0.72912), with t=1.20242, d.f=75. The 1-tailed p-value 
(recommended) is 0.11649, and the 2-tailed p-value is 0.23298. 
 
 
Figure 3.11. Funnel plot of SE for the effect of interventions supplementing nuts on LDL-C (mg/dl) 
was not completely symmetrical, suggesting some slight publication bias. However, the Egger tests 
(p=0.23860) did not give sufficient evidence that the present study had publication bias. 
 
The intercept: -0.33700, 95% CI (-0.90219, 0.22819), with t=1.18808, d.f=74. The 1-tailed p-value 
(recommended) is 0.11930, and the 2-tailed p-value is 0.23860. 
 




















Funnel Plot of Standard Error by Difference in means

















Funnel Plot of Standard Error by Difference in means
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Figure 3.12.  Funnel plot of SE for the effect of interventions supplementing nuts on TG (mg/dl) was 
asymmetrical, suggesting this study has publication bias. However, the Egger tests (p=0.54563) did 
not give sufficient evidence that the present study had publication bias. 
 
The intercept: 0.15445, 95% CI (-0.35281, 0.66172), with t=0.60727, d.f=70. The 1-tailed p-value 
(recommended) is 0.27282, and the 2-tailed p-value is 0.54563. 
 
 
Figure 3.13.  Funnel plot of SE for the effect of interventions supplementing nuts on VLDL-C (mg/dl) 
was asymmetrical, and statistical analysis using Egger’s test (P=0.39967), and this revealed that a 
risk of publication bias was not presented. 
 
The intercept: 0.29150, 95% CI (-0.43581, 1.01880), with t=0.87325, d.f =12. The 1-tailed p-value 
(recommended) is 0.19983, and the 2-tailed p-value is 0.39967. 


















Funnel Plot of Standard Error by Difference in means





















Funnel Plot of Standard Error by Difference in means
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Figure 3.14.  Funnel plot of SE for the effect of interventions supplementing nuts on Apo B (mg/dl) 
was asymmetrical, and statistical analysis using Egger’s test (P=0.00006), and this revealed that a 
risk of publication bias was presented. 
 
The intercept: -1.18151, 95% CI (-1.68773, -0.67530), with t=4.80699, d.f=25. The 1-tailed p-value 

































Funnel Plot of Standard Error by Difference in means
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Random-effect model – Total cholesterol (TC) regression of length of nuts intervention 
(days) on difference in means. Difference in means in included studies of TC vs. placebo. 
The centreline shows the predicted values. Meta-regression analysis was performed by 
mixed effects regression (unrestricted maximum likelihood) to assess/evaluate the 
relationship of the cardiovascular biomarkers with difference in means in mixed nuts 
consumption. Dose of nuts that were not clarified in trials were excluded.  
Figure 3.15(a). Meta-regression analysis preformed no significant correlations between duration of 
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Fig 3.15(b). Meta-regression on the effects of the daily dose of nuts consumption (g) on mean 
differences in TC indicated that daily dose of nuts consumption may not be associated with lower TC 
(Slope = 0.00128, Q = 0.00151; d.f. = 1; P > 0.05 (0.96900)) in 72 studies. 
 
 
Fig 3.16(a). Meta-regression on the effects of the length of nuts consumption (d) on mean differences 
in HDL-C indicated that a longer duration of nuts consumption may not be associated with higher 
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Fig 3.16(b). Meta-regression on the effects of the dose of nuts consumption (g) on mean differences 
in HDL-C. The meta-regression indicated that the length of nuts consumption may not be associated 
with difference on HDL-C (P>0.05 (0.29533); Slope = 0.00995; Q = 1.09517; d.f = 1) in 73 trials.  
 
 
Fig 3.17(a). 74 studies performed meta-regression on the effects of the length of nuts consumption 
(g) on mean differences in LDL-C. The meta-regression indicated that a longer duration of nuts 
consumption may be associated with higher LDL-C (p<0.05 (0.00996); slope = 0.01358; q = 6.64190; 
d.f = 1). 
 
Fig 3.17(b). 74 studies performed meta-regression on the effects of the dose of nuts consumption 
(g) on mean differences in LDL-C. The meta-regression indicated that a higher amount of nuts 
consumption may be not associated with lowering LDL-C (P>0.05 (0.50307); Q = 0.44845; d.f = 1; 
Slope = -0.01117).  
























































                                                                                                                                                                                                 




Fig 3.18(a) Meta-regression analysis preformed a significant positive correlation between the length 
of nuts consumption and difference in means of TG and longer duration of nuts intake may be 
associated with higher TG. (P <0.05 (0.00240); Q =9.21674; Slope = 0.03270; d.f = 1) in 71 studies.  
 
 
Fig 3.18(b) Meta-regression analysis preformed a significant positive correlation between the dose 
of nuts and difference in means of TG in 71 trials. Greater dose of nut consumption may be 
associated with lower TG (P <0.05 (0.00392); Q = 8.32139; Slope = -0.12699; d.f = 1). 
























































                                                                                                                                                                                                 




Fig 3.19(a). Meta-regression analysis preformed no significant correlations between the length of 
nuts consumption and difference in means of VLDL-C (p >0.05 (0.64548); Q = 0.21165; Slope = 






























































                                                                                                                                                                                                 
- 314 - 
 
Fig 3.19(b). Meta-regression analysis preformed no significant correlations between the daily dose 
of nuts consumption (g) and difference in means of VLDL-C (P >0.05 (0.32391); Q = 0.97309; d.f =1; 




Fig 3.20(a). Meta-regression analysis preformed a significant correlation between the length of nuts 
consumption (days) and difference in means of Apo B (P <0.05 (0.00019); Q = 13.92838; d.f = 1; 
Slope = 0.15828) in 27 studies. However, longer duration of nuts intake may not be associated with 
lower Apo B.  
 
 
























































                                                                                                                                                                                                 





Fig 3.20(b). Meta-regression analysis preformed no significant correlations between the daily dose 
of nuts consumption (g) and difference in means of Apo B (P >0.05 (0.18515); Q = 0.75581; d.f = 1; 
Slope = -0.03376) in 27 trials.  
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Table C1: PRISMA Checklist 
Section/topic  # Checklist item  
Reported 
on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  140 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study 
eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; 
limitations; conclusions and implications of key findings; systematic review registration number.  
140 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  141 -142 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, 
comparisons, outcomes, and study design (PICOS).  
142 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, 
provide registration information including registration number.  
142 - 143 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years 
considered, language, publication status) used as criteria for eligibility, giving rationale.  
143 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to 
identify additional studies) in the search and date last searched.  
143 -144 
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Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could 
be repeated.  
143 -144 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if 
applicable, included in the meta-analysis).  
143 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any 
processes for obtaining and confirming data from investigators.  
144 -145 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any 
assumptions and simplifications made.  
145 -146 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether 
this was done at the study or outcome level), and how this information is to be used in any data synthesis.  
147 - 149 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  149 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of 
consistency (e.g., I2) for each meta-analysis.  
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Figure C2. Meta-analysis of studies consuming olive oil on TC (mmol/L).  
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Figure C4. Meta-analysis of studies consuming olive oil on LDL-C (mmol/L). 
 
 
Figure C5. Meta-analysis of studies consuming olive oil on TG (mmol/L). 
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Figure C7. Meta-analysis of studies consuming olive oil on DBP (mmHg). 
 
Figure C8. Meta-analysis of studies consuming olive oil on sICAM-1 (ng/mL). 
 
Figure C9. Meta-analysis of studies consuming olive oil on sVCAM-1 (ng/mL). 
 
Figure C10. Meta-analysis of studies consuming olive oil on IL-6 (pg/mL). 
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Figure C12. Meta-analysis of studies consuming olive oil on CRP (mg/dL). 
 
 
Figure C13. Meta-analysis of studies consuming olive oil on adiponectin (ug/mL). 
 
 
Figure C14. Meta-analysis of studies consuming olive oil on TNF-alpha (pg/mL). 
 
 
Figure C15. Meta-analysis of studies consuming olive oil on vWF (%). 
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Figure C17. Meta-analysis of studies consuming olive oil on ET-1 (pg/mL). 
 
Figure C18. Meta-analysis of studies consuming olive oil on plasma E-Selectin (ng/mL). 
 
Figure C19. Meta-analysis of studies consuming olive oil on Apo B (mg/dL). 
 
Figure C20. Meta-analysis of studies consuming olive oil on ApoA1 (mg/dL). 
 
Figure C21. Meta-analysis of studies consuming olive oil on IL-8 (pg/mL). 
 
Figure C22. Meta-analysis of studies consuming olive oil on IL-10 (pg/mL). 
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Appendix D1.  
Message generated by ClinicalTrials.gov Protocol Registration and Results System  
Northumbria University Protocol Record HLS-JLG-OO study, Effect of Olive Oil Consumption on 
Cardiovascular Biomarkers, has been reviewed and will be made public on ClinicalTrials.gov.  
RECORDS USUALLY APPEAR ON ClinicalTrials.gov WITHIN 2 BUSINESS DAYS of the receipt of 
this message. 
The record has been edited by ClinicalTrials.gov as follows: 
Made minor editorial changes 
QUESTIONS?  Contact us at:  register@clinicaltrials.gov 
Thank you, 
PRS Team 
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Appendix D2.  
Dear fan.liang, 
Submission Ref: 10527 
Following independent peer review of the above proposal*, I am pleased to inform you 
that APPROVAL has been granted on the basis of this proposal and subject to continued compliance 
with the University policies on ethics, informed consent, and any other policies applicable to your 
individual research.  You should also have current Disclosure & Barring Service (DBS) clearance if 
your research involves working with children and/or vulnerable adults.   
* note: Staff Low Risk applications are auto approved without independent peer review. 
The University’s Policies and Procedures are here: 
All researchers must also notify this office of the following: 
1. Any significant changes to the study design, by submitting an ‘Ethics Amendment Form’ 
2. Any incidents which have an adverse effect on participants, researchers or study outcomes, by 
submitting an ‘Ethical incident Form’ 
3. Any suspension or abandonment of the study. 
Please check your approved proposal for any Approval Conditions upon which approval has 
been made. 
Use this link to view the submission: View Submission 
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Appendix D3.  
Dear all, 
I am studying for a PhD in the final year at Northumbria university in Newcastle. Currently I am 
looking forward to finding more participants to take part in my study. I will be appreciating if people 
would like to be interested in my olive oil study. 
We are looking for participants either Caucasians or East Asians (healthy male adults ages 18 - 70) 
to participate in a study investigating the effects of consuming olive oil on cardiovascular markers (4 
visits to the clinical room across the intervention). 
You will be taking a daily dose of olive oil for two weeks or butter for 2 weeks with 2-week washout 
period in between. Each visit around 30 minutes. There is a £20 Eldon Square gift voucher to 
compensate for your time and inconvenience caused. Please contact fan.liang@northumbria.ac.uk 
for more information. 
Visits take place at Northumberland Building (City Campus), if you are interested in my olive oil study 
trial, please do not hesitate to contact me. 
  
With thanks and kind regards, 
Fan 
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30 Participants needed! 
Are you a healthy male adult of Asian or Caucasian origin aged 18-70 years old? 
This study has received approval from Northumbria University’s Faculty of Health and Life Sciences Ethics Committee 
Participants needed for a study examining the effects of consuming olive oil on cardiovascular markers. 
The study will involve 4 study visits (around 40 mins each per visit) to our research facilities and taking a daily dose of olive oil for two weeks or butter for 2 weeks with 
2-week washout period in between. 
Visits take place at Northumberland Building (City Campus) 
To compensate for your time, you will receive £20 voucher for taking part in the study 
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Participant Information sheet 
TITLE OF PROJECT: Effect of olive oil consumption on cardiovascular biomarkers in Asians and 
Caucasians: A randomized, crossover, controlled interventional trial 
 
Principal Investigator: Fan Liang 
Principal Supervisor: Dr Jose Lara Gallegos 
Email: fan.liang@northumbria.ac.uk;  
Number of participant payment: £20 voucher will be provided at the end of the study  
 
What is the Purpose of the project? 
 
Olive oil, a central element to the Mediterranean diet, has been associated with beneficial 
effects on markers of cardiovascular risk.  
This study aims to compare the efficacy of consumption of olive oil for two weeks on different 
cardiovascular risk factors including blood pressure and blood lipids in adult individuals of 
Asians and Caucasian origin.  
 
Why have I been selected to take part? 
You have indicated that you are:  
1. Interested in taking part in the study  
2. Healthy  
3. Aged 18-70 years (inclusive)  
4. Either Caucasians or the Orient Asians (such as Chinese, Japanese, Korean, Malaysia 
Chinese) 
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What are the exclusion criteria (i.e. are there any reasons why I should not take part)? 
You should not take part if you:  
1. Have been diagnosed and/or are taking medications for hypertension (>140/90mmHg), 
diabetes, high blood cholesterol and heart problems (e.g. arrhythmia, high-grade stenosis 
of the carotid artery or carotid sinus syndrome). 
2. Are aged below 18 or above 70 years old 
3. Have been told to have an allergy to olive oil or olive oil products 
4. Have been diagnosed with lactose intolerance  
5. Take omega-3 supplements or fish oil and vitamins supplements (regularly during the 
last six months). 
 
What will I have to do if I take part in the study?  
 
Key points 
1. After signing the consent forms, the researcher will ask you to complete a brief medical 
and lifestyle questionnaire to assess your general health conditions. Participants will be 
asked to complete a 3-day food record as well as international physical activity 
questionnaire to evaluate habitual dietary habits as well as physical status prior to study 
visits. 
 
2. All study activity will take place at Northumbria University. You will be asked to attend 1 
screening visit (about 30 minutes) to confirm you are eligible, and 4 study visits over a 6-week 
study period to provide blood and urine samples. These visits will be scheduled in the 
morning and will last for around 40 minutes and will be held in Norhtumberland building 
(NB425) at Northumbria University.  
 
3. Before each study visit, you will be required to fast overnight (i.e. please consume your 
evening meal the day before to the visit before 8:00PM and thereafter only water). 
 
4. You will be asked to consume either olive oil (30ml) for 2 weeks or butter (30g) for 2 weeks, 
with a 2-week period in between in which you will refrain from consuming any of these. These 
foods will be incorporated into soup and consumed at lunchtime. These foods will be 
provided to you. 
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5. You will be asked to keep a record of your dietary intake for 3 non-consecutive days (i.e. 
type of foods, preparation and amount of food/drink consumed), in addition you will be 
required to keep record of your dietary intake during the first 2 weeks of the study and then 
asked to repeat your food consumption during the next 4 weeks.  
 
6. Independently of the foods to be tested in this study, you will be asked to maintain your 
usual diet as well as to maintain your usual exercise patterns.  
 
7. Researchers will not be able to provide medical advice to participants. However, 
participants’ results could be provided to your GP if you wish to do so.   
 
General procedure 
Pre-screening visit: (approx. 30 minutes) 
During this visit, the participants will be asked to read the participant information sheet firstly. 
Next, participants meeting our inclusion criteria will be asked to sign the consent forms. After 
you complete the consent forms, the investigator will explain the nature of the research and 
will ask you to complete pre-screening questionnaire including a 3-day food record, physical 
activity questionnaire as well as medical and lifestyle questionnaire. At this point, future visit 
1 will be scheduled at least three days after this pre-screening visit. Before visit 1 you will be 
asked to complete a 3-day dietary record.  
 
Study visits 1: (approx. 40 minutes) 
You will attend the trial at an agreed time in the morning (for example: 8:00AM), having 
been fasted from 8:00PM the last evening (12 hours). You will return the completed 3-day 
dietary record. 
 
Next, we will measure blood pressure, body weight/height without shoes, hand grip 
strength and body fat. At this session you will also be required to provide a urine sample 
and fasting venous blood samples. 18ml of fasting venous blood sample (total 72ml for 4 
visits) will be taken by a trained researcher. A spot urine sample will be collected into a 
flask (provided). The whole procedure will be taken within 30 minutes to complete.  
 
Then, you will be given 30ml/day olive oil or 30g/day butter as treatment to consume for 
two-week duration which you will incorporate into your habitual diet (in combination with 
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soup during lunch meals). In addition, participants will also be provided with a 3-day dietary 
record. You will be requested to maintain your usual dietary pattern (i.e. based on the 3-
day dietary record you have reported) and usual exercise patterns. 
 
Study visit 2 (approx. 40 minutes) 
This appointment will take place 2 weeks after visit 1 (ideally the same day of the week when 
visit 1 took place). Participants will undergo the same baseline measurements. Fasting urine 
and venous blood samples will be collected as in the same as visit 1. On arrival, we will check 
that you have complied with the study. After this visit, you will be asked to avoid olive oil or 
butter for 2 weeks (‘washout’ period).  
 
Study visit 3 & 4 (approx. 40 minutes each visit) 
Study visit 3 will take place 2 weeks after visit 2. Visit 3 will be identical in procedure as visit 
1. Study visit 4 will take place 2 weeks after visit 3. Visit 4 will be identical in procedure as 
Visit 2. Additionally, you will be debriefed and you will be asked to complete a “Research 
Participants Experience questionnaire” at the end of Visit 4.  
 
Will my participation involve any physical discomfort?       
 
1. Venous blood samples will be taken using standard techniques with minor discomfort 
and will only be carried out by trained phlebotomists (Fan Liang and Jose Lara). However, 
there might be a slight risk for minor bruising. You will be advised to avoid heavy lifting or 
strenuous exercise after taking part to minimize bruising. 
 
2. You will have your blood pressure taken at all appointments using a standard battery 
operated monitor and cuff. You may find the pressure of the cuff tightening on your arm 
uncomfortable during this procedure, however this last only a few seconds. 
 
3. These products to be consumed during this study will be foods commonly eaten and there 
will be no known side-effects associated with participants’ consumption.  
 
4. Will my participation involve any psychological discomfort or embarrassment? 
No.  
However, we would like you to be aware that in the medical and lifestyle questionnaire 
include questions related with your health.  
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5. Will I have to provide any bodily samples (i.e., blood, saliva)? 
Yes.  
You will be required to provide a fasting venous blood sample and a spot urine sample at 
each appointment. Blood samples will be taken only after you have given consent to this 
study for tissue removal, storage and usage. Venous blood sample (18ml for each 
measurement, total 72ml for 4 visits) will be collected at fasted state. At each visit, you will 
be also provided with a flask to collect a urine sample in private.  
 
6. Will my taking part in this study be kept confidential and anonymous? 
Yes.   
You will be allocated a participant code number that will always be used to identify any data 
that you provide during the study. Only the research team will have access to any identifiable 
information; paper records will be stored in a locked filing cabinet and electronic information 
will be stored on a password-protected computer. Any personal details will be kept separate 
from data and will be treated in accordance with the Data Protection Act.  
 
Who will have access to the information that I provide? 
Only the research team (Fan Liang, Jose Lara) will have access to the information that you 
provide. However, any data that leaves the site will only be identifiable by an identification 
number and it will not be possible for anybody outside of the investigational site to identify 
you. Should the results of research be presented or published in any form, then that 
information will be generalized. Rest assure that your personal information or data will not be 
identifiable. 
 
How will my information be stored / used in the future?  
It is a possible that the results of the study will be published in scientific journals or 
disseminated in scientific conferences. After the final report has been completed, all study 
related materials will be archived in accordance with General Data Protection Regulation 
(GDPR) or the Data Protection Act (DPA) for a minimum of 7 years. At no time you will be 
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Has this investigation received appropriate ethical clearance? 
Yes. 
This study has received ethical approval from the Faculty of Health and Life Sciences Ethics 
committee. If you require confirmation of this, please contact the Chair of this Committee, 
stating the title of the research project and the name of the principal investigator:  
Chair of Faculty of Health and Life Sciences Ethics Committee, Northumberland Building, 
Northumbria University, Newcastle upon Tyne, NE1 8ST 
 
Will I receive any financial rewards / travel expenses for taking part?  
Yes. You will receive £20 in vouchers for completing the study. 
 
How can I withdraw from the project? 
 
If you do decide that you do not wish to take any further part of the study, you are free to 
withdraw from the study at any time, without having to give any reasons and without 
prejudice. Please inform one of the research team as soon as possible, and they will facilitate 
your withdrawal and discuss with you how your data will be used in the future. After 
completion of the study, you can still withdraw your data. However, kindly do so by contacting 
the research team and give them your participation number within a month of your 
participation. After this date, it may not be possible to withdraw your individual data as the 
results may already have been published. As all data are anonymised, your individual data 
will not be identifiable in any way. 
 
If I require further information who should I contact and how? 
If you need further information or wish to withdraw from the study, would like to discuss your 
participation, or experience any problems as a consequence of taking part in the study you 
should contact Fan Liang (fan.liang@northumbria.ac.uk) or alternatively, supervisor of the 








                                                                                                                                                                                                 





Physical Examination and Intervention Visit Information Form 
Physical examination after sitting in an upright position for 5 minutes. A first reading is taken but 
discarded. If the average reading is out of range, but the third is lower than the second reading, a 
fourth reading can be taken. This reading alone will then be used as the final measurement. Readings 
should be taken > 1-minute intervals. If BP is >139-89, subject must be referred to GP. 
 
Project Title: Effect of olive oil consumption on cardiovascular biomarkers in Asians and 
Caucasians: A randomized, crossover, controlled interventional trial 
Principal Investigator: Dr Jose Lara Gallegos 
Student Investigator: Fan Liang 
 
Subject ID Number: ______________________        
Date: ______________ (Visit number: _______) 
Subject initials: ___________________         
Time of arrival: _________________ 
Date of Birth (dd/mm/yyyy): ________________ 
 
Has subject observed a fast from 20:00 last night?               Y/N 
Has subject complete 3-day diet recall?                                  Y/N 
Anthropometric data: 
BP (systolic blood pressure /diastolic blood pressure /heart rate) 
1st reading: ________________________        
2nd reading: ________________________        
3rd reading: ________________________     
4th reading: ________________________    
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Height: ___________(m) Weight: ___________ (kg) Body Mass Index: 
________________ (kg/m2) 
Are you a right-handed or left-handed? 
____________________________________________________ 
Grip strength 1: ___________kg       Grip strength 2: ___________kg       Grip strength 3: 
___________kg                                                                                                                    
Body composition: 
Body fat: ___________% (normal range: _____ - _____ %)   
Body fat: ___________kg (normal range: _____ - _____ %)          
Lean: ___________% (normal range: _____ - _____ %)   
Lean: ___________kg (normal range: _____ - _____ kg)     
Total: _____________kg (normal range: _____ - _____ %)          
Dry lean weight: __________kg (normal range: _____ - _____ %)                                                                                                            
Water: _____________% (normal range: _____ - _____ %)            
Water: _____________It (normal range: _____ - _____ %)      
Basal MET.RATE: ____________kcal            
BMR: ___________ kcal/kg           
EST.AVERAGE REQ: ___________kcal     
BMI: ____________kg/m2 (normal range: _____ - _____ %)  
Impedance 50KHz: ______________Ω 
Investigation: 
1. Blood sample   Y/N  
                                                                                                                                                                                                 



































                                                                                                                                                                                                 





Study Completion Sheet 
Project Title: Effect of olive oil consumption on cardiovascular biomarkers in Asians and 
Caucasians: A randomized, crossover, controlled interventional trial 
Principal Investigator: Dr Jose Lara Gallegos 
Student Investigator: Fan Liang 
Subject I.D.: ___________________        
Date of Completion/early withdrawal:  ___________________ (dd-mm-yy) 
 
Did the subject complete the study as planned?         Yes             No    
 
If No, please give primary reason for premature termination / discontinuation 
 
         Adverse event(s) (also specify on the Adverse Event form)  
         Major protocol violation, including non-compliance            
         Subject withdrew consent            
         Lost to follow-up   
         Other please specify: 
_________________________________________________________________        
 
Please provide any relevant information related to the reason for premature 
discontinuation: 
_______________________________________________________________________ 
I have reviewed and found all data pertaining to this subject to be complete and accurate:  
Principal Investigator’s Signature       _______________________  
  
Date: _____________________(dd-mm-yy) 
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Research Participants Experience questionnaire  
PROJECT TITLE: Effect of olive oil consumption on cardiovascular biomarkers in 
Asians and Caucasians: A randomized, crossover, controlled 
interventional trial 
RESEARCHER: Fan Liang 
PRINCIPAL INVESTIGATOR: Dr Jose Lara Gallegos 
We value your opinion on what it was like to be involved in research. We would be grateful 
if you could complete this anonymous questionnaire about your experience to help us 
improve in the future. 
 
Subject ID Number: ________________ (optional) 
After taking part in this study, I feel that I will try olive oil more often in the future. 
 
         Strongly Agree 
         Agree 
         Not Sure 
         Disagree 
         Strongly Disagree 
 
On a scale of 1-5, with 1 meaning “not at all” and 5 meaning “very much”, how would you 
rate the researcher (Fan Liang) on the following points? If you did not have any contact with 














1 2 3 4 5 
     
1 2 3 4 5 
     
1 2 3 4 5 
     
1 2 3 4 5 





                                                                                                                                                                                                 









I felt valued as a participant in research. 
 
         Strongly Agree 
         Agree 
         Not Sure 
         Disagree 
         Strongly Disagree 
 
It is important to me to know the results of a research study. 
 
         Strongly Agree 
         Agree 
         Not Sure 
         Disagree 
         Strongly Disagree 
 
I would recommend taking part in a research study to other people. 
 
         Strongly Agree 
         Agree 
         Not Sure 
         Disagree 
         Strongly Disagree 
 
Please tell us if there is anything that could have made your overall experience better: 
 
1 2 3 4 5 
     
1 2 3 4 5 
     
Approachable 
Supportive 
                                                                                                                                                                                                 









Please tell us about your reasons for taking part in this study.  
Choose all options that apply: 
       To help others 
 
       For my own benefit or care 
 
       Health professional recommended it 
 
       I am interested in research  
 
       Other: _______________________________________________ 
 












1 2 3 4 5 
     
1 2 3 4 5 6 7 8 9 10 
          
Strongly  
Disagree 
Very poor Excellent 
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PARTICIPANT DEBRIEF 
Name of Researcher: Fan Liang 
Name of Supervisor: Dr Jose Lara Gallegos 
Participant Number: __________ 
 
Project Title: Effect of olive oil consumption on cardiovascular biomarkers in Asians and 
Caucasians: A randomized, crossover, controlled interventional trial 
  
1. What was the purpose of the project? 
Epidemiological evidence suggests an association between consumption of olive oil and 
low risk for cardiovascular diseases (CVDs).  
How factors such as ethnicity plays a role in this association are not fully investigated. The 
main aim of this study was to examine the effect of oral olive oil consumption in improving 
several cardiovascular risk markers in between Caucasians and Asians.  
 
2. How will I find out about the results? 
If you require information about the overall results and conclusion of the project simply send 
an email to the researcher.  
 
3. Have I been deceived in any way during the project? 
No. Everything has been stated in the consent form and information form what was required 
of you and what you had to do to help with this project.  
 
4. If I change my mind and wish to withdraw the information I have provided, how 
do I do this? 
If you wish to withdraw, simply contact Fan Liang (fan.liang@northumbria.ac.uk) with your 
participant number within a month of your participation. After this date, it may not be 
possible to withdraw your individual data as the results may already have been published. 
However, as all data are anonymous, your individual data will not be identifiable in any 
way. 
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  5. How will the results be disseminated? 
The data collected in this study may also be published in scientific journals or presented at 
scientific conferences.  However, rest assured that at no time will you personally be 
identified. 
  
6. What will happen to the information I have provided? 
Your consent forms have been separated from your other data and stored in a locked filing 
cabinet. The other data will be stored on a password-protected staff PC or in a separate 
locked filing cabinet until the findings have been published. At no time will you personally 
be identified as having taken part. We will not provide any information on your own individual 
performance. After the final report has been completed, all study related materials will be 
archived in accordance with General Data Protection Regulation (GDPR), for a minimum of 
7 years. 
 
If you wish to receive feedback about the findings of this research study then please contact 
the researcher at fan.liang@northumbria.ac.uk 
 
This study and its protocol have received full ethical approval from Faculty of Health and 
Life Sciences Research Ethics Committee. If you require confirmation of this, or if you have 
any concerns or worries concerning this research, or if you wish to register a complaint, 
please contact the Chair of this Committee (Dr Nick Neave: 
nick.neave@northumbria.ac.uk). 
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Olive oil consumption self-report sheet 
If you take olive oil today, Please place a tick ( ) in the correct box. 
Monday Tuesday Wednesday Thursday Friday Saturday Sunday 
Take olive oil  
 
Take olive oil  Take olive oil  Take olive oil  Take olive oil  Take olive oil  Take olive oil  
Take olive oil  Take olive oil  Take olive oil  Take olive oil  Take olive oil  Take olive oil  Take olive oil  
Take olive oil  Take olive oil  Take olive oil  Take olive oil  Take olive oil  Take olive oil  Take olive oil  
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Take olive oil  





Take olive oil  





Take olive oil  





Take olive oil  





Take olive oil  





Take olive oil  





Take olive oil  





Take olive oil  





Take olive oil  





Take olive oil  





Take olive oil  





Take olive oil  





Take olive oil  





Take olive oil  
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Butter consumption self-report sheet 
If you take olive oil today, Please place a tick ( ) in the correct box. 
Monday Tuesday Wednesday Thursday Friday Saturday  Sunday 
Take butter  
 
Take butter  Take butter  Take butter  Take butter  Take butter  Take butter  
Take butter  
 
Take butter  
 
Take butter  
 
Take butter  
 
Take butter  
 
Take butter  Take butter  
Take butter  Take butter  Take butter  Take butter  Take butter  Take butter  Take butter  
Take butter  





Take butter  





Take butter  





Take butter  





Take butter  





Take butter  





Take butter  
















Take butter  






Take butter  





Take butter  





Take butter  





Take butter  





Take butter  





Take butter  
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Adverse Event Report 
Project Title: Effect of olive oil consumption on cardiovascular biomarkers in Asians and Caucasians: A randomized, crossover, controlled interventional trial 
Name of Researcher: Fan Liang 
Name of Supervisor: Dr Jose Lara Gallegos 
Participant ID Number: __________-
___________ 
 
Visit Date: ______________________ (mm/dd/yy) 
 
Has the subject had any Adverse Events during this study? Yes      No   (If yes, please list all Adverse Events below) 









Stop Date (mm/dd/yy) 
OR 
Check  If 
continuing 
Relationship 





Treatment of Adverse 
Event? 
Final 
Outcome of Event 
 
1.     
 
      
2.           
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3.           
4.           
5.          
6.          
7.          
8.          
9.          
10.          
11.          
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12.          
13.          
14.          
15.          
16.          
 
Severity: 1 = Mild, 2 = Moderate, 3 = Severe; 
Action Taken: 1 = None, 2 = Discontinued permanently, 3 = Interrupted temporarily, 4 = Reduced Dose, 
 5 = Increased Dose, 6 = Delayed Dose 
Final Outcome of AE: 1 = Resolved, No Sequelae, 2 = AE still present- no treatment, 3 = AE still present-being treated, 4 = Residual effects present-not treated,  
5 = Residual effects present- treated, 6 = Death, 7 = Unknown 
Relationship to Study Intervention: 1 = Definitely related,  2 = Possibly related,  3 = Not related 
Expected: 1 = Yes 2 = No 
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Appendix Table D8. CONSORT 2010 checklist of information to include when reporting a randomised trial. 
Section/Topic Item No Checklist item Reported on page No 
Title and abstract 
 1a Identification as a randomized trial in the title 156 






2a Scientific background and explanation of rationale 157 - 158 
2b Specific objectives or hypotheses 158 
Methods 
Trial design 3a Description of trial design (such as parallel, factorial) including allocation ratio 161 - 162 
Participants 4a Eligibility criteria for participants 162 - 163 
4b Settings and locations where the data were collected 163 
Interventions 5 The interventions for each group with sufficient details to allow replication, including how and when they were 
actually administered 
163 - 164 
Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, including how and when they 
were assessed 
167 
6b Any changes to trial outcomes after the trial commenced, with reasons N/A 
Sample size 7a How sample size was determined 172 
7b When applicable, explanation of any interim analyses and stopping guidelines 172 




Sequence generation 8a Method used to generate the random allocation sequence 164 - 165 




9 Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), 
describing any steps taken to conceal the sequence until interventions were assigned 
 
164- 165 
Implementation 10 Who generated the random allocation sequence, who enrolled participants, and who assigned participants to 
interventions 
164 
Blinding 11a If done, who was blinded after assignment to interventions (for example, participants, care providers, those 
assessing outcomes) and how 
164 
11b If relevant, description of the similarity of interventions N/A 
Statistical methods 12a Statistical methods used to compare groups for primary and secondary outcomes 167- 173 
12b Methods for additional analyses, such as subgroup analyses and adjusted analyses 173 
Results 
Participant flow (a 
diagram is strongly 
recommended) 
13a For each group, the numbers of participants who were randomly assigned, received intended treatment, and 
were analyzed for the primary outcome 
174 - 189 
13b For each group, losses and exclusions after randomization, together with reasons 174 - 189 
Recruitment 14a Dates defining the periods of recruitment and follow-up 163 - 164 
14b Why the trial ended or was stopped N/A 
Baseline data 15 A table showing baseline demographic and clinical characteristics for each group 175 - 176 
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Numbers analyzed 16 For each group, number of participants (denominator) included in each analysis and whether the analysis was 




17a For each primary and secondary outcome, results for each group, and the estimated effect size and its 
precision (such as 95% confidence interval) 
180- 189 
17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended 180- 189 
Ancillary analyses 18 Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing 
pre-specified from exploratory 
180- 189 
Harms 19 All-important harms or unintended effects in each group (for specific guidance see CONSORT for harms) N/A 
Discussion 
Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses 197- 199 
Generalizability 21 Generalizability (external validity, applicability) of the trial findings 191 -192 
Interpretation 22 Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence 193 -199 
Other information 
Registration 23 Registration number and name of trial registry 161 
Protocol 24 Where the full trial protocol can be accessed, if available N/A 
Funding 25 Sources of funding and other support (such as supply of drugs), role of funders N/A 
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Appendix D9. Manufacturer’s instructions for Human P-selectin ELISA kit. 
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Appendix D14.  Manufacturer’s instructions for Human sICAM-1 ELISA kit. 
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Appendix D16. Manufacturer’s instructions for Human Syndecan-1 ELISA kit. 
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Appendix D17. G-power sample size calculation 
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